StudyID,TypeOfEligibilityCriteria,EligibilityCriteria
NCT00357227,Exclusion Criteria,"[Diagnosis of vascular or degenerative dementia, History of psychiatric disorders, Herzschrittmacher, Schwangerschaft, Metallimplantate, History of severe brain injury, History of brain tumors, History of acute stroke]"
NCT00357227,Inclusion Criteria,"[Alter 50 bis 85 Jahre, Klinische Diagnose von permanentem, paroxysmalem oder episodischem Vorhofflimmern in der Vergangenheit oder Gegenwart]"
NCT00626548,Exclusion criteria,"[A history of epilepsy or seizures, Currently using opiate based pain killers for cancer related pain, Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial, Suffering from heart failure or had a myocardial infarction within last 6 months]"
NCT00626548,Inclusion criteria,"[18 Years and older, Currently receiving treatment with surgical or medical castration, Male, Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment, Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT spread to the other parts of the body (metastases). Patients with lymph node involvement may be eligible if specified criteria is met.]"
NCT01428726,Medical Concepts,"[Corticosteroid therapy, Breast feeding, Nursing, Drug abuse, Recurrent Disease, Multiple Sclerosis, Relapsing-Remitting , Alter, Diagnose, Diabetes mellitus, Hyperurikämie, Hypotonie, Compliance, Kurtzke multiple sclerosis rating scale, Expanded Disability Status Scale , Chemotherapie, Insulinom, Schwangerschaftstest, Lebertransplantation]"
NCT01428726,Inclusion Criteria,"[clinical disability measured by EDSS score between 0 and 5.0, Patients who meet the diagnosis criteria for RRMS, Alter 18 bis 55 Jahre]"
NCT01428726,Exclusion Criteria,"[Positive pregnancy test, breast feeding women or childbearing potential, Patients treated with chemotherapy, Patients with corticosteroid therapy in the last month, interferon-beta or glatiramer acetate in the last 3 months, or natalizumab in the last 6 months, Relapse in the 30 days period before baseline visit , Patients with medical conditions such as diabetes, hypotension, insulinoma, hyperuricemia, or other conditions (drug abuse, inability to consent or to perform all the procedures of the clinical trial), Patients who had received or are candidates for liver transplantation]"
NCT00554502,Inclusion Criteria,"[Male or female patients from 18-70 years with histologically proven primary IgAN with typical mesangioproliferative features. Diagnosis has to be made by a neuropathologist., Proteinuria above 0.75 g/day within 12 weeks prior to or at the first visit in the run-in phase (month -6)and presence of at least one further risk factor for the development of end stage renal disease  1. arterial hypertension, defined as ambulatory blood pressure >140/90 mm Hg or the  use of antihypertensive medication or  2. impaired renal function, defined as creatinine clearance or estimated GFR <90  ml/min. , Alter 18 bis 70 Jahre]"
NCT00554502,Exclusion Criteria,"[Contraindication for immunosuppressive therapy, like, Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study, Additional other chronic renal disease., Alcohol or drug abuse, Krebs, Known allergy or intolerance to study medication (except in case of ACE-inhibitor, in which case a change to an angiotensin receptor blocker is possible)., Subjects who have been committed to an institution by legal or regulatory order., Any prior immunosuppressive therapy., Subjects who are in any state of dependency to the sponsor or the investigators., Employees of the sponsor or the investigators., Need of permanent immunosuppression, (e.g. transplanted patients,  steroid-dependent inflammatory diseases), Participation in a parallel clinical trial or participation in another clinical trial within the last 3 months., Variants of primary IgAN (e.g. rapidly progressive IgAN with crescents in >50% of glomeruli or minimal change GN with glomerular IgA deposits)., Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study, Secondary IgAN or diseases associated with glomerular deposits of IgA., active intestinal bleeding, active gastric or duodenal ulcer, leukocytopenia, thrombocytopenia or known allergy against prednisolone,  cyclophosphamide or azathioprine, acute or chronic infectious disease incl. hepatitis and HIV positive patients, Creatinine clearance below 30 ml/min (mean of 3 measurements)., Significant liver dysfunction (more than three fold increased GPT compared to norm), Women who are pregnant or breastfeeding and women without sufficient contraception.]"
NCT00153062,Medical concepts,"[Thrombocytopenia, Peptic Ulcer, Ischemic stroke, Life expectancy, Heparin, hyperkalemia, Medication, Age, Systolic Blood Pressure, Coronary artery disease (CAD), Complication of surgical and medical care, unspecified, Hypertensive disease, Brain Neoplasms, Peripheral Arterial Diseases, Obesity, Dementia, Brain hemorrhage, Platelet count - finding, Smoker, Diabetes mellitus, Acute myocardial infarction, Therapeutic procedure, Asthma, Body mass index, Anticoagulant treatment, Neutropenia, Antithrombic Drugs, Left Ventricular Hypertrophy, Microalbuminuria, Retinopathy, Renal Insufficiency, White Blood Cells, Rankin score, Warfarin, Diagnosis, Hepatic Insufficiency, Hyperlipidemia, Stroke, Angiotensin II receptor antagonist, Bleeding tendency]"
NCT00153062,Inclusion Criteria,"[Male or female subjects 55 year or older who have suffered an ischemic stroke within the past 90 days and who meet all other inclusion criteria. Include also patients of ages 50 - 54 years and/or 90 to 120 days after the qualifying stroke provided the patient has at least two of the following additional risk factors: Diabetes mellitus,
Hypertension (systolic blood pressure (BP)>=140 millimeters of Mercury (mmHg) or diastolic BP>=90mmHg), Smoker at time of qualifying stroke, 
Obesity (Body mass index (BMI)>30, BMI=weight in kilograms (kg)/[height in meters (m)]2), Previous vascular disease (stroke, MI, or peripheral arterial disease prior to qualifying stroke), End-organ-damage (retinopathy, left ventricular hypertrophy (LVH), or microalbuminuria),
Hyperlipidemia, 50 Years and older]"
NCT00153062,Exclusion Criteria,"[unlikely to be released from hospital following the qualifying stroke or presence of a severe disability likely to lead to being bedridden or demented or a non-vascular disease or condition which makes it unlikely that the patient will survive to the end of the trial, Systolic blood pressure (SBP) 120 mmHg or less for hospitalized patients. Currently taking an Angiotensin II receptor blocker (ARB) and not able or willing to switch to alternative. Required or planned continuing treatment with antithrombotics or anticoagulants including heparin or warfarin or non-study platelet inhibitors, scheduled for major surgery, carotid endarterectomy, or carotid angioplasty (4 weeks post surgery is allowed), known brain tumor, severe renal or hepatic insufficiency, current active peptic ulcer disease, severe coronary artery disease including unstable angina pectoris or an MI within the previous 3 months,or history of a hemostatic disorder or systemic bleeding, syndrome of asthma, rhinitis and nasal polyps, hyperkalemia, uncorrected volume or sodium depletion, qualifying stroke induced by surgical or cardiovascular procedure, unable to give informed consent, uncontrolled hypertension at entry above 180/110 mmHg (goal blood pressures are lower), pre-stroke history of dementia, modified Rankin score greater than 4, history of thrombocytopenia or neutropenia, hemorrhagic stroke (must be ruled out by imaging)]"
NCT00289978,Inclusion Criteria,"[Patients with a relapsing-remitting disease course, Patients with EDSS score of 0-5.5, Alter 18 Jahre bis 55 Jahre]"
NCT00289978,Medical Concepts,"[schwanger, Alter, Lungenerkrankung, EDSS, akut, Heart failure, Multiple Sclerosis, Relapsing-Remitting, chronische Erkrankung des Immunsystems, disorder, Krebs, Stillzeit, Multiple Sklerose, MS]"
NCT00289978,Exclusion Criteria,"[Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc., Pregnant or nursing women]"
NCT00778388,Medical Concepts,"[Immunomodulatory or immunosuppressive therapy, pregnant, Serum pregnancy test (B-HCG), congenital immunodeficiency, Age, Vaccination, Malignant Neoplasms, 
Informed Consent, Contraception, Enrollment, Hypersensitivity, Healthy Subject, Diagnosis, Autoimmune Disease]"
NCT00778388,Exclusion Criteria,"[History of autoimmune diseases and malignancies , Clinically significant diseases as judged by the investigator , Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine , Active or passive vaccination 4 weeks before and during the entire study protocol, Immunodeficiency due to immunosuppressive therapy, A family history of congenital or hereditary immunodeficiency, History of severe hypersensitivity reactions and anaphylaxis , Known hypersensitivity or allergic reactions to one of the components of the vaccine]"
NCT00778388,Inclusion Criteria,"[healthy adults aged between 18 and 65 years, written informed consent obtained prior to study entry , no clinically relevant pathological findings in any of the investigations at the Screening visit. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance , In female subjects either childbearing potential terminated by surgery or a negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception ]"
NCT00355849,Inclusion Criteria,"[age >=18 Years, once-daily insulin glargine, HbA1c greater than or equal to 7.5 and less than or equal to 10.5%, Diabetes mellitus Typ II, Nichtraucher, one or more oral antihyperglycemic medications]"
NCT00355849,Exclusion Criteria,"[history of renal transplantation, Have had a lower respiratory infection in the 3 months prior, more than two episodes of severe hypoglycemia during the 6 months prior, aktives oder unbehandeltes Malignom, klinische Zeichen oder Symptome einer Lebererkrankung, akute oder chronische Hepatitis, Require more than 150 U/day of insulin glargine, systemische Steroidtherapie, taking a TZD dose greater than what is indicated]"
NCT01094678,Inclusion Criteria,"[Alter mindestens 18 Jahre, stenosis of the above-the-knee femoropopliteal artery, appropriate size and location of the lesion ]"
NCT01094678,Exclusion Criteria,"[pregnant or breast feeding, simultaneously participating in another drug or device study, failure or inability to give informed consent]"
NCT00586794,Inclusion Criteria,"[Clinical indication for the invasive diagnostic procedures planned for the study is given. This is evaluated on the basis of observation before, during and after medicinal therapy), Written informed consent obtained, Diagnose, combinations thereof , Other diagnoses with univentricular physiology/ hemodynamics. , Presence of PAH as diagnosed by invasive methods with Rp:Rs > 0.5 measured at rest, before testing of pulmonary vasodilatory reserve, Atrial Septal Defect Sinus Venosus, Sinus venosus atrial septal defect , non-corrected large congenital shunting defect at atrial, ventricular or  arterial level:, Vorhofseptumdefekt, ASD, No participation in another AMG driven study attendancing this treatment protocol, Surgically corrected shunting defect (diagnoses as above) with significant  residual defect, Aortopulmonary window, Aortopulmonary septal defect, Ventrikelseptumdefekt, VSD, Herzkammerscheidewanddefekt, Atrioventricular septal defect, Atrioventricular septal defect and common atrioventricular junction, Presence of cyanosis with < 93 % arterial oxygen saturation (measured by transcutaneous pulse oximetry), Ductus arteriosus apertus persistens, TAC, Alter mindestens 14 Jahre, Partial anomalous pulmonary venous drainage, Partial Anomalous Pulmonary Venous Return]"
NCT00586794,Exclusion Criteria,"[mitral valve dysfunction, Anämie, impairment of renal function (GFR < 30 ml/min/1,73 m2 BSA), acute decompensated heart failure within the 7 days before the invasive diagnostic procedure, substance abuse (alcohol, medicines, drugs), PERICARDIAL CONSTRICTION, pulmonary hypertension secondary to any etiology other than those specified in the inclusion criteria, patients who lost vision on one eye due to a non arteriitic anterior ischaemic neuropathy of the opticus (NAION)., obstruction of pulmonary venous return, any diseases or impairment that, in the opinion of the investigator exclude a subject from participation, aortic or mitral valve disease (more severe than \""mild\""), subjects who are not able to perform Cardio-Pulmonary Exercise Testing (CPX)., other sources of pulmonary blood flow which prohibit measurement of the blood flow into the lungs and therefore of the pulmonary vascular resistance:, symptomatic coronary artery disease, any existing medication that, in the opinion of the investigator, may interfere with sildenafil treatment., Subjects with trisomy 21 (reproducibility of 6-MWT and CPX doubtful; communication as to side effects and subjective quality of life doubtful), History of stroke, myocardial infarction or life-threatening arrhythmia within the 6 months before screening, BT - Blalock-Taussig shunt, Subclavian to pulmonary artery shunt operation, significant number of MAPCAs; (details: 4.2.2. exclusion criteria), PCWP/LVEDP > 15 mmHg, Existing anti-pulmonary hypertensive medication (in any form) with:, secondary impairment of organic function:, Significant valvular diseases other than tricuspid or pulmonary regurgitation (these are not exclusion criteria; details: 4.2.2. exclusion criteria)., Bronchopulmonary dysplasia (BPD) and other chronic lung diseases, other medical, psychological or social circumstances that would adversely affect a patient's ability to participate reliably in the study or increase the risk to themselves or others if they participated, Left heart diseases:, women of child-bearing age who are sexually active without practising highly effective methods of contraception, missing willingness to storaging and transferring pseudonymous disease data within this study., Other relevant diseases (e.g. HIV, diabetes mellitus requiring medical treatment), Unspecified concomitant medication, prostanoids (e.g. iloprost, prostacyclin, beraprost) In case the patient is stable and on Bosentan therapy at least for 6 months. Bosentan (Tracleer) is unprohibited as concomitant medication., Glenn shunt, Anastomosis of superior vena cava to pulmonary artery, impairment of hepatic function (ALT and/or AST > 3 x ULN and bilirubin ≥ 2 mg/dl), decompensated symptomatic policythemia; (details: 4.2.2. exclusion criteria), ritonavir, nicorandil (act through K+ channels), begin of a new medication regimen within the last 30 days before screening, arterial hypotension (as defined by age-specific values), subjects with known intolerance of NO and iloprost or their constituents, clinically significant haemoptysis within the last 6 months, cytochrome P450-CYP2C9 and CYP3A4 inhibitors (e.g. erythromycin/ketoconazole/itraconazole/protease inhibitors), Obstruction of pulmonary outflow tract, insufficient compliance, pregnancy or lactation, Prohibited concomitant medication:, Alpha-Blocker, L-arginin (acts through NO axis), Other medication with vascular action:, Thrombocytopenia, Instable medication (details: 4.2.5 prohibited concomitant medication):, Medication that is not compatible with sildenafil or interferes with the metabolism:, Other significant medication (a.o. chronic intake of systemic immunosuppression as e.g. systemic glucocorticoids, cytostatic drugs, ciclosporin), hemodynamic instability which would represent an unjustifiable risk during testing of pulmonary arterial vasoreagibility, change in the dosage of existing medication within the last 7 days before cardiac catheterization, all contraindications against the study medication (see also \""4.2.3 concomitant medication\""), History of significant pulmonary embolism, PDE-5 antagonists (e.g. sildenafil), restrictive or congestive cardiomyopathy, Any medication listed below which has not been discontinued at least 30 days prior to screening. Specific pulmonary vasodilators during cardiac catheterization are allowed., hypersensitivity against the active ingredients as well as supplementaries]"
NCT01179620,Exclusion Criteria,"[Hypersensitivity to study medication, Genetic abnormality or disease of clotting system, Other protocol-defined inclusion/exclusion criteria may apply, Prior major surgery or bleeding]"
NCT01179620,Inclusion Criteria,"[Alter mindestens 18 Jahre, Written informed consent , Patients requiring hemodialysis, Patients requiring anticoagulation therapy during hemodialysis]"
NCT00556270,Exclusion Criteria,"[Schwangerschaft, Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3), Co-administration of monoaminooxidase-inhibitors, COPD, Drug abuse, Hypersensitivity of fentanyl, Atemdepression, Impairment of CNS functions]"
NCT00556270,Inclusion Criteria,"[Patients with severe, chronic pain , Alter mindestens 18 Jahre]"
NCT01255046,Exclusion Criteria,"[patient with a severe or uncontrolled diagnostic and statistical manual of mental disorders (dsm-iv) axis i disorder other than alzheimer's disease, including amnestic disorders, schizophrenia or schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, or post-traumatic stress disorder;, patient suffering from cerebral disturbances following a stroke or a cerebral trauma (if the event occurred within the last 6 months);, participation in any research study within the last 30 days;, patient who has a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine (e.g., addison's disease), immune, neurologic, or hematologic disease as determined by the clinical judgment of the investigator;, patient with significant alcohol or drug abuse as judged by the investigator., patient with a history of hypersensitivity to study drugs;, patient with significant clinically central nervous system illness other than ad (e.g. parkinson's disease, human immunodeficiency virus (hiv) induced dementia, hachinski ischaemic score (his) >4) or dementia complicated by other organic disease or delirium;, brain image (computed tomography (ct) scan or magnetic resonance imaging (mri) done within past 12 months prior to the study) and laboratory tests to exclude secondary dementia or non-alzheimer's dementia;]"
NCT01255046,Inclusion Criteria,"[patient able to participate in all study evaluations and ingest oral medication as indicated;, male or female patient aged ≥ 50 years;, patient has a responsible caregiver who will accompany the patient to all clinic visits during the study;, mmse score between 10-26, inclusive;, probable alzheimer's disease diagnosed by the national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association (nincds-adrda) criteria;, patient and the responsible caregiver have provided written informed consent before undergoing any study procedures., patient has been treated with donepezil 10 mg per day for at least 3 months prior to screening;]"
NCT00158834,Inclusion Criteria,"[children with a documented history of asthma., must have a positive rast or skin prick test., must be able to perform reproducible lung function tests., using inhaled steroids from 100 mcg up to 500 mcg twice daily for at least 1 month before study start., during the treatment period, the patient has to be hyperreactive (defined as pd20 methacholine < 150 mcg) and/or have a cumulative symptom score of 14 based on the daily record card filled in during the last 2 weeks of the run-in period.]"
NCT00158834,Exclusion Criteria,"[received oral corticosteroids within 4 weeks prior to visit 1., admitted to hospital due to a respiratory disease 4 weeks prior to visit 1., clinical or laboratory evidence of a serious systemic disease, or suspected hypersensitivity to corticosteroids, lactose or short/long acting b2-agonists., history of an acute upper or lower respiratory tract infection, middle ear, or sinus infection 4 weeks prior to visit 1., existence of any disorder that affects growth.]"
NCT01837849,Inclusion Criteria,"[patients were classified as nyha class iii-iv, ejection fraction <40%]"
NCT01837849,Exclusion Criteria,"[significant valvular stenosis, blood pressure <95/60 mmhg or >140/90 mmhg, hypovolemia, intravenous administration with rhbnp or dobutamine in the 2 weeks before study entry, serious ventricular arrhythmia (frequent ventricular premature beat of >5 bpm, nonsustained and sustained ventricular tachycardia), shock, hepatic or renal impairment, pregnant and lactating women., acute myocardial infarction]"
NCT00136539,Exclusion Criteria,"[uncontrolled diabetes, prior history of breast cancer unless: diagnosed at least 2 years ago, present cancer is not in a previously irradiated breast, no prior therapy with anthracycline or taxane, no prior high-dose chemotherapy with stem cell or bone marrow transplant., active or severe cardiovascular or pulmonary disease, prior history of malignancy treated without curative intent, pregnant or breast-feeding women, peripheral neuropathy of any etiology that exceeds grade 1, uncontrolled infection, excisional biopsy, sentinel node dissection or axillary node dissection.]"
NCT00136539,Inclusion Criteria,"[creatinine < 1.5mg/dl, patients must have stage ii or iii histologically diagnosed breast cancer, eastern cooperative oncology group (ecog) performance status of < 1, primary invasive breast cancers that overexpress the her2/neu oncogene, age older than 18 years, bilirubin < 1 x upper limit of normal (uln), normal cardiac function and electrocardiogram (ekg) showing absence of ischemic changes or ventricular hypertrophy, white blood cell (wbc) > 4000/mm3, platelet count > 100,000/mm3, sgot < 1 x uln]"
NCT00968201,Exclusion Criteria,"[patient required a visit to the emergency room due to an asthma exacerbation, or has been hospitalized for asthma with in 1 month prior to the study, patient had used inhaled, nebulized, intramuscular, or intravenous steroids with in 1 month before study, patient and/or parent of guardian intends to move or vacation away from home during the course of the study, patient had active sinus disease within 3 weeks before the study, patient had any major surgical procedure within 4 weeks before the study, patient is hospitalized, patient had required intubation for asthma in the past]"
NCT00968201,Inclusion Criteria,"[patient is in otherwise good stable health, patient has history of physician diagnosed asthma, patient is able to chew a tablet]"
NCT00144963,Inclusion Criteria,"[patients with prior history of stem cell transplant are eligible if they meet all other eligibility requirements., previously treated, relapsed or refractory all (including lymphoblastic lymphoma and burkitt's subtypes) with measurable disease., negative pregnancy test in females of childbearing potential., all ages are eligible. those aged 12 years or older may be counted towards the mtd in the phase i portion of the trial. pediatric patients are eligible, but must be treated at a dose level previously tested in an adult (one full course)., performance status ≤3 (ecog)., adequate liver function (bilirubin ≤2 x upper limit normal), and renal function (creatinine ≤2 x upper limit normal).]"
NCT00144963,Exclusion Criteria,"[prior history of hypersensitivity reactions to vincristine or any of the other components of vsli., active serious infection not controlled by oral or intravenous antibiotics., pregnant and/or lactating women; or fertile men or women not willing to use contraception., history of active neurologic disorders unrelated to chemotherapy (including familial neurologic diseases and acquired demyelinating disorders)., known cns leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy or with cns neuropathy limiting evaluation of study drug. patients with controlled cns disease (no progression signs or symptoms at the time of study entry) may be eligible after approval by the principal investigator. lumbar puncture not required in asymptomatic patients., concurrent treatment with other anti-cancer agents other than dexamethasone., prior history of grade 3 or 4 sensory or motor neuropathy related to chemotherapeutic treatment, or persistent grade 2 or greater active neuropathy., treatment with any investigational agents or chemotherapy agents in the last 21 days before study entry, unless full recovery from side effects has occurred or the patient has rapidly progressive disease judged to be life threatening by the investigator.]"
NCT02269982,Exclusion Criteria,"[4. unwillingness to be followed longitudinally for serial ctc biomarker studies., 2. treatment with an anthracycline or mitoxantrone within 1 week of ctc collection, 3. prior docetaxel in the castration resistant metastatic setting.  patients treated with docetaxel for metastatic castration sensitive disease will be eligible., 1. history of intercurrent or past medical or psychiatric illness that would make participation in a blood drawing protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s).]"
NCT02269982,Inclusion Criteria,"[5. evidence of disease progression on or following most recent therapy as evidenced by the following:
• radiographic evidence of disease progression as defined by one or more new bone scan lesions that is not consistent with flare/healing, or growth of soft tissue/visceral metastases to greater than one centimeter (cm) in longest diameter (2 cm shortest diameter for lymph nodes)., 8. ability to understand and the willingness to sign a written informed consent document., 7. age > 18 years., 1. anemia with a hemoglobin <12.0 g/dl, 1. histologically confirmed diagnosis of adenocarcinoma of the prostate.  pure small cell or neuroendocrine tumors of the prostate are not permitted., 5. presence of visceral metastasis on imaging, 3. high lactate dehydrogenase (ldh) above the upper limit of normal, 6. at least two of the following high risk features during screening for rapid disease progression:, 7. patients with a cellsearch ctc > 5 cells per 7.5 ml whole blood (if available as standard of care) are eligible without additional high risk features, 2. clinical or radiographic evidence of metastatic disease., 3. planned therapy with either enzalutamide and/or abiraterone acetate within the coming 6 weeks, 2. elevated alkaline phosphatase above the institution upper limit of normal, 4. castrate levels of testosterone (<50 ng/dl) at most recent assessment., 4. prior therapy with either enzalutamide or abiraterone acetate in patients planned to receive the converse therapy.  patients are not permitted if they are continuing on the same therapy or restarting a therapy that they have been exposed to in the past., 6. presence of clinically significant pain requiring opioid analgesia, 8. psa doubling time under 3 months on most recent therapy]"
NCT00001572,Criteria,"[bilirubin less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma or gilbert's disease. sgot/sgpt less than or equal to 3.5 x upper limit of normal., stage iii or iv lymphoma., karnofsky status greater than or equal to 70%., age: patients must be greater than or equal to 18 years old., ability to give informed consent.  ability to return to clinic for adequate follow-up for the period that the protocol requires., serum creatinine less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma., sex distribution: male and female., patients must meet all of the following eligibility criteria:, tissue diagnosis of: follicular small cleaved cell or follicular mixed lymphoma with surface igm, iga, or igg phenotype with a monoclonal heavy and light chain. pathology slides must be submitted to the nih pathology department for review., life expectancy of greater than 1 year., a single peripheral lymph node of at least 2x2 to 3x3 cm size and accessible for biopsy/harvest.]"
NCT00001572,Exclusion Criteria,"[patients with previous or concomitant malignancy, regardless of site, except curatively treated squamous or basal cell carcinoma of the skin, or effectively treated carcinoma in situ of the cervix., patient unwilling to give informed consent., patients with cns lymphoma (current or previously treated) will not be eligible., any medical or psychiatric condition that in the opinion of the protocol chairman would compromise the patient's ability to tolerate this treatment., prior total body irradiation., presence of antibodies to hiv or hepatitis b surface antigen or other active infectious process., pregnant or lactation.  fertile men and women must plan to use an effective contraception. a beta-hcg level will be obtained in women of child-bearing potential., the presence of any exclusion criteria (listed below) will prohibit entry onto study:]"
NCT01119261,Exclusion Criteria,"[severe cognitive impairment, non-eligible subject, presence of a mechanical heart valve, pregnancy or lactation, known genotype cyp2c9 or vkorc1 at start of the study, previous or current treatment with any coumarin]"
NCT01119261,Inclusion Criteria,"[ability to attend scheduled visits, signed informed consent, age ≥ 18 years, patients with either venous thromboembolism (vte) or atrial fibrillation (af) requiring coumarin therapy for at least 12 weeks and a target inr in the low intensity range (inr range 2-3 in the united kingdom, sweden, germany, austria and greece and inr 2.5-3.5 in the netherlands)]"
NCT00977275,Inclusion Criteria,"[lymph node staging by sentinel node excision or axillary dissection confirms node negative status (if node positive, implant is used to deliver boost to tumor bed), low risk of multifocal disease within the breast whose tumor location is favorable for brachytherapy catheter placement, location of primary tumor is not immediately adjacent to the nipple of chest wall, 18 years of age or older, no lymphatic or vascular invasion, diagnosis of invasive breast carcinoma (biopsy or fine needle aspiration cytology) and be clinical stage t1n0 (primary tumor < 2cm, clinically negative nodes), assessment of final surgical margins should be predominantly negative, but a single small region of focal positivity is allowable as it is for whole breast radiation, all histologic types and pathologic grades of primary tumor, no extensive intraductal component (substantial intraductal carcinoma away from the primary tumor location), no evidence of two or more separate tumors within the breast]"
NCT00977275,Exclusion Criteria,"[tumor is too close to the chest wall to allow placement of catheters, contraindications to radiation therapy are present, including a history of scleroderma, systemic lupus or other active connective tissue disease, pregnancy, or prior chest wall radiation]"
NCT00251706,Inclusion Criteria,"[informed consent, non-emergent coronary artery bypass surgery or valve replacement or repair]"
NCT00251706,Exclusion Criteria,"[prolonged qt interval, clinical hypo- or hyperthyroidism, myocardial infarction within two weeks, history of sustained atrial tachyarrhythmias, any heart rhythm other than sinus, treatment with amiodarone within 3 months, advanced conduction system disease, sinus bradycardia (less than 50 bpm) while awake, requirement for antiarrhythmic drug therapy, class iv congestive heart failure, women of child bearing potential]"
NCT00004038,Criteria,"[platelet count greater than 100,000/mm3, creatinine less than 1.8 mg/dl, at least 3 cutaneous or subcutaneous lesions required, hemoglobin greater than 8 g/dl, not pregnant, patient characteristics:, at least 6 months since radiotherapy to lesions that are to be injected, pt/ptt within normal range, performance status: ecog 0-2, prior adjuvant radiotherapy to the chest wall allowed, age: over 18, recovered from prior therapy, histologically confirmed epithelial breast cancer, at least 4 weeks since prior chemotherapy, if starting a new regimen, at least 4 weeks since radiotherapy, concurrent cytotoxic chemotherapy allowed, if stable and responding, sgot/sgpt less than 2 times upper limit of normal, bilirubin less than 2 mg/dl, fertile patients must use effective contraception during and for 3 months after therapy, prior concurrent therapy:, measurable disease that includes, but is not limited to, cutaneous or subcutaneous metastases, absolute granulocyte count at least 1,500/mm3]"
NCT01885403,Exclusion Criteria,"[patients with carbon monoxide toxicity, participants in whom positive airway pressure (pap) therapy is medically contraindicated., postpartum cardiomyopathy, lactation, resting respiratory rate >30 breaths per minute, uncontrolled hypertension (systolic ≥200 mm hg/diastolic ≥120 mm hg), active participation in another interventional research study, implanted pacemaker / cardiac resynchronization therapy (crt) / implantable cardioverter-defibrillator (icd) except for medtronic devices with opti vol algorithm, incompetent patients or patients who, in the judgment of the investigator, are too unstable or are otherwise not capable of performing study procedures, patients with severe sepsis, primary mitral valve stenosis, Hypertrophic cardiomyopathy (obstructive or non-obstructive), patients chronically classified (prior to admission) as new york heart association (nyha) class iv or american heart association class d heart failure, patients requiring more than 50 percent supplemental oxygen or patients requiring more than 4 lpm oxygen, surgery of the upper airway, nose, sinus or middle ear within the last 90 days, major medical or psychiatric condition that would interfere with the demands of the study or the ability to complete the study., patients requiring mechanical ventilation or patients with an artificial airway (endotracheal or tracheostomy tube), pregnancy, patients with persistent ventricular arrhythmias, unable to use pap therapies due to physical issues (e.g. facial structural abnormalities) or cognitive issues (e.g. dementia), patients with glomerular filtration rate (gfr) <30 or obligatory dialysis]"
NCT01885403,Inclusion Criteria,"[systolic blood pressure >80 mm hg at time of enrollment, able and willing to provide written informed consent or not able to give informed consent because of mechanical respiration, left ventricular ejection fraction (lvef) < 40 percent in 3d- echocardiography, resting pulse oximetry (spo2) at the time of enrollment of at least 88 percent at 21 percent iron oxides (feo2), males and females, ages 18-75, agreement to be measured with the study devices according to study protocol by patient or legal representative, diagnosis of acute or chronic decompensated heart failure with pulmonary congestion or edema]"
NCT00003736,Criteria,"[sex: female, prior breast cancer allowed if patient meets the greater than 25% lifetime risk, no contraindications to mri scan including patients with pacemakers, magnetic aneurysm clips or other implanted magnetic devices, or severe claustrophobia, patients with greater than 5 years since diagnosis must have at least 50% probability for developing breast cancer by the couch model or be positive for brca1 or brca2 mutation, age: 25 and over, patients at greater than 25% lifetime risk for breast cancer on the basis of family history or a genetic test, not pregnant, other:]"
NCT01260987,Exclusion Criteria,"[known herpes simplex virus infection in treatment areas, patients with pigmented or morphea basal cell carcinomas, patients with gorlins syndrome, patients with known allergy to metvix, Must not be pregnant or breast feeding, patients who are not considered able to follow the treatment protocol, patients with porphyria, patients with a tendency to produce hypertrophic scars or keloids]"
NCT01260987,Inclusion Criteria,"[difficult to treat nodular basal cell carcinomas in the face, fertile women using secure birth control, must be skin type I-III, age 18 or older, moderate to severe actinic keratoses in the face or on the hands,]"
NCT00001984,Criteria,"[availability of donor tissue for testing.  this could include splenic or peripheral blood lymphocytes from a cadaveric donor or a willing living donor enrolled on the clinic center living donor protocol who consents to periodic phlebotomy for peripheral blood lymphocyte isolation., willingness and legal ability to give informed consent, or permission from a legal guardian., willingness to travel to the clinical center for protocol specific samples to be taken, or in some cases, the ability to send samples via overnight mail., candidates for a kidney transplant performed at the warren g. magnuson clinical center.]"
NCT00001984,Exclusion Criteria,"[significant coagulopathy or requirement for anticoagulation therapy that would contraindicate protocol allograft biopsies., chronic hypotension (sbp less than 100 mmhg)., any condition that precludes serial follow-up., platelet count less than 100,000/mm(3)., hla identical status with a living donor., panel reactive antibody greater than 20% due to hla antibodies., any active malignancy or any history of a hematogenous malignancy or lymphoma.  patients with primary, cutaneous basal cell or squamous cell cancers may be enrolled providing the lesions are appropriately treated prior to transplant., any condition that would likely increase the risk of protocol participation or confound the interpretation of the data., ebv negative status receiving an organ from a known ebv positive donor., cmv negative status receiving an organ from a known cmv positive donor., any history of uncompensated cardiac insufficiency, major vascular disease, or symptomatic coronary artery disease., systemic or pulmonary edema., inability to be effectively dialyzed., immunosuppressive drug therapy at the time of or 2 months prior to enrollment. specifically, candidates must not be taking prednisone, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, antilymphocyte agents, cyclophosphamide, methotrexate, or other agents whose therapeutic effect is immunosuppressive., any known immunodeficiency syndrome., hemoglobin less than 9.0 mg/dl.  patients may be on erythropoietin therapy, but will not be placed on therapy solely to facilitate research sample acquisition.]"
NCT00005586,Criteria,"[radiotherapy: concurrent radiotherapy allowed in adjuvant chemotherapy arm provided chemotherapy administered on the once weekly schedule, no positive peritoneal washings, completely resected stage ii or iii colorectal cancer, no distant metastases, other: no clear definite indication for, or contraindication against, systemic chemotherapy with l-leucovorin and fluorouracil, age: 18 and over, no positive resection margins, chemotherapy: no concurrent chemotherapy in observation only arm]"
NCT00003254,Criteria,"[surgery: at least 2 weeks since prior surgery for colorectal cancer and recovered no prior resection of the stomach or small intestine, patients with history of prior malignancy must be currently disease free and off all therapy for that malignancy, performance status: swog 0-2, other: no other concurrent anticancer therapy, not pregnant or nursing fertile patients must use effective contraception, hematopoietic: platelet count at least 100,000/mm3, absolute granulocyte count at least 1,500/mm3, other: must be able to swallow and retain oral medications no nutritional support by gastrostomy feeding tube or parenteral support no intractable vomiting or nausea, endocrine therapy: no concurrent hormonal therapy, disease progression while on fluorouracil adjuvant therapy, bidimensionally measurable disease, radiotherapy: prior adjuvant pelvic radiation or radiation to one area of recurrence allowed at least 4 weeks since prior radiotherapy and recovered total area of bone marrow irradiation must not exceed 25% no concurrent radiotherapy, biologic therapy: no concurrent immunotherapy chemotherapy; at least 3 weeks since prior chemotherapy and recovered; no concurrent flucytosine; no other concurrent chemotherapy, age: over 18, no prior treatment for metastatic disease, hepatic: bilirubin no greater than 1.5 times upper limit of normal (uln) sgot or sgpt no greater than 3 times uln (no greater than 5 times uln if liver involvement), renal: creatinine clearance at least 50 ml/min, prior surgery required]"
NCT00073489,Inclusion Criteria,"[no previous therapy for cll., 18 years or older., expected remaining life span greater than or equal to six months., diagnosis of cll established by bone marrow aspiration and biopsy or flow cytometry of peripheral blood., willingness and ability to sign an informed consent.]"
NCT00073489,Exclusion Criteria,"[evidence of cns involvement., previous therapy for cll., any condition or any medication which may interfere with the conduct of the study., use of an investigational medication or device within one month of initiating study therapy., history of other malignancy which could affect the diagnosis or assessment of osi-461., other active malignancy or history of treatment of any malignancy (excluding non-melanoma skin cancer) within the previous three years., serious uncontrolled intercurrent medical or psychiatric illness, including serious infection., use of steroids at the time of enrollment (patients who require steroids after enrollment may remain on study)., pregnant or nursing women., concurrent immunotherapy.]"
NCT02231268,Inclusion Criteria,"[de novo prescription of gladem, treatment with gladem  intended for at least 6 months, depressive disorders, men and women at least 18 years old]"
NCT02231268,Exclusion Criteria,"[instable epilepsy, patients with restricted liver functions, patients with stable epilepsy, suicidal patients, patients in emotional state and marked sleeping disorders, according to product information (october 1998) gladem should only be prescribed during pregnancy and lactation period, if the expected benefit was greater than the risk. women of childbearing age should use gladem only in combination with sufficient contraception., known hypersensitivity against sertraline, concomitant treatment with monoamine oxidase (mao)-inhibitors, selegiline, moclobemide (washout for at least 14 days necessary), concomitant treatment  with other serotoninergic substances like tryptophan or fenfluramine, according to product information (october 1998) gladem prescription was  possible with precautions in the following  cases:]"
NCT00124072,Exclusion Criteria,"[child bearing potential, no clear contraindication to study treatments, concurrent treatment with cyclosporin (or condition likely to result in organ transplantation and the need for cyclosporin), nefazodone, methotrexate, systemic azole antifungal or systemic macrolide antibiotics, no other predominant medical problem (other than coronary heart disease [chd]) which might limit compliance with 5 years of study treatment, concurrent treatment with fibrates or high-dose niacin, inflammatory muscle disease, chronic liver disease, screening plasma total cholesterol <3.5 mmol/l  in patient already on statin therapy, or <4.5 mmol/l in patient not on statin therapy, severe renal disease or evidence of renal impairment]"
NCT00124072,Inclusion Criteria,"[no clear indication for folic acid, statin therapy indicated, prior myocardial infarction]"
NCT00150878,Exclusion Criteria,"[renal failure (creatinine > 200 µg/ml), aml with t((8;21), contraindications to receive prescribed study medication, concomitant neurological or psychiatric disease, clinically relevant heart failure (nyha ii-iv), liver function failure (bilirubin > 3 mg/dl), aml with t(5;17), pregnancy, hiv infection]"
NCT00150878,Inclusion Criteria,"[hla-matched related or unrelated donor available (in case of high-risk     disease), age 18 to 60, standard-or high-risk marrow cytogenetics, consent of donor to donate peripheral blood stem cells, sufficient liver function (elevation of transferases < 2.5 x upper limit), informed consent, diagnosis of acute myeloid leukemia in first remission]"
NCT00121550,Inclusion Criteria,"[patients aged 18 to 85 years and, signed informed concent, previous or present angina pectoris and, previous acute myocardial infarction (ami) or]"
NCT00121550,Exclusion Criteria,"[breast feeding women, individuals incapable of managing own affairs or not able to sign written consent, participation in other clinical trials within one month before this trial, earlier inclusion in the claricor trial or participation in another drug trial within four weeks, revascularisation (ptca or cabg) within the preceding six months, treatment with methylxanthines, carbamazepine, cisapride, astemizole, terfenadine, or coumarin anticoagulants, intolerance to macrolides, lack of written consent, active malignancy, ami or unstable angina pectoris within the last three months, women of childbearing age not using reliable contraceptives, severe heart failure (new york heart association (nyha) functional class iv), known impaired renal or hepatic function]"
NCT00543829,Exclusion Criteria,"[previous cytotoxic treatment for any condition., active infection or other significant illness that could influence tolerability of treatment., psychiatric illness or drug addiction that would preclude obtaining informed consent., locally advanced (stage t4), bilateral, metastatic, or inflammatory breast cancer (tethering or dimpling of the skin as well as nipple inversion may not easily be interpreted as skin infiltration). if one of these conditions is suspected it has to be excluded before enrollment onto study., preexisting neurotoxicity greater than grade ii (who)., current treatment with sex hormones (treatment has to be discontinued before the start of systemic therapy)., previous treatment for breast cancer, including surgery, radiation, cytotoxic or endocrine treatments. surgical diagnostic procedures are allowed., previous malignancy other than breast cancer or non-invasive breast lesions if the disease-free interval is less than 10 years.]"
NCT00543829,Inclusion Criteria,"[karnofsky index >=70%., negative pregnancy test and appropriate non-hormonal contraception in fertile women., anamnestic and electrocardiographic evidence of normal cardiac function, without or with medication. normal cardiac function measured by echocardiography or muga-scan., adequate haematologic, renal and hepatic function (wbc >4000, platelets >100000, bilirubin, serum creatinine and transaminases within the normal range)., age >= 18 years and <= 70 years., written informed consent and presumed compliance of the patients., life expectancy at least 10 years, ignoring the diagnosis of cancer., no evidence of distant metastases (as confirmed by chest x-ray, liver ultrasound and bone scintigraphy), bidimensionally measurable tumour, either by mammography or breast ultrasound or breast mri, primary tumour >= 3 cm in largest diameter. in patients with multifocal or multicentric breast cancer the largest lesion should be measured., unilateral primary carcinoma of the breast, confirmed histologically by core-cut needle or incisional biopsy. fine needle aspiration is not sufficient.]"
NCT00572013,Inclusion Criteria,"[at least 19 years of age, subjects without serious disease or condition that, in the opinion of the investigator, would compromise the subject's ability to participate in the study., subjects with out history of t-cell lymphoma, non-pregnant and non-lactating women, expected survival  of at least 6 months, male or female subjects of reproductive potential who are able to follow accepted birth control measures., any low-grade b-cell, cd20 positive, non-hodgkin's lymphoma that is felt to otherwise be a transplant candidate (relapsed, induction failure, first pr or cr). specifically: small lymphocytic, marginal zone, mantle cell, and follicular histologies., who performance status greater or equal to 2, signed written informed consent]"
NCT00193089,Inclusion Criteria,"[adequate bone marrow, liver and kidney function, no previous chemotherapy for metastatic disease, measurable disease, age > 18 years, must give written informed consent prior to entering this study., one or more previous hormonal therapies for metastatic disease., metastatic breast cancer confirmed by biopsy, overexpression of the her-2 oncogene, able to perform activities of daily living with minimal assistance, patients with < grade 1 peripheral neuropathy are eligible.]"
NCT00193089,Exclusion Criteria,"[please note:  there are additional inclusion/exclusion criteria.  the study center will determine if you meet all of the criteria.  if you do not qualify for the trial, study personnel will explain the reasons.  if you do qualify, study personnel will explain the trial in detail and answer any questions you may have., brain metastases untreated, pre-existing symptomatic peripheral neuropathy, previous treatment with trastuzumab, abnormal heart function, serious underlying medical conditions]"
NCT00188136,Inclusion Criteria,"[hla-compatible donor (maximum one hla-antigen mismatch), newly-diagnosed aml, either poor risk cytogenetics and/or bad response to the first cycle of ic defined by more than 10% marrow blasts on day 15]"
NCT00188136,Exclusion Criteria,"[no donor, impaired renal function (creatinine > 2 times normal or creatinine clearance < 50% for age, weight, height), female patients who are pregnant or breast feeding due to risks to fetus from conditioning regimen and potential risks to nursing infants, hepatic disease, with ast > 2 times normal, cardiac insufficiency requiring treatment or symptomatic coronary artery disease, severe hypoxemia , po2 < 70 mm hg, with decreased dlco < 70% of predicted; or mild hypoxemia, po2 < 80 mm hg with severely decreased dlco < 60% of predicted, hiv-positive patients due to risk of reactivation or acceleration of hiv replication, age < 16 years > 75 years, life expectancy severely limited by diseases other than malignancy]"
NCT00194896,Inclusion Criteria,"[not receiving more than two oral hypoglycemic agents., hba1c in established patients (on an oral hypoglycemia agent for over 4  months) of greater than 6% and under 10%., fasting c-peptide greater than or equal to 0.8 ng/ml., women must be either post-menopausal or on adequate birth control (i.e. oral contraceptives, tubal ligation, hysterectomy, condoms, or diaphragm) or use abstinence., not taking a thiazolidinedione agent., no history of ketonuria or ketoacidosis., not requiring insulin to achieve glycemic control., age at onset of diabetes - 35-69 years old.]"
NCT00194896,Exclusion Criteria,"[not able to adhere to the protocol., patients receiving systemic corticosteroids., patients with history of chronic pancreatitis or other secondary causes of diabetes., creatinine greater than 1.4 or liver enzymes greater than 2 times the upper limits of normal., patients with severe systemic illness (e.g. recent mi, chf or cerebral vascular disease).]"
NCT00154440,Exclusion Criteria,"[insufficient liver and renal function (see above), primary gastric low-grade malt lymphoma, stages >ii1e or gastric high-grade lymphoma or other lymphoma entities of the stomach e.g. lymphoblastic lymphoma or burkitt’s lymphoma, age < 18 and > 75 years, karnofsky-index < 60%, pregnancy or nursing, hiv-infection]"
NCT00154440,Inclusion Criteria,"[histologically diagnosed, primary gastric low-grade b-cell malt lymphoma stages ie or ii1e, helicobacter pylori-negative (in histology, urease test, and serology) for inclusion into helyx part ii, patients who achieved a study end point of helyx i: partial remission or no change 12 months after successful antibiotic therapy for inclusion into helyx part ii,, written informed consent, age > 18 and < 75 years, karnofsky-index > 60%, complete clinical tumor staging, histologically diagnosed, primary gastric low-grade b-cell malt lymphoma stages ie or ii1e, helicobacter pylori-positive (in histology, urease test , and serology) for inclusion into helyx part i, sufficient liver function, defined as bilirubin < 34µmol/l, sufficient renal function, defined as creatinine < 133µmol/l]"
NCT02177422,Inclusion Criteria,"[age 18 or older, patients who have met the inclusion criteria for the preceding clinical trial of telmisartan. all patients must give a separate written informed consent for participation in the open-label follow-up., patient's written informed consent in accordance with gcp (good clinical practice) and local legislation, mild-to-moderate essential hypertension defined as a mean seated diastolic blood pressure measurement of ≥ 95 mmhg measured by manual cuff sphygmomanometer, a 24-hour mean diastolic blood pressure, measured by abpm (ambulatory blood pressure measurement), of ≥ 85 mmhg, mean seated systolic blood pressure ≥ 140 mmhg, measured my manual cuff]"
NCT02177422,Exclusion Criteria,"[any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan, patients who have developed a medical condition during the preceding clinical trial that, in the investigator's opinion, may be worsened by treatment or may compromise the safety evaluation of telmisartan, patients with a clinically significant change in ecg from baseline that was reported as an adverse event during the preceding clinical trial, patients who discontinued the preceding telmisartan clinical trial due to an adverse event]"
NCT00332787,Exclusion Criteria,"[lifetime history of any psychotic disorder, including psychotic depression, does not agree to use an effective form of contraception (i.e., iud, birth control pills, or barrier devices), lifetime history of anorexia nervosa or bulimia, pregnant or breastfeeding, a first degree relative has bipolar i disorder, previous adequate treatment with fluoxetine was ineffective (defined as at least 20 mg/day for 4 weeks), diagnosis of bipolar i or ii disorder, currently taking medication with psychotropic effects (i.e., anticonvulsants, steroids, etc.), other than stable stimulant treatment, history of alcohol or substance abuse or dependence within 6 months of study entry, any chronic medical illness requiring regular medication]"
NCT00332787,Inclusion Criteria,"[currently attending school, diagnosis of non-psychotic major depressive disorder (mdd), normal intelligence, currently being treated on an outpatient basis, duration of illness is at least 4 weeks, in good general medical health]"
NCT00207428,Exclusion Criteria,"[presence of concomitant acute or chronic severe diseases, age younger than 16 years old, long-term history of smoking, allergy or adverse reactions to investigational drug, pregnancy or lactating, abnormal baseline haematology, blood chemistry or urinalysis]"
NCT00207428,Inclusion Criteria,"[out patients, absence of long-term remissions of asthma (lasting more than 1 month), poorly controlled asthma, due to various reasons, non-smokers, bronchial asthma has been known at least for 1 year]"
NCT00697242,Exclusion Criteria,"[chronic alcohol consumption., any acute disease at the moment of entry., any treatment with immunosuppressive or immunostimulant therapy., any vaccination against hepatitis b in the past., administration of any other vaccine(s) or any immunoglobulin during the study period., positive titres for anti hepatitis antibodies, simultaneous participation in any other clinical trial., history of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease., any chronic drug treatment, which in the investigator's opinion, precludes inclusion into the study., elevated serum liver enzymes at two subsequent determinations 14 days apart., history of allergic disease likely to be stimulated by any component of the vaccine., any previous administration of mpl, axillary temperature > 37.5°c at the time of injection.]"
NCT00697242,Inclusion Criteria,"[written informed consent will have been obtained from the subjects., good physical condition as established by physical examination and history taking at the time of entry, healthy male or female subjects between 50 and 70 years old.]"
NCT00001805,Criteria,"[must not have a history of coronary artery disease, ny class ii-iv chf, arrhythmia requiring treatment and any contraindication to pressor therapy., must not have fev1 and fvc less than or equal to 65% of the predicted value., must not have lymphoma., must be greater than or equal to 18 years old and be able to give informed consent., must not have baseline serum albumin of less than 3.0 g/dl., must not have any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results., must not have a history of cns metastasis and/or known seizure disorders, or concurrent malignancy., must not have positive hepatitis b surface antigen, hepatitis c antibody or hiv., must have the presence of b3 antigen on the surface of greater than 30% of the tumor cells., must have recovered from the toxic effects of prior chemotherapy or radiation therapy.  at least 3 weeks must have elapsed since the last dose of chemotherapy, hormonal therapy or radiation therapy.  at least six weeks must have elapsed since the last dose of mitomycin c and a nitrosourea., must not have a history of allergic reaction to penicillin., must not have serum neutralizing antibodies to lmb-1., must have an ecog performance status of 0 or 1 and a minimum life expectancy of 3 months., must not have an acute bacterial infection that requires antibiotic therapy (unless infection is completely resolved)., must have normal renal function (creatinine less than or equal to 1.4 mg/dl), sgot and sgpt less than or equal to 2.5 x of the upper limits of normal.  total bilirubin less than 1.5 mg/dl;  agc greater than or equal to 1.5 x 10(3) microliter;  platelets greater than 100,000 per mm(3)., must not be pregnant or breastfeeding.  patients of childbearing potential must agree to use an effective method of contraception.]"
NCT02171351,Inclusion Criteria,"[Suspected insulin-resistance (at least one criteria below):, Hdl-cholesterol < 50 mg/dl (female); < 40 mg/dl (male), hba1c : 6-10%, Type 2 diabetes for at least 12 month, Waist circumference > 80cm (female); > 94cm (male), Triglycerides > 150 mg/dl, Low background physical activity (ricci-gagnon score < 27), Treatment by oral hypoglycemic agents and/or glp1 agonists]"
NCT02171351,Exclusion Criteria,"[Type 1 diabetes, Treatment with insulin, Pace maker, Seizure]"
NCT00001759,Criteria,"[no evidence of lung disease other than asthma; no evidence of autoimmune or inflammatory disease which could affect lung function such as lupus erythematosus (except for the control subjects with wegener's granulomatosis)., no breast feeding., control subjects must not have any response to inhaled methacholine with a fall in fev1 in excess of 20% to less than or equal to 25 mg/ml., subjects must have access to a primary medical care provider outside of the nih., control subjects must not have a history of asthma, atopic rhinitis or atopic dermatitis., no allergy to methacholine., asthmatic subjects must not have chronic bronchitis or a diagnosis of chronic obstructive lung disease (copd)., subjects in the negative control group must have no history of asthma or other lung disease., asthmatic subjects must have positive prick skin tests to one or more allergens used., control subjects must have negative prick skin tests to the allergens used., no smoking in the last 3 years, or greater than 6 months of smoking in the past ten years., asthmatic subjects must have asthma as defined in this study., negative pregnancy test within two days of the scan and willingness to adhere to reliable birth control until the completion of the protocol., no history of coronary artery disease., no antihistamines one week prior to the skin test on the first visit., subjects must be able to give informed consent., no diabetes, or history of glucose intolerance (e.g., gestational diabetes)., no beta-adrenergic blocking medication., no evidence of either acute (e.g., bacterial or viral pneumonia) or chronic (e.g., bronchiectasis) lung infection., subjects must weigh less than 136 kg.]"
NCT00193037,Exclusion Criteria,"[prior chemotherapy for metastatic breast cancer, receiving herceptin therapy., please note:  there are additional inclusion/exclusion criteria.  the study center will determine if you meet all of the criteria.  if you do not qualify for the trial, study personnel will explain the reasons.  if you do qualify, study personnel will explain the trial in detail and answer any questions you may have., women who are pregnant or lactating., meningeal metastases., pre-existing moderate peripheral neuropathy, history of significant heart disease, no measurable disease (including bone only, pleural effusions, etc.)]"
NCT00193037,Inclusion Criteria,"[able to perform activities of daily living with minimal assistance, adequate bone marrow, liver and kidney function, normal heart function, metastatic breast cancer confirmed by biopsy, prior adjuvant/neoadjuvant treatment allowed, measurable disease, written informed consent, age 18 years or older]"
NCT00967161,Inclusion Criteria,"[40 patients between the ages of 50 and 75 yrs undergoing unilateral total knee replacement for non-inflammatory degenerative osteoarthritis will participate, as well as 10 control participants will be recruited from the general population for the present study matching to experimental groups for age, gender and bmi.patients who do not meet any exclusion criteria.]"
NCT00967161,Exclusion Criteria,"[6. patients requiring structural bone grafts., 3. patients with evidence of active infection., 5. patients with neuropathic joints., 8. patient with a bmi larger than 30 kg/m2., 1. patients suffering from any other lower-limb joint disorders other than the one for which total knee arthroplasty., 2. patients with any other joint replacement in the ipsilateral and contralateral limb., exclusion for patient group, 7. patients with a documented allergy to cobalt chromium molybdenum., 4. patients with neurologic or musculoskeletal disease that may adversely affect gait, weight-bearing or quadriceps function., potential participants for the control group will be asked if they have had degenerative osteoarthritis of lower-limb joints (hip, knee and ankle) and if they have they will be excluded.]"
NCT01202084,Exclusion Criteria,"[presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatological, neurological, psychiatric or chronic respiratory disease other than asthma, use of oral or parenteral corticosteroid within the 3 months prior to study beginning, chronic use of β-blocker medications, per routine oral or intravenous route, or also as ophthalmic solutions, presence of active smoking, defined as the use of cigarette, pipe, cigar or any form of smoking at any amount within the last 3 months, recent (< 6 months) or predicted participation during this study in other clinical studies involving drugs of any nature or in studies of any form of intervention for treating asthma, intolerance or allergy to any of the components of the drugs assessed in the study, pregnancy or lactation, requirement of admission due to asthma within the 3 months prior to study beginning]"
NCT01202084,Inclusion Criteria,"[serum cortisol assessment within normal values., current use of inhaled corticosteroid (beclomethasone dipropionate dose of up to 1000, µg), associated or not with long-term β2-adrenergic agents and breakthrough medication (salbutamol or equivalent), initial fev1 of at least 40% of the predicted normal value, sign the icf, age ≥ 12 years, persistent asthma diagnosis, as per the gina classification (www.ginasthma.com),18 with symptoms for at least 6 months and clinically stable for at least 1 month, with the acq-745 test (see appendix c) ≤ 3.0]"
NCT00227812,Exclusion Criteria,"[taking medications that interact with the study medication (mao inhibitors, anticonvulsants, haloperidol, phenothiazines,selegiline, anesthetics, pregnant or breastfeeding., have other psychiatric diagnoses requiring therapy or medication., currently being treated with bupropion hydrochloride (e.g. zyban)., physically dependent on opiates or alcohol.]"
NCT00227812,Inclusion Criteria,"[willing and able to participate in the 12 week treatment study and one year follow up., meets cocaine dependence by dsm-iv criteria, aged 18-55, meets major depressive disorder or substance-induced depression disorder by dsm-iv criteria., generally physically healthy]"
NCT00046748,Criteria,"[With evidence of poor asthma symptom control at screening (based on patient history) and during the 4 weeks immediately prior to baseline., Receiving high dose inhaled corticosteroid (at least 1000ug beclomethasone dipropionate or equivalent) and a regular inhaled long acting b-2 agonist for at least 3 months prior to screening and prior to at least two independent asthma exacerbations requiring unscheduled clinical intervention with a systemic corticosteroid in the past year or the severe asthma exacerbation requiring the hospitalization/er visit., Demonstrating 12% increase in fev1 over baseline value within 30 minutes of taking up to 4 puffs  salbutamol (albuterol) or nebulized salbutamol up to 5mg (or equivalent of alternative b-2 agonist) documented within the past year, at screening, during the run-in period or at baseline prior to randomization., With total serum ige level 30 to 700 iu/ml., 1. pef or fev1< 60% of predicted/personal best, or patient is too breathless to provide pef., Who are receiving an ics dosage > 1000ug beclomethasone dipropionate or  equivalent and a regular inhaled long acting b-2 agonist for the last 4 weeks of the run-in period and at randomization (to be maintained throughout the study)., 3. requiring treatment with systemic corticosteroids, With a positive prick skin test (diameter of wheal > 3 mm) to at least one perennial allergen (e.g. dust mite, animal dander, cockroaches), within the past 5 years or at visit 1, to which the patient will be exposed on a regular basis (most days) for the duration of the study. a rast test may be performed for patients with a borderline skin prick test result., Who have either experienced at least two independent asthma exacerbations requiring unscheduled clinical intervention with a systemic corticosteroid in the past year., Whose asthma medication remains unchanged in the final 4 weeks of the run-in period (to be maintained throughout the study)., Been admitted to hospital (including intensive care unit) or received emergency room (including urgent care centers) treatment in the past 12 months for an asthma exacerbation, which in accordance with the gina guidelines met all of the following criteria for a severe exacerbation:, 2. no improvement after initial treatment and therefore requiring repeated treatment with inhaled b-2 agonist (high dose, spacer or nebulized)., With fev1 40-80% of predicted normal value for the patient (demonstrable at least 6 hours after short acting b-2 agonist use or 12 hours after long acting b-2 agonist use) at baseline.]"
NCT00184769,Inclusion Criteria,"[to be included in the trial, patients must meet all of the following inclusion criteria a.)-c.):, a.) male or female infants with a chronological age of 12 ± 3 months, appropriate metabolic control for severe hyperparathyroidism, hydroelectrolyte balance, acid-base balance and calcium-phosphorus balance, conservative treatment or chronic peritoneal dialysis, c.) growth retardation documented at the start of the trial, according to the following criteria: length less than -2 sds by chronological age and sex and linear growth velocity <p50 according to the hernández standards and to lubchenko in the case of infants born prematurely (<37 weeks), optimal nutritional management criteria met, patients will be infants of both sexes aged 12 ± 3 months with chronic renal insufficiency and growth retardation., b.) chronic renal insufficiency with glomerular filtration rate less than 60 ml/min./1.73m2, according to the method used routinely in each participating center, the parent or guardian must give informed consent to the child's participation in the study before any trial related activities. trial related activities are any procedures that would not have been performed during the normal management of the subject, euthyroid]"
NCT00184769,Exclusion Criteria,"[any primary endocrinological disorder and severe renal osteodystrophy.other causes, apart from cri, giving rise to growth retardation.hydrocephalus., known or suspected malignancy., renal disease due to the fanconi syndrome or to oxalosis (except if not  under dialysis)., treatment with corticosteroids within the last six months., known or suspected allergy to the trial product or related products.]"
NCT00193050,Inclusion Criteria,"[ability to perform activities of daily living with minimal assistance, be informed of the investigational nature of this study, sign an informed consent form, sentinel lymph node and/or axillary dissection prior to enrollment, adequate bone marrow, liver and kidney function, adenocarcinoma of the breast confirmed by biopsy, female patients >18 years of age, normal cardiac function, chemotherapy naïve or have received prior chemotherapy > 5 years ago]"
NCT00193050,Exclusion Criteria,"[prior chemotherapy or hormonal therapy, history of significant psychiatric disorders, life expectancy of < than 6 months, concurrent trastuzumab therapy, history of significant heart disease, please note:  there are additional inclusion/exclusion criteria.  the study center will determine if you meet all of the criteria.  if you do not qualify for the trial, study personnel will explain the reasons.  if you do qualify, study personnel will explain the trial in detail and answer any questions you may have., history of active uncontrolled infection]"
NCT00697853,Exclusion Criteria,"[any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection., history of chronic alcohol consumption and/or intravenous drug abuse, history of allergic disease or reactions likely to be exacerbated by any component of the vaccine., previous vaccination against hepatitis b., history of significant and persisting hematological, hepatic, renal, cardiac or respiratory disease., administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination., planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after., pregnant or lactating female., hepatomegaly, right upper quadrant abdominal pain or tenderness., administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration/ administration during the study period., a family history of congenital or hereditary immunodeficiency., oral temperature of ≥37.5°c (99.5°f)., use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine., acute disease at the time of enrollment.]"
NCT00697853,Inclusion Criteria,"[free of obvious health problems as established by medical history and clinical examination before entering into the study., a male or female between 15 and 50 years of age at the time of the first vaccination., written informed consent obtained from the subject and/or from the parents or guardians of the subject., if the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or use adequate contraceptive precautions for one month prior to vaccination and up to two months after the last vaccination]"
NCT00109785,Criteria,"[not pregnant, stage t3 t4, n2 or n3 disease, fertile patients must use effective contraception, no history of psychiatric illness that would preclude giving informed consent, 18 and over, male or female, karnofsky 80-100%, histologically confirmed locally advanced breast carcinoma]"
NCT02071927,Exclusion Criteria,"[treatment with an unapproved, investigational agent within 21 days of the first dose of study drug, conditions that could interfere with treatment and procedures, patients with acute promyelocytic leukemia (apl), active gvhd, allogeneic hematopoietic stem cell transplant or donor lymphocyte infusion within 90 days prior to to the first dose of study drug, unable to receive medications by mouth, any other current malignancy, significant neurotoxicity/neuropathy (grade 3 or higher) within 14 days prior to day 1, major surgery within 28 days before cycle 1 day 1, refractory nausea and vomiting or other situation that may preclude adequate absorption, uncontrolled, active infection; patients who are known to have hiv infection/seropositivity, hepatitis a, b, or c, or cmv reactivation]"
NCT02071927,Inclusion Criteria,"[peripheral blood blast count must be ≤ 30,000 cells/µl., all patients must have bone marrow involvement of their tumor, with documented blast percentage of > 5%., adequate hepatic, renal, and cardiac function, diagnosis of aml or all, relapsed or refractory after at least 1 prior treatment regimen.  newly-diagnosed patients ≥ 60 years old who have refused or are considered unfit for standard chemotherapy regimens or stem cell transplantation are also eligible., patients must have no available approved therapies that confer clinical benefit, eastern cooperative oncology group (ecog) performance status of 0-2]"
NCT00014079,Criteria,"[794751: postoperative radiation versus postoperative radiation plus sequential chemotherapy with methyl ccnu and 5-fu, tissue blocks from the primary colorectal cancer must have been received by the ncctg operations office, 784852: no treatment control versus levamisole versus levamisole plus fluorouracil (5-fu), 844652: an intergroup study - an evaluation of levamisole plus 5-fu as surgical adjuvant treatment for resectable adenocarcinoma of the colon, 874651: m/n - a controller evaluation of recombinant interferon-gamma (ifl gm) and 5-fu and folinic acid with or without levamisole as adjuvant treatment for resectable adenocarcinoma of the colon, 894651: a controller phase iii evaluation of 5-fu combined with levamisole and leucovorin as adjuvant treatment for resectable colon cancer, 794604: no treatment control versus 5-fu by portal vein infusion, must have had a resectable adenocarcinoma of the colon or rectum and must have participated in one of the following ncctg randomized clinical trials:, 864751: phase iii protocol for surgical adjuvant therapy of rectal carcinoma: a controller evaluation of (a) protracted-infusion 5-fu as a radiation enhancer and (b) 5-fu plus methyl-ccnu chemotherapy]"
NCT00003694,Inclusion Criteria,"[must not be a candidate for an early allogeneic bone marrow transplant; potential transplant candidates must be counseled about alternative donor transplants and must decline that treatment option, polymerase chain reaction (pcr) positive fusion transcripts for bcr/abl, ecog performance status 0-2, bilirubin =< x upper limit of normal, creatinine =< 1.5 mg/dl, patients must meet one or more of the following criteria:, no prior treatment for cml with agents other than hydroxyurea; thus, prior treatment for cml with agents such as interferon, busulfan or cytarabine will render patients ineligible, non-pregnant and non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control, bcr/abl protein detectable by immunoblotting, no previous therapy with homoharringtonine (hht), histologic diagnosis of chronic myelogenous leukemia (cml) in chronic phase; patients in either accelerated or blastic phases are not eligible; clonal cytogenetic evolution alone does not exclude patients, registration within eight weeks of the diagnosis and confirmation of ph+ or bcr/abl+, cytogenetically determined philadelphia chromosome (ph+), bcr/abl translocation present by fluorescence in situ hybridization (fish), no more than eight weeks of prior hydroxyurea therapy]"
NCT00001507,Exclusion Criteria,"[any patient testing positive for hiv (aids) or hepatitis b or c will be ineligible., any patient with an active second malignancy (excluding treated skin cancers or carcinoma in situ) will be ineligible., any patient with a need for chronic steroids or anticoagulation will be ineligible., patients with inflammatory breast cancer but with metastatic disease., any female patient known or found to be pregnant will be considered ineligible.  patients of childbearing potential unwilling to practice contraception will be ineligible., any patient may be excluded from this study at the discretion of the principal investigator if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.]"
NCT00001507,Inclusion Criteria,"[anc greater than l000/mm(3)., age greater or equal to 18 years., karnofsky performance status of greater than 70% (ecog 0 or 1)., patients must be able to give informed consent., no history of abnormal bleeding tendency or predisposition to repeated infections., bilirubin less than 1.5 (except in cases of gilbert's disease)., ast and alt less than 3 times the upper limit of normal., all patients must have a histologically confirmed diagnosis of inflammatory breast carcinoma stage iii b.  patients with no clinical inflammatory signs but with tumor invasion of dermal lymphatic on histology are eligible.  patients with metastatic disease and inflammatory breast carcinoma are not eligible.  all pathologic material must be reviewed and confirmed by the department of pathology of the treating institution prior to treatment (there will be no central pathology review)., creatinine clearance of greater than 60 cc/mm., dlco greater than 50%., patients may be untreated or may have received prior induction chemotherapy outside the nci.  if patients received prior induction chemotherapy, they may not have been unresponsive to it.  they may have received chemotherapy either before (neo-adjuvant setting) or after local surgery (adjuvant setting)., ejection fraction by muga or 2-d echocardiogram within institution normal limits., no history of medical or psychiatric disease which would preclude safe treatment in the view of the principal investigator., platelet count greater than 90,000/mm(3).]"
NCT00006346,Criteria,"[no drug abuse dependency disorder, life expectancy: more than 3 months, sex: female, no history of major psychiatric disorders, prior concurrent therapy:, performance status: ecog 0-2, diagnosis of stage ii, iii, or iv breast cancer, no brain or cns metastases, no non-cancer life-threatening illness, age: 55 and over]"
NCT01141439,Exclusion Criteria,"[For the therapy increase patient cohort, any patients receiving a combination inhaler in addition to their separate ics inhaler in the year prior to ipd were also excluded., Had a diagnostic read code for chronic obstructive pulmonary disease (copd) at any time, Had a diagnostic read code for chronic respiratory disease at any time]"
NCT01141439,Inclusion Criteria,"[Evidence of asthma: a diagnostic code of asthma or ≥2 prescriptions for asthma in baseline year at different points in time including one of ics, On current therapy at the ipd, defined as ≥1 ics script and ≥1 other asthma prescriptions in the 12 months prior to first change in therapy, Had definite dosing instructions, Have at least 1 year of up-to-standard (uts) baseline data before ipd, aged 5-60 years, Have at least 1 year of uts outcome data after ipd.]"
NCT02177448,Inclusion Criteria,"[blood pressure is measured 3 times or more during the 4-week observation period; the last 2 measurements in the sitting position (intervals between measurements must be less than 4 weeks) are stabilized for both of systolic pressure (within +/- 30 mmhg) and diastolic pressure within +/- 15 mmhg) with the mean exceeding 160 mmhg for systolic and 95 mmhg for diastolic pressure, outpatient. change to inpatient is not allowed during the study period, patient is ≥ 25 years of age]"
NCT02177448,Exclusion Criteria,"[patient has a history of severe cardiac failure, unstable angina, or myocardial infarction within previous six months, patient has renal dysfunction (serum creatinin ≥ 2.1 mg/dl), patient has uncontrolled diabetic (either of the following tests exceeds the specified standards: fasting blood glucose exceeding 151 mg/dl or hba1c exceeding 8%), patient has severe hypertension (the last 2 measurements in the observation period exceed 120 mmhg in terms of diastolic blood pressure), patient has hyperkalemia (k exceeding 5.5 meq/l), patient has received treatment with any other investigational drug(s) within three months of the start of observation period, patient has secondary or malignant hypertension, patient has any symptoms of cerebrovascular disorder, patient has received enalapril just before the start of observation period, patient has atrioventricular conduction disturbance, atrial fibrillation or severe arrhythmia, patient has serious hepatic dysfunction (either got (glutamic-oxaloacetic transaminase) or gpt (glutamic-pyruvic transaminase) exceeds 100 u), patient has a history of drug sensitivity to ace (angiotensin converting enzyme) inhibitors and angiotensin ii receptor antagonists, patients is pregnant, breast-feeding, or possible pregnant, or wants to be pregnant during the study period, patient has any other condition that the investigator or subinvestigator feels would be inappropriate for the study participation, patient has a history of angioedema due to ace inhibitors]"
NCT00001854,Criteria,"[an important group of patients who were enrolled in the current study, were patients who participated in the clinical research protocol 98-dk-0003 (combination of alpha interferon with long-term ribavirin for patients with chronic hepatitis c) and who did not have a sustained virological response to this treatment.  these patients were eligible to enroll into the current study once they had finished the therapy and follow up period in that trial.  these patients fit the inclusion criteria listed above with one exception: some patients were receiving ribavirin monotherapy as a part of their participation in 98-dk-0003.  these patients were eligible to be immediately enrolled into this study without a medication-free period in between., age above 18 years, male or female., contraindications to the use of alpha interferon, either in the form of specific contraindications to its use (depression, psychiatric illness, neurological impairment, severe thrombocytopenia, autoimmune disease), or the history of severe side effects or intolerance during a previous course of alpha interferon, or lack of a sustained virological (sustained lost of hcv rna from serum for more than six months after stopping treatment) response to an adequate course (6 months) of the combination of alpha interferon and ribavirin or (after september 1, 2003) the combination of peginterferon and ribavirin., presence of anti-hcv and hcv rna in serum tested at least once during the previous six months., inclusion criteria for patients in 98-dk-0003:, evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a histology activity index of at least 6 (out of a maximum of 22)., written informed consent., elevated alanine (alt) or asparate (ast) aminotransferase activities averaging at least twice the upper limit of normal on three determinations taken at least one month apart during the previous 6 months.  the mean of these three determinations will be defined as \""baseline\"" alt and ast levels.]"
NCT00001854,Exclusion Criteria,"[active or recent (within one year) alcohol or drug abuse or psychiatric illness that is likely to interfere with compliance and requirements for safety monitoring during this study., pre-existing anemia (hematocrit less than 32%) or known history of hemolytic anemia., pregancy or, in women of childbearing potential, inability to practice adequate contraception.  men with spouses or sexual partners of childbearing potential also be excluded if they are unable to practice adequate contraception., interferon or immunosuppressive therapy within the last 6 months., evidence of another form of liver disease in addition to viral hepatitis, such as autoimmune or alcoholic liver disease., significant systemic illnesses other than liver disease, including a history of congestive heart failure, cerebral vascular disease, renal failure (creatinine clearance less than 50 ml/min), and angina pectoris., patients with an abnormal stress test or carotid untrasound will not be enrolled into this study.]"
NCT00148135,Exclusion Criteria,"[4. men < 50 years of age presenting with predominant mediastinal and/or retroperitoneal nodal involvement and biopsy showing undifferentiated or poorly differentiated carcinoma., 3. women presenting with predominant peritoneal carcinomatosis, the following groups of patients will not be eligible for the study as they represent populations of patients with cup for whom more specific  treatment approaches are available:, 1. patients presenting with squamous carcinoma isolated to middle and   high cervical lymph nodes, no concurrent chemotherapy, biological or radiotherapy is allowed., patients with brain metastasis are not eligible., pregnant or lactating women are not eligible. women and men of  childbearing potential must agree to use effective contraception throughout the treatment period, and for six months after treatment has been discontinued., patients with previous invasive malignancy within the preceding 5 years are ineligible unless clinicopathologic information regarding the current neoplasm is clearly discordant from prior disease.  patients with non-melanoma skin cancer or in situ cancer of any site are eligible., 2. women presenting with isolated axillary lymphadenopathy]"
NCT00148135,Inclusion Criteria,"[laboratory evaluation including serum beta-human chorionic gonadotropin (hcg), serum alpha-fetoprotein for undifferentiated or poorly differentiated carcinomas and serum prostate specific antigen (psa) in men., patients may be previously untreated or have received one chemotherapy regimen provided it did not include carboplatin, gemcitabine or capecitabine., complete history and physical, patients must be at least 18 years of age and have a zubrod performance   status 0-2., directed radiologic evaluation including, at a minimum, computerized tomography (ct) of chest, abdomen and pelvis and bilateral mammography for female patients., histologic or cytologic diagnosis of carcinoma, with clinical evidence of metastasis and the primary site not clear after the following work-up:, patients must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and  federal guidelines prior to the initiation of therapy., patients must have measurable disease. (partial response [pr] - at least a 30% decrease in the sum of ld of target lesions taking as reference the baseline sum ld.), adequate organ function, defined as absolute neutrophil count (anc) > 1500/ul, platelet count of > 100,000/ul, serum creatinine less than or equal to 2.0 mg/dl, serum bilirubin less than or equal to 1.5 mg/dl., pathologic immunohistochemistry studies of the surgical or biopsy specimen, including studies for estrogen receptor/progesterone receptor and psa stains when clinically appropriate., patients must have no serious intercurrent medical or psychiatric illness that would limit their ability to provide informed consent or receive protocol therapy.]"
NCT00006346,Criteria,"[diagnosis of stage ii, iii, or iv breast cancer, performance status: ecog 0-2, no drug abuse dependency disorder, life expectancy: more than 3 months, no brain or cns metastases, age: 55 and over, sex: female, prior concurrent therapy:, no history of major psychiatric disorders, no non-cancer life-threatening illness]"
NCT00201344,Inclusion Criteria,"[patients must have histologically proven nasopharyngeal carcinoma who have just completed curative radiotherapy treatment., patients must give signed informed consent., creatinine clearance ＞ 45ml/min if creatinine ＞ 1.5mg/dl., performance status scale  ecog  grade 0，1., patients must have a complete response, partial response or stable disease assessed 4 weeks after radiotherapy., original stage must be stage iv disease (m0), patients must be younger than 70 year-old., creatinine ≦ 1.5mg/dl and bilirubin ≦ 2.0mg/dl, wbc ≧ 3,000/mm3 and plt ≧ 100,000/mm3,]"
NCT00201344,Exclusion Criteria,"[history of prior malignancy excluding basal cell carcinoma or squamous carcinoma of the skin or in-situ cervical cancer within 3 years of the diagnosis of npc cancer., patients had progressive disease after radiotherapy, pregnancy., patients had completed radiotherapy for more than 7 weeks., patients had evidence of distant metastasis., previous chemotherapy., the presence of life-threatening illness]"
NCT00003088,Criteria,"[3. age > 18. there is no upper age limit for enrollment on this study., 1.3 patients with any erp/pgr status are eligible., 1.2 tumors that are locally advanced at diagnosis are not eligible. this is left to investigator judgment. patients with tumors fixed to the chest wall, peau d'orange skin changes, skin ulcerations, or clinical inflammatory changes (t4 disease) are excluded from this study. dermal lymphatic involvement noted on pathology without clinical inflammatory changes will not exclude a patient from this study., 2.2 surgical resection margins - all tumor should be removed by either a modified radical mastectomy or a segmental mastectomy. node dissection: patients may have had either an axillary node dissection or sentinel lymph node biopsy before beginning treatment on protocol., segmental mastectomy (lumpectomy): although clear margins are preferable, dcis or lcis at the surgical resection margin will not render a patient who has undergone a segmental mastectomy ineligible for this study. invasive tumor at the final resection margin will render a patient ineligible., mastectomy:  there should be no evidence of gross or microscopic tumor at the surgical resection margins noted in the final surgery or pathology reports for patients who have had a modified radical mastectomy. patients with close margins (tumor < 1 mm from margin) are eligible., 2.3  no prior chemotherapy., platelet count > 100,000/mm3, 2.1 <84 days from mastectomy or within 84 days of axillary dissection if the patient's most extensive breast surgery was a breast sparing procedure., 1.1 patients with operable, histologically confirmed adenocarcinoma of the female breast and positive lymph nodes. node positivity may be determined by either an axillary node dissection or a positive sentinel node finding by immunohistochemistry or histology. this includes any patient with one or more positive lymph nodes whose tumors are t0, t1, 2 or 3 and n1, n2, mo. patients with metaplastic carcinoma are eligible. bilateral disease does not exclude patients from entry., 2.4  no prior radiation therapy for this malignancy. patients who received radiation to the breast for dcis are eligible. patients who have had segmental mastectomy will be treated with radiotherapy according to standard procedures in the treating physician's institution after completion of all chemotherapy. patients who have had modified radical mastectomy may also receive radiotherapy at the discretion of the treating physician according to institutional guidelines., 2.5 patients may receive up to four weeks of tamoxifen therapy for this malignancy and still be eligible for study entry. patients who received tamoxifen for purposes of chemoprevention (e.g., breast cancer prevention trial) or for other indications (including previous breast cancer) are eligible. tamoxifen therapy should be discontinued before the patient is enrolled on this study., bilirubin within upper limits of normal, granulocyte count > 1000/mm3]"
NCT00588029,Exclusion Criteria,"[a personal history of breast cancer, lobular carcinoma in situ or atypia., for the prospective acquisition of blood or saliva from control subjects without breast cancer, ineligibility criteria include:, a first degree relative (mother, daughter, sister, father, brother or son) who has been diagnosed with breast cancer.]"
NCT00588029,Inclusion Criteria,"[all subjects must be 18 years or older, for the prospective acquisition of blood, saliva, pleural fluid or cerebrospinal fluid from patients who have or are suspected of having breast cancer or carcinoma in-situ, eligibility criteria include:, any female patient, or any female over the age of 18 accompanying a patient under the care of a physician in the department of urology, department of surgery, or department of medicine., for the prospective acquisition of blood or saliva from control subjects without breast cancer, eligibility criteria include:, any patient with a previous diagnosis of invasive breast cancer who undergoes a palliative procedure related to the presence of a pleural effusion is eligible for the pleural fluid collection aspect of this protocol., any patient with a previous diagnosis of invasive breast cancer with leptomeningeal metastasis who undergoes a routine procedure associated with the collection of cerebrospinal fluid is eligible for the cerebrospinal fluid collection aspect of this protocol., any patient at mskcc with a previously confirmed or suspected diagnosis of malignant or premalignant (e.g., carcinoma in situ) breast disease is eligible for inclusion in the blood acquisition aspect of this protocol., for acquisition of existing breast cancer tissue specimens from the mskcc tissue procurement service, the only criteria are a pathologically-confirmed diagnosis of invasive breast cancer and the availability of corresponding nonmalignant tissue from each case., any patient with a previous diagnosis of invasive breast cancer who undergoes a palliative procedure related to the presence of a pleural effusion is eligible for the pleural fluid collection aspect of this protocol., subjects will be eligible without regard to racial, or ethnic status. attending physicians authorized to obtain informed consent may exercise discretion in excluding individuals for appropriate medical or other (e.g., mentally impaired) reasons., subjects will be eligible without regard to sex, racial, or ethnic status.   it is anticipated that approximately 99% of the patients will be female. attending physicians authorized to obtain informed consent may exercise discretion in excluding individuals for appropriate medical or other (e.g., mentally impaired) reasons., subjects will have no history of preinvasive (carcinoma in situ) or invasive breast cancer., subjects may have received prior hormonal therapy, cytotoxic chemotherapy, radiation therapy, or surgical therapy at mskcc or another institution., if, after pathologic diagnosis, preinvasive or invasive breast disease is not found, patients previously consented for the blood collection aspect of this protocol will not be included., all subjects must be under the care of one or more members of the mskcc breast disease management team at the time of enrollment.]"
NCT00026637,Inclusion Criteria,"[must meet the dsm-iv criteria for major depression., must be willing to provide written informed consent., must have a seizure disorder., must be age 21 to 75 years old., must be compliant, cooperative, reliable, and able to follow instructions, and to visit the clinic on schedule.]"
NCT00026637,Exclusion Criteria,"[have a progressive central nervous system disorder (such as a tumor or multiple sclerosis), or severe hepatic or renal disease (serum creatinine >3 mg/dl)., currently taking an antidepressant medication or seeing a therapist regularly., have current alcohol or other substance abuse disorders or a history of bipolar depression or any psychotic disorder., are pregnant or lactating., are known to be hypersensitive to sertraline., have active suicidal or homicidal ideation.]"
NCT01113866,Inclusion Criteria,"[cardiomegaly, reduced exercise tolerance, impaired or preserved left ventricular ejection fraction, symptomatic congestive heart failure lasting at least six months]"
NCT01113866,Exclusion Criteria,"[chronic renal failure (serum creatinine level > 2.0 mg/dl, >177 micromol/l), diabetes mellitus, primary cachectic states (cancer, thyroid disease, severe liver disease), acute infection, myocardial infarction within the previous 20 weeks, severe chronic lung disease, rheumatoid or other autoimmune diseases, neuromuscular disorders]"
NCT00002700,Criteria,"[newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma with more than 30% blasts in bone marrow, no severe pulmonary disease, no prior chemotherapy, hiv negative (if tested), no prior radiotherapy, no prior surgery, no severe cardiac disease, creatinine less than 2 mg/dl (unless elevation due to leukemic involvement of kidneys), no prior biologic therapy, no other prior malignancy except nonmelanomatous skin cancer, stage i cervical carcinoma, or other curatively treated malignancy, no severe neurological or metabolic disease, Age 15 to 60, bilirubin less than 2 mg/dl (unless elevation due to leukemic involvement of liver), no prior endocrine therapy]"
NCT00005605,Criteria,"[not pregnant, chemotherapy: see disease characteristics, sex: female, histologically proven stage i or ii breast cancer, prior concurrent therapy:, endocrine therapy: see disease characteristics, must be scheduled to receive adjuvant chemotherapy with or without tamoxifen, menopausal status: premenopausal by follicle-stimulating hormone and estradiol levels, age: 35 to 50]"
NCT00343902,Inclusion Criteria,"[ambulatory individuals 18 years and older who had been diagnosed with chf (nyha functional classes ii-iv) for > 3 months, receiving indicated standard therapy (if not contraindicated or intolerant for > 3 months) defined as a diuretic, an ace-inhibitor or an angiotensin receptor blocker (arb) and a beta-blocke, left ventricular ejection fraction (lvef) of ≤ 40 percent, patients with nyha class iii or iv symptoms were also required to receive spironolactone.  doses of these drugs had to be stable for ≥ 3 months, except for diuretics, for which ≥ 1 month of stability was required.]"
NCT00343902,Exclusion Criteria,"[active myocarditis, hemodynamically severe uncorrected primary valvular disease, hypertrophic cardiomyopathy, symptomatic or sustained ventricular tachycardia not controlled by antiarrhythmic drugs or an implantable cardioverter-defibrillator, myocardial infarction, stroke, unstable angina, coronary artery bypass    graft surgery, valvular surgery, or angioplasty < 3 months before randomization, any condition other than heart failure that would be expected to limit exercise (e.g., angina, peripheral vascular disease, pulmonary disease, arthritis, or an orthopedic problem severe enough to limit exercise), nursing mothers, pregnant women and those planning a pregnancy during the study period, restrictive cardiomyopathy]"
NCT02088411,Inclusion Criteria,"[womac-a pain subscale score greater than or equal to 25, knee osteoarthritis confirmed by radiography or tomography, lequesne functional index score of 10-14]"
NCT02088411,Exclusion Criteria,"[known sensitivity to non-steroidal anti-inflammatory drugs (nsaids), use of glucosamine/chondroitin, known sensitivity to paracetamol, history of knee trauma, use of cox-ii inhibitors, history of joint infection, known sensitivity to oral enzymes, history of gastrointestinal diseases, history of intra-articular injection (viscotherapy), history of joint surgery, use of corticosteroids]"
NCT00414687,Inclusion Criteria,"[secondary pulmonary hypertension, mean pulmonary artery pressure equal or above 40 mmhg or primary pulmonary hypertension with a pressure equal or above 30 mmhg while resting during appropriate conventional treatment, written informed consent after having been duly informed about all diagnostic and therapeutic measures involved in the study]"
NCT00414687,Exclusion Criteria,"[myocardial infarction or major cardiac surgery within 3 months prior to baseline, pulmonary venous obstruction, hiv positive, congenital or acquired valvular defects and myocardial function disorders not related to pulmonary hypertension, pulmonary arterial or valvular stenosis, collagenosis, clinical instability at baseline, cerebrovascular events, bleeding disorders or bleeding risk, severe hepatic insufficiency or renal insufficiency, malignant diseases, pregnancy,  female patients of child-bearing potential without adequate contraception and nursing mothers, prior pulmonary embolism, global respiratory insufficiency, obstructive ventilation disorders,  interstitial pulmonary disease]"
NCT00668616,Exclusion Criteria,"[prior radiation, chemotherapy, hormontherapy and immunotherapy, heart infection during the last 6 months or therapeutically not compensated heart failure or cardiac arrhythmias of at least lown ii, bilateral breast cancer or second carcinoma of the breast, afflicted lymph nodes on the cantralateal side and/or afflicted supraclavicular or intraclavicular lymph nodes, patients with more than 3 afflicted lymph nodes, pregnant or breastfeeding women or women of child-bearing age who do not use effictive contrazeptiva, existing clinically relevant peripheral neuropathie, patients with active infections and/or not controlled hypercalcemia, inflammatory breast cancer and/or distant metastases]"
NCT00668616,Inclusion Criteria,"[start of adjuvant therapy not later than 4 weeks after surgery, women with histologically proven breast cancer (pt1/pt2/pt3, pn1, n0), hematology: platelets at least 100xgpt/l, neutrophiles  at least 2xgpt/l, normal liver function as defined by: bilirubine till 1.5 x normal value, sgot/sgpt till 1.25 x normal value, written informed consent, ecog performance status 0-1, negative pregnancy test for patients before menopause and effective contraception, normal kidney function as defined by: creatine till 1.5 x normal value]"
NCT02148250,Inclusion Criteria,"[Willing to be fasting for up to 24 hours, A1c between 7-9.5% within the past month, willing to discontinue oral/injectable non-insulin hypoglycemic agents for minimum of 1 week prior to study, On >200 units of insulin per day (>150 units if also on oral/glp-1 agents), Age 30-65 years, Willing to avoid exercise 48 hours prior to study, Diabetes Mellitus Type 2, Bmi between 25 and 38 kg/m2]"
NCT02148250,Exclusion Criteria,"[Pregnant or actively trying to conceive, Unwillingness to stop alcohol consumption for 24 hours before each study visit, Current transplant recipient, Current diagnosis of active infection, cancer (other than basal cell carcinoma), vascular disease, organ failure, Systemic corticosteroids in preceding 3 months, heavy alcohol consumption (>21 drinks/week men, >14 drinks/week women)]"
NCT02203773,Inclusion Criteria,"[5. subject must have adequate liver function., 2. subjects must have received no prior treatment for aml with the exception of hydroxyurea, allowed through the first cycle of study treatment. note: subject may have been treated for prior myelodysplastic syndrome (excluding hypomethylating agents)., 3. subjects must have an eastern cooperative oncology group (ecog) performance status of 0 to 2., 4. subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 50 ml/min; determined via urine collection for 24-hour creatinine clearance or by the cockcroft gault formula., 1. subjects must have histological confirmation of aml by who criteria and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidity or other factors.]"
NCT02203773,Exclusion Criteria,"[6. subject has received the following within 7 days prior to the initiation of study treatment:
potent cyp3a inducers such as rifampin, carbamazepine, phenytoin, and st. john's wort;
warfarin or requires the use of warfarin and its equivalent drugs, such as phenprocoumon; (due to potential drug-drug interactions that may potentially increase the exposure of warfarin and complications of anticoagulant effect).
cyp3a inhibitors such as fluconazole, ketoconazole, and clarithromycin., 7. subject has a history of other malignancies  prior to study entry, with the exception of:
adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
previous malignancy confined and surgically resected (or treated with other modalities) with curative intent., 3. subject has t(8;21), inv(16) or t(15;17) karyotype abnormalities., 5. subject has known active cns involvement with aml., 8. subject has a white blood cell count > 25 × 10^9/l.  note:  hydroxyurea is permitted to meet this criterion., 9. subject is a candidate for a bone marrow or stem cell transplant within 12 weeks after study enrollment., 2. subject must not have favorable risk cytogenetics as categorized by the nccn guidelines version 2, 2014 for acute myeloid leukemia., 4. subject has acute promyelocytic leukemia (french-american-british class m3 aml)., 1. subject has received treatment with a hypomethylating agent and/or cytarabine for a pre-existing myeloid disorder.]"
NCT02450058,Exclusion Criteria,"[metastatic disease, including metastasis in the ipsilateral supraclavicular lymph nodes, recent myocardial infarction, congestive heart failure, or serious arrhythmia, pregnant or nursing, other malignancy except adequately treated, cone-biopsied in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin, prior chemotherapy or prior cytotoxic regimens or prior hormonal therapy, prior or concurrent ipsilateral or contralateral invasive breast carcinoma within the last 10 years, other serious medical illness requiring medication, uncontrolled infections]"
NCT02450058,Inclusion Criteria,"[lymph node-positive disease with less than 10 involved axillary lymph nodes, platelet count ≥ 100,000/mm³, postoperative regional radiotherapy limited to the remaining breast admitted for patients who received breast-conserving surgery, women with histologically confirmed breast cancer who had undergone radical mastectomy or breast-conserving surgery in addition to full ipsilateral axillary lymph node dissection, wbc ≥ 3,000/mm³, absolute neutrophil count ≥ 2,000/mm³, surgery performed not more than 5 weeks before randomization, written informed consent, ast and alt ≤ 1.5 times uln, bilirubin ≤ 1.5 times upper limit of normal (uln), ecog performance status 0]"
NCT00001384,Criteria,"[patients must have a normal ejection fraction by muga scan and have no angina.  patients should not currently require therapy for cardiac arrhythmias, congestive heart failure, or coronary artery disease., there must be no history of previous malignancy except for cured non-melanoma skin cancer (basal or squamous cell carcinoma), cervical cancer in situ, or a past malignancy that has been inactive for over 5 years.  patients with a prior history of lower stage contralateral breast cancer, treated with surgery, and/or radiation, but not chemotherapy, are eligible for this study., patients and/or their partners must be willing to practice a non-hormonal method of contraception during therapy and for 6 months following therapy., patients with stage iii disease will be eligible to receive this regimen as neo-adjuvant chemotherapy or as adjuvant therapy if surgery was performed prior to patient referral., no pregnant or lactating women., patients will be eligible for study either before or after receiving adjuvant radiation therapy., no patients with allergy to any study medication., patients who are poor medical or psychiatric risks because of nonmalignant systemic disease which would preclude them from being subjected to any treatments in this protocol are excluded., patients must be previously untreated with chemotherapy., the patient must be able to give an informed consent, and to return to nci for treatment and adequate follow-up for the period the protocol requires., patients must be greater than or equal to 18 years of age., patients with bleeding disorders are ineligible for study entry as are patients requiring chronic anticoagulation., absolute granulocyte count greater than 1500 per microliter and platelet count greater than 100,000 per mm(3)., no patients with a history of symptomatic cns disease., performance status (karnofsky scale) must be greater than 70; ecog 0 to 2., liver function tests (sgot, and total bilirubin) should be less than 2x upper limits of normal.  serum creatinine should be less than 1.7 or creatinine clearance should be greater than 45 ml per min.]"
NCT00003577,Criteria,"[no prior cancer except for basal cell carcinoma or carcinoma in situ, no more than 6 weeks since prior surgery to the breast, prior complete excision of tumor required (wide local excision or mastectomy), adequate hepatic function, sex: female, adequate renal function, no prior chemotherapy, renal:, surgery: see disease characteristics, no prior radiotherapy but concurrent radiotherapy allowed, concurrent hormone therapy allowed, Hormone receptor status: not specified, fertile patients must use effective contraception, not pregnant or nursing, adequate bone marrow function, histological confirmation of invasive, early stage breast cancer]"
NCT00724386,Exclusion Criteria,"[patients with a documented hypersensitivity to e.coli derived proteins are excluded., subjects must not be pregnant (females able to have children must have negative pregnancy test and agree to use adequate contraception), no other serious medical condition such as uncontrolled infection that in the opinion of the investigators places patient at undue risk for study treatment, prior breast or chest wall radiation is not allowed unless the proposed site radiation port does not overlap with prior ports]"
NCT00724386,Inclusion Criteria,"[1. patients with locally advanced unresectable stage iiia or iiib;, calgb performance status of 0 - 2, prior palliative radiation to sites of metastases allowed (i.e. bone, brain, lung), platelet count > 100,000/mm3, bilirubin ≤ 1.5 mg/dl, 4 weeks since any prior treatments (excluding hormonal therapy).  concurrent hormonal therapy is not allowed., aged 18 years or older, anc count > 1500/mm3, 3. patients with metastatic disease and uncontrolled locoregional disease are eligible., life expectance of at least 12 weeks, histologically or cytologically confirmed adenocarcinoma of the male or female breast (male or female) with gross, uncontrolled, unresectable breast and/or chest wall disease including:, 2. patients with locally recurrent (including locoregional lymph nodes) disease for which curative surgery is not thought possible, initial laboratory data:, alt (sgpt) ≤ 3 times the upper limit of normal, signed informed consent, creatine ≤ 2.0 mg/dl, prior chemotherapy allowed, except for nitrosoureas and mitomycin chemotherapy or high dose chemotherapy with marrow or stem cell rescue.]"
NCT00010803,Exclusion Criteria,"[currently being treated with psychopharmacological drugs for depression, cancer diagnosed and treated within the past two years (except for skin cancer), baseline white blood count>or=15,000, baseline blood creatinine >2, baseline hematocrit<30, baseline sggt is a marker of liver function (3 x normal>or=90 iu), currently on anticoagulant therapy, taking aricept (or similar agents) for cognitive problems or dementia, participant with class iii - iv congestive heart failure, hospitalized for depression within the last year]"
NCT00010803,Inclusion Criteria,"[willing informant who has frequent contact with the participant, english is their usual language, non-demented participants, willing to participate in a seven-year follow-up trial of ginkgo biloba]"
NCT02164578,Exclusion Criteria,"[CV event with need for oral anticoagulation or dual platelet inhibitor therapy or acute coronary syndrome < 12 month before study entry, Chronic renal failure with egfr < 15 ml/min (mdrd formula), Active clinically significant bleeding, Hepatic disease associated with coagulopathy and clinically relevant bleeding risk, Significant risks for major bleeding, Concomitant treatment of acs with antiplatelet therapy in patients with a prior stroke or a transient ischaemic attack (tia), Pregnant or breast-feeding woman and woman without adequate method of contraception., Hypersensitivity to the active substance, Sustained uncontrolled hypertension: systolic bp > 180 mmhg or diastolic bp > 100 mmhg]"
NCT02164578,Inclusion Criteria,"[Carotid ultrasound showing an imt > 1 mm and plaque of carotid artery, Documented atherosclerotic cvd:, Macroalbuminuria in the absence of other renal diseases, Stable treatment with statins (if tolerated), Coronary angiography showing a coronary artery stenosis of > 50 % or, Left ventricular hypertrophy, Major cardiovascular event in medical history, Type 2 diabetes duration between 2 and 20 years, Increased hscrp (> 2 mg/l but < 10 mg/l) and/or increased pai 1 (> 15 ng/ml), Age 40 - 75 years]"
NCT00006436,Criteria,"[anc greater than or equal to 1000/mm(3), nhl previously untreated with cytotoxic chemotherapy., bilirubin less than 2.0 mg/dl, or total bilirubin less than or equal to 4.5 mg/dl with direct fraction less than or equal to 0.3 mg/dl in patients for whom these abnormalities are felt to be due to protease inhibitor therapy, ast and alt less than or equal to 3x uln (ast and alt less than or equal to 6x uln for patients on hyperalimentation for whom these abnormalities are felt to be due to the hyperalimentation), age greater than or equal to 18 years, platelet greater than or equal to 75,000/mm(3) (unless impairment due to itp), aggressive cd20 positive diffuse large b-cell lymphoma confirmed by laboratory of pathology, nci., ability of patient to provide informed consent., hiv + serology., ecog performance status 0-4, creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than or equal to 50 ml/min, all stages (i-iv) of disease.]"
NCT00006436,Exclusion Criteria,"[primary cns lymphoma., sever intractable diarrhea, pregnancy or nursing., concurrent anti-retroviral therapy during epoch therapy., doxorubicin, etoposide, vincristine and cyclophosphamide are teratogenic and may be excreted in milk., current clinical heart failure or symptomatic ischemic heart disease., previous rituximab, antiretroviral therapy is indicated during pregnancy and nursing., active inadequately treated opportunistic infection of the cns, serious underlying medical condition or infection other than hiv that would contraindicate sc-epoch-r., severe aids-related wasting]"
NCT00193024,Exclusion Criteria,"[males with metastatic breast cancer, please note:  there are additional inclusion/exclusion criteria.  the study center will determine if you meet all of the criteria.  if you do not qualify for the trial, study personnel will explain the reasons.  if you do qualify, study personnel will explain the trial in detail and answer any questions you may have., age < 18 years., cardiac ejection fraction < 45%., women who are pregnant or lactating., history of hypersensitivity reaction to taxotere, moderate peripheral neuropathy, patients with meningeal metastases are ineligible.]"
NCT00193024,Inclusion Criteria,"[able to perform activities of daily living without considerable assistance, received no previous chemotherapy for metastatic breast cancer., metastatic breast cancer confirmed by biopsy., adequate bone marrow, liver and kidney function, must be able to understand the nature of this study and give written informed consent., measurable or evaluable disease., prior hormonal therapy is acceptable.]"
NCT00970983,Inclusion Criteria,"[axillary lymph nodes that cannot be palpated or that are not clinically suspicious for metastasis., those patients with nonpalpable lesions will be subjected to preoperative radioactive occult lesion localization (roll) or stereotactic biopsy., clinical, mammographic or ultrasonographic diagnosis of a unicentric carcinoma with an ultrasonographic diameter of equal or less than 2.0 cm., no previously executed therapy (including biopsy) at any outside institution., adequate patient information and signature of the informed consent., age between 40 and 75 years., although not a factor of exclusion, a breast scintigraphy using mdp-99m is recommended for accurate determination of possible multifocality or multicentricity of the tumor, as well as for the determination of possible bone metastasis.]"
NCT00970983,Exclusion Criteria,"[lesions diagnosed as non-infiltrating (in-situ) ductal or lobular carcinoma., clinically metastatic lymph nodes., patients previously biopsied at other institutions., histotypes diverse from breast carcinoma lesions., history of previous malignancy (excluding basocellular carcinoma, in-situ cervical carcinoma and/or contralateral breast carcinoma without recurrence for at least 15 years of follow-up)., paget's disease., documented multicentricity and/or abundant multifocality of the neoplasm., carcinomas detected during pregnancy or lactation.]"
NCT00001858,Exclusion Criteria,"[any active malignancy.  patients with primary, cutaneous basal cell or squamous cell cancers may be enrolled providing these are appropriately eliminated prior to transplant., inability or unwillingness to comply with protocol monitoring and therapy, including, among others, a history of noncompliance, circumstances where compliance with protocol requirements is not feasible due to living conditions, travel restrictions, access to urgent medical services, or access to anti-rejection drugs after the research protocol is completed., platelet count less than 100,000/mm(3)., significant coagulopathy or requirement for anticoagulation therapy that would contraindicate protocol allograft biopsies.]"
NCT00001858,Criteria,"[candidates for a kidney or combined kidney-pancreas transplant performed at the national institutes of health, or non-uremic healthy volunteers who are not on immunosuppressive medications., for transplant patients, availability of donor tissue for testing.  this could include splenic or peripheral blood lymphocytes from a cadaveric donor or a willing living donor enrolled on the clinical center living donor protocol who consents to periodic phlebotomy for peripheral blood lymphocyte isolation., willingness to travel to the clinical center for protocol specific samples to be taken, or in some cases, the ability to send samples via overnight mail., recipients of kidney or combined kidney-pancreas transplants interested in participation in the recurrent disease allograft registry., previous recipients of kidney or combined kidney-pancreas transplants., willingness and legal ability to give informed consent or permission from a legal guardian.]"
NCT00270400,Exclusion Criteria,"[has a clinical condition expected to require therapy with more than one intravenous vasoactive agent or dopamine during the 24-hour treatment holter monitoring period, cannot tolerate a 24-hour baseline holter monitoring period without intravenous vasoactive medications, and/or cannot tolerate the specified washout period (if applicable) of intravenous vasoactive medications before starting the baseline holter monitoring, has received treatment with dopamine or any intravenous vasoactive medication such as dobutamine, milrinone, nitroprusside or intravenous nitroglycerin for more than 4 hours for the current episode of decompensated chf or related illness, requires an intravenous antiarrhythmic medication during the 48 hours before starting the study, has systolic blood pressure consistently < 85 mm hg, cardiogenic shock, or other evidence of significant hemodynamic instability requiring the immediate institution of inotropic/pressor support]"
NCT00270400,Inclusion Criteria,"[receiving stable doses of oral antiarrhythmic medications (medications that help regulate irregular heart beats) for at least the 48 hours before starting study drug, or receiving no antiarrhythmic medications., history of nyha (new york heart association) class iii or iv congestive heart failure (chf), has symptomatic, decompensated chf for which inpatient therapy with either dobutamine or natrecor®, administered as a single intravenous vasoactive agent (drugs that influence the tone and caliber of blood vessels) with or without diuretics, is deemed appropriate]"
NCT01404013,Exclusion Criteria,"[7. subjects who are diagnosed with past or present disease, which as judged by the investigator, may affect the outcome of this study. these diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease. e.g.nasal-sinus infection, lower respiratory tract infection, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis or bronchopulmonary dysplasia., 2. patients who is a smoker or ex-smoker and has smoked within the previous year or has a cumulative smoking history ＞10 pack-years or equivalence., inhaled/systematic corticosteroid, long-acting β2 agonist, theophylline sustained release., 3. patients with concomitance of gerc (gastroesophageal reflux-related chronic cough), chronic bronchitis , bronchiectasis, bronchial tuberculosis, acei induced cough, bronchogenic carcinoma, psychologic cough, pulmonary fibrosis, bronchus foreign body, microlithiasis, tracheobroncheopathia osteochondroplastica, mediastinal tumor, left ventricular dysfunction., 6. subjects who have received any therapy in the previous seven days, e.g. oral/, 4. female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study., 1. patients demonstrate fev1/fvc ＜70% in lung function test. fev1 stands for forced expiratory volume in 1 second, fvc stands for forced vital capacity., 5. subjects who are known or suspected to be hypersensitive to any component of the study medication or relief medications., 8. subjects who demonstrate significant abnormality on biochemistry, hematology, ecg.]"
NCT01404013,Inclusion Criteria,"[1. patients who have a history of cough as sole or main symptom lasting more than 8 weeks, often irritating cough more cough at night., 2. patients who were diagnosed with positive result in bronchial provocation test by methacholine inhalation challenge., 5. patients who was aged from 18 years old (≥ 18 years old ) to 75 years old (≤ 75 years old)., 4. patients whose chest x-ray outcome was normal or without any active focus., 3. there is evidence that bronchodilator treatment* is efficient for cough symptom (symptom score improved 1 at least).]"
NCT01435902,Inclusion Criteria,"[best pre-bronchodilator fev1 of at least 70%., physically able to perform exercise testing on a treadmill when albuterol has been withheld, females of child-bearing potential must be willing to use birth control or commit to abstinence during the study, ability to withhold albuterol 6 hours prior to visits., outpatient male or female 12 to 50 years of age, diagnosis of persistent asthma for at least 6 months, current use of a low- to moderate-dose inhaled corticosteroid]"
NCT01435902,Exclusion Criteria,"[respiratory infection within 4 weeks of first visit leading to asthma medication change or could affect subjects's asthma status or participation, abnormal, clinically significant electrocardigraph, allergy to study drugs or study drug excipients, inability to comply with requirements of the study, respiratory diseases or other concurrent disease that would put subject at risk or confound results interpretation, asthma exacerbation within 12 weeks of first visit, affiliation with investigator's site (example: family member), investigational medicines within 30 days of first visit or less than five half-lives of medication in prior study, intermittent asthma, seasonal asthma, or exercise-induced asthma only, symptomatic allergic rhinitis and/or thrush, concomitant medications that could interact with study medications or affect the course of asthma, tobacco use within last year and/or a 10 pack-years history]"
NCT00118404,Exclusion Criteria,"[previous failure to experience a reduction in depressive symptoms after 6 weeks of 40 mg of prozac, active alcohol or other substance dependence within 6 months prior to study entry, schizophrenia, unable to attend clinic twice weekly during business hours, bipolar, schizoaffective, obsessive compulsive, or eating disorders, previous failure to experience a reduction in depressive symptoms after 8 weeks of cognitive therapy with a certified therapist, unable to complete questionnaires, pregnancy or plan to become pregnant in the next 11-12 months, unable to stop mood-altering medications, mood disorders due to a medical condition or substance abuse, currently at risk for suicide, current use of medication or diagnosis of a medical disorder that may cause depression (e.g., diabetes, head injury, stroke, cancer, multiple sclerosis)]"
NCT00118404,Inclusion Criteria,"[have experienced at least one period of recovery during a depressive episode or have a history of dysthymia (a mood disorder characterized by depression) prior to the onset of current or past depressive episodes, willing and able to comply with all study requirements, recurrent unipolar major depressive disorder, able to speak and read english, have experienced at least two episodes of major depression]"
NCT01849133,Inclusion Criteria,"[patients with non-palpable lesions will undergo preoperative centering and stereotactic and/or ultrasound-guided cytology (the execution of this last procedure is not mandatory)., clinical mammographic/ultrasound diagnosis of unicentric carcinoma, with ultrasound diameter ≤2.5 cm. advisable, but not mandatory, the execution of mammoscintigraphy with mdp-99mtc (methyl diphosphonate technetium-99m) : this procedure allows the bone staging and the mapping of eventual multi-focality/multi-centricity of the breast neoplasm., no previous therapy (biopsy included) for breast cancer in other institutions., adequate information to the patient and informed consent., age ≥ 48 and < 75]"
NCT01849133,Exclusion Criteria,"[patients who underwent excisional biopsy in other institutions., tumor in close proximity to the skin., paget disease., personal anamnesis positive for malignancy (basocellular carcinoma, in situ carcinoma of the cervix, contralateral breast cancer free of disease after 15 years of follow-up excluded)., histology different from carcinoma., documented multi-centricity/multi-focality of the tumor., general contraindications to regular follow-up or radiotherapy., tumor in the axillary tail., ductal or lobular non-infiltrating carcinoma.]"
NCT00201916,Exclusion Criteria,"[prior or active malignancy other than non-melanoma skin cancer; or colon or thyroid cancer treated a minimum of five years prior to study entry and presumed cured, geographic inaccessibility for follow-up, serious non-malignant disease which would preclude radiotherapy or surgical biopsy, previous therapy for carcinoma of the prostate other than biopsy or turp, including patients previously on hormone therapy for treatment of their prostate cancer, unable to commence radiation therapy within 26 weeks of the date of last prostatic biopsy, simulated volume exceeds 1000 cm3, previous pelvic radiotherapy, psa > 40 mcg/l, inflammatory bowel disease, failure to give informed consent to participate in the study, psychiatric or addictive disorder which would preclude obtaining informed consent or adherence to protocol]"
NCT00201916,Inclusion Criteria,"[histologic diagnosis of adenocarcinoma of the prostate with no evidence of metastatic disease to the nodes, bone or lung, stage t1a moderately or poorly differentiated, t1b, t1c or t2 by the current uicc-tnm classification]"
NCT00271063,Inclusion Criteria,"[adequate renal function, no chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of study drug and recovered from toxic side effects of that therapy, unless treatment is indicated due to progressive disease., no investigational therapy within 4 weeks of first dose of study drug, signed informed consent, age greater than or equal to 15 years, ecog performance status (ps) 0 to 2., diagnosis of refractory or relapsed all (acute lymphocytic leukemia), adequate liver function]"
NCT00271063,Exclusion Criteria,"[pregnant, lactating or not using adequate contraception., cardiac ejection fraction less than 40%, concommitant therapy that includes other chemotherapy that is or may be active against all (except central nervous system [cns] therapy), known allergy to doxorubicin or anthracyclines., any condition which in the opinion of the investigator, places the subject at unacceptable risk if he/she were  to participate in the study., clinically relevant serious co-morbid medical conditions.]"
NCT00001381,Criteria,"[renal: creatinine no greater than 1.5 mg/dl., no significant prostatic obstructive symptoms associated with impaired or incomplete bladder emptying., at least 4 weeks since intravesical treatment, with resolution of any local or systemic toxicity., bilirubin no greater than 1.5 mg/dl;, age: 18 and over., wbc at least 3,300;, medically able to undergo cystoscopy., performance status:  ecog 0 or 1., no pregnant women., hemoglobin at least 10 g/dl., ast and alt no greater than 2 times normal., clinically useful pretreatment bladder function required., at least 1 course of prior standard intravesical therapy required., histologically confirmed superficial transitional cell carcinoma of the bladder pathologically staged as tis, ta, or t1. visible tumors at time of treatment not required. no metastatic disease or muscle invasion., no active urinary tract infection.]"
NCT00476541,Exclusion Criteria,"[juvenile myelomonocytic leukemia (jmml),, myelodysplastic syndrome (mds),, down syndrome (ds),, fanconi anemia,, aml secondary to previous bone marrow failure syndrome,, positive pregnancy test, previous chemo- or radiotherapy,, acute promyelocytic leukemia (apl),]"
NCT00476541,Inclusion Criteria,"[age < 19 years at time of study entry,, aml as defined by the diagnostic criteria,, written informed consent]"
NCT00194701,Inclusion Criteria,"[patients must have had evidence of at least one clinical episode of hf diagnosed by a physician or nurse practitioner as fatigue, shortness of breath, and pulmonary congestion., patients had to have stable hf (defined as no hospitalizations for 3 mos, no medication changes for 1 mo, no dyspnea at rest, and no sustained resting heart rate greater than 95 bpm)., classified by the cardiologist, primary physician, or nurse practitioner as having no dyspnea (shortness of breath, air hunger) at rest but fatigue, dyspnea, or anginal (primarily chest/arm/back/neck) pain or discomfort with either ordinary (new york heart association classification, nyha class ii) or less than ordinary (nyha class iii) physical activity. they could have been class i (no symptoms) if they were originally diagnosed as having nyha class ii or iii but had responded to treatment.]"
NCT00194701,Exclusion Criteria,"[already participating in an exercise program meeting or exceeding the level of activity in this study., routine use of theophylline;, kyphoscoliosis (spinal curvature) to the extent that chest and abdominal bands used in sleep recordings could not be kept in place;, receiving antidepressant therapy;, psychiatric diagnoses of manic depression, dementia, or depression;, diagnosed with pickwickian syndrome, an extreme variant of sleep apnea characterized by severe obesity, respiratory insufficiency, and bi-ventricular failure;, inability to speak/read english;, known atrial fibrillation;, aortic stenosis;, inability to walk without assistance;, unstable angina, myocardial infarction, or cardiac surgery 3 mos prior to study entry;, known obstructive sleep apnea;, current use of nocturnal continuous positive airway pressure (cpap) or oxygen therapy; and, cardiac transplant recipient;]"
NCT00001921,Exclusion Criteria,"[3. criteria for substance dependence met in the last year. if criteria for dependence were met in the past, then the duration of the disorder was less than 3 years, or not judged to have produced long-term brain changes to allow the patient to be in the study., 2. pregnancy (only for purpose of mri procedures under separate protocols), 5. concomitant medications which could interfere with performance on the task., 2. criteria for substance abuse met in the last 6 months., 1. impaired hearing., 4. major concurrent medical illness likely to interfere with the acquisition of the task., 6. presence of dyskinetic movements of the face and tongue (likely to interfere with eyeblink measures), or of gross involuntary movements of the whole body (likely to interfere with positioning in the mri scanner)., 1. coexistence of another major mental illness at the time of the study. if the patients experienced other mental illnesses in the past (e.g. a learning disability or major depression), then this should be judged to be fully recovered., 3. head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma.  patients or healthy volunteers with a known risk from exposure to high magnetic fields (e.g. patients with pace makers) and those who have metallic implants (e.g. braces) in the head region (likely to create artifact on the mri scans) will be excluded from participating in the fmri studies.]"
NCT00001921,Criteria,"[3. there is no upper age limit the lower age limit is 18 years., 1) schizophrenia, any subtype or schizoaffective disorder according to dsm iv, as detailed in protocol # 89-m-0160 (\""inpatient evaluation of neuropsychiatric inpatients\"", dr. jose apud, principal investigator) and # 95-m-0150 (\""a longitudinal investigation of siblings of schizophrenic and manic-depressive patients\"", dr. daniel r. weinberger, principal investigator)., 1. no psychiatric or severe chronic medical illness at the time of the study, and by history. this includes the absence of substance abuse histories, learning disabilities and all dsm iv disorders. the investigators will evaluate medical histories and medical conditions that are judged not to interfere with the study may be allowed., 2. no use of psychotropic substances in the last 3 months.]"
NCT01470937,Inclusion Criteria,"[75 g ogtt 2hr glucose >120 mg/dl, fasting plasma glucose <140 mg/dl, age at least 25 years, bmi > 25 or history of gestational diabetes mellitus or family history of type 2 diabetes]"
NCT01470937,Exclusion Criteria,"[chronic infectious disease (hiv, hepatitis), cancer within 5 years, elevated ast or alt, serum creatinine >1.4 mg/dl (men) or >1.3 mg/dl (women), tg >600 mg/dl, known glucosidase intolerance, inability to comply with protocol requirements., uncontrolled hypertension or requiring beta blockers or thiazide diuretics for control, cvd event within 6 months]"
NCT00178256,Exclusion Criteria,"[patients with myocardial infarction within the preceding six months or symptomatic heart disease, including uncontrolled or unstable angina, uncontrolled congestive heart failure, and uncontrolled arrhythmia., women who are pregnant., patients with medical contraindication to chemotherapy or radiotherapy., patients with small cell carcinoma or mesothelioma]"
NCT00178256,Inclusion Criteria,"[age > 18., a signed informed consent., karnofsky performance status > 70., inoperable stage i (t1-2n0) and ii (t1-2n1, t3n0) disease, or stage iiia (t3n1 andt1-3n2m0) and iiib (txn3m0, t4nxm0) diseases according to the american joint committee of cancer criteria 1998, fev1 sufficient for patients to tolerate radiation therapy which is at the discretion of the radiation oncologist, usually > 800 ml, laboratory values must be obtained < 3 weeks prior to registration., patients who failed prior chemotherapy are eligible. patients with prior radiotherapy to the chest region are eligible as long as the normal tissue tolerance is not violated by repeat radiotherapy., labs: wbc > 3000; platelet count > 100,000; serum creatinine < 1.5 mg/dl or creatinine clearance >60 ml/min., the primary tumor must be radiographically measurable., histologically confirmed lung cancer, excluding small cell carcinoma]"
NCT00983684,Inclusion Criteria,"[operable invasive breast cancer (t1 and small t2, n0-1, m0) confirmed by cytological or histological examination, suitable for breast conserving surgery, available for regular follow-up for at least ten years., note: individual centres may wish to restrict entry to a more exactly defined subset of patients, in which case, only patients with these characteristics may be entered by that particular centre.  for example, centres may decide at outset to recruit only women over 50 or even over 65 years of age.  such policies must be pre-defined in writing and approved by the international steering committee., age 45 years or older, previously diagnosed and treated contralateral breast cancer may be entered but will be randomised to a separate stratum.]"
NCT00983684,Exclusion Criteria,"[ipsilateral breast had a previous cancer and/or irradiation., no more than 30 days can have elapsed between last breast cancer surgery (not axillary) and entry into the trial for patients in the post-pathology stratification., lobular cancer or extensive intraductal component (eic =>25% of the tumour is intraductal) on core biopsy or initial pathology (if performed), more than one obvious cancer in the same breast as diagnosed by clinical examination, mammography or ultrasonography., bilateral breast cancer at the time of diagnosis., patients with any severe concomitant disease that may limit their life expectancy., any factor included as exclusion criterion in the local centre's treatment policy. this is particularly relevant to patients entered into the post pathology stratum., patients presenting with gross nodal disease, considered to be clinically malignant or proven cytologically or by scanning. in general, 4 or more positive nodes or extranodal spread are not suitable for targit alone and should receive ebrt as well. however, individual centres may decide that anything more than micrometastasis should receive ebrt., patients undergoing primary medical treatment (hormones or chemotherapy) as initial treatment with neoadjuvant intent of reducing tumour size should be excluded; those given short duration (up to 4 weeks) systemic therapy can be included., previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years is 90% or greater., patients known to have brca2 gene mutations, but testing for gene mutations is not required]"
NCT00006164,Inclusion Criteria,"[age at entry at least 18 years., previous treatment with any interferon or interferon and ribavirin for at least 3 months., a liver biopsy demonstrating significant liver scarring., documented non-response to treatment with interferon., positive for hepatitis c.]"
NCT00006164,Exclusion Criteria,"[no recent abuse of alcohol or illicit drugs., no major complications of cirrhosis., no other liver disease., no unstable major medical diseases or conditions.]"
NCT00157651,Exclusion Criteria,"[major bleed within last 3 months, patients nephrologist has refused consent, woman of child-bearing age who has not agreed to use an adequate method of birth control for the duration of the study, catheter likely needed for 2 weeks or less, allergic to, or intolerant of, warfarin, pregnant, patient previously took part in the study, active peptic ulcer disease, patient has refused consent, platelet count less than 50 x 10 9/l or current coagulopathy (most recent inr > 1.5, not due to warfarin), patient has known aortic aneurysm of 6cm or greater, taking warfarin for an indication other than access prophylaxis, anticipated need for invasive intervention within next 2 weeks]"
NCT00157651,Inclusion Criteria,[newly placed double-lumen hemodialysis catheter]
NCT00260832,Inclusion Criteria,"[1. must have diagnosed acute myeloid leukemia., 2. must have a life expectancy of at least 12 weeks., 3. must sign informed consent.]"
NCT00260832,Exclusion Criteria,"[3. must not have inaspirable bone marrow., 1. must not have acute promyelocytic leukemia (m3 classification), 8. must not have known hiv., 2. must not have any other active systemic malignancies., 6. must not have received any experimental drug within 4 weeks before randomization., 7. must not be a candidate for a bone marrow or stem cell transplant within 12 weeks after randomization., 4. must not have received previous chemotherapy (except hydroxyurea) for any myeloid disorder., 5. must not have chronic respiratory disease that requires continuous oxygen use.]"
NCT00002720,Criteria,"[histologically proven stage i, invasive breast cancer, Age: 65 to 80, postmenopausal, no serious disease that would preclude surgery, Sex: female, estrogen receptor positive, no other prior or concurrent malignancy except basal cell carcinoma or carcinoma in situ of the cervix]"
NCT00296725,Inclusion Criteria,"[meets dsm-iv criteria for current major depression, dysthymia or depression nos, ages between 18-65]"
NCT00296725,Exclusion Criteria,"[nonresponse to adequate trial of both study medications (i.e., > 4weeks on > escitalopram 30 mg/d, and imipramine 200 mg/d); patients having an inadequate response to one study medication could be enrolled and receive the other; patients having responded to an adequate trial of either study medication would be offered a retrial; also excluded will be subjects having non responded to an adequate trial with citalopram (i.e., > 4 weeks on > citalopram 60 mg/d), known hearing impairment, active suicidal ideation (history of suicide attempts will be evaluated on a case by case basis), hamd > 20, medical condition likely to require intervention contraindicated with study medication (e.g., known arrhythmia likely to be exacerbated by imipramine), current (past six months) alcohol and/or drug abuse or dependence, not currently depressed (whether considered due to current treatment or not), left-handed, premenopausal women not using known effective birth control, if currently taking antidepressants or mood stabilizers, cannot be off psychotropic medication for 7 weeks (10 weeks for prozac) or felt to require other psychiatric medication (other than occasional sleep or anxiety medication), psychosis, bipolar i]"
NCT01360190,Exclusion Criteria,"[subjects with a history of current or past active suicidal ideation, or suicide attempts will be excluded, as will patients who previously have failed to respond to an adequate clinical trial of fluoxetine, or have failed to tolerate the medication., in addition, patients meeting criteria for cluster a or b axis ii diagnoses will be excluded., we will exclude patients also meeting criteria for the following groups of axis i diagnoses:  delirium or dementia, substance-related disorders, schizophrenia or other psychotic disorders, or eating disorders., subjects will have no serious medical illness., subjects who have had suboptimal trials, however, may still be considered for the study.]"
NCT01360190,Inclusion Criteria,"[all subjects will be under the care of a clinician not affiliated with the study at the time of entry into the study, and through the course of the study., all subjects will meet dsm-iv criteria for major depression based upon the structured clinical interview for dsm-iv - patient version (scid-p) (first et al., 1994).  all research personnel have undergone scid-p training, and soon will extend this training to the dsm-iv version., subjects also will have a score on the 17-item hamilton depression rating scale of > 18 (with item #1 > 2).]"
NCT00322673,Inclusion Criteria,"[diagnosis of acute myeloid leukemia (except aml fab-m3 or acute promyelocytic leukemia [apl]) based on the world health organization (who) classification of ≥ 20% blasts in the bone marrow or peripheral blood at initial diagnosis (prior to start of standard chemotherapy), signed informed consent, subjects with newly-diagnosed aml or subjects with relapsed aml after at least 2 chemotherapy regimens., adequate liver and renal function, ecog performance status of 0 or 1]"
NCT00322673,Exclusion Criteria,"[hematopoietic stem cell transplantation within the previous 6 weeks, known hiv, anticancer therapy including chemotherapeutic, biologic, or investigative agents within 30 days of xl999 treatment, pregnant or breastfeeding females, immunosuppressive therapy (eg, cyclosporine, steroids, tacrolimus) for graft-versus-host disease (gvhd) within 30 days prior to the start of xl999, the subject has not recovered to grade ≤ 1 or to within 10% of baseline from adverse events due to investigational or chemotherapeutic drugs or stem cell transplantation which were administered > 4 weeks prior to study enrollment, uncontrolled and/or concomitant illness]"
NCT00161538,Exclusion Criteria,"[patients with reduced expectancy of life due to other diseases, symptomatic hypo- or hyperthyreosis, permanent atrial tachycardia that cannot be transferred into sinus rhythm by drugs or electric cardioversion, planned cardiac surgery intervention, patients involved in other studies, patients, who cannot attend follow-up visits due to their place of residence, patients, already implanted with other (cardiac) leads, decompensated heart failure, hypertrophic obstructive cardiomyopathy, patients under 18 years of age, myocardial infarction less than 6 months ago, dilatative cardiomyopathy with an ejection fraction < 35%, pregnant woman, patients who are not able to agree in participation of the study]"
NCT00161538,Inclusion Criteria,"[symptomatic sa block, symptomatic sinus bradycardia, binodal diseases, sinus node syndrome and high degree av-block, in case of antiarrhythmic drug therapy: patient must be on a stable dose for at least 3 months before enrollment, sick sinus syndrome, bradycardia-tachycardia-syndrom]"
NCT00970385,Exclusion Criteria,"[abnormal cardiac or hepatic functions, age < 18 and > 70, previous treatment, cutaneous form of ptcl, hiv-, hcv- or hbv- positivity, performance status > 2]"
NCT00970385,Inclusion Criteria,"[age 18 and 70 years, normal hepatic function (asat, alat, pal < 2.5 uln), newly diagnosed untreated ptcl, normal cardiac ventricular ejection fraction over 50%, ann arbor stage i to iv, performance status ≤ 2]"
NCT01204957,Inclusion Criteria,"[restricting alcoholic intake to #2 drinks (24 g alcohol)/wk -continuing habitual intake of vitamins, supplements, and medications during the study.   -, if breast cancer survivor, all therapy completed at least 6 months prior to enrollment, postmenopausal (self-reported cessation of menstruation 1 y prior to enrollment), agreed to eat their normal diet, avoiding seaweeds and phytoestrogen-rich foods,]"
NCT01204957,Exclusion Criteria,"[no oral antibiotics, iodine containing medications, or corticosteroids treatment within the previous 3 mo., no hormone replacement therapy or for breast cancer survivors, no chemotherapy or radiation treatments within the preceding 6 mo, no history of cancer (other than breast cancer), no allergies to seaweed, soy, shellfish, or iodine, no current use of tobacco;, negative thyroid peroxidase antibodies as determined by screening;, no thyroid dysfunction or treatment within the previous 5 y;, no current gastrointestinal disorders or diabetes; omnivorous eating habits, including meat and dairy products at least twice/wk]"
NCT00161408,Exclusion Criteria,"[pregnancy, insufficient knowledge of the german language, contraindications to neuroleptic treatment, serious physical illness, substance abuse or addiction as primary clinical problem, organic brain disease, residence outside of the catchment area]"
NCT00161408,Inclusion Criteria,"[age between 18 and 55, willingness to give informed consent also to a double blind pharmacological treatment study, diagnosis of schizophrenic disorder according to icd 10: f20, first episode]"
NCT00467168,Inclusion Criteria,"[types and doses of antidiabetic agents had been unchanged for four weeks before the postprandial study;, ability to hold hypoglycemic drugs on the day of the study until postprandial tests are completed;, type 2 diabetes;, nonsmokers;, no use of medications or vitamins known to affect plasma lipids;, dietary fat provided energy less than 35% in last two weeks;, no prior cardiovascular disease, hepatic and renal diseases, or other diseases influencing fat absorption;, no previous history of gastro-enteral surgery;, ability to provide verbal informed consent to participate.]"
NCT00467168,Exclusion Criteria,[females with menstrual cycles]
NCT00627783,Exclusion Criteria,"[negative stress test or myocardial perfusion imaging within the last three years, history of myocardial infarction, coronary artery disease, or stroke,, previous positive stress test or myocardial perfusion imaging,]"
NCT00627783,Inclusion Criteria,"[urinary albumin excretion > 30 mg/l or > 30 mg/24 hours,, treated or untreated hypertension,, history of transient ischemic accident,, patients 55 to 75 years old had type-2 diabetes and at least two of the following cardiovascular risk factors:, familial history of premature cardiovascular disease., peripheral arterial disease,, tobacco consumption, treated or untreated lipid abnormality,]"
NCT01026870,Inclusion Criteria,"[subject must have been using a low daily maintenance dose of inhaled corticosteroids (ics), with or without added long-acting β2-agonist (laba), for >=12 weeks prior to screening, and must have been on a stable regimen (daily dose unchanged) for at least the last 2 weeks of that period., at screening, the subject must have a prebronchodilator fev1 between 60% and 90% of the predicted value when restricted medications have been withheld., an adult or adolescent subject with a diagnosis of persistent asthma of >=6 months duration may be selected for this study., both subject (and/or parent/guardian, if appropriate) and investigator must agree that changing therapy is acceptable and poses no inherent risk., to be randomized, the subjects must be symptomatic with fev1 at baseline must be between 50% and 85% of predicted.]"
NCT01026870,Exclusion Criteria,"[a subject must not have been admitted to the hospital for management of airway obstruction within the last 3 months prior to screening, and must not have experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication, as judged by the clinical investigator at any time from screening to baseline/randomization., in addition, a subject must not have demonstrated a decrease in absolute fev1 of >20% at any time from screening to baseline, or a decrease in am peak expiratory flow (pef) below the pef stability limit on any 2 consecutive days prior to baseline/randomization.]"
NCT00003016,Criteria,"[no other serious medical problems, curatively treated carcinoma of the breast, no contraindications to receiving tamoxifen, currently taking adjuvant tamoxifen, must be substantial uncertainty as to whether or not to continue tamoxifen (i.e., no clear indication or definite contraindication to further treatment with tamoxifen), not pregnant or nursing]"
NCT00033514,Exclusion Criteria,"[for phase ii, prior cytotoxic chemotherapy and/or prior herceptin for their metastatic disease.  prior treatment in the adjuvant setting is allowed.]"
NCT00033514,Inclusion Criteria,"[her2 positive using fish, for the phase ii portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral ct scan), ecog performance status of 0 to 2, women aged > 18 years, use of effective means of contraception, histologically documents metastatic breast cancer, for phase i, patients who have previously received treatment for their metastatic disease are allowed to participate., a life expectancy of  > 3 months]"
NCT01471340,Exclusion Criteria,"[taking ltra, xanthine or saba monotherapy with an acq-6 total score < 1.5 (controlled), taking high dose ics with or without other adjunctive therapy who have an asthma control questionnaire 6 (acq6) total score ≥ 1.5, history of life-threatening asthma, including an asthma episode that required intubation and/or was associated with hypercapnia requiring noninvasive ventilatory support, known or suspected hypersensitivity or intolerance to corticosteroids, beta-2 agonists, or any of the (inactive ingredients) excipients present in the medications used in this study, had more than 4 asthma exacerbations or 2 hospitalizations within 52 weeks of the randomization visit, had an asthma exacerbation within 4 weeks of the baseline visit, history of smoking greater than 10-pack years, unstable asthma, significant underlying cardiovascular condition which may contraindicate use of a beta-agonist., clinically significant abnormality, illness or disorder of any body or organ system, lactating, pregnant, or plans to become pregnant during the course of the trial, requires the use of beta-blockers, chronic obstructive pulmonary disease (copd), cystic fibrosis (cf), or other significant, non-asthmatic, lung disease, require the use of chronic systemic steroids, omalizumab, or other monoclonal or polyclonal antibodies]"
NCT01471340,Inclusion Criteria,"[must use a daily asthma controller medication for at least 4 weeks prior to randomization, including an inhaled corticosteroid (ics) with or without a long-acting beta agonist (laba) or other adjunctive asthma therapy or be using a leukotriene receptor antagonist (ltra), xanthine or short acting beta agonist (saba) as a monotherapy., persistent asthma for at least 1-year, must be able to discontinue current asthma medication, must have a history of at least one asthma exacerbation in previous 4 to 52 weeks]"
NCT00234455,Exclusion Criteria,"[4. has an ejection fraction <=35%;, 2. has unstable angina classified as braunwald a i-iii, or iii b or c, or is having a peri infarction;, 1. patient has experienced a q-wave or non-q-wave myocardial infarction with documented elevation of ck levels > 2 times normal or ck-mb levels > 3 times normal within the preceding 24 hours and/or the ck and ck-mb enzymes remain above normal at the time of treatment;, 6. has a totally occluded vessel., 5. there is presence of thrombus in the bifurcation lesion;, 3. has a bifurcation lesion in a non protected left main;]"
NCT00234455,Inclusion Criteria,"[4. has a main branch vessel that is <=2.5 mm and <=3.5 mm in diameter by on-line qca proximal to the bifurcation;, 2. involves a single treatment of a de novo bifurcation lesion in native coronary arteries of patients with single or multivessel disease; patients with multiple lesions can be included only if other lesions treated during the index procedure are successfully treated prior to the treatment of the bifurcation lesion;, 3. has a true bifurcation lesion defined as stenosis > 50% in both the main branch and the ostium of the side branch;, 5. has a side branch vessel that is <=2.5 mm and <=3.5 mm in diameter by on-line qca., diagnosis of angina pectoris as defined by canadian cardiovascular society classification (ccs i, ii, iii, iv) or unstable angina pectoris (braunwald classification b&c, i-ii) or patients with documented silent ischemia;]"
NCT00317265,Exclusion Criteria,"[6. one or two vessel coronary disease and isolated left main stenosis, 10. redo-cardiac surgery, 14. presence of the combination of  severe adiposity and chronic obstructive pulmonary disease requiring therapy, 5. concomitant non-cardiac disease likely to limit long-term prognosis (e.g. cancer), 20. recent (< 2weeks) cerebrovascular event (tia, rind, stroke), 9. need for concomitant major cardiac or non-cardiac surgery (e.g. valve surgery, left ventricular aneurysm, aortic aneurysm, carotid artery desobliteration, etc.), 18. inadequate quality of saphenous vein material, 19. inadequate quality or number of arterial conduits to achieve complete revascularization likely (e.g. chest irradiation, major abdominal surgery), 17. unstable angina pectoris class a and c according to braunwald classification (i.e. secondary unstable angina and postinfarction unstable angina within one week after acute mi), 15. severe hepatic disease, 1. no informed consent, 3. participation in another study with any investigational drug or coronary revascularization procedure, 16. emergent operation for coronary artery disease with signs of ischemia (e.g. failed ptca, ongoing myocardial infarction), 11. presence of the combination of insulin dependent diabetes mellitus and chronic obstructive pulmonary disease requiring therapy, 7. estimated left ventricular ejection fraction < 25%, 8. myocardial infarction within seven days, 12. renal insufficiency requiring dialysis, 2. age > 65 years, 4. when follow up over a period of five years is difficult or unlikely, 13. presence of the combination of severe adiposity and insulin dependent diabetes mellitus]"
NCT00317265,Inclusion Criteria,"[4. patients with stable angina pectoris (canadian cardiovascular society 1, 2, 3, or 4) or unstable angina pectoris (braunwald classification 1b, 2b, 3b)  or proven silent myocardial ischemia., 1. patient eligible for surgical myocardial revascularization, 3. triple vessel coronary disease with significant coronary artery stenosis defined as a stenosis of at least 50% in luminal diameter, 2. age 70 years or less]"
NCT00159263,Exclusion Criteria,"[hypersensitivity to any of the investigational drugs or lactose, current upper respiratory tract infections, previous randomization in this study, subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason, any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study, use of any -blocking agent (including eye-drops), inability to tolerate temporary withdrawal of bronchodilatory therapy, use of inhaled and/or oral gcs within 4 weeks prior to visit 1, treatment with antileukotrienes, theophylline, tiotropium and ipratropium within 2 weeks prior to screening visit, women who are pregnant, breast-feeding or planning a pregnancy during the study. women must be postmenopausal (at least one year must have passed after the last menstruation), surgically sterile or using acceptable contraceptives, as judged by the investigator]"
NCT00159263,Inclusion Criteria,"[written informed consent, able to produce sputum after sputum induction, patients with mild steroid-naïve asthma (ats criteria) of either sex with fev1 >70 % pred, exhaled no (flow 50 ml/s) ≥ 20 ppb]"
NCT00287690,Exclusion Criteria,"[asthma, female patients with fsh<40 iu/l (postmenopausal), hypertension, female patients currently taking hormone therapy, or who have taken hormone therapy in previous 6 months, unwilling to give written informed consent, concomitant medication with persantin (dipyridamole) or theophyllines, sino-atrial disease or significant bradycardia, age <30 or >75 years, participation in another study within previous 60 days, allergy to radiographic contrast media, left ventricular hypertrophy or dysfunction (clinical/ecg/echo/cxr)]"
NCT00287690,Inclusion Criteria,"[willing to give informed, written consent, female patients must be postmenopausal (fsh>40 iu/l), presence of coronary artery disease on angiogram but with at least one non-obstructed (lesions <70% narrowed compared with the adjacent normal part of the vessel) atheromatous vessel (confirmed at diagnostic cardiac catheterisation), aged 30-75 years, patients requiring diagnostic coronary angiography]"
NCT00166634,Inclusion Criteria,"[no current drug therapy for hypertension being taken., standing height between 45 inches and 73 inches, agree to refrain from swimming, showering and other activities that might result in damage to abp monitor during the two 24 hour intervals that the monitor is worn., informed parental consent and patient assent., male and female children 5-16 years of age., must be ambulatory and willing to wear an abp monitor for 24 hours, borderline or mild systolic and or diastolic  hypertension as defined by 1996 task force criteria.]"
NCT00166634,Exclusion Criteria,"[any other disease that, in the opinion of the investigator, might interfere with the accurate measurement of the blood pressure or place the subject at risk unnecessarily., non-ambulatory, significant arrhythmia, any severe bleeding disorder or concurrent treatment with anticoagulant medications, previous history of significant non-compliance with prescribed medical care., severe or life threatening hypertension., any drug therapy that may raise or lower the blood pressure.]"
NCT00002848,Criteria,"[no major psychiatric illness requiring hospitalization or medication other than depression or anxiety for less than 1 year, clinical follow-up by a urologist, medical oncologist, or radiation therapist required at least semi-annually, clinical stage i/ii (t1b-c or t2, n0 or nx, m0) disease, no second malignancy within 10 years except nonmelanomatous skin cancer, pathologic local upstaging (e.g., to t3) allowed, no nx disease if pathologic or partial pathologic (e.g., lymph node biopsy or dissection) staging performed, biopsy-proven prostate cancer diagnosed within 1 year prior to entry]"
NCT01961882,Exclusion Criteria,"[Patients who are scheduled for hematopoietic stem cell transplantation, Patients who have a severe concurrent disease or psychiatric illness likely to interfere with participation in this trial., Patients judged to be ineligible by the investigator (or subinvestigator) for any other reasons., Patients who have cirrhosis., Patients who have received drugs potentially affecting the immune system within 4 weeks before starting imp administration or who may receive such drugs after start of the trial., Patients who are hiv antibody positive, hbv-dna positive or  have unrecovered chronic hepatitis c with positive hcv antibody., Patients who have acute promyelocytic leukemia (apl) with t(15;17) (q22;q12), (pml/rara) karyotype abnormalities, and other variant types.]"
NCT01961882,Inclusion Criteria,"[Patients who are 60 years or older., Patients who have provided written informed consent within 90 days from the last dose of consolidation therapy on an informed consent form that has been approved by an institutional review board or independent ethics committee., Patients with aml who achieved first complete remission within one or two courses of standard induction therapy, and completed standard consolidation therapy (more than one course).]"
NCT00317122,Exclusion Criteria,"[acute disease at the time of enrolment., a birth dose of hepatitis b vaccine given outside the frame of this study., a family history of congenital or hereditary immunodeficiency., any confirmed or suspected immunosuppressive or immunodeficient condition, based on physical examination., known exposure to diphtheria, tetanus, pertussis, hepatitis b, haemophilus influenzae type b and/or meningococcal disease since birth., any neurologic disorders or seizures., administration of immunoglobulins and/or any blood products since birth or planned administration during the study period., major congenital defects or serious illness.]"
NCT00317122,Inclusion Criteria,"[healthy infants aged 7 days +/- 3 days old born to mothers who are tested as seronegative for hiv & hbsag, written informed consent obtained from the parents, born after a gestation period of 36 to 42 weeks.]"
NCT00196079,Exclusion Criteria,"[patient has other medical condition that may cause the patient to be non-compliant with the protocol, confound the results or is associated with limited life expectancy., patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye that., patient is pregnant., the patient is simultaneously participating in another investigative interventional cardiovascular device or drug study., patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions., patient is less than 18 years old.]"
NCT00196079,Inclusion Criteria,"[patient must be an acceptable candidate for coronary artery bypass surgery., patient agrees to return at one month for an office visit to assess cardiovascular status and at 4-6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram., patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery., patient must have given signed informed consent.]"
NCT00419497,Exclusion Criteria,"[poor general condition, drug treatment with oral steroid, dementia, unwillingness/inability to prepare food at home (by study participant or partner), drug treatment with hypoglycemic agents, drug treatment with warfarin, participation in another medical trial, body mass index <20 kg/m2, chronic inflammatory bowel disease, serum creatinine >130 µmol/l]"
NCT00419497,Inclusion Criteria,"[coronary heart disease, increased waist circumference, hyperglycemia]"
NCT01993329,Exclusion Criteria,"[inhaled or systemic corticosteroids (oral, intravenous, intramuscular) within 4 weeks prior to screening., exacerbation of asthma or lower respiratory tract infection during the 4 weeks before screening., short-acting or long-acting antihistamines within 48hrs or 7 days, respectively, prior to screening., upper respiratory tract infection during the 4 weeks before screening or prior to randomization requiring treatment with antibiotics., hospitalized or attended the emergency department for an asthma attack in the 12 months prior to screening.]"
NCT01993329,Inclusion Criteria,"[non-smokers or former smokers, who stopped smoking 6 months prior to screening. former smokers should not have a smoking history of more than 5 pack years (1 pack of 20 cigarettes per day over 5 years)., history or diagnosis of asthma for at least 6 months prior to screening according to the global initiative in asthma guidelines (gina, 2012)., pre-bronchodilator (after abstaining from short acting β2-agonist for ≥8 hrs) forced expiratory volume (fev1) ≥70% of the predicted normal value or if less than 70% must be within +/- 12 % of screening fev1 prior to randomization., positive response to atp challenge (pc20 ≤ 200 µmol/ml) at screening., pre-bronchodilator (after abstaining from short acting β2-agonist for ≥8 hrs) forced expiratory volume (fev1) ≥70 percent of the predicted normal value at the screening visit., positive response to methacholine challenge (pc20 ≤ 8 mg/ml) at screening., use of short acting β2-agonist therapy only (≤ 8 puffs per day) for at least 4 weeks prior to screening and prior to randomisation.]"
NCT01999907,Exclusion Criteria,"[other chronic respiratory disease (broncho-pulmonary dysplasia; cystic fibrosis), plan to leave the province during the next 6 months., disorder/ disease with associated malabsorption (inflammatory bowel disease), infants <12 months of age, unable to attend medical visit in 3-4 months, vitamin d supplementation >1000 iu/ day in past 3 months, extreme prematurity (<28 weeks gestation), sickle cell anemia, kidney/ liver disease, endocrine disorder of calcium/ vitamin d metabolism, recent (<1 year) immigrants from countries where rickets and malnutrition prevalent, medications known to interfere with bone metabolism/ vitamin d levels, breastfed infants with no vitamin d supplementation]"
NCT01999907,Inclusion Criteria,"[physician-diagnosed asthma as per gina guidelines, ≥4 respiratory infections in the past 12 months, children aged 1-5 years, ≥1 exacerbation requiring rescue oral steroids in the past 6 months or ≥2 in the previous 12 months., upper respiratory tract infections as the main asthma exacerbation trigger]"
NCT02508324,Inclusion Criteria,"[Patients with a confirmed diagnosis of aml or mds, according to who classification (excluding acute promyelocytic leukaemia) who have received two or three previous induction/re-induction regimens. one of the (re-)induction regimens could be stem cell transplantation (sct) for achievement of remission. maintenance and consolidation (including sct) may have been given, but are not counted as previous regimens., Women of child-bearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to treatment start, Patients younger than 60 years should have received previous treatment with cytarabine, Patients must be capable of understanding and complying with protocol requirements, and must be able and willing to sign a written informed consent form, Patients must be 18 years of age or older, Patients have failed initial induction therapy, and have attained cr or cri after salvage therapy(ies), and then relapsed within < 6 months, Patients have attained cr or cri after initial induction therapy and relapsed within <12 months, and failed to respond to salvage therapy(ies); or have relapsed after the latest cr or cri within < 6 months, Patients must have ecog performance status (ps) of 0 - 2, have never attained cr or cri (primary refractory)]"
NCT02508324,Exclusion Criteria,"[Known positive status for human immunodeficiency virus (hiv), Iimpairment of hepatic or renal function to such an extent that the patient, in the opinion of the investigator, will be exposed to an excessive risk if entered into this clinical study, Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements, Persistent clinically significant toxicities from previous chemotherapy, Any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities, active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure. any nyha grade 3 or 4., pregnant and nursing patients]"
NCT00256321,Inclusion Criteria,"[patient must not have active gastric/duodenal bleeding, patient must have histologically proven, pathologically verified and surgically incurable(unresectable, recurrent, or metastatic) gastric/gastroesophageal junction carcinoma. gastric lymphoma and  gastrointestinal stromal tumor(gist) are ineligible for this study.  at least 6 unstained paraffin-embedded pathologic specimen slides will be required for the cox-2 expression assays., all patients must undergo a ct of abdomen and chest within 30 days prior to registration., patients must have a  zubrod performance status of 0-2., patient must not have known allergic or other adverse reaction to celecoxib, pregnant or nursing women are not eligible to participate in this trial because the safe use of these drugs in pregnancy have not been established.  urine pregnancy test must be done prior to the study., patients with brain metastases are not eligible for this study.  it is not mandatory to obtain brain ct or mri on all patients.  however, patients who exhibit neurological symptoms or have pulmonary metastases on radiographic studies must obtain brain ct w/ iv contrast or mri prior to registration to ascertain the presence of brain metastasis., patient must not have known allergic reaction to sulfonamides, patient must have bidimensionally measurable disease as defined in section 10.1a. all measurable lesions must be assessed (by physical examination, ct scan, radionuclide scan or plain x-ray) within 30 days prior to registration. the patient's disease status must be completely assessed and reported., patient must not have persistent peripheral neuropathy, patient must not have had a sensitivity reaction to aspirin or other nsaids [experiencing asthma,  urticaria, or allergic-type reactions after taking aspirin or other nsaids], patients may have received prior surgery. prior surgery must have been completed at least 30 days before registration., patient must not have known hypersensitivity reactions to 5-fu or platinum, patients may have received prior radiation therapy. radiation therapy must have been completed at least 30 days before registration., patients must not have received capecitabine or oxaliplatin.  prior use of cisplatin, carboplatin, 5-fu are permitted.  prior systemic therapy must have been completed at least 30 days before registration.]"
NCT00171756,Inclusion Criteria,"[mild to moderate hypertension (msdbp >= 95 and >= 110 mmhg and / or mssbp >140mm hg) at visit 1, requiring pharmacological intervention. for newly diagnosed patients, hypertensive blood pressure values must be noted on at least two successive examinations prior to entry into the study. in addition, patients must require therapy despite having been following dietary & lifestyle advice for at least 3 months., ability to communicate and comply with all study requirements, written informed consent to participate in the study, prior to any study procedures., male or female, aged between 18 - 75 years of age inclusively.]"
NCT00171756,Exclusion Criteria,"[clinically significant laboratory abnormalities that may interfere with the assessment of safety and/or efficacy of the study drug, clinical evidence of congestive heart failure., uncontrolled atrial fibrillation (>100 b.p.m. at rest) or other conditions which may require anti-aggregant or anti-vitamin k therapies., history of clinically significant angina, lvh, transient ischemic attack, stroke, intermittent claudication, deep vein thrombosis (dvt), pulmonary embolism or peripheral vascular disease., history of a vascular event or intervention (e.g. mi, ptca or cabg) within 6 months preceding the study., o uncontrolled hypertension defined as seated blood pressure of either systolic bp >180 mmhg and/or diastolic bp >110mmhg., evidence of second or third degree heart block or sick sinus syndrome., any condition resulting from or leading to platelet or clotting abnormalities (eg. hemophilia, von willebrand's disease)., patients with severe medical condition(s) that in the view of the investigator may prohibit participation in the study, diabetes mellitus, renal artery stenosis]"
NCT00140439,Inclusion Criteria,"[6. requirement for ≥3 doses of nebulized albuterol in the ed at the time of enrollment., 5. residence in washington, dc or a contiguous maryland county; and, 1. age between 12 months and 17 years, inclusive;, 2. prior physician-diagnosed asthma;, 4. a parent/guardian available for interview;, 3. ≥1 other unscheduled visit for asthma in the previous 6 months and/or ≥1 hospitalization for asthma in the prior 12 months;]"
NCT00140439,Exclusion Criteria,"[4. enrollment in another asthma research study;, 2. a visit to an allergist or a pulmonologist in the prior 6 months;, 1. significant medical co-morbidities affecting the cardiorespiratory system;, 5. unavailability for telephone follow-up; or, 6. primary language other than english or spanish., 3. ≥2 of the following: a current written asthma medical action plan, current use of >1 controller medication, or a scheduled visit for asthma care with their pcp in the prior two weeks;]"
NCT00007189,Inclusion Criteria,"[willingness to limit use of the following for the duration of the study: vitamin e (at doses greater than 400 iu per day), non-aspirin nsaids, histamine h2 receptor antagonists (tagamet, for example), corticosteroids, anti-inflammatory or analgesic doses of aspirin (greater than 81 mg per day), ginkgo biloba extracts, aged 70 years or older., ability and intention to participate in regular study visits, in the opinion of the study physician., provision of informed consent., study partner available to provide information on the cognitive status of the participant and to assist with monitoring of trial medications, if needed., family history of parent, brother, or sister who has, or had, serious age-related memory loss, senility, dementia, or alzheimer's disease., sufficient fluency in written and spoken english to participate in study visits and neuropsychological testing.]"
NCT00007189,Exclusion Criteria,"[clinically significant liver or kidney disease., use of anti-coagulant medication., history of hypersensitivity to aspirin, ibuprofen, celecoxib, naproxen, or other nsaids., history of peptic ulcer disease with bleeding or obstruction., current alcohol abuse or dependence, cognitive impairment or dementia.]"
NCT00832182,Exclusion Criteria,"[known or suspect abuse of alcohol or narcotics, known or suspected allergy to trial product or related products, impaired renal function, total daily insulin requirements of more than 1.4 u/kg, any condition that the investigator and/or sponsor feels would interfere with trial participation or evaluation of results, current hypoglycaemic unawareness as judged by the investigator, cardiac problems, uncontrolled hypertension, impaired hepatic function, women breastfeeding or having the intention of becoming pregnant, or if judged not to be using adequate contraceptive measures (adequate measures are intrauterine device (iud), oral contraception and barrier methods)]"
NCT00832182,Inclusion Criteria,"[signed informed consent obtained before any trial-related activities. (trial-related activities are any procedure that would not have been performed during normal management of the subject), the subject must have completed the ana/dcd/065 trial]"
NCT02029417,Inclusion Criteria,"[have an unequivocal histologic diagnosis of acute myeloid leukemia (aml) (including secondary aml), must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, no prior therapy for aml except hydroxyurea to control counts, patients who are not eligible for standard induction chemotherapy (or any standard therapy known to be life prolonging) because of poor performance status, significant tissue comorbidities, or unfavorable risk of disease, subject or legal representative must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure]"
NCT02029417,Exclusion Criteria,"[unwilling or unable to follow protocol requirements, received an investigational agent for another disease within 30 days prior to enrollment, patients with sickle cell disease and sickle cell crisis, any condition which in the investigator's opinion deems the subject an unsuitable candidate to receive study drug, subjects with the diagnosis of acute promyelocytic leukemia (t[15;17]), the patient has an uncontrolled and active infection that would preclude study conduct and assessment]"
NCT00105547,Exclusion Criteria,"[chronic or acute renal, hepatic or metabolic disorder., history or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. men with prostate cancer may be enrolled at the discretion of the sponsor., use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of ad immunotherapy prior to screening., current evidence of other causes of dementia., major surgery and related complications not resolved within 12 weeks prior to day 1.]"
NCT00105547,Inclusion Criteria,"[subjects must have a reliable caregiver who can read, understand and speak english or spanish., men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility)., ability to read and understand english or spanish to ensure compliance with cognitive testing and study visit procedures., signed the subject informed consent form and is willing and able to participate for the duration of the study., subjects currently taking approved medication for alzheimer's disease for at  least six months prior to day 1 may be enrolled., have had a diagnosis of probable alzheimer's disease., female subjects must be surgically sterile or postmenopausal for > 1 year.]"
NCT02323217,Inclusion Criteria,"[successful completion of the camcog., subject is ambulant and capable of attending a pet scan visit as an outpatient., excellent understanding of english (for questionnaires), body weight ≥50 kg., male between 40 and 65 years at the time of signing the informed consent non-smoker, willing to comply with protocol and lifestyle restrictions, adequate collateral flow to the radial and ulnar arteries in both hands as determined by an allen's test., subjects with female partners of child-bearing potential must agree to use one of the contraception methods permitted by the study. this criterion must be followed from after the first pet scan until after the follow-up contact., healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history (including family), physical examination, objective physiological measures, previous laboratory studies, and other tests.]"
NCT02323217,Exclusion Criteria,"[previous inclusion in a research and/or medical protocol involving study medication within the last 3 months, current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of gilbert's syndrome or asymptomatic gallstones)., history of or suffers from claustrophobia or subject feels unable to lie flat and still on their back for a period of up to 2 hours in the pet/ct scanner., current or past history of major psychiatric disorder, in the opinion of the study team they are unlikely to comply with the study protocol and restrictions that it imposes., previous inclusion in a research and/or medical protocol involving nuclear medicine, pet or radiological investigations or occupational exposure resulting in radiation exposure greater than 10 msv over the past 3 years or greater than 10 msv in a single year including the proposed study. clinical exposure from which the subject receives a direct benefit is not included in these calculations., contraindications for subjects undergoing an mr scan (including but not limited to metal implants pacemakers, etc.), current or past history of substance use disorder, clinically significant brain injury or abnormality]"
NCT01894048,Inclusion Criteria,"[r5>130% predicted and r5-r20>0.03kpa/l/s, ability to give informed consent, ability to withhold long-acting beta-agonists for the duration of the study, ability to perform spirometry, impulse oscillometry, bronchial challenge and all domiciliary measurements, fev1 >60 percent predicted, asthma control questionnaire score >1.0 (at end of run-in), male and female volunteers aged 18-65, with persistent asthma, asthmatic patients receiving treatment at step 2, 3, or 4 of british thoracic society asthma guidelines]"
NCT01894048,Exclusion Criteria,"[inability to comply with protocol, known or suspected sensitivity to the investigational medicinal product, pregnancy or lactation, patients already receiving extra-fine particle inhaled corticosteroids (qvar, fostair, alvesco), participation in previous trial within 30 days, any clinically significant medical conditions that may either endanger the health or safety of the participant, or jeopardise the protocol, an asthma exacerbation requiring systemic steroid therapy or lower respiratory tract infection requiring antibiotics within 3 months prior to study commencement]"
NCT02358525,Exclusion Criteria,"[alcohol or drug abuse, fluid retention of cardiac decompensation, necessitating i.v. diuretic therapy, psychiatric disorders, myocardial infarction within the last 2 months, uncontrolled proinflammatory comorbidities  (e.g. diabetes mellitus hba1c >9%, copd ( chronic obstructive pulmonary disease) >ii, active rheumatic diseases and autoimmune disorders), current infectious diseases ( e.g. pneumonia, copd exacerbations or urinary tract infections), morbid obesity: bmi > 40, surgery including cardiovascular or valvular surgery within 3 months]"
NCT02358525,Inclusion Criteria,"[diagnosis of heart failure with reduced ejection fraction (hfref) with an ef ≤ 45%, nyha (new york heart association) i - iii; acc/aha (american college of cariology/, ability to fully understand all elements of and sign the written informed consent before initiation of the study, clinically stable patients without deterioration or hospitalization due to heart failure within the   last 4 weeks, american heart association) stage c, irrespective of etiology, neuro-hormonal medication according to the esc (european society of cardiology) guidelines for the treatment of chronic heart failure consisting of antagonists of the renin-angiotensin-aldosterone system (raas) and beta-blockers as indicated.]"
NCT02344342,Exclusion Criteria,"[receiving dialysis, enrollment into a hospice program, patients with dgfr less than 20ml/min., patients being evaluated for heart valve intervention., patients with primary pulmonary hypertension., patients being worked up for heart surgery., patients with dementia, prisoners, residents of long term nursing facilities, patients being evaluated for revasuculariztion., patients being worked up for heart transplant.]"
NCT02344342,Inclusion Criteria,"[2. patients must be receiving an oral loop diuretic on their home regimen or have received intravenous loop diuretic during the index hospitalization at the time of enrollment., 4. patients must have lvef ≤ 40%, or lvef >40 with evidence of left atrial enlargement (la dimension > 40 mm), bnp > 200 ng/ml or pcw > 18 mmhg., 3. patients must have an assessment of left ventricular function within the previous 2 years., 1. university of michigan patients hospitalized for the treatment of heart failure, within the past 30 days.]"
NCT01026506,Exclusion Criteria,"[primary and secondary immune deficiency, usage of systemic corticoids, alcohol and drug abuse, intolerance against milk protein, sit within the last 2 years]"
NCT01026506,Inclusion Criteria,"[willingness to use only the recommended drugs, doctor-diagnosed bronchial asthma, age 6-18 years, allergic sensitization (house dust mite, grass pollen), competence regarding the daily documentation of peak-flow data and symptoms]"
NCT00095394,Inclusion Criteria,"[men and women ages 18 and older;, willing to provide written informed consent;, wocbp must have a negative serum or urine pregnancy test within 72 hours prior to the start of study medication., must be willing to discontinue antihypertensive medication, if applicable;, women of childbearing potential (wocbp) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to one week after the study in such a manner that the risk of pregnancy is minimized., must have uncontrolled hypertension defined as:  currently untreated with a diastolic blood pressure greater than 110 mmhg or currently receiving antihypertensive monotherapy with a diastolic blood pressure greater than 100 mmhg.  monotherapy is defined as treatment with one antihypertensive medication for at least four weeks; fixed combination therapy does not represent monotherapy;]"
NCT00095394,Exclusion Criteria,"[significant kidney disease;, heart attack, angina or bypass surgery within the past 6 months;, systemic lupus erythematosus;, gastrointestinal disease or surgery that may interfere with drug absorption;, hypertension emergencies or stroke within the past 12 months;, currently pregnant or lactating;, known allergy to irbesartan or diuretics., cancer during the past five years excluding localized squamous cell or basal cell carcinoma of the skin;, mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope, and possible consequences of the study;, women who are pregnant or breastfeeding;, known or suspected secondary hypertension;, significant liver disease;, drug or alcohol abuse within the last five years;]"
NCT00148863,Exclusion Criteria,"[alcool consummation, cirrhosis, pregnancy or plan of pregnancy, hiv infection, psychiatric pathology, breastfeeding]"
NCT00148863,Inclusion Criteria,"[positive anti-hcv antibodies, metavir over f2 on the most recent biopsy, without lower dosage during previous treatment, non responder to the previous treatment with peg-interferon alpha 2b and ribavirin, with detectable hcv rna at w24 or decrease of less than 2 log10 copies/ml at w12 or decrease greater than 2 log10 but detectable hcv rna, positive hcv rna (quantitative method), alt increase over normal value twice during last 6 months, previous treatment with peg-interferon alpha 2b 1.0 to 1.5 micro g/kg (during at least 12 weeks) with ribavirin (at least 800 mg/day during at least 12 weeks),stopped since at least 3 months]"
NCT00141596,Inclusion Criteria,"[bp >140/85, 3 antihypertensive drugs (ace/arb + calcium channel blocker + thiazide diuretic)]"
NCT00141596,Exclusion Criteria,"[unstable heart failure, contraindication to (or intolerance of) drug used in study, creatinine >120 mcmol/l, chronic liver disease, pregnancy, breast feeding, bp > 180/110]"
NCT00145756,Inclusion Criteria,"[estimated daily sodium intake of 260mmol/24hrs (about 15g/24hrs of nacl) or above and expectation that at least 50% of daily dietary salt intake can be replaced with the salt-substitute.  this will be estimated through interview of the potential participant and the individual responsible for daily food preparation (if this is not the patient) using a structured questionnaire., treated diabetes and age 55 years or older, surgery or angioplasty for peripheral vascular disease, hospitalisation for management of any acute coronary syndrome, stroke or transient ischaemic attack, a doctor-confirmed high risk of future vascular disease defined as a history of any one of:, systolic blood pressure >160mmhg, provision of informed consent, participant inclusion will be based upon the presence of:]"
NCT00145756,Exclusion Criteria,"[there is an established history of significant renal impairment that would preclude the use of the salt-substitute in the opinion of the responsible physician., they are on potassium-sparing medication, potential participants will be excluded if:, there is any reason why either the salt-substitute or normal salt are definitely indicated or definitely contra-indicated.]"
NCT00132834,Exclusion criteria,"[exclusion criteria for part a participants: ics or oral corticosteroid use in the month prior to study entry, smoker, unable to use the r-tube. more information on this criterion can be found in the dait icac-ebc protocol., diagnoses indicating other lung-related disorders (e.g., cystic fibrosis, bronchopulmonary dysplasia [bpd]), allergy to latex, albuterol use within 12 hours of study entry, long-acting bronchodilator or leukotriene modifier use within 24 hours of study entry]"
NCT00132834,Inclusion Criteria,"[physician-diagnosed asthma, able to speak and understand english, symptoms consistent with persistent asthma in the year prior to study entry, parent or guardian willing to provide informed consent]"
NCT00144144,Inclusion Criteria,"[patients with type 2 diabetes mellitus., patients who show a systolic blood pressure (blood pressure) > 135 mm hg or a diastolic blood pressure > 85 mm hg, which is measured (in a sitting position) on an outpatient basis at the time of start of the observation period, and show the mean (blood pressure level measured at home after getting up before the start of study) of systolic blood pressure > 130 mm hg or diastolic blood pressure > 80 mm hg measured at home after getting up for last 5 days during the last 2-week observation period., patients whose consent is obtained at age 20 years or over., patients who have been treated by the single use of aii antagonist at usual for at least 8 weeks or patients who have been treated by the combined use of aii antagonist at usual doses and calcium channel blocker or a antihypertensive drug other than ace inhibitors for at least 8 weeks., patients whose consent is obtained from themselves in written form. with regard to 2) and 3), however, the case, in which the mean of the systolic blood pressure levels measured at home after getting up for last 5 days during the first 1-week observation period is > 180 mm hg or the mean diastolic blood pressure level is > 110 mm hg, is included in the present study.]"
NCT00144144,Exclusion Criteria,"[patients who have participated in the trial within 3 months before the start of the observation period or who attend the trial simultaneously with the present study., patients with a past history of hypersensitiveness to study drugs., other patients judged as being inappropriate for the subjects of the study by investigators., pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant during the study period., patients with secondary hypertension., patients who show a systolic blood pressure > 180 mm hg or diastolic blood pressure > 110 mm hg on the measurement (in a sitting position) on an outpatient basis at the time of start of the observation period., patients with severe hepatic dysfunction., patients with severe renal dysfunction.]"
NCT00001669,Criteria,"[no history of insulin-producing tumors or reactive hypoglycemia., stage ii - known by history to have a mean enhancing lesion frequency of 0.5 per month or greater;, no first or second degree relatives with breast cancer., if a female patient, not of child bearing potential (surgically sterilized or post-menopausal) or if of child bearing potential, documented to be nonpregnant by urine pregnancy test and not lactating with adequate contraception and counseling., no history of substance use disorder (dsm-iv criteria) within the past two years., no clinically significant medical condition (e.g., within 6 months of screen had myocardial infarction, angina pectoris, untreated hypertension, and/or congestive heart failure [chf] that, in the opinion of the investigator would compromise the safety of the patient., patient may not be hiv (human immunodeficiency virus), htlv-1 (human t cell leukemia virus), or hb/c ag (hepatitis b or c surface antigen) positive., male patients should also receive adequate counseling and exercise adequate contraception., ability to tolerate mri examinations due to claustrophobia, or have contraindications to mri scanning, such as pacemakers, aneurysm clips, or shrapnel fragments.  welders and metal workers must have radiographic evidence to document lack of foreign bodies in the eyes or they will be excluded, due to the risk of eye injury while in the mri machine., no type i or type ii diabetes treated with hypoglycemic agents (diet-controlled type ii diabetes may be included.), ability to comply with protocol requirements;, have previously received interferon-alpha, interferon-beta, copolymer 1, cyclophosphamide, intravenous immunoglobulin, oral myelin, or other immunosuppressive drugs within 6 months of screen., provide written informed consent;, no history of cancer (with the exception of localized skin cancers with no evidence of metastasis, significant invasion, or recurrence) within three years of screening., no clinically significant abnormalities on the prestudy laboratory evaluations, physical examination, electrocardiogram (ecg), chest x-ray, mammogram or ophthalmologic exam., stage i - known by history to have a mean enhancing lesion frequency of 0.3 per month or greater;, have not used an investigational drug within 30 days of the screen visit., no connective tissue or rheumatic disorder (systemic lupus erythematosus [sle] ; rheumatoid arthritis [ra]; progressive systemic sclerosis [pss]; sjogren's syndrome [ss]).]"
NCT00077649,Inclusion Criteria,"[chc (genotype 1);, adult patients >=18 years of age;, liver biopsy (in <24 calendar months of first dose), with results consistent with chc infection;, body weight >85kg (187lbs);, use of 2 forms of contraception during study and 6 months after the study in both men and women.]"
NCT00077649,Exclusion Criteria,"[conditions associated with decompensated liver disease;, male partners of women who are pregnant;, women who are pregnant or breastfeeding;, previous treatment with an interferon, ribavirin, viramidine, levovirin or amantadine., other forms of liver disease, including liver cancer;, human immunodeficiency virus infection;]"
NCT01567059,Inclusion Criteria,"[serum bilirubin, aspartate transaminase (ast)/alanine transaminase (alt) =< 3.0 × uln, female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse, adults age 18 to 59 with untreated aml or high-risk mds and a transplant-related mortality (trm) score of >= 9.2; previous data suggests these people would have a 25% mortality with standard therapy, making this treatment a reasonable alternative, all adults >= 60 years of age with untreated aml or high-risk mds (10-19% marrow blasts) including those with prior myelodysplasia (mds)/aml, therapy-related aml, aml with trilineage dysplasia (aml-tld), and aml with adverse cytogenetics; patients may be enrolled if they received prior treatment with hydroxyurea to control blood counts or demethylating agents specifically for the purpose of treating mds, serum creatinine =< 2.0 mg/dl; if serum creatinine > 2.0 mg/dl, then the estimated glomerular filtration rate (gfr) must be > 50 ml/min/1.73 m^2 as calculated by the modification of diet in renal disease equation, capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent, male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse, alkaline phosphatase =< 2.5 × uln, eastern cooperative oncology group (ecog) performance status of 0 - 2]"
NCT01567059,Exclusion Criteria,"[known infection with human immunodeficiency virus (hiv), current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol, diagnosed or treated for another malignancy within 1 year of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy, active uncontrolled infection, current or history of congestive heart failure new york heart association (nyha) class 3 or 4, unless a screening echocardiogram (echo) or multiple gate acquisition scan (muga) performed within 1 month prior to study screening results in a left ventricular ejection fraction (lvef) that is >= 45% (or institutional lower limit of normal value), medical condition, serious concurrent illness, or other extenuating circumstance that, in the judgment of the principal investigator, could jeopardize patient safety or interfere with the objectives of the study, uncontrolled angina or myocardial infarction within 6 months; patients with recent myocardial infarction apparently due to medical causes unrelated to underlying cardiac abnormalities must have a cardiac consult, and be cleared to participate in the research by the cardiologist prior to initiation of treatment and may be enrolled at the discretion of the primary investigator (pi) and treating physician]"
NCT00211874,Inclusion Criteria,"[current patient in a general medicine, geriatrics, or cardiology clinic or office at a participating site., community-dwelling at enrollment, and, english- or spanish-speaking,, • adults >18 years,, systolic dysfunction documented on a cardiac test (echocardiography, radionuclide ventriculography, myocardial stress sestamibi/thallium testing, or left-heart catherization),]"
NCT00211874,Exclusion Criteria,"[procedures that corrected systolic dysfunction, such as heart transplantation., • medical conditions that prevented a patient’s interacting with the nurse, including blindness, deafness, and cognitive impairment;, medical conditions that required individualized management that might differ from standard protocol, namely pregnancy, renal dialysis, and terminal illness; and]"
NCT00338962,Inclusion Criteria,"[outpatient, sober from alcohol and other abused substance for at least 2 days before randomization, a recent episode of heavy drinking, dsm-iv diagnosis of alcohol dependence and current dsm-iv depressive disorder or ptsd, women on adequate methods of contraception, stable medication regiment for at least 2 weeks]"
NCT00338962,Exclusion Criteria,"[history of psychotic disorders or current treatment with antipsychotic medications, current opioid dependence or abuse, current (within the lst 6 months) use of mao inhibitors, history (within the last 3 months) of opioid dependence or abuse, medication thought to influence drinking including: acamprosate, disulfiram, naltrexone, ondansetron, valproic acid or tegretol, suicidal active ideation or intent, significant underlying medical condition, pregnant, history of cardiac condition abnormalities]"
NCT01358734,Inclusion Criteria,"[white blood cell (wbc) count ≤ 10 x 10⁹/l at screening, newly diagnosed acute myeloid leukemia (aml), aml with antecedent hematologic disorder or therapy-related aml, eastern cooperative oncology group (ecog) performance status of 0, 1 or 2, male or female subjects aged ≥ 65]"
NCT01358734,Exclusion Criteria,"[suspected or proven acute promyelocytic leukemia, previous treatment with azacitidine, decitabine, cytarabine or lenalidomide, presence of malignant disease within the previous 12 months with exceptions, aml antecedent hematologic disorder such as chronic myelogenous leukemia or myeloproliferative neoplasms, prior bone marrow or stem cell transplantation, candidate for allogeneic bone marrow or stem cell transplantation, previous cytotoxic or biologic treatment of any kind for aml or prior use of targeted therapy agents.]"
NCT00157326,Inclusion Criteria,"[are able to comply with study procedures and visits, have a documented medical history of hypertension., have cuff seated diastolic blood pressure values greater than or equal to 95 and less than or equal to 104 mm at study entry, have a negative serum pregnancy test at the time of enrollment and agree to use two medically reliable methods of contraception until study completion, if female is of child-bearing potential, between menarche and 1 year post menopause and not surgically sterilized.]"
NCT00157326,Exclusion Criteria,"[are obese, defined as having body mass index (bmi) greater than or equal to 35., are females who are pregnant or breast feeding., have symptomatic heart failure requiring treatment, or significant disease of the heart valves., have resistant hypertension or systolic hypertension., have a glycosylated hemoglobin a1c (hba1c) greater than or equal to 10% during the screening period., have been treated for severe asthma, bronchospasm, or copd within 3 months of study entry., have a significant or unstable cardiac history such as history of heart attack, unstable angina, or stroke within 6 months of study entry, history of angina that was treated with long- or short-acting nitrates within 90 days of study entry, history of coronary artery bypass graft surgery or cardiac angioplasty within 90 days of study entry, history of abnormal heart rhythms such as sick sinus syndrome or 2nd- or 3rd-degree av block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia, a history of recurrent ventricular tachycardia, or symptomatic bradycardia, a history of sudden cardiac arrest., have severe peripheral vascular disease., have a history of severe renal insufficiency or significant thyroid, renal or hepatic disease., have a documented diagnosis of sleep apnea., have significant anemia.]"
NCT00156884,Exclusion Criteria,"[change in steroid dose within 4 weeks, previous hemibody rt within 6 weeks, significant neurological disorder, active uncontrolled infection, impending or present spinal cord compression, severe urinary incontinence, previous cytotoxic chemotherapy within 4 weeks, prior strontium therapy, use of bisphosphonate medications within 4 weeks, impending pathological fracture]"
NCT00156884,Inclusion Criteria,"[discontinued anti-androgens for > 4 weeks, adenocarcinoma of the prostate, prior treatment (chemo) > 4 weeks previous, life expectancy > 3 months,, stable level of pain control, ability to complete assessments, >18 years, radiologic evidence of metastatic bone disease, symptomatic from bone metastases]"
NCT00473681,Exclusion Criteria,"[acute and/or terminal condition precluding participation such as terminal cancer or acute myocardial infarction, psychiatric diagnosis precluding participation such as schizophrenia and cognitive impairment measured by self-report, chart review, or clinical assessment.]"
NCT00473681,Inclusion Criteria,"[self-identified as first-generation korean american, sbp≥140 or dbp≥90mmhg at the krc hbp verification visit, resident of greater baltimore census tracts, written consent to participate in the screening/eligibility visit, written consent to participate in the clinical trial:agreeing to participate in study data collection procedures, receiving hbp education, using hbpmt, and permitting contact with their own medical care provider., sbp≥140 or dbp≥90mmhg on hbp medication, age 40 to 65 years of age]"
NCT01907763,Exclusion Criteria,"[12. participation in study using an experimental medication within 1 month before visit 1, 6. clinically significant and uncontrolled psychiatric disease, 2. emergency room treatment for asthma within 1 month or hospitalization for asthma within 3 months before visit 1, 10. administration of the antiasthma agent within 1 week of visit 1, 7. history of drug or alcohol abuse, 3. any evidence of infectious, oncologic, or other active pulmonary disease obtained by chest radiography within 12 months before visit 1, 11. administration of any other medication which may affect the course of asthma, or interact with sympathomimetic amines, 8. inhaled, oral or parenteral corticosteroids within 4 weeks before visit 1, 5. hypersensitivity to any β2-agonist, sympathomimetic drug, leukotriene receptor antagonist or sophora tonkinensis radix rhizoma, 1. active upper or lower respiratory tract infection within 3 weeks before visit 1, 9. change of immunotherapy within 6 months before visit 1, 13. other ineligible subject in the opinion of the investigator, 4. clinically significant, in the opinion of the investigator, hematological, liver, renal, heart, neurological disease, or other serious disease]"
NCT01907763,Inclusion Criteria,"[2. a female is eligible if she is of:, 3. non-smoker for at least 1 year, a pack history of ≤ 10 pack years, ß-agonist for 6 hours), non-child bearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is at least 2 year after post- menopausal, child bearing potential and agrees to the acceptable contraceptive methods used consistently and correctly, 4. symptom of persistent asthma, as defined by the national institute of health (nih) 5.50 percent ≤ fev1 ≤ 80 percent predicted at screening visit (withholding inhaled, short acting, ß-agonist (salbutamol 2 puffs; 200㎍) at visit 1 or within 6 months before visit 1 7.capable of withholding salbutamol use for ≥ 6 hours prior to clinic visits 8.appropriately signed and dated informed consent has been obtained, negative pregnancy test at screening, 6.fev1 reversibility ≥ 12 percent and 200 ml at 20-30 minutes after inhalation of a short acting, 1. male or eligible female subjects aged 15 years or more]"
NCT02344420,Inclusion Criteria,"[indication for a \""de novo\"" implantation of a crt device according to esc guidelines, give written informed consent, understand the nature of the procedure]"
NCT02344420,Exclusion Criteria,"[nyha class iv heart failure, subjects with irreversible brain damage from pre existing cerebral disease, permanent / persistent atrial fibrillation, have a life expectancy of less than 12 months, heart transplantation six months prior to the enrolment or expected within next 3 months., crt device replacements, pregnant and breastfeeding women, cardiac surgery 3 months prior to the enrolment or planned within next 3 months., crt upgrades, subjects with acutely de compensated heart failure, age< 18 years]"
NCT02192099,Inclusion Criteria,"[4. female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (eg oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the course of the study. female subjects may be included without a negative serum pregnancy test if they are surgically sterile or at least 2 years post-menopausal., 6. ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments., 1. participants who have completed 8 weeks of treatment in the preceding study (glyx13-c-202, nct01684163., 2. participants who wish to continue treatment with glyx-13 after the preceding study., 3. meets diagnostic and statistical manual, fourth edition, text revision (dsm-iv-tr) criteria for major depressive disorder (mdd)., 7. based on the investigator and naurex medical monitor's clinical judgment, subjects with eating disorders, obsessive compulsive disorder (ocd), panic disorder, post-traumatic stress disorder (ptsd), and generalized anxiety disorders secondary to major depressive episodes (mdes) are permitted., 5. clinical laboratory values <2 times the upper limit of normal (uln) or deemed not clinically significant per the investigator and naurex medical monitor.]"
NCT02192099,Exclusion Criteria,"[5. currently hospitalized or residing in an in-patient facility during study participation., 4. huntington's, parkinson's, alzheimer's, multiple sclerosis, or a history of seizures or strokes., 2. a clinically significant current axis ii diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder, 8. allergy or intolerance to current antidepressant or other current medications., 10. positive screen for drugs of abuse: cocaine, marijuana, pcp, ketamine, opioid or other agent that in the opinion of the investigator is being abused, 3. experiencing hallucinations, delusions, or any psychotic symptomatology in the current episode; lifetime history of psychosis., 9. participation in any clinical trial of an investigational product or device within 30 days of enrollment in this trial with the exception of glyx13-c-202., 11. pose current (past 6 months) suicide risk based on administration of the c ssrs and the investigator's clinical judgment., 7. women who are planning to become pregnant during the course of the study., 12. human immunodeficiency virus (hiv) infection (based on the based on the hiv-1 & hiv-2 antibody screen) or other ongoing infectious disease., 1. axis i diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar i or ii disorder, eating disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder, acute stress disorder, agoraphobia, social phobia, attention-deficit hyperactivity disorder (adhd), or ptsd., 6. substance abuse since the end of participation in glyx13-c-202, including greater than or equal to 5 units of alcohol per day where 1 unit = ½ pint of beer, 1 glass of wine 4 oz, or 1 oz. of spirits consumed most weeks or in the opinion of the investigator]"
NCT00203606,Inclusion Criteria,"[4. serum alt > 1.5 times upper limit of normal, 7. negative urine or blood pregnancy tests (for women of childbearing potential) documented within 24-hours prior to first dose of study drug., 2. chronic hepatitis c infection based on a history of positive anti-hcv antibody and/or hcv rna at least 6 months prior to study entry., 3. positive hcv-rna by roche amplicor hcv test at screening, 1. men or women age 18 to 75 years., 5. active or past use of injection drugs or crack cocaine by self-report. active use is defined as injection drug use at least 1/month and within 3 months of the date of randomization. past use is defined as no injection drug use or crack cocaine use within the past 5 years., 6. compensated liver disease, 8. all fertile males and females must use effective contraception during treatment and during the 6 months after treatment end if sexually active (this will be provided free of charge to active idus).]"
NCT00203606,Exclusion Criteria,"[7. unstable or uncontrolled thyroid disease 8. treatment with interferon- and/or ribavirin within the previous 12 months 9.  presence of clinically significant cryoglobulinemia vasculitis (e.g. skin rash, arthritis, or renal insufficiency due to cryoglobulinemia) 10. presence or history of autoimmune hepatitis, alpha-1-anti-trypsin deficiency, genetic hemochromatosis, wilson disease, drug- or toxin-induced liver disease, alcohol-related liver disease, primary biliary cirrhosis, or sclerosing cholangitis., 2. platelet count < 60,000/mm3, 13. a disease known to cause significant alteration in immunologic function, including hematological malignancy or autoimmune disorder., 4. serum creatinine level > 1.5 times the upper limit of normal (deleted february 27, 2007, protocol amendment #4, ethics approval march 28, 2007), 15. history of unstable or deteriorating cardiac, pulmonary or renal disease. 16. preexisting (within last two years) or active psychiatric condition including severe untreated depression, major psychoses, suicidal ideation or suicidal attempts., 5. hematology outside of specified limits: neutrophil count < 1000/mm3, hemoglobin < 10 g/l in males and < 9 g/l in females, 11. chronic hepatitis b infection or positive hbsag at screening 12. known history of hiv infection or positive hiv antibody test by western blot., 19. patients who have had a liver transplant 20. patients infected with hcv genotypes 4, 5 or 6 (< 1% of infected current/past idus), 3. serum alt level > 10 times upper limit of normal, 1. presence of clinically evident ascites requiring active diuretic therapy, history of or therapy for hepatic encephalopathy, or history of variceal bleeding within the last two years., 14. concurrent therapy with immunosuppressive drugs or cytotoxic agents, such as prednisone, cyclosporine, azathioprine or chemotherapeutic agents., 17. severe or poorly controlled diabetes mellitus 18. any serious or chronic disease that may affect the assessment of safety or efficacy parameters.]"
NCT00097435,Criteria,"[have compensated liver disease with the following minimum criteria:  white blood cell count > 3,000/mm3, absolute neutrophil count (anc) > 2,000/mm3, platelets > 125,000/mm3, and hemoglobin (hb) > 13 g/dl for males or > 12 g/dl for females., pregnant or lactating female., evidence of decompensated cirrhosis or portal hypertension., major exclusion criteria:, have previously failed to respond to treatment with any interferon alfa (ifna) product, history of any other medical disease or condition that would make the subject (in the opinion of the investigator) unsuitable for the study., a current drug or alcohol addiction, have a clinical diagnosis of chronic hep c    established on the basis of detectable viral load, as measured by a serum hcv rna test during the screening period.]"
NCT00148408,Inclusion Criteria,"[physician diagnosed asthma, inadequate asthma control over preceding two months, post-bronchodilator fev1 of at least 75% of predicted, regular use of prescribed asthma medication over preceding year, age 15 or older]"
NCT00148408,Exclusion Criteria,"[serious asthma exacerbation within previous three months, pregnancy, lack of effective contraception (when appropriate), lactation, current use of montelukast or history of adverse reaction to montelukast, history of respiratory failure due to asthma, inability or unwillingness to perform study procedures, concomitant interfering medical condition, participation in another clinical trial, current or past smoking (greater than 10 pack-years), regular use of oral corticosteroids]"
NCT00510939,Exclusion Criteria,"[4. patients with aml of fab m3 classification (apl), 9. patients with documented cases of human immunodeficiency virus (hiv), 7. participation in an investigational drug study within the 30 days prior to entry, 1. serum bilirubin 2 x> upper limit of normal (uln), 13. rasgrp1/aptx gene expression ratio calculated at the screening <10 (part b.2 only), 2. aspartate aminotransferase (ast/sgot) or alanine aminotransferase (alt/sgpt) >3.5 x uln, 5. patients with a history of another primary malignancy within the previous 1 year other than basal cell carcinoma or carcinoma in situ, the patient is in remission, 10. peripheral neuropathy or neuropathic pain grade > or = 2, 6. any clinically defined central nervous system aml., 11. has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used, 3. serum creatinine ³ 2.5 x uln or 24-hour creatinine clearance £ 60 ml/min (measured or calculated by cockcroft-gault), 8. evidence of uncontrolled infection or cns-hemorrhagic, 12. uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, new york heart association (nyha) class iii or iv heart failure (attachment 7,nyha classification of cardiac disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis]"
NCT00510939,Inclusion Criteria,"[1. provision of written informed consent, 2. male or female aged >18 years with newly diagnosed acute myeloid leukemia (aml), de novo or secondary, unfit for conventional chemotherapy, 3. male or female with acute myeloid leukemia in first relapse ( > 60 years), 6. rasgrp1/aptx gene expression ratio calculated at the screening >10 (part b.2 only), 4. who performance status ³ 2, or/and unwillingness to receive conventional chemotherapy, 5. negative pregnancy test or evidence of post-menopausal status for female patients.]"
NCT00131872,Inclusion Criteria,"[the vascular access graft can be placed in the upper extremity (forearm, including across the elbow, or upper arm), patient has given informed consent to participate in the trial and is willing to comply with the study protocol, patient is male or female, 18 years of age or older, patient is undergoing or will undergo hemodialysis at a hospital or hemodialysis center, patient has a vein 4 mm or larger to which the graft can be anastomosed, patient has chronic renal failure and requires vascular access for hemodialysis]"
NCT00131872,Exclusion Criteria,"[patient has a known sensitivity to polyurethane or porcine heparin, patient has an immunodeficiency syndrome, patient is unable to comply with the study follow-up, patient is pregnant, patient has a prior history of bacterial infection within 8 weeks of implantation of graft, patient has a history of heparin-induced thrombocytopenia syndrome (hit), patient has a severe coagulation disorder, patient has an elevated platelet count of greater than 1 million, patient has a previous vascular access graft implanted and it is not possible to place the study graft proximal to the existing device and no other sites are available, patient has a fever greater than 100 degrees fahrenheit]"
NCT00225654,Inclusion Criteria,"[patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery., patient or legal guardian must have signed informed consent., patient agrees to return at one month for an office visit to assess cardiovascular status and at 6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram., patient must be an acceptable candidate for coronary artery bypass surgery.]"
NCT00225654,Exclusion Criteria,"[patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye that., patient is simultaneously participating in another investigative interventional cardiovascular device or drug study., patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions., women of child bearing potential., patient has been diagnosed with a myocardial infarction within 72 hours prior to procedure., patient must be less than 18 years old., patient has other medical condition that may cause non-compliance with the protocol, confound the results, or is associated with limited life expectancy.]"
NCT00686517,Exclusion Criteria,"[history or evidence of symptoms of severe cardiac, gastrointestinal and kidney disease, liver disease unrelated to hcv infection, history of having received any systemic anti-neoplastic or immunomodulatory treatment in the previous 6 months, women with ongoing pregnancy or who are breast feeding, positive anti-human immunodeficiency virus (hiv) antibodies, hemoglobin (hgb) <12g/dl in women and <13g/dl in men; white blood cells (wbc) <3,000/ul; platelets (plts) <100,000/ul, history or other evidence of severe illness or any other conditions which would make the participants, in the opinion of investigator, unsuitable for the study (active drug addict except those under methadone treatment, thalassemic, dyalized included), history of severe psychiatric disease, especially depression, positive anti-nuclear antibodies (ana) and/or anti-smooth muscle antibody (asma) (>1/80), history of neurologic disease, especially epilepsy, positive hepatitis b surface antigen (hbsag)]"
NCT00686517,Inclusion Criteria,"[negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of the drug. additionally, all fertile males with partners of childbearing age and females must be using reliable contraception during the study and additionally for participants treated with ribavirin,  for 6 months  (for woman) and 7 months (for man and his partner) after treatment completion, normal and elevated serum alanine transferase (alt) levels, positive serum hcv-rna., diagnosed with acute hepatitis c virus (hcv)., aged between 18 and 65 years.]"
NCT00177528,Inclusion Criteria,"[17-item ham-d score of >15 for potential subjects who have not received any antidepressant treatment during this illness episode or ham-d > 11 for potential subjects who have received treatment with an antidepressant (other than venlafaxine-xr) during this illness episode;, a dsm-iv diagnosis of major depressive episode without psychotic features;, men and women of all races who are 60 years old or older;, a mmse score of >15.]"
NCT00177528,Exclusion Criteria,"[history of receiving venlafaxine-xr or venlafaxine immediate release formulation of 6 or more weeks at 300mg/d during index depressive episode; (7) ekg revealing qtc > 480 msec;, the presence of active suicidal ideation with intent., history of meeting dsm-iv criteria for mania, schizophrenia or other psychotic disorder;, untreated or uncontrolled hypertension;, myocardial infarction, unstable angina, palpitation or cardiogenic syncope within 3 months prior to entering this study;, current hyponatremia (as defined as a serum sodium level < 130 meq/l);, history of substance abuse or dependence, including alcohol, within the last three months;, a history of being unable to tolerate venlafaxine-xr or venlafaxine immediate release formulation;]"
NCT02359227,Criteria,"[current or historical new york heart association (nyha) functional class ≥ ii, key exclusion criteria:, known hepatic impairment as indicated by any of the following: a) total bilirubin > 3 mg/dl; b) albumin < 2.8 mg/dl, with other signs or symptoms of hepatic dysfunction; c) increased ammonia levels, if performed, with other signs or symptoms of hepatic dysfunction, symptomatic postural hypotension, known hypersensitivity or allergy to natriuretic peptide or its components, nesiritide, other natriuretic peptides or related compounds, acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns), male or female, ≥ 18 years of age, clinically significant aortic or mitral valve stenosis, stable and compliant treatment with oral heart failure medications for at least 4 weeks prior to screening, severe renal failure defined as creatinine clearance < 45 ml/min as estimated by either the cockcroft-gault or the mdrd equations, body mass index (bmi) of 18-40 kg/m2, inclusive, current clinical diagnosis of acute decompensated heart failure (adhf), systolic blood pressure 100-160 mmhg, at least one of the following: documented systolic heart failure with an ejection fraction (ef) ≤ 40% and/or a historical measurement of plasma bnp ≥ 150 pg/ml (or nt-probnp ≥ 600 pg/ml), significant pulmonary disease (e.g., history of oral daily steroid dependency, history of carbon dioxide (co2) retention or need for intubation for acute exacerbation, or currently receiving iv steroids), clinical diagnosis of acute coronary syndrome (acs) within 30 days prior to screening., evidence of uncorrected volume or sodium ≤ 130 mmol/l or other condition that would predispose the patient to adverse events]"
NCT00087594,Inclusion Criteria,"[enrolled in a methadone maintenance program with documented attendance for at least 3 months, naive to treatment for chc infection, adult patients at least 18 years of age, chc infection, genotype 1, 2, or 3, use of 2 forms of contraception during the study on both men and women]"
NCT00087594,Exclusion Criteria,"[previous treatment for chc infection, decompensated cirrhosis, current use of iv or other illicit drugs, co-infection with human immunodeficiency virus (hiv), women who are pregnant or breastfeeding]"
NCT00083772,Exclusion Criteria,"[lv ejection fraction < 40% (must be done within the last 30 days prior to signing consent), significant valvular disease or constrictive cardiomyopathy, if patient is of child-bearing age, a pregnancy test will be performed, and the patient is excluded if pregnancy test is positive., hypersensitivity to nesiritide or any of its components., patients with clinically significant hypotension (defined as a systolic blood pressure (sbp) <90 mm hg), active infection/sepsis as defined by fever > 101.5 f, currently on iv antibiotics, creatinine greater than 3.0 mg/dl, pulmonary capillary wedge pressure (pcwp) <16 mmhg, severe thrombocytopenia (as defined by platelets less than 20,000) or inr  > 1.6]"
NCT00083772,Inclusion Criteria,"[admitted with acute heart failure determined by: symptoms of fatigue; shortness of breath; edema; physical evidence of volume overload; and/or pulmonary edema by cxr, baseline systolic blood pressure > 90 mm hg, nyha class iii or iv on admission, age 18 to 85 years old, able to sign informed consent and return for follow-up assessments, baseline bnp level > 100 pg/ml, lvef > or = 40% on recent (< or = 1 month) echo or muga]"
NCT01996891,Exclusion Criteria,"[random glucose > 200 mg/dl, hemoglobin < 11 g/dl for males age 10-18 years; < 11. g/dl for females age 10-18 years; <11.4 g/dl for males >18 years; or <10.9 g/dl for females age > 18 years, use of systemic steroids for indication other than asthma, known eating disorder, any food allergy, any other major illness as assessed by medical history or the following screening tests:, body mass index (bmi) < 3rd centile (age- and gender- adjusted normative range from center for disease control), celiac disease, alanine aminotransferase (alt) > twice upper limit of normal for age, creatinine > 1.0  mg/dl  for age 10-18 years; > 1.2 mg/dl for females > 18 years; or > 1.4 mg/dl for males > 18 years)]"
NCT01996891,Inclusion Criteria,"[clinical diagnosis of moderate or severe persistent asthma, willingness to comply with study diet, currently prescribed inhaled corticosteroids for asthma with anticipated stable dosing regimen for the duration of the study, admission to boston children's hospital for clinical asthma exacerbation, age 10-21 years, medical clearance from primary care provider]"
NCT01511042,Exclusion Criteria,"[subjects with diastolic blood pressures greater than 100 mm hg while on anti-hypertensive medications, or systolic blood pressures greater than 160 mm hg while on anti-hypertensive medications will be excluded., history of coronary atherosclerotic disease, mi, cva, or significant peripheral vascular disease, subjects taking other medications (except thyroid supplements, oral hyperglycemic agents and insulin) will be excluded, subjects who are on medications that cannot be discontinued such as anti-depressants, anti-seizure medications, etc that may interfere with salt and water handling will not be studied., bmi > 40, current alcohol or drug abuse]"
NCT01511042,Inclusion Criteria,"[in overall good health, age between 18-65 years, bmi < 40, type ii diabetes mellitus]"
NCT00564811,Exclusion Criteria,"[patients with hepatitis auto-imune., cirrhosis, suckles, to be enclosed in another project of research or form of treatment, restriction for oral ingestion, the existence of surface of antigen of the hepatitis b virus(ag hbs), don't agree to the project or don't have signed the term of clarified free assent, pregnant women, the existence of antibody for the human immunodeficiency virus]"
NCT00564811,Inclusion Criteria,"[age: 24-70 years, to present genotype type 1,2,or 3, to have been informed and signed adequately the free and clarified assent, initiating the anti-viral treatment (interferon or pegylated interferon associate the ribavirin), race : all races, conditions full to the oral ingestion, body mass index- >18,5 e < 35kg /m2, gender :both the gender, to present serology positive to the  anti-vhc elisa]"
NCT00010738,Inclusion Criteria,"[local residence, able to attend training sessions and meetings]"
NCT00010738,Exclusion Criteria,"[cognitive/psychological/substance abuse impairment, renal failure, atrial fibrillation, predominant pacemaker rhythm or significant conduction system disease, comorbid disease precluding survival in group, class iii or iv heart failure, significant valvular heart disease, participating in a formal stress management program, mi, unstable angina, cabg or ptca within last three months., participation in another trial]"
NCT01918462,Inclusion Criteria,"[histological verification on liver biopsy, exclusion of other liver pathology including biliary disease, bilirubin > 80 mol/l, written, informed consent, neutrophil granulocytes > 10x10^9/l, diagnosis of alcoholic hepatitis:, relevant history of alcohol consumption (>40g/day for a minimum of 6 months with cessation      of consumption no earlier than 3 months prior to admission)]"
NCT01918462,Exclusion Criteria,"[other chronic inflammatory or autoimmune diseases, cancer, severe, acute bacterial infection (peritonitis, sepsis, pneumonia, urinary tract infection etc.), pregnancy, prednisolon or pentoxifylline treatment within the past 8 weeks]"
NCT02442180,Exclusion criteria,"[patient who refuses to participate in clinical trial, hypovolemic shock due to gastrointestinal hemorrhage or who need packed red blood cell (rbc) transfusion more than 3 units or increased modified discriminant factor (df) score greater or equal to 32 from below 32 due to gastrointestinal hemorrhage, myeloblast on peripheral blood smear test, portal vein thrombosis, hemochromatosis, autoimmune hepatitis, wilson's disease, alpha-1-antitrypsin deficiency, hepatic encephalopathy grade 3-4, history of adverse event including allergic response, hypersensitivity to g-csf, pregnancy, breast feeding, or who refuses contraception, or who cannot do contraception, hepatitis b surface antigen (hbsag), anti-hepatitis c virus (anti-hcv), or anti-human immunodeficiency virus (hiv) (+), history of steroid or pentoxifylline treatment within 3 months, hepatocellular carcinoma, sepsis or uncontrolled acute infection, critical comorbidities (type i hepatorenal syndrome, serum creatinine >2.5mg/dl, heart failure, pulmonary disease, psychiatric disease, acute pancreatitis etc.)]"
NCT02442180,Inclusion criteria,"[transjugular liver biopsy shows typical feature of alcoholic hepatitis or meet the clinical diagnosis (total serum bilirubin level over 5 mg/dl, aspartate aminotransferase/alanine aminotransferase ratio >2, aspartate aminotransferase < 300 iu/l), included patients should meet the all above criteria and lille score > 0.16  at the day 7 of prednisolone 40mg (or 32 mg of methylprednisolone) daily treatment., clinical significant alcohol intake history (men over 50g within 3 months, women over 40g within 3 months), modified df score greater than or equal to 32]"
NCT02188290,Inclusion Criteria,"[Double umbilical cord blood transplantation between 1 january 2010 and 31 december 2012 with no more than 2 human leukocyte antigen (hla)-mismatches at hla-a,  b, and/or -dr between each of the units and the recipient (ucb group), Allogeneic t-cell depleted hsct without atir administration from a haploidentical donor between 1 january 2006 and 30 june 2013 (haplo group), Male or female, age ≥ 18, ≤ 65 years., Myelodysplastic syndrome, allogeneic hsct from a fully matched or 1-locus mismatched unrelated donor between 1 january 2010 and 31 december 2012 (mud/mmud groups), Acute myeloid leukemia (aml) in remission at the time of the transplantation, Acute lymphoblastic leukemia (all) in remission at the time of the transplantation]"
NCT02188290,Exclusion Criteria,[allogeneic stem cell transplantation prior to the transplantation qualifying for the study.]
NCT00062569,Criteria,"[women and minorities are encouraged to participate., must be married couples or life partners living with alzheimer's disease or related disorder living within a 15-mile radius of boston college., not fluent in english., have no anticipated admission for long term care within 3 months., live in the community in a home setting (house, apartment, condominium);, have a primary caregiver spouse or partner who lives with the care recipient and agrees to be in the study; and, spouse or caregiver partner is the primary caregiver, including assistance with bathing., severe concomitant medical conditions of patient or spouse., have a diagnosis of probable alzheimer's disease or a related disorder according to standard criteria., couple does not meet the above inclusion criteria., have functional dependence in bathing;, couple resides in an institutional setting., couple anticipates a significant change of living situation within three months., demonstrate resistiveness to care during bathing;, exclusion:]"
NCT00225212,Inclusion Criteria,"[eastern cooperative oncology group (ecog) performance status 0 to 1, bilirubin < 2.0 mg/dl, creatinine < 2 mg/dl, b-cell, cd20+ nhl, liver function tests (lfts) < 5 x upper limit of normal (uln), evidence of engraftment post-autologous peripheral blood stem cell transplant (pbsc-t), aka autologous stem cell transplant (asct)]"
NCT00225212,Exclusion Criteria,"[graft source from bone marrow, evidence of active infection, progressive disease after asct, concurrent prednisone or other systemic steroid medication, evidence of active pneumonitis, presence of anti-murine antibody (hama) reactivity, nitrosourea therapy within 6 weeks of the first treatment with rituximab, concomitant treatment with radiotherapy, chemotherapy or immunotherapy including rituximab, post-asct radiotherapy, non-responders [progressive disease (pd) or stable disease (sd)] to prior anti-cd20 therapy]"
NCT01982162,Inclusion Criteria,"[4. the parent / guardian, or where appropriate the child must be able to read, comprehend, and write at a sufficient level to complete study related materials., 3. male or female subject aged between 1 - 17 years inclusive at screening., 2. assent should be obtained from all children in the study where appropriate., 5. subjects will be allowed to enrol in other studies while taking part on this study. however, permission from the scientific board must be obtained to enrol or allow the continued participation of a subject enrolled in another study., 1. parent / guardian must be able to give written informed consent prior to participation in the study, which includes ability to comply with the requirements and restrictions listed in the consent form. informed consent must be obtained prior to undertaking any study procedures.]"
NCT01982162,Exclusion Criteria,"[5. those who, in the opinion of the investigator, have a risk of non-compliance with study procedures., 6. prematurity ≤35 weeks gestation, 4. the child has participated within 3 months of the first dose in a study using a new molecular entity, or the first dose in any other study investigating drugs or having participated within three months in a study with invasive procedures. any u-biopred assessments should be deferred until 3 months after the first dose or invasive procedure. permission from the scientific board must be obtained to enroll or allow the continued participation of a child enrolled in another study., 1. as a result of medical interview, physical examination or screening investigation the physician responsible considers the child unfit for the study., 2. the subject has a history of drug or other allergy, which, in the opinion of the responsable physician, contra-indicates their participation., 8. history or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessment (assessment should be deferred)., 3. subject is female who is pregnant or lactating or up to 6 weeks post partum or 6 weeks cessation of breast feeding. if a woman is subsequently found to have been pregnant at the time of an assessment data from that assessment will not be included in the analyses, 7. the child had changed asthma medication within 4 weeks of the screening assessment(except those using the symbicort maintenance and reliever therapy (smart) regime)(assessment should be deferred), 9. the child has had a severe exacerbation (requiring er attendance or hospital admission and/or a course of high dose ocs for at least 3 days duration) within 4 weeks of the baseline assessment (assessment should be deferred).]"
NCT02330406,Inclusion Criteria,"[patients with low-density lipoprotein cholesterol equal to or greater than 100 mg/dl in the at least two of three measurements after the administration of statins, patients with type 2 diabetes with coronary heart diseases who treated with diet, exercise or antidiabetic medications, % if patients were not treated with dipeptidyl-peptidase 4 inhibitors) and lesser than 10.5 %, patients with glycerated hemoglobin (hba1c, ngsp) equal to or greater than 6.0 % (7.0, patients who were treated with statins for 8 weeks or longer]"
NCT02330406,Exclusion Criteria,"[patients with type 1 diabetes, patients whom physician in charge considered inappropriate for the study, patients with severe infections, perioperative status, or severe trauma, patients who were received glucagon-like peptide-1receptor agonists, rapid insulin secretagogue, or sodium glucose cotransporter 2 inhibitor, patients with triglyceride equal to or greater than 400 mg/dl in the previous fasting measuments, patients with pregnancy, possible pregnancy, or on breast-feeding, patients who were received insulin therapy or considered to need insulin therapy]"
NCT00195884,Inclusion Criteria,"[hba1c 0.066-0.099, male or female, age 40-70, treated with diet and/or oral agents (no insulin), type 2 diabetes mellitus as defined by the 1998 cda guidelines]"
NCT00195884,Exclusion Criteria,"[unwillingness to sign informed consent., other illness, judged by the patient or study physician to make participation in this study inadvisable., insulin therapy, or uncontrolled hyperglycemia (hba1c>0.099).  insulin therapy is an exclusion criterion because it would render homa insulin sensitivity calculation invalid., restrictions in physical activity due to disease: intermittent claudication, severe peripheral neuropathy or active proliferative retinopathy, unstable cardiac or pulmonary disease, disabling stroke, severe arthritis., changes in medications for diabetes, bp or lipids in the 2 months prior to enrollment., pregnancy at the start of the study, or intention to become pregnant in the next year., participation during the previous 6 months in a regular program of exercise or aerobic sports greater than 2 times per week for at least 20 minutes per session, or in any resistance training during the previous 6 months, inability to communicate in english or french., significant cognitive deficit resulting in inability to understand or comply with instructions., significant renal disease: serum creatinine greater than 200 meq/l. or proteinuria >1 g/24 hours., significant weight change (increase or decrease of greater than 5% of body weight during the two months before enrollment)., uncontrolled hypertension: bp >160 mm hg systolic or >95 mm hg diastolic bp in a sitting position.]"
NCT02003911,Exclusion Criteria,"[previous enrollment in study, receiving albuterol every 4 hours (q4h) at the time of enrollment, pregnancy, significant cardiac co-morbidity (including hemodynamically significant cardiac disease or arrhythmia), chronic systemic steroid use, invasive or non-invasive mechanical ventilation required acutely as result of current asthma admission, chronic lung disease other than asthma (including bronchopulmonary dysplasia, cystic fibrosis, bronchiectasis) or home oxygen requirement, immunodeficiency (primary or acquired), concurrent bacterial infection requiring antibiotics, liver disease (hepatitis), seizure disorder, currently on anti-epileptic medication), antibiotics received within previous 2 weeks, contraindication to azithromycin (including allergy to macrolides)]"
NCT02003911,Inclusion Criteria,"[history of persistent asthma (as defined by national heart, lung, and blood institute), admission diagnosis of asthma at the children's hospital at montefiore, 4-12 years of age]"
NCT01908075,Inclusion Criteria,"[baseline fp/sal therapy: ≥2 prescription for ics/laba therapy as fp/sal, evidence of asthma: a diagnostic code for asthma or two scripts for asthma.., aged: 18-80 years 61-80 years to be non-smokers only, evidence of switching for economic reasons: fp/sal patients from practices with ≥5 switches to fostair in a 3 month period to minimise data taken from switching of anomalous patients; optimal practices for inclusion are those switching \""wholesale\"" for economic reasons., evidence of continuing therapy: include only patients who receive ≥2 prescriptions for the therapy under study during the outcome year (i.e. ≥1 prescription at the index date and ≥1 other). uk average is 3-4 prescriptions refilled per year, so ≥2 ensures capture of \""real-life\"" data.]"
NCT01908075,Exclusion Criteria,"[are receiving maintenance oral steroid therapy during baseline period, any chronic respiratory disease other than asthma]"
NCT00331305,Inclusion Criteria,"[score of greater than 11 on the beck depression inventory (bdi), dsm-iv diagnosis of major depressive disorder (mdd)]"
NCT00331305,Exclusion Criteria,"[may require treatment with additional psychotherapeutic agents (other than chloral hydrate for sleep) during the course of the study, currently receiving antidepressant medication or actively engaged in psychotherapy, any of the following dsm-iv diagnoses: dementia or delirium; obsessive compulsive disorder (ocd); schizophrenia, schizoaffective, or other psychotic disorder; psychotic features, including any delusions or hallucinations during the current depressive episode; current alcohol or other substance abuse disorder; acute risk for suicide (e.g., score of greater than 2 on the suicide item on the ham-d) or acute risk for homicide, significant medical conditions that may cause an increased risk for a significant adverse experience during the course of the trial (e.g., unstable angina, myocardial infarction within 3 months of study entry, etc.), unable to be randomly assigned to an exercise condition due to medical conditions such as musculoskeletal problems or abnormal cardiac response to exercise (e.g., exercise-induced ventricular tachycardia, abnormal blood pressure response, etc.), unable to be randomly assigned to the study drug due to a risk for adverse cardiac events, such as prolonged qt interval, use of other medications that would be counterindicated for use with sertraline, or other conditions that may make study participation unsafe, currently exercising regularly, primary psychiatric diagnosis other than major depressive disorder (e.g., bipolar disorder)]"
NCT00233818,Exclusion Criteria,"[6. ejection fraction <=30%;, 8. totally occluded vessel;, 4. angiographic evidence of thrombus within target lesion;, 5. calcified lesions which cannot be successfully predilated;, 2. unprotected left main coronary disease with >=50% stenosis;, 7. target lesion involves bifurcation (either stenosis of both main vessel and major branch or stenosis of just major branch);, 3. have an ostial target lesion;, 1. a q-wave or non-q-wave myocardial infarction within the preceding 72 hours unless the ck and ck-mb enzymes are back to normal;]"
NCT00233818,Inclusion Criteria,"[4. target lesion is  >=3.0mm and <=3.5mm in diameter (visual estimate);, 3. target lesion is <=18mm in length (visual estimate);, 5. target lesion stenosis is >50% and <100% (visual estimate);, 1. diagnosis of angina pectoris as defined by canadian cardiovascular society classification (ccs) or a positive ischemia study;, 2. single de novo lesion requiring treatment in a major native coronary artery;]"
NCT02017795,Inclusion Criteria,"[3. ability to understand english and follow the material included in the two different interventions., 1. physician diagnosed asthma., 5. patients on maintenance inhaled corticosteroids alone or with a combination inhaler. subjects on other controller therapies will not be excluded as long as they fulfill these inclusion criteria., 2. a history of an asthma exacerbation requiring oral corticosteroids or admission to emergency department/hospital in the previous year., 4. ownership of a mobile phone with the capacity to support text messaging.]"
NCT02017795,Exclusion Criteria,"[4. subjects only taking a reliever medication and on no controller medication., 1. inability to provide written informed consent., 6. a history of an asthma exacerbation requiring oral corticosteroids in the previous six weeks., 3. not owning a mobile cell phone., 2. a history of smoking cigarettes for greater than ten pack years., 5. a history of significant co morbid disease judged by the investigator to preclude enrolment., 7. plans to move out of the study area in the next year. -]"
NCT02033252,Exclusion Criteria,"[3. having anatomical occlusion or deformation in nasal cavity., 8. received herbal medication for allergic rhinitis or asthma within 14 days., 13. who cannot participate clinical trial properly., 4. signs of infection in chest x-ray or having active respiratory disease except asthma, 5. below or equal to 4 on total nasal symptom score (tnss) in the latest week., 9. pregnant, planning the pregnancy or breast-feeding, 7. received following treatments for allergic rhinitis or asthma within six months ; traditional korean medicine interventions such as acupuncture, moxibustion, cupping therapy and herbal medication inhalation or cam including homeopathy., 2. experience of acute respiratory tract infection treated with antibiotics within 14 days, 12. night-shift workers staying up all night, 10. tuberculosis, hepatitis or more than 2 x normal limit of serum creatinine, ast/alt., 1. having experience using ventilator due to exacerbation of asthma symptoms within six months., 6. received drugs affecting directly to allergic rhinitis such as h1-antihistamines, decongestants (nasal, oral or ocular), corticosteroids within 14 days., 11. skin lesion on acupoint or other systemic disease insufficient for acupuncture.]"
NCT02033252,Inclusion Criteria,"[7. no problem with expression of opinion, 5. no changes in asthma or allergic rhinitis drugs for the past month, 9. no other disease except allergic rhinitis or asthma which could affect the disease., 2. moderate-severe symptoms according to allergic rhinitis and its impact on asthma (aria) criteria., 4. stable asthma symptoms with diagnosis of asthma by respiratory or allergic disease specialist., 8. provided with written consent, 1. suffering from persistent allergic rhinitis (par; nasal obstruction, rhinorrhoea, sneezing and nasal itching) symptoms for more than 4 days/week, and greater than 4 consecutive weeks., 6. aged greater than or equal to 18 years, either sex., 3. positive reaction for more than or equal to one respiratory allergen (spt or mast)]"
NCT01705132,Inclusion Criteria,"[4. alport syndrome diagnosis: clinical and/or histopathologic and/or genetic diagnosis of alport syndrome, as per the subject's physician and/or genotyping., 1. able to understand and comply with the requirements of the study and able to provide written informed consent., 3. physically able to provide a single first-morning urine sample of at least 30 ml (one ounce)., subjects eligible for inclusion in this study have to fulfill all of the following criteria:, 2. male and female subjects ≥ 5 years of age.]"
NCT01705132,Exclusion Criteria,"[1. use of investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations., 3. ongoing chronic hemodialysis therapy and/or renal transplant recipient., 4. nephrotic-range proteinuria: spot urine protein-to-creatinine ratio ≥ 3 on at least 2 of the last 3 clinical assessments., subjects fulfilling any of the following criteria are not eligible for inclusion in this study:, 2. chronic kidney disease, defined as a known diagnosis of ckd, and/or receiving chronic phosphate-lowering therapy or erythropoietin therapy.]"
NCT01902290,Inclusion Criteria,"[ics ≥ 200 and ≤ 1000/μg/day fluticasone powder or equivalent, percent of predicted fev1 ≥ 40% and ≤ 80% at screening, ongoing asthma symptoms with acq composite score at screening and baseline ≥ 1.5 points, diagnosis of asthma, and presently has reversibility over pre-bronchodilator fev1 of, ≥ 20 percent at screening]"
NCT01902290,Exclusion Criteria,"[subject has previously used any anti-il17  biologic therapy, female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile, subject has severe depression measured by personal health questionnaire depression scale (phq-8) or suicidal ideation/behavior as measured by and columbia suicide severity rating scale (e-cssrs), respiratory infection within 4 weeks of screening or 1 week of baseline visit, history of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma, subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study, subject has a history or evidence of psychiatric disorder or substance abuse considered by the investigator to pose a risk to subject safety, history of allergic bronchopulmonary aspergillosis, subject has known history of crohn's disease subject has any other significant concurrent medical condition of laboratory abnormalities, as defined in the study protocol]"
NCT02258893,Exclusion Criteria,"[no chronic respiratory condition other than asthma, no intention to move or relocate within 6 months, not using steroid medication for a condition other than asthma]"
NCT02258893,Inclusion Criteria,"[for potential subjects satisfying these inclusion criteria, a passive no2 monitor will be sent to the home for placement in the main living space for one week. families will be called after one week and instructed to cap and return the no2 monitor in a pre-paid mailer. families of children living in homes where the one-week integrated average no2 concentration is > 20 ppb will be invited to participate. we will permit the enrollment of more than one eligible child per family., β2-agonists, inhaled steroids, oral steroids, theophylline, cromones, and/or leukotriene inhibitors). based on symptoms and medication, asthma severity will be categorized with a score adapted from the global initiative for asthma guidelines (1=mild transient, 2=mild persistent, 3=moderate, 4=severe). only children in categories 2 (mild persistent, 3 (moderate) or 4 (severe) will be eligible.], 5-11 years of age, enrolled in grades k-5 and living in one of 16 selected towns, [the screening questionnaire will determine asthma symptoms in the past 12 months (wheeze, persistent cough, shortness of breath, chest tightness); and asthma medication use in the past 12 months (short-acting β2-agonists, long-acting]"
NCT00836368,Exclusion Criteria,"[4. use of anticoagulants including warfarin, heparin, or clopidogrel., 7. children will not be included in this study as the potential risk to a growing child cannot be justified., 5. diagnosis of anemia or abnormal blood counts at screening.   abnormal pt or ptt values at screening (pt that is prolonged more than 1-2 sec and ptt prolonged more than 3-5 sec of normal.  the normal values used will be those defined by mclendon lab.), 10. use of any tobacco product within the past 6 months, 6. pregnancy or nursing a baby.  as this is a phase i study, the potential risk to a fetus cannot be justified., 9. known vagal response to venipuncture, 11. hypertension, classified as a systolic blood pressure of equal to or greater than 140, and a diastolic blood pressure equal to or greater than 90., 8. adults age 51 and older are excluded as the potential for concomitant illness in this population increases the risk for confounding the data., 2. use of inhaled steroids, cromolyn or leukotriene inhibitors (montelukast or zafirlukast) which have been used for at least one month are allowed. patients must be on a stable regimen of maintenance asthma therapy which has not changed in the past month prior to entrance into the study., 1. any chronic medical condition considered by the pi as a contraindication to receiving gamma-t, including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, chronic thyroid disease, kidney disease or coagulation defects., 3. non-steroidal anti-inflammatory drugs (nsaids) or aspirin (asa) use within 48 hours of beginning the study, and inability to suspended use of these medications during the length of the study.]"
NCT00836368,Inclusion Criteria,"[1. specific allergy to house dust mite farinae confirmed by positive immediate skin test response., 2. asthma symptoms occurring at night or during sleep at least 1 time per week, 4. physician diagnosed moderate or severe persistent asthma which is currently treated or controlled with maintenance medication including moderate or high dose inhaled corticosteroid, or any dose of inhaled corticosteroid and a long-acting inhaled b2-agonist, 3. measured fev1 or fvc is <80% of predicted or, 2. oxygen saturation of > 94 % at baseline 3. blood pressure within the following parameters (systolic between 140 - 90, diastolic between 90-60 mm hg) 4. moderate or severe persistent asthma according to nhlbi definitions including history of one of the following:, 1. episodic wheezing, chest tightness or shortness of breath consistent with asthma occurring at least once a week that may affect activity]"
NCT02246959,Exclusion Criteria,"[will not or cannot give consent, co-morbidities likely to lead to death within a short period (e.g. metastatic cancer), under 18 years old, a contraindication to further statin use or have suffered statin side effects, such as myopathy, participating in another clinical trial with related aims, a history of active liver disease or abnormal liver function tests on baseline screening [alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 3x the upper limit of normal].]"
NCT02246959,Inclusion Criteria,"[diabetes and/or history of cvd (defined as diagnosis with myocardial infarction, stroke, or peripheral vascular disease), ldl greater than or equal to 130 mg/dl measured during screening of potential participants, medication possession ratio (mpr) less than 80%., a prescription filled for a statin medication within the last 12 months (derived from pharmacy records)]"
NCT00197002,Exclusion Criteria,"[administration of immunoglobulins and/or any blood products within three months prior to the first dose of study vaccine or planned administration at any time during the entire study period., use of any investigational or non-registered drug or vaccine within 42 days preceding the first dose of study vaccine, or planned use during the study period,, a family history of congenital, hereditary or infectious immunodeficiency or parental risk factors for hiv infection,, administration of the acip-recommended fourth dose of prevnar prior to entering the enrollment phase of the study,, history of hepatitis a or known exposure to hepatitis a,, history of any neurologic disorder (history of febrile seizures not associated with an underlying neurological disorder does not exclude the subject),, history of allergic disease/reactions or hypersensitivity likely to be exacerbated by any component of havrix (e.g., neomycin, 2-phenoxyethanol) or prevnar (e.g., diphtheria toxoid),, previous vaccination against hepatitis a,, major congenital defects or serious chronic illness,, planned administration or administration of any vaccine not foreseen by the study protocol within the period of 42 days before and 30 days after each dose of study vaccine(s),, acute disease, defined as the presence of a moderate or severe illness with or without fever, at the time of vaccination,, any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection,, chronic administration of immuno-suppressant or other immune-modifying drugs within six months prior to vaccination or planned administration at any time during the study period. (for corticosteroids, this will mean prednisone, or equivalent, less than 0.5 mg/kg/day. inhaled, nasal and topical steroids are allowed.),]"
NCT00197002,Inclusion Criteria,"[a male or female child 12 or 13 months of age at the time of entry into the enrollment phase,, subjects must have previously received three doses of prevnar in his/her first year of life., free of obvious health problems,]"
NCT01976208,Inclusion Criteria,"[written informed consent provided, male or female aged 15~65 years, poor response to moderate to high dose inhaled corticosteroid (400ug/day~800ug/day) >= 4 weeks, duration of allergic asthma >= 1 year according to gina(2008), agreed to be not pregnant, contraception during study and later 6 months., total serum ige >=60iu/ml]"
NCT01976208,Exclusion Criteria,"[prior exposure to xolair, patients with diabetes or uncontrolled hypertension(systolic blood pressure>160mmhg or diastolic blood pressure>95mmhg), an active lung disease other than allergic asthma, patients with significant underlying medical conditions, be regular smokers(>10 cigarettes per day and for at least 2 years), copd, according to the guideline of chinese society of respiratory diseases, patients who are currently pregnant or nursing or intend to become pregnant over the course of the study or later 6 months, patients who met the below criteria were excluded:, allergic to immunoglobin or any formulation ingredient of the product, hiv positivity or cancer patient]"
NCT02263794,Exclusion Criteria,"[subject is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material, subject has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants.)  (at the discretion of the mri technologist/3t manager), subject is pregnant, recent (within 4 weeks of bl visit 1) or current asthma exacerbation and/or respiratory tract infection, in the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the mri, such as severe claustrophobia., subject is unable to perform spirometry or plethysmography maneuvers]"
NCT02263794,Inclusion Criteria,"[inhaled corticosteroid (ics), other asthma medication such as leukotriene modifier, or anti-ige, are acceptable, beta-agonist reversibility of fev1>12%, or, subject able to perform reproducible pulmonary function testing (i.e., the 3 best acceptable spirograms have fev1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater.), long-acting beta agonist (laba), fev1 > 50%pred pre-bronchodilator, subject is judged to be in otherwise stable health on the basis of medical history, subject is a non-smoker for 1 year or greater (if former smoker less than 10 pack years total smoking history)., methacholine fev1 pc20 ≤ 8 mg/ml if not receiving ics or ≤ 16mg/ml if receiving an ics., subject has asthma and is taking regular maintenance medication for the past 12 months that includes:, male and female aged 18-60 years of age with a clinical diagnosis of asthma, as per:, subject assigned by the clinical team to receive bronchial thermoplasty as part of their asthma treatment plan, subject understands the study procedures and is willing to participate in the study as indicated by signature on the informed consent]"
NCT00009191,Criteria,"[stable medical history and general health, in the opinion of the study psychiatrist, patient has a current substance use disorder, as determined by the scid, patients who currently are being treated with antidepressants but continue to meet criteria for md (i.e., have not responded to the medications) and who are willing to discontinue the other medication and enter the study also will be included, diagnosis of current major depressive episode (md), by dsm-iv, based on the scid-iv examination, a caregiver who knows the patient well (spends at least 10 hours per week with him or her), and who is in reasonably good health, agrees to participate as well, currently residing in the community (own home,family member's home, or small group home) and agreeing to 13 weeks of followup in the study, diagnosis of probable alzheimer's disease (ad) by nincds/adrda criteria (mckann et al., 1984), with a mmse score greater than 10, may enter with any drug except another antidepressant., no psychotropic medicine dose changes, including cholinesterase inhibitors, after study entry, patient is acutely suicidal or requires inpatient psychiatric hospitalization, as determined by the study psychiatrist, patient has a lifetime diagnosis of schizophrenia, bipolar disorder, or pre-ad anxiety disorder, as determined by the scid, participant and his/her legal representative provide informed consent, exclusion:, patients will be included even if they have a pre-ad history of unipolar depression, use of sertraline is contraindicated, based on the food and drug administration package insert for sertraline]"
NCT00089635,Exclusion Criteria,"[use of systemic chemotherapy or radiotherapy within 30 days before enrollment, symptomatic brain metastases requiring treatment, prior anti-egfr antibody therapy with the exception of the small molecule egfr tyrosine kinase inhibitors, which are permitted, prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than 1 week) serum half-life within 30 days before enrollment, or prior experimental or approved proteins within 6 weeks before enrollment, patient with a history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis]"
NCT00089635,Inclusion Criteria,"[metastatic colorectal carcinoma, bidimensionally measurable disease, tumor expressing low to negative levels of egfr by immunohistochemistry, documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer, radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen is required, pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue biopsy), at least 2 but no more than 3 prior chemotherapy regimens for metastatic colorectal cancer, adequate hematologic, renal and hepatic function, eastern cooperative oncology group of 0, 1 or 2]"
NCT00110890,Exclusion Criteria,"[have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator, have had a parathyroidectomy in the 6 months before day 1, have received vitamin d therapy for less than 21 days before day 1 or required a change in prescribed vitamin d brand or dose within 21 days before day 1. if subjects are not prescribed vitamin d therapy, they must remain free of vitamin d therapy for the 21 days before day 1., are currently enrolled in, or have not yet completed at least 30 days before day 1, other invasive investigational device or investigational drug trials, or are receiving other investigational agents (experimental dialysis machines are acceptable), have a gastrointestinal disorder that may be associated with impaired absorption or orally administered medications or an inability to swallow tablets, experienced a myocardial infarction within 3 months prior to day 1, received, within 21 days before day 1 of the dose titration phase, therapy with medications that are predominantly metabolized by the enzyme cyp2d6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine, and most tricyclic antidepressants). the tricyclic antidepressant amitriptyline is permitted. -]"
NCT00110890,Inclusion Criteria,"[the mean of 2 serum calcium determinations (corrected for albumin) drawn on the same day as the pth determinations must be greater than or equal to 8.4 mg/dl (2.1 mmol/l), the mean of 2 ipth determinations within 21 days before randomization and drawn at least 2 days apart must be greater than or equal to 300 pg/ml (31.8 pmol/l) and less than 800 pg/ml (84.8 pmol/l). if bipth is determined, the mean levels must be greater than or equal to 150 pg/ml (15.9 pmol/l) and less than 410 pg/ml (43.5 pmol/l), esrd patients requiring maintenance dialysis (haemodialysis, haemodiafiltration, haemofiltration, or peritoneal dialysis) for at least 1 month]"
NCT01427855,Inclusion Criteria,"[agrees to abstain from alcohol and dietary supplements during the study, willing to consume all study foods as instructed, 30-65 years old, non-smoking]"
NCT01427855,Exclusion Criteria,"[blood pressure > 150/90, fasting triglyceride levels >500 mg/dl, fasting blood sugar >126 mg/dl, taking hormones or drugs known to affect lipid metabolism, history of heart disease, cerebrovascular disease, peripheral vascular disease, bleeding disorder, liver or renal disease, lung disease, diabetes, human immunodeficiency virus (hiv), or cancer (other than skin cancer) in the last 5 years, total- and ldl cholesterol >95th percentile for age and sex, not weight stable, body mass index (bmi) > 35 kg/m2 or < 20 kg/m2, abnormal thyroid stimulating hormone, pregnant or breastfeeding]"
NCT02072486,Exclusion Criteria,"[uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, any condition which in the investigator's opinion deems the subject an unsuitable candidate to receive study drug, patients who have had prior anti-angiogenic therapy, including but not limited to sorafenib, brivanib, bevacizumab, or sunitinib; prior treatment with liver directed, ablative or surgical therapies will be permitted as long as there is documented progression justifying the need for starting sorafenib therapy, unwilling or unable to follow protocol requirements, pregnant or nursing female subjects, no known contraindications to anti-angiogenics such as severe coronary artery disease, recent myocardial infarction or stroke within 6 months, bleeding peptic ulcer or varices within last 3 months, and any other major illness that may jeopardize study treatment or follow up]"
NCT02072486,Inclusion Criteria,"[outpatients with histologically/cytologically documented or radiographically diagnosed unresectable hepatocellular carcinoma (hcc) who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made; radiographic diagnosis needs typical findings of hcc by a radiographic method, i.e. on multi-dimensional dynamic computed tomography (ct), ct hepatic arteriography (ctha)/ct arterial portography (ctap) or magnetic resonance imaging (mri), patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding, subject or legal representative must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure, patients must have a life expectancy of at least 8 weeks]"
NCT00040378,Inclusion Criteria,"[62 years or older if other ethnic origin, or 60 years or older if african-american or hispanic;, general good health with no neurological or psychiatric illness., participating in select prevention study;]"
NCT00040378,Exclusion Criteria,"[the select doctors or staff will review the preadvise applicants' medical history and drugs to verify that they have no condition(s) that would exclude them from this study. the participant must not have any of the following neurological conditions based on self report (were told by a physician):, alzheimer's disease, or any other form of dementia such as pick's disease, dementia with lewy bodies, frontotemporal dementia, vascular dementia, significant cognitive and motor impairment from a stroke or corticobasal degeneration;, the participant must not have had a head injury with prolonged loss of consciousness (over 30 minutes) within the past five years;, the participant must not have had a diagnosis of depression or anxiety disorder in the past 4 months and must not currently be under treatment for depression or anxiety disorder.  [a participant who was previously diagnosed with depression or anxiety disorder but completed treatment more than four months ago is eligible.];, the participant must not have blindness, deafness, language difficulties or any other disability that may prevent completion of the memory screen., the participant must not have a current alcohol or substance abuse diagnosis, or must have been treatment free for the past 24 months;, huntington's disease, epilepsy, parkinson's disease, brain tumor, multiple sclerosis, manic-depressive disorder, or schizophrenia;, the participant must not currently use of any of the following medications: aricept, cognex, exelon, reminyl, or hydergine;]"
NCT02012400,Exclusion Criteria,"[severe hypotension, physician-diagnosed chronic obstructive lung disease, fev1 < 60 percent of predicted in spirometry, dementia, use of bronchodilating medication at least 4 times daily, serious coronary heart disease, severe musculoskeletal disorder, patients who exercise regularly already at baseline at least 3 times a week at least 30 min at a time, pef variability > 30 % at least 2 times during a 1-week monitoring period, permanent, daily steroid tablet treatment, severe heart failure]"
NCT02012400,Inclusion Criteria,"[diagnosis of asthma made by physician, or reimbursement for asthma medication from the national social insurance institution of finland (code 203), or patient fulfills the diagnostic criteria for asthma as outlined in the finnish guidelines for asthma management (käypä hoito -suositus 2006 and 2012)]"
NCT01507311,Inclusion Criteria,"[diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current oha (oral hypoglycaemic agent) treatment with stable dose for at least six months, fasting plasma glucose between 6 and 15 mmol/l (both inclusive), anti-gad (glutamic acid decarboxylase) negative, bmi (body mass index) between 24 and 35 kg/m^2 (both inclusive)]"
NCT01507311,Exclusion Criteria,"[with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides), liver or renal disease, recurrent severe hypoglycaemia as judged by the investigator, use of any drug (except oral hypoglycaemic agents (ohas)) which in the investigator's opinion could interfere, known or suspected allergy to trial product or related products, receipt of any investigational drug within three months prior to this trial, cardiac disease or any clinically significant abnormal ecg (electrocardiogram)]"
NCT00131846,Inclusion Criteria,"[aged 30 to 79 years, no history of gout, with blood pressure being >140/>90 if they are already on antihypertensive drugs, no history of type 2 diabetes, with blood pressure being >150/>90 if they are not on any antihypertensive treatment]"
NCT00131846,Exclusion Criteria,"[pregnant, possibility of pregnancy, or during breast feeding, patients already on thiazide diuretics, with history of malignant tumor within 5 years, patients who should be on thiazide diuretics, with erectile dysfunction, patients who are deemed not eligible for this study for any reason, patients already on antihypertensive treatment if duration of treatment and drugs used are not identified, with type 2 diabetes, with heart failure or left ventricular dysfunction (ejection fraction<40%), with hypokalemia（<3.5mmol/l）, with history of serious adverse reaction to thiazide diuretics, with history of percutaneous coronary intervention (pci) or coronary artery bypass graft (cabg) within 6 months or in whom these interventions are planned, with supine blood pressure being >200/>120, with history of stroke or myocardial infarction within 6 months, with renal dysfunction (s-creatinine > 2.0 mg/dl), with gout or hyperuricaemia (>8.0 mg/dl)]"
NCT00171054,Exclusion Criteria,"[certain hormonal therapy, severe hypertension, allergy to certain medications used to treat high blood pressure, history of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm, other protocol-defined inclusion/exclusion criteria may apply., ldl > 4.1 mmol/l if not taking anti-hyperlipidemic medication, liver, kidney, or pancreas disease, diabetes, raynaud's disease or any other significant peripheral vascular disease]"
NCT00171054,Inclusion Criteria,"[statin therapy or ldl≤ 4.1 mmol/l, mild to moderate hypertension, postmenopausal women]"
NCT00022880,Exclusion Criteria,"[patients with progressive disease within 1 year of irradiation arising in a field that has been previously irradiated with >3500 cgy., patients with new york heart association class iii or iv heart disease or other serious illness that would preclude evaluation., patients with prior malignancy other than cll, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years. patients who have been disease-free of another cancer for greater than 5 years must be carefully assessed at the time of study entry to rule out recurrent disease., patients with evidence of active infection requiring intravenous treatment with anti-infectives., patients with known hiv infection., patients with active obstructive hydronephrosis., patients who have received prior therapy with cytotoxic chemotherapy or immunosuppressants (with the exception of maintenance prednisone therapy not to exceed a dose of 20 mg/day for autoimmune hemolysis only) within four weeks prior to study entry (6 weeks for nitrosourea compounds) or who exhibit persistent clinical evidence of toxicity.  the prednisone must have been started more than 4 weeks prior to study entry., patients who are pregnant or nursing.  patients of childbearing potential must undergo a serum pregnancy test within 7 days prior to study entry.  males and females must agree to use a contraceptive method from enrollment to 6 months after receiving iodine-131 anti-b1 antibody., patients who are concurrently receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics., patients known to be hama positive.]"
NCT00022880,Inclusion Criteria,"[the bone marrow aspirate must demonstrate that greater than or equal to 30% of all nucleated cells are lymphoid., patients must fulfill the criteria for the diagnosis of intermediate-risk b-cell cll or high-risk b-cell cll, patients must have adequate renal function (defined as serum creatinine <1.5 x upper limit of normal [uln]) and hepatic function (defined as total bilirubin <1.5 x uln and ast <3 x uln) within 14 days of study entry.  for patients with autoimmune hemolytic anemia, the bilirubin must be less than or equal to 8 x uln., patients must have evidence that their leukemic lymphocytes express the cd20 antigen., patients must have an absolute granulocyte count >500 cells/mm3 and a platelet count of either >100,000 cells/mm3 (cohort a) or a platelet count of 75,000-100,000 cells/mm3 deemed to be secondary to cll by the investigator, (cohort b) within 14 days of study entry.  these blood counts must be sustained for 4 weeks without support of hematopoietic cytokines or transfusion of blood products., patients must have a karnofsky performance status of at least 60% and an anticipated survival of at least 3 months., patients must have been previously treated with chemotherapy or biologic therapy and have progressed on, failed to achieve an objective response (cr or partial response [pr]) on, or progressed after completion of last therapy.  patients must have received at least one therapy containing a purine nucleoside analogue. patients must not have received more than 4 prior therapies.  this includes both chemotherapy and biologic therapy.]"
NCT00263705,Exclusion Criteria,[n/a-]
NCT00263705,Inclusion Criteria,"[4. transaminases < 2.5 x upper normal limit for the institution, endocrine responsive (er and pgr > 5 according to harvey score or > 30% of positive cells by immunohistochemistry) and at least two risk factors (pt³ 2 cm, n+, g3, her-2/neu positive, etc.) or, symptomatic ventricular arrhythmias;, 5. calculated creatinine clearance of > 30ml/min (using the crockoft and gault formula), very high risk (n>3) any er/pgr., 1. women aged ³70 years, clinical and/or ecg evidence of myocardial infarction within the last 12 months;, 6. absence of, clinically significant congestive heart failure;, endocrine responsiveness doubtful (er and/or pgr- or poor [3 to-5 according to harvey score (12) or £ 30% of positive cells by immunohistochemistry) and other risk factors (pt³2 cm or n+ or g3 or her-2/neu positive, etc.) or, 2. platelets ³100 x 109 / l, 3. bilirubin < 1.25 x upper normal limit for the institution, 7. written informed consent obtained according to local ethics committee guidelines -, coronary artery disease requiring medication., 3. ecog performance status £ 1, endocrine non responsive (er- and pgr -) and pt>1 cm, any t if n+ or, 2. histologic diagnosis of early breast cancer for which the treating physician considers adjuvant chemotherapy to be beneficial. recommended situations are for example:, 1. neutrophils ³ 1.5 x 109 /l, 6. absence of any psychological, familial or sociological condition or comorbidities that may affect compliance, 5. adequate organ function including:, 4. no previous exposition to chemotherapy in the neoadjuvant setting]"
NCT00317187,Inclusion Criteria,"[• healthy infants 56-83 days of age at the time of the first vaccine dose, written informed consent obtained from the parents, born after a gestation period of 36 to 42 weeks & has received a birth dose of hepatitis b vaccine within the first 3 days of life.]"
NCT00317187,Exclusion Criteria,"[use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period., any confirmed immunodeficient condition, based on medical history and physical examination., chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth., history of diphtheria, tetanus, pertussis, hepatitis b, haemophilus influenzae type b and/or meningococcal disease or known exposure to these diseases since birth., bacille calmette-guérin (bcg) vaccine received after the first 2 weeks of life., planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine, or planned administration during the study period with the exception of oral polio vaccine (opv)., previous vaccination against diphtheria, tetanus, pertussis, haemophilus influenzae type b, and/or meningococcal disease., administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.]"
NCT00400036,Inclusion Criteria,"[overweight or obese (bmi between 25 and 40 kg /m2), fasting plasma insulin above 90 pmol/l, fasting plasma glucose below 7.0 mmol/l and 2-h plasma glucose below 11.1  mmol/l, waist circumference above 88 cm for women and 102 cm for men]"
NCT00400036,Exclusion Criteria,"[subjects with dietary incompatibility with fish consumption (allergy, intolerance or dislike) and/or calcium supplementation, smokers, individuals taking any medication known to affect lipid or glucose metabolism, individuals with diagnosed diabetes or any chronic, metabolic or acute disease, individuals who had a major surgery within the last 3 months, individuals who had a significant weight loss (±10%) within the last 6 months]"
NCT00458848,Criteria,"[no other concurrent malignant disease, phenotype t (t-all) or b (b-all), no mature b-all (fab l3, serum immunoglobulin-positive, terminal deoxynucleotidyl transferase-negative), creatinine ≤ 2.5 mg/dl (after adequate hydration), patient characteristics:, lvef ≥ 50%, negative myeloperoxidase stain, no other concurrent chemotherapy or radiotherapy, no prior antiblastic chemotherapy, no presence of documented infections not responding to antibiotic and/or antifungal therapy, not pregnant, no prior steroids, prior concurrent therapy:, diagnosis of acute lymphoblastic leukemia (all) meeting the following criteria:, no severe psychiatric disorders, sgot and sgpt ≤ 3 times upper limit of normal]"
NCT00251953,Exclusion Criteria,"[any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study, history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells), received any investigational product in other clinical studies within 12 weeks, new york heart association heart failure class iii or iv, type 1 diabetes, creatine kinase above 3 times the upper limit of normal, creatinine levels above twice the normal range, treatment with chronic insulin, history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin)]"
NCT00251953,Inclusion Criteria,"[provision of a written informed consent, treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents, men or women who are >=18 years of age, diagnosed with type 2 diabetes, female patients:  postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control]"
NCT00643045,Exclusion Criteria,"[or who were experiencing end of dose wearing-off;, who were depressed,, female patients of childbearing potential;, had evidence of dementia or cognitive dysfunction,, patients with medical conditions and/or taking concomitant medications that would have put them at risk, interfered with the study evaluations, or made them unable to complete the requirements of the study;, patients who have previously received safinamide., a history of psychosis,, patients with a diagnosis or recent history of substance abuse,]"
NCT00643045,Inclusion Criteria,"[who were receiving treatment with a single dopamine agonist at a stable dose for at least 4 weeks prior to visit 1 (screening)., patients with a diagnosis of idiopathic parkinson's disease of less than 5 years duration, and a hoehn and yahr stage of i to iii,]"
NCT00251589,Exclusion Criteria,"[patient had prior treatment with vorinostat or erlotinib., patient has any of the following conditions: active infections including hepatitis b or c, unstable brain metastases, swallowing difficulties, heart problems, significant eye abnormalities, drug or alcohol abuse, mental illness or pregnancy.]"
NCT00251589,Inclusion Criteria,"[at screening the patient must have normal lab results and can not be pregnant., women and men must agree to practice adequate birth control during the study., patients must be 2 weeks out from radiation therapy., patient has the ability to understand and sign the consent form., males and females 18 years of age and older with a confirmed diagnosis of non-small-cell lung cancer (nsclc) who have failed at least one prior treatment for nsclc., patients must have proven disease by ct scan or mri., patients must be at least 4 weeks from any chemotherapy for cancer or from any surgeries or from any treatment using an investigational drug.]"
NCT00068068,Exclusion Criteria,"[patients who are candidates for complete surgical resection., known uncontrollable serious reactions such as anaphylaxis, to the contrast agents used in this study., platelet count less than 100,000., serum creatinine greater than 2.5 x uln., pt or ptt greater than 1.5x control., patients must be excluded if any of the following apply:, neutrophils less than 2000/mm., hemoglobin less than 9 g/dl., total bilirubin greater than 1.5 x uln., wbc less than 2500/mm., pregnancy or breast-feeding.  a negative pregnancy test (urine or serum) is required prior to enrollment., liver enzymes greater than 3 x uln.]"
NCT00068068,Inclusion Criteria,"[patients with 4 or fewer lesions greater than 1 cm and with no single lesion greater than 7 cm in maximum diameter., biopsy proven evidence of colorectal cancer., patients with metastatic liver lesions from colorectal disease who have failed or progressed on a chemotherapy regimen for metastatic disease., ecog performance status 0-2., age greater than or equal to 18 years., patients must be able to sign informed consent., off chemotherapy for 4 weeks.  must have recovered from the chemotherapy effects., patients with extrahepatic disease in addition to their hepatic metastases are eligible and will receive systemic therapy for their extrahepatic disease following litx therapy., life expectancy greater than or equal to 3 months.]"
NCT00235859,Inclusion Criteria,"[therapy with mtx for at least 6 months prior to screening and on a stable dose of mtx for at least 4 weeks prior to screening visit, age 18 years and older, subjects must have received at least one prior dmard besides mtx, but may have had efficacy failures on no more than four standard dmards other than mtx, meet acr criteria for diagnosis of active ra and have at >6 swollen joints and >9 tender joints]"
NCT00235859,Exclusion Criteria,"[history of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (tb), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin., female who is pregnant or breast-feeding., prior treatment with any tnf antagonist, including adalimumab, chest x-ray with calcified granuloma and/or pleural scarring, subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-cd4 antibody, within 6 months prior to the screening evaluation, prior treatment with any tnf antagonist, including adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide., positive tb skin test, rt23 dose skin test, >5 mm at 48 to 72 hours, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 3 months of the screening evaluation) or any poorly controlled medical condition, intra-articular, intramuscular or iv administration of corticosteroids within 4 weeks prior to screening evaluation]"
NCT00065143,Exclusion Criteria,"[aml with the following cytogenetic abnormalities: t(15;17), t(8;21), inv(16). cytogenetic results do not need to be available if immediate induction is required (see inclusion #7)., cardiac ejection fraction < 30%. pretreatment assessment of ejection fraction is not necessary if immediate induction is required as long as by history and physical examination patients have </= nyha class ii disease (see inclusion #7)., active and uncontrolled infection or any other severe concurrent disease considered life-threatening, or which, in the judgement of the investigator and after discussion with the principal investigator, would make the patient inappropriate for entry into the study.]"
NCT00065143,Inclusion Criteria,"[patients who are considered to require immediate induction (rapidly rising wbc >/= 50,000 and/or organ involvement as per the assessment of the treating physician) can be treated without final cytogenetic results and pretreatment assessment of cardiac ejection fraction (muga or echocardiogram) if by history and physical examination patients have </= nyha class ii disease., age > 50 years to < 74 years (diploid cytogenetics) and < 69 years (abnormal cytogenetics)., ecog performance status  </= 2., sign a written informed consent form., previously untreated acute myeloid leukemia (aml) or high-risk myelodysplastic syndrome (mds)  (> 10% blasts).  prior therapy with hydroxyurea, single agent chemotherapy (e.g. decitabine), hematopoietic growth factors, biological or \""targeted\"" therapies are allowed., adequate liver function (total bilirubin < 2mg/dl, sgpt or sgot < x 4 uln) and renal function (serum creatinine < 2mg/dl)., male and female patients who are fertile agree to use an effective barrier method of birth control (ie, latex condom, diaphragm, cervical cap, etc) to avoid pregnancy. female patients need a negative serum or urine pregnancy test within 7 days of study enrollment (applies only if patient is of childbearing potential. non-childbearing is defined as >= 1 year postmenopausal or surgically sterilized).]"
NCT01577420,Exclusion Criteria,"[regularly using foot massage, bedridden, receiving hospice care at intake, receiving investigational new drug chemotherapy, undergoing bone marrow transplant, regularly using pedicure with foot massage, living in nursing home or similar facility, regularly using reflexology]"
NCT01577420,Inclusion Criteria,"[able to speak and understand english, palliative prognostic score of 11 or lower, free of diagnosis of mental illness on chart, access to a telephone, receiving chemotherapy at intake into the study, oriented to time, place, and person as determined by nurse recruiter, diagnosis of stage iii or iv breast cancer, or stage i or ii with metastasis or recurrence, able to perform basic adls]"
NCT00202345,Exclusion Criteria,"[14. adult polycystic kidney disease, 10. iron deficiency* (ferritin <30ug/l and tsat <15%)or other haematinic disorder, 9. persistent sepsis* or significant chronic inflammation (crp > 25)*, 11. active and significant haemolysis*, 5. haemochromatosis or iron overload* (ferritin >300µg/l and tsat >25%), 6. liver failure, 13. concurrent or significant past (>6 months) immuno-suppression, 3. unstable ischaemic heart disease*, 15. current use of an esa, 8. active malignancy or gastrointestinal bleeding*, 16. on dialysis *: patients can still be considered eligible after condition is reversed or treated, 4. uncontrolled, severe, congestive cardiac failure, 2. pregnancy*, 1. age > 80, 7. myelodysplastic syndromes or monoclonal gammopathies, 12. previous organ transplantation]"
NCT00202345,Inclusion Criteria,"[3. demonstration of a clinically significant rise in creatinine and/or a drop in hb concentration in the previous 18 months. if such data are not available, the investigator will make a decision regarding eligibility based on the clinical circumstances., 1. initial hb concentrations ≥ 110g/l (males and females), 2. calculated gfr  ≤ 35ml/min (≤ 50ml/min for diabetics)]"
NCT00065325,Inclusion Criteria,"[written informed consent to participate in the trial, breast cancer has continued to grow after having received treatment with an aromatase inhibitor, postmenopausal women defined as a women who has stopped having menstrual periods, biopsy confirmation of breast cancer, evidence of hormone sensitivity]"
NCT00065325,Exclusion Criteria,"[previous treatment with faslodex (fulvestrant) or aromasin (exemestane), any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor, a history of allergies to any active or inactive ingredients of faslodex or exemestane (i.e. castor oil or mannitol), treatment with an investigational or non-approved drug within one month, an existing serious disease, illness, or condition that will prevent participation or compliance with study procedures]"
NCT00452374,Exclusion Criteria,"[3. pregnancy or lactation., 1. untreated or uncontrolled life-threatening infection., 2. oxaliplatin, fludarabine, cytarabine or rituximab intolerance., 5. medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results., 4. chemotherapy and/or radiation therapy within 4 weeks.]"
NCT00452374,Inclusion Criteria,"[1. histologically or cytologically confirmed richter's transformation, fludarabine-refractory chronic lymphocytic leukemia or prolymphocytic leukemia., 4. patients must have adequate renal function (serum creatinine below or equal to 2mg/dl or creatinine clearance greater than 30ml/min), unless renal dysfunction is considered due to organ infiltration by disease., 6. female patients of childbearing potential (including those <1 year post-menopausal) and male patients must agree to use contraception., 3. patients must have a performance status of 0-2 (zubrod scale)., 7. patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital., 2. patients must be 18 years of age or older., 5. patients must have adequate hepatic function (bilirubin less than or equal to 2.0 mg/dl; serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvic transaminase (sgpt) less than or equal to 3 times the upper limit of normal (uln) for the reference lab unless considered due to leukemia or congenital hemolytic disorder (for bilirubin)., 8. patients must have platelet counts greater or equal to 20,000, unless due to disease involvement, or autoimmune disorders.]"
NCT00333138,Inclusion Criteria,"[a positive gd-enhanced mri scan at screening (in case the first mri scan obtained at screening was negative, a second scan could have been obtained 1 month later), patients with an expanded disability status scale (edss) score of 0-6, patients with at least two documented relapses in the previous 2 years or one documented relapse in the last year, diagnosis of relapsing multiple sclerosis (ms), neurologically stable with no evidence of relapse within 30 days prior to randomization,or during the screening and baseline periods., female patients either post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control. females of childbearing potential with a negative pregnancy test at baseline prior to entry into the treatment period., extension study]"
NCT00333138,Exclusion Criteria,"[patients with other chronic disease of the immune system, malignancies, pulmonary or heart disease, etc, patients who had permanently discontinued study drug prior to the month 6 visit of the core study, patients with diabetes mellitus (to reduce the risk of me), and therefore ongoing patients with diabetes mellitus or who developed diabetes mellitus were discontinued from the study), extension study, other protocol-defined inclusion/exclusion criteria may apply, core study, pregnant or nursing women]"
NCT00089310,Criteria,"[18 and over, not specified, not pregnant or nursing, chemotherapy, patient characteristics:, renal, not specified, surgery, no prior mediastinal radiotherapy, planned surgical resection of lung cancer, endocrine therapy, ecog 0-2, diagnosis of non-small cell lung cancer, performance status, clinical stage i disease, not specified, not specified, not specified, other, resectable disease, other, see disease characteristics, hepatic, radiotherapy, life expectancy, biologic therapy, prior concurrent therapy:, fertile patients must use effective contraception, no prior therapy for the malignancy, hematopoietic, not specified, not specified]"
NCT00396136,Inclusion Criteria,"[age greater than or equal to 18 years, successfully implanted biotronik crt-d system, including the corox otw steroid lv lead, from 1-30 days prior to enrollment, available for follow-up visits on a regular basis at the investigational site, able to understand the nature of the registry and give informed consent]"
NCT00396136,Exclusion Criteria,"[pregnancy, expected to receive a heart transplant within 6 months, enrolled in another cardiovascular or pharmacological clinical investigation, presence of another life-threatening, underlying illness separate from their cardiac disorder, life expectancy less than 6 months, planned cardiac surgical procedures or interventional measures within the next 6 months]"
NCT00183963,Exclusion Criteria,"[history of dvt or pulmonary embolism, underlying medical, psychiatric or social conditions that would preclude patient from receiving treatment., prior hormonal therapy (antiestrogens, estrogen, serm's, progestins, or aromatase inhibitors) within 6 months of study entry.]"
NCT00183963,Inclusion Criteria,"[total bilirubin less than or equal to 2.0 upper limit of normal (uln), transaminases (sgot and/or sgpt) and alkaline phosphatase may be up to 2.5 x institutional upper limit of normal (uln), agc greater than or equal to 1500, platelets greater than or equal to 100,000, hemoglobin greater than or equal to 8.0 g/dl, postmenopausal women with newly diagnosed dcis.  women will be considered to be in menopause if they fall into one of the following groups:, fsh/estradiol levels in postmenopausal range for the institution, peripheral neuropathy grade 0-1., dcis must have been diagnosed with a minimally invasive biopsy technique, such as a vacuum-assisted large core tool (mammotome) or an equivalent method., swog performance status of less than or equal to 1, there must be available tissue from the diagnostic biopsy to perform molecular markers., status post bilateral oophorectomies, age > 60, no prior therapy for dcis., baseline mammogram within 8 weeks of study entry., serum creatinine less than or equal to 2.0 mg/dl., all patients must provide informed written consent, age > 45 with amenorrhea > 1 year with intact uterus]"
NCT00920842,Criteria,"[disease in remission, healthy sibling of a childhood leukemia survivor, not pregnant, prior concurrent therapy:, patient characteristics:, survivor of childhood leukemia, meeting all of the following criteria:, has undergone hematopoietic stem cell transplantation (hsct) at fairview university medical center or fred hutchinson cancer research center ≥ 2 years ago, 21 years of age and under at diagnosis, negative pregnancy test, see disease characteristics, meets 1 of the following criteria:]"
NCT00933634,Exclusion Criteria,"[af of more than 48 hours', use of antiarrhythmic drugs, hypothermia, sepsis, electrolyte disturbances, acute onset atrial fibrillation due to acute coronary syndrome, unclear duration of symptoms, hemodynamic instability, high embolic risk, fever, untreated hyperthyroidism]"
NCT00933634,Inclusion Criteria,[atrial fibrillation of less than 48 hours' duration.]
NCT00323557,Exclusion Criteria,"[6. chemotherapy other than campath, fludarabine, cyclophosphamide, in 4 weeks., 7. patients who have previously received pneumococcal vaccine within the preceding 12 months., 5. known history of allergy to granulocyte/ macrophage colony stimulating factor (gm-csf) or pneumococcal vaccine., 2. patients will not be entered while febrile (temperature > 38 degrees c) within 1 week., 3. active infection., 8. absolute lymphocyte count less than 500 cells/mm3., 1. patients will not be entered while neutropenic (pmns < 500 cells/mm3) or having received rituximab within 6 months., 4. patients with known human immunodeficiency virus (hiv) infection.]"
NCT00323557,Inclusion Criteria,[1) patients in complete / partial remission or those with active chronic lymphocytic leukemia (cll) with rai stage 0 to 4.]
NCT00256243,Inclusion Criteria,"[patients must meet one of the criteria defined below (indicate one):, patients must have a serum creatinine and bilirubin ≤ the institutional upper limit of normal, and an serum glutamic oxaloacetic transaminase  (sgot) or serum glutamic pyruvic transaminase  (sgpt) ≤ 2x the institutional upper limit of normal.  these tests must have been performed within 90 days prior to registration., 2. stage iiib (t4, any n, m0) or (any t, n3, m0) disease., physical examination, chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration., pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen.  women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.  a urine pregnancy test is required for women of childbearing potential., patients must have a performance status of 0-2 by zubrod criteria, 1. selected stage iib (t3, n0, m0) or iiia (t3, n1-2, m0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment., patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma.  histologic confirmation shall be by either core needle biopsy or incisional biopsy.  punch biopsy is allowed if invasive breast cancer is documented., patients must have an absolute neutrophil count  (anc) of ≥ 1,500/μl and a platelet count of ≥ 100,000/μl.  these tests must have been performed within 90 days prior to registration., patients with the clinical diagnosis of congestive heart failure or angina pectoris are not eligible.  patients with hypertension or age > 60 years must have a multiple gated acquisition (muga) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (na) if no muga required) and left ventricular ejection fraction  (lvef) % must be greater than the institutional lower limit of normal., all patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.]"
NCT00519545,Exclusion Criteria,"[12. inability to understand instructions on how to complete a questionnaire., 13. no access to a phone., 6. uncontrolled diabetes mellitus., 1. concurrent treatment with chemotherapy or radiation therapy, 2. less than 3 months since last dose of chemotherapy or radiation therapy., 8. severe liver disease. severe lung disease., 10. psychological or psychiatric disorder that would interfere with study compliance., 11. history of missed appointments or poor medical compliance., 7. severe heart disease., 4. less than 21 or greater than to 80 years old., 9. history of smoking within 5 years of study enrollment., 3. breast cancer diagnosis more than 5 years prior to study enrollment, 5. life threatening or severe concurrent non-malignant conditions.]"
NCT00519545,Inclusion Criteria,"[7. willing to comply with monthly follow-up phone calls., 1. primary histological diagnosis of stage i-iv breast cancer., 8. willing to complete questionnaires at regular oncology clinic visits., 5. ecog performance status of 0, 1, or 2., 3. not currently receiving chemotherapy or radiation therapy. hormone therapy is allowed., 4. life expectancy of at least 12 months., 6. willing to sign informed consent indicating that they are aware of the investigational nature of the study and the randomized study design., 2. initial diagnosis of breast cancer within 5 year of study enrollment., 9. able to read write & understand english.]"
NCT00263042,Exclusion Criteria,"[pregnant or breastfeeding women, allergy to rimonabant or excipients, or prior participation in a rimonabant trial, obesity of known endocrine origin, likely cardiovascular intervention within next 1 month, receipt of investigational product within past 30 days, presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation, including uncontrolled serious psychiatric illness, very low calorie diet or weight loss surgery within past 6 months]"
NCT00263042,Inclusion Criteria,"[age > or = 65 years for males, age > or = 70 years for females, documented type 2 diabetes mellitus, documented symptomatic coronary artery disease, recent (within 3 years) ischemic cerebrovascular episode (stroke or tia), major risk factors:, documented symptomatic peripheral arterial disease, elevated high-sensitivity c-reactive protein, asymptomatic cerebrovascular, renal, or peripheral arterial disease, or past abdominal aortic aneurysm repair, recent (within 3 years)documented heart attack, metabolic syndrome (ncep criteria), waist circumference >102 cm (40 inches) males, >88 cm (35 inches) females, with one coronary heart disease (chd) equivalent or two major risk factors for cardiovascular disease., chd equivalents:]"
NCT01674062,Exclusion Criteria,"[history of any cardiac ae related to herceptin therapy, brain metastases, previous treatment with an anti-cancer vaccine or any targeted therapy other than herceptin, any other malignancy in the last 5 years, except for basal cell cancer or cancer in situ of the cervix]"
NCT01674062,Inclusion Criteria,"[lvef>= 55% at study entry, adult patients, >=18 years of age, with histologically-confirmed her2-positive breast cancer, last herceptin dose <=9 weeks before study entry for patients reciving pertuzumab +, <=3 chemotherapy regimens prior to study entry, herceptin, and >=4 weeks for patients receiving pertuzumab monotherapy, metastatic breast cancer, with progression on herceptin-based therapy as last treatment for metastatic disease]"
NCT00744835,Inclusion Criteria,"[age between 18 and 70, history of symptomatic permanent atrial fibrillation, willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study]"
NCT00744835,Exclusion Criteria,"[any ventricular tachyarrhythmias currently being treated where the arrhythmia or the management may interfere with this study, left atrial thrombus at the time of ablation, any history of cerebral vascular disease including stroke or tias, known sensitivities to heparin or warfarin, prior ablation for arrhythmias other than af within the past three months, pregnancy or lactation, untreatable allergy to contrast media, enrollment in any other ongoing arrhythmia study protocol, severe comorbidity or poor general physical/mental health that, in the opinion of the investigator, will not allow the patient to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, shortened life expectance, etc.), severe copd (identified by an fev1 < 1), active infection or sepsis, structural heart disease of clinical significance, any diagnosis of af secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiovascular causes, history of blood clotting (bleeding or thrombotic) abnormalities, any prior ablation for atrial fibrillation]"
NCT00684489,Exclusion Criteria,"[serum creatinine >2.5 mg/dl unless documented stable for at least one year, intolerance to two or more classes of antihypertensive medications, normal home bp (<140/90 mmhg at baseline), i.e., office only hypertension., uncontrolled diabetes or hyperlipidemia requiring medication changes, any life-threatening illness, dialysis for chronic renal failure, even if creatinine stable for at least one year, history of alcohol or drug abuse in past 5 years, any active disease process requiring new diagnostic and therapeutic plans, mental illness or personality disorder that interfere with adherence to study protocol]"
NCT00684489,Inclusion Criteria,"[bp and treatment criteria noted above, ability to adhere to study protocol, age, 21 years of age and older, willingness to provide written, informed consent, male or female (post-menopausal or effective method of birth control)]"
NCT00474604,Exclusion Criteria,"[subjects found to have any constitutionally present non-mr compatible ferromagnetic materials will be excluded from this study., patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study, subjects who have vascular access ports or other implanted devices rated as anything other than \""safe\"" or \""conditional 6\"", subjects for whom an mri is technically not feasible (e.g. breast volume, obesity), children will be excluded from this study., pregnant women and women who are breast feeding will be excluded from this study. (the vanderbilt university medical center radiology \""mri procedure screening form\"" will be used to identify and exclude subjects who are pregnant or breastfeeding. a urine pregnancy test/or serum beta hcg will also be performed for each pre-menopausal subject.)]"
NCT00474604,Inclusion Criteria,"[has diabetes, hiv, renal disease or hx of renal cancer, had abnormal creatinine in the last 60 days, women who satisfy the following conditions are the only subjects who will be eligible for this study:, subjects must be ≥ 18 years old., patients with an egfr>90ml/min reported within 30 days, and who have not had intervening chemotherapy or other treatment or condition that might deteriorate renal function, may receive any gadolinium agent., subjects with known or suspected breast disease, normal creatinine and estimated gfr* within 30 days under the following circumstances, normal volunteers, * gfr will be calculated using: http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm, the protocol nurse will check with the patient that there is no h/o kidney disease, has received chemotherapy within the past 30 days, subjects must have signed an approved consent form., are over 60 years of age]"
NCT00386373,Exclusion Criteria,"[1. grade iii/iv cardiac problems as defined by the nyhac, 4. hiv positive, 3. pregnant and lactating women, 2. history of hypersensitivity to imatinib]"
NCT00386373,Inclusion Criteria,"[2. the disease must be beyond first chronic phase according to ibmtr criteria (i.e. accelerated phase, blastic phase, second chronic phase) at the time of transplant., 6. unsupported anc at least 1500 and unsupported platelet count of at least 50k following bmt., 11. adequate hepatic (bilirubin </= 3 mg/dl, transaminases < 4 x upper limit of normal) and renal function (serum creatinine </= 3 mg/dl ), 7. patients may have received prior chemotherapy for their disease or be previously untreated., 1. patients with ph(+) cml and/or cml with bcr-abl rearrangement and diploid cytogenetics not eligible for protocols of higher priority (e.g. id02-901, dm99-081, dm97-206, etc)., 8. patients must have received an allogeneic bone marrow or stem cell transplant. allogeneic transplant types may include matched sibling donors, mismatched related donors, or unrelated donors. all preparative regimens acceptable., 4. patients with diploid cytogenetics but molecular evidence of bcr-abl rearrangement are also eligible., 9. signed informed consent, 3. patients with ph(+) acute lymphocytic (or myeloid) leukemia., 5. age >/= 16 years, 10. zubrod status </= 3]"
NCT02443467,Exclusion Criteria,"[abnormal laboratory results within 14 days prior to registration, left ventricular ejection fraction (lvef) < 50%, presence of central nervous system (cns) metastasis, advanced pulmonary disease, severe dyspnea, peripheral neuropathy]"
NCT02443467,Inclusion Criteria,"[human epidermal growth factor receptor 2 (her2)-neu overexpression, life expectancy > or = 12 weeks, eastern cooperative oncology group (ecog) score < or = 2, previously treated with adjuvant antracycline containing chemotherapy, left ventricular ejection fraction (lvef) > 50%, female patients > or = 18 years of age]"
NCT00286585,Exclusion Criteria,"[severe hepatic disease, severe chronic obstructive pulmonary disease (forced expiratory volume in 1 second [fev1] < 1 litre), unstable angina pectoris, absence of written patient consent, emergency surgery, renal insufficiency (creatinine clearance < 30 ml/min), preoperative hemodynamic instability, ongoing medication with sulfonylurea derivatives (unless stopped ≥ 2 days before surgery) or theophylline]"
NCT00286585,Inclusion Criteria,[patients scheduled for a non-cardiac surgical procedure of high or intermediate cardiac risk are eligible if they have documented coronary artery disease (cad) or are at high risk of cad.]
NCT00509600,Inclusion Criteria,"[5. performance status: have a karnofsky score >50., 2. a diagnosis of jmml is confirmed only if the following criteria for jmml are met: a) all of the following: absence of t(9;22) or bcr-abl by pcr or fish; absolute monocyte count >1000 (1 x 109/µl); <20% bone marrow blasts; b) at least 2 of the following: elevated hb f hemoglobin; myeloid precursors in peripheral blood; wbc >10,000 (10 x 109/µl); gm-csf hypersensitivity in methylcellulose culture of bone marrow progenitors cells., 4. adequate renal function (serum creatinine equal or less than 2 x normal), 1. all children greater than 6 months of age and less than 18 years of age with newly-diagnosed previously untreated or previously diagnosed jmml, which has reoccurred after treatment with chemotherapy, stem cell transplantation, and/or cis-retinoic acid., 6. written, informed consent according to institution guidelines., 3. adequate hepatic function (bilirubin equal or less than 2.0 mg/dl; alt equal or less than 3x normal)]"
NCT00509600,Exclusion Criteria,"[1. pregnant or lactating., 2. receiving any other chemotherapy. patients must have been off chemotherapy for at least 2 weeks and must have recovered from acute toxicity of all previous therapy prior to enrollment., 3. febrile neutropenia at study entry.]"
NCT00409760,Exclusion Criteria,"[type 2 diabetes mellitus with poor glucose control as defined by fasting glycosylated hemoglobin (hba1c) >8% at visit 1 (week -2 to -4)., known or suspected contraindications, including history of allergy to angiotensin receptor blockers or calcium channel blockers., history of hypertensive encephalopathy or cerebrovascular accident at anytime prior to visit 1 (week -2 to -4)., severe hypertension (grade 3 who classification; msdbp >=110 mmhg diastolic and/or mssbp >= 180 mmhg systolic)., inability to discontinue all prior anti-hypertensive medications safely for a period of 14 weeks)., type 1 diabetes mellitus., administration of any agent indicated for the treatment of hypertension within a minimum 4 weeks prior to randomization into the study (visit 2, week 0), with the permitted exception of those anti-hypertensive medications requiring tapering down commencing at visit 0 (week -4 to -6)., evidence of a secondary form of hypertension, such as coarctation of the aorta, hyperaldosteronism, unilateral renal artery stenosis, or pheochromocytoma, etc., other protocol-defined inclusion/exclusion criteria may apply, transient ischemic cerebral attack during the last 12 months prior to visit 1 (week-2 to -4)., known keith-wagener grade iii or iv hypertensive retinopathy.]"
NCT00409760,Inclusion Criteria,"[male or female patients are eligible., patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written informed consent)., patients with mild to moderate essential diastolic hypertension (grades 1 and 2 who classification) measured by calibrated standard sphygmomanometer., female patients must be either post-menopausal for one year or surgically sterile, or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. hormonal contraceptive use is disallowed., patients must have an absolute difference of =< 10 mmhg in their average sitting diastolic blood pressure between visits 1 and 2., outpatients 18 years and older., patients must have a msdbp >= 90 mmhg and < 110 mmhg at visit 1 (week -2 to -4), and a msdbp >= 95 mmhg and < 110 mmhg at visit 2 (week 0).]"
NCT00201045,Inclusion Criteria,"[taking 0-3 antihypertensive medications with no changes in regimen or dose within the past 4 weeks, males or females, age 21-85, non-diabetic with clinic bp 145-179 / 95-109 or diabetic with bp greater than 135/85]"
NCT00201045,Exclusion Criteria,"[previous 24 hour bp monitoring consult service within the past 6 months, recent mi or stroke within the past 6 months, uncontrolled atrial fibrillation, serious hepatic disease (total bilirubin greater than 3.0), pregnancy, class iii or iv congestive heart failure, serious renal disease (serum creatinine greater than 3.5), unstable angina, stage 3 hypertension greater than 180/110, poor prognosis with less than a 3 year life expectancy]"
NCT00280735,Inclusion Criteria,"[stage i-iiia disease, alkaline phosphatase (ap), ast, and alt must meet 1 of the following criteria:, ap ≤ 5 times uln and ast and alt normal, negative pregnancy test, bilirubin normal, no history of severe hypersensitivity to docetaxel or polysorbate 80, hemoglobin ≥ 8.0 g/dl, ap normal and ast and alt ≤ 5 times upper limit of normal (uln), must have undergone a complete resection, histologically confirmed non-small cell lung cancer, patient characteristics:, no breastfeeding, 2-8 weeks since prior surgery and recovered, platelet count ≥ 100,000/mm^3, ap ≤ 2.5 times uln and ast and alt ≤ 1.5 times uln, prior history of malignancy allowed provided the attending medical oncologists believes that adjuvant chemotherapy is indicated and will potentially benefit the patient, no peripheral neuropathy ≥ grade 2, serum creatinine normal or creatinine clearance ≥ 40 ml/min, absolute neutrophil count ≥ 1,500/mm^3, must begin adjuvant chemotherapy within 8 weeks of surgical resection, fertile patients must use effective contraception during and for at least 3 months after study therapy, ecog performance status 0-1, prior concurrent therapy:]"
NCT00399789,Exclusion Criteria,"[patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment) or new york heart assoc. class ii-iv congestive heart failure., patients with rapidly progressing disease, as defined by progression within 12 weeks of initiation of the previous regimen., hiv-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with perifosine., uncontrolled intercurrent illness including, but not limited to, ongoing or active infection and psychiatric illness/social situations that would limit compliance with study requirements., history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine)., patients receiving any other investigational agents or devices.]"
NCT00399789,Inclusion Criteria,"[patients must have ability to understand and the willingness to sign a written informed consent document., at least 18 years of age., patients should have a performance status of 0 to 1 according to the ecog criteria. however, patients with ecog performance status of 2 may be admitted with approval from the study chairman or medical monitor., patients must have measurable disease.   since the outcome for a patient is to be based on response using recist criteria, the patient must have at least one measurable lesion that can be accurately measured in at least one dimension and fit one of the following criteria: longest diameter 20 mm using conventional techniques or 10 mm with spiral ct scan., patients must have histologically or cytologically confirmed diagnosis of non-small cell lung cancer, must have progressed despite standard therapy and must not be candidates for surgical or combined modality therapy., patients should have received at least one but no more than two prior chemotherapy regimens for metastatic disease. the study chairman or medical monitor will consider extenuating circumstances for patients with more than two such regimens., patients must have a life expectancy of more than 3 months., female patients who are pregnant or lactating are ineligible.  all females of childbearing potential must have a negative serum pregnancy test within 72 hours of treatment.  men and women of childbearing potential must agree to employ adequate contraception to prevent pregnancy while on therapy and for four weeks after the completion of treatment.]"
NCT00007241,Inclusion Criteria,"[able to give conformed consent., age > 18., pain symptoms provoked by activity in the more symptomatic knee of between (and inclusive of) 3/10 and 8/10 on a verbal analog scale.]"
NCT00007241,Exclusion Criteria,"[lateral instability of > 15 degrees, or posterio-anterior instability of greater than 1 cm., active alcohol or substance abuse., history of cancer (other than skin cancer) not in remission., intra-articular steroids in the past 3 months, or hyaluronic acid in the last 9 months., active fibromyalgia., uncontrolled hypertension., participation in a strengthening program of the knees in the past month., arthroscopy of either knee in the past six months., symptomatic spine, hip, ankle, or foot disease other than osteoarthritis that would interfere with assessment of the knee., knee flexion contracture greater than 10 degrees., pregnancy., knee pain due to pes anserine bursitis., arthritis other than osteoarthritis in the more symptomatic knee., uncontrolled or functionally limiting cardiac disease., poor health that would impair compliance or assessment., severe peripheral neuropathy (i.e., insensate to the simmes 5.07 monofilament).]"
NCT00338455,Exclusion Criteria,"[not have systolic blood pressure (sbp) consistently < 80 mm hg, or have clinically significant orthostatic hypotension, not weigh > 130 kg, not have received antibiotic treatment within 7 days before randomization-antibiotics are permissible for any prophylactic use., not have a ventricular assist device (vad), or anticipate the need for a vad, during the 28-day study drug treatment period, not require chronic hemodialysis or peritoneal dialysis to treat renal failure, or had acute dialysis or ultrafiltration within 7 days before randomization, not have received placement of an internal cardiac defibrillator (icd) or external cardiac defibrillator (ecd) within 72 hours before randomization]"
NCT00338455,Inclusion Criteria,"[must also be a primary transplant candidate waiting to receive a single cardiac allograft, male and female subjects of childbearing potential agree to use two highly effective methods of birth control for the duration of the study., must be receiving continuous intravenous infusion of dobutamine or milrinone through a double-lumen central catheter or a double-lumen percutaneously inserted central catheter for at least 3 consecutive days before randomization, must be willing and able to participate in the study assessments and follow up procedures, meet the criteria for a  united network for organ sharing (unos) status 1b heart transplant candidate, or, if outside the us, have comparable status]"
NCT00386087,Exclusion Criteria,"[within 6 months have had a serious heart condition, have brain cancer from breast cancer, pregnant or breastfeeding, have an inability to swallow tablets, more than 2 chemotherapy regimens for metastatic or locally recurrent disease.]"
NCT00386087,Inclusion Criteria,"[have received prior therapy with an anthracycline (class of drugs) and a taxane (class of drugs)., may have received high dose chemotherapy for autologous stem cell support greater than or equal to 6 months of starting this study., disease that can be definitely measured on cat scans or other radiological tests., clinical diagnosis of metastatic breast cancer or recurrent breast cancer where surgery can not be done for curative intent, tumors must not be positive for her2, but if positive, the treatment plan should not include further treatment with the drug herceptin.]"
NCT00098072,Criteria,"[main:  the main study will enroll three groups of individuals: 1) patients who have either ipah or a secondary form known to have similar histopathology (pah), 2) patients with ph ascribed to a nonvascular injury process, and 3) age, gender, and race matched control subjects for each pah patient.  subjects must be at least 18 years of age and must be able to provide informed, written consent for participation in this study.  there is no exclusion based on race or gender., volunteers may be excluded if in the opinion of the study investigators they have a condition that may adversely affect the outcome of the study or the safety of the volunteer., 2. age less than 18 years, 1)  implanted cardiac pacemaker or defibrillator, crcl = (140-age) (wt in kg)/72 x serum cr (mg/dl)   for men, a.  heartburn, gerd, 5. no history of causes of pulmonary hypertension such as collagen vascular disease, chronic liver disease with alt or ast greater than 2 times the upper limit of normal or cirrhosis of the liver, chronic thromboembolic disease, congenital heart defects, or pulmonary parenchymal disease with hypoxemia, 10. no more than 20 cigarettes per years for the previous 2 years and no cigarette use for 30 days prior to the screening evaluation until completion of the study, iii  liver disease with portal hypertension, exclusion criteria for mri in subjects with pulmonary hypertension:, 6. no history of diseases thought to be related to development of endothelial dysfunction including systemic hypertension or diabetes requiring drug therapy, hypercholesterolemia and obesity, inclusion criteria for patients with nonvascular injury-induced pulmonary hypertension:, exclusion criteria for control subjects:, the creatinine clearance (crcl) will be calculated using the cockroft formula where age is in years, kg is weight in kilograms, and cr is the serum creatinine.  if there is no history of kidney disease from the patient or referring physician, additional testing will not be performed.  if a patient has a history of renal insufficiency, a recent blood cr will be used unless the physician performing the test believes the cr may have changed since the last test.  if the cr may have changed, a blood sample will be obtained for cr or the subject will be excluded from receiving gadolinium., 3. ekg and echocardiogram with no evidence of clinically relevant heart disease, 1)  lactating women, c)  cochlear implants, 7. no history of anemia, thrombocytopenia or coagulopathy, 4. inability to provide informed written consent for participation in the study, 6. patients receiving more than 1 year of oral therapy or more than 6 months of iv therapy., 1. any healthy man or woman who is the appropriate age, race, and gender for matching to a pah patient, 4. spirometry with no evidence of clinically relevant lung disease, 4)  neural stimulator, 2. pulmonary parasitic diseases, 5. pcw greater than 16 mmhg unless increase accounted for by increased transpulmonary gradient greater than or equal to 10 mmhg, 2)  central nervous system aneurysm clips, 3. contraindications to mri contrast agent administration, inclusion criteria for control subjects:, pilot:  the pilot study will enroll two groups of individuals:  1) patients who have either ipah or a secondary form known to have similar histopathology (pah), and 2) age, gender, and race matched control subjects for each patient., 2. patients diagnosed with secondary pulmonary hypertension known to have histopathology similar to the primary form or pah.  clinical conditions causing pulmonary hypertension with histopathology similar to the primary form are listed below., e.  treated and stable thyroid disease, depression, or anxiety., 2)  renal disease (crcl less than 20 ml/min), 4. mean pa less than or equal to 25mmhg or pvr less than 3 wood units, h)  claustophobia, f)  insulin pump, 8. history of recreational drug use with the exception of marijuana.  no marijuana use within 3 months of protocol screening through completion of the study., c.  asthma with no history of oral steroid use, weekly inhaled steroids, or hospitalization for asthma exacerbation, 2. contraindication to mri scanning including individuals with the following devices:, a)  implanted cardiac pacemaker or defibrillator, the inclusion criteria are as follows:, 9. intravenous drug abuse., furthermore, the following patient groups will be excluded from studies involving the administration of mri contrast agents:, d)  implanted neural stimulator, 1. pregnant women (all women of childbearing age will be required to have a screening urine or blood pregnancy test), 3. inability to provide informed written consent for participation in the study, exclusion criteria for patients with nonvascular injury induced pulmonary hypertension:, 2. no history of hiv infection, exclusion criteria for patients with pulmonary arterial hypertension:, e)  ocular foreign body (e.g. metal shavings), 3)  cochlear implants, 7)  metal shrapnel or bullets, the inclusion criteria for this study are as follows:, 6)  insulin pump, 9. no medical conditions requiring chronic medication use with the exception of:, 1. congenital or acquired valvular or myocardial disease, patients diagnosed with pulmonary hypertension not known to have histopathology similar to the primary form.  etiologies are listed below., 7. mean pa greater than 25mmhg or pvr greater than 1.5 wood units, or pcwp greater than 15 mmhg, 5)  ocular foreign body (e.g. metal shavings), v.  hiv disease, b)  central nervous system aneurysm clips, 5. chronic, medically refractory atrial tacharrhythmias, 1. patients diagnosed with ipah, d.  dermatologic conditions that do not require the use of oral steroids or other immunosuppressants, iv. toxin induced injury (anorexic agents, rapeseed oil), ii. collagen vascular disease, g)  metal shrapnel or bullet, 2. age less than 18 years, b.  environmental allergies, post nasal drip or non-allergic rhinitis, 6. symptoms of heart failure., 1. current pregnancy, lactation or women not currently using medically acceptable birth control. (all women of childbearing age will be required to have a screening urine or blood pregnancy test), vi. sickle cell disease, 1. pregnant women (all women of childbearing age will be required to have a screening urine or blood pregnancy test), 7. pulmonary hypertension due to congenital abnormalities of the lungs, thorax and diaphragm, 5. interstitial lung disease with reduced total lung capacity greater than 2 standard deviations from normal and infiltrates on chest x-ray, 3. inability to provide informed written consent for participation in the study, 8)  claustrophobia., 6. pulmonary thromboembolic disease as evidenced by lung perfusion scan or pulmonary angiogram, or intravenous drug abuse, 3. arterial hypoxemia with hypercapnea, 4. mean pa less than or equal to 25mmhg or pvr less than 3 wood units, 8. no history of renal insufficiency, i.  eisenmenger syndrome, inclusion criteria for pulmonary arterial hypertension patients:, 4. copd with hypoxemia and forced expiratory volume/forced vital capacity (fev1/fvc) greater than 2 standard deviations from normal, crcl = (0.85) (140-age) (kg)/72 x serum cr (mg/dl)   for women]"
NCT00057499,Inclusion Criteria,"[positive for iaa, gad65, or ia2 antibodies or positive for gad65 or ia2 antibodies after 2 weeks of starting insulin treatment, diagnosed with type 1 diabetes mellitus within 3 months prior to study entry]"
NCT00057499,Exclusion Criteria,"[ongoing use of medications known to influence glucose tolerance, history of treatment with any oral hypoglycemic agent for more than 3 months, severe active liver, heart, kidney, or immunodeficiency disease that may limit life expectancy or may require immunosuppression during the study, prior participation in a trial for prevention of type 1 diabetes mellitus. individuals who are known to have been in the placebo arm of a completed prevention trial are not excluded., history of immunosuppressive or steroid therapy for more than 3 months within the 2 years prior to study entry, prior complications related to routine vaccinations, pregnancy or planned pregnancy within the time frame of the study, any condition that may interfere with a participant's ability to comply with the study]"
NCT00452439,Exclusion Criteria,"[3. inability to sit or stand upright for at least 30 minutes, 2. hypersensitivity to risedronate or other bisphosphonates, 1. hypocalcemia of less than 8.4 (corrected to account for the albumin level, [see appendix e for formula]), 7. concomitant use of bisphosphonates, calcitonin, anabolic steroids, or fluoride., 8. corrected calcium above 10.2, due to a cause not related to leukemia/lymphoma (i.e. hyperparathyroidism, multiple myeloma)., 6. patients with a 25-hydroxyvitamin d concentration of less than 20 ng/ml and evidence of osteomalacia (low ionized calcium and high intact pth)., 5. renal insufficiency (calculated creatinine clearance <30cc/min,[see appendix f for formula]), 4. bone density t-score of -2.5 s.d or less.]"
NCT00452439,Inclusion Criteria,"[5. patients must be enrolled within 6 weeks of starting induction chemotherapy., 2. newly diagnosed all or ll receiving chemotherapy with augmented bfm, hyper-cvad or any variant of hyper-cvad., 3. female patients of childbearing potential (i.e. no hysterectomy, no loss of menses for 12 consecutive months), must be willing to use contraception., 4. negative pregnancy test in female patients., 1. age greater than or equal to 18 years]"
NCT00543244,Exclusion Criteria,"[unwilling to have contraception, poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus, co-infection with hepatitis b virus (hbv) or human immunodeficiency virus (hiv), thrombocytopenia (platelet < 90,000 per cubic milliliter), anemia (hemoglobin < 13 gram per deciliter for men and < 12 gram per deciliter for women), serum creatinine level more than 1.5 times the upper limit of normal, unwilling to receive serial blood sampling during the study, autoimmune liver disease, an organ transplant, decompensated liver disease (child-pugh class b or c), evidence of drug abuse, chronic alcohol abuse (daily consumption > 20 gram per day), neutropenia (neutrophil count < 1,500 per cubic milliliter), neoplastic disease, immunosuppressive therapy]"
NCT00543244,Inclusion Criteria,"[a liver biopsy consistent with the diagnosis of chronic hepatitis c, treatment naïve, anti-hcv (abbott hcv eia 2.0, abbott diagnostic, chicago, il) positive > 6 months, serum alanine aminotransferase levels above the upper limit of normal with 6 months of enrollment, detectable serum quantitative hcv-rna (cobas amplicor hcv monitor v2.0, roche molecular  systems, pleasanton, ca) with dynamic range 600~< 500,000 iu/ml, over 18 years old]"
NCT00344825,Inclusion Criteria,"[who performance status  </= 2, life expectancy  </= 6 months, aged  >/=18 years, patients of either sex with b-cll, who are starting a new pharmacological treatment for b-chronic lymphocytic leukemia (1st, 2nd, 3rd, 4th), signed informed consent for personal data's treatment and availability to fill in the qol questionnaire, foreseen duration of cll therapy </= 6 months, b-chronic lymphocytic leukemia progressive stage a, stage b or c (according to binet system), or ii-iv (according to rai system)]"
NCT00344825,Exclusion Criteria,"[previous stem cells transplantation, concurrent or in the last 30 days participation to any other clinical trial, chronic lymphocytic leukemia therapy in the last 30 days before v0, more than 3 previous cll treatments (the therapy is defined by the drug and/or the treatment period), patients with any other tumour disease, any medical or psychological conditions that might compromise the capacity to sign the consent for  personal data's treatment or to fill in the qol questionnaire]"
NCT00375427,Inclusion Criteria,"[histologically confirmed stage iv breast cancer with at least one bone metastasis radiologically confirmed., previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months., female patients ≥ 18 years of age., written informed consent given., life expectancy ≥ 1 year., eastern cooperative oncology group (ecog) performance status ≤2 .]"
NCT00375427,Exclusion Criteria,"[more than 3 months since last infusion of zoledronic acid (zometa®)., current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (onj), of exposed bone in the mouth, or of slow healing after dental procedures., use of any other investigational agent in the last 30 days., pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, iud, vaginal diaphragm or sponge, or condom with spermicide)., corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/l) or > 12 mg/dl ( 3.0 mmol/l)., recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)., history of non-compliance to medical regimens or potential unreliable behavior., patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study, treatments with other bisphosphonate than zoledronic acid (zometa®) at any time prior to study entry., serum creatinine > 3 mg/dl (265 μmol/l) or calculated (cockcroft-gault formula) creatinine clearance (clcr) < 30 ml/min crcl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dl)])x 0.85, known sensitivity to study drug(s) or class of study drug(s).]"
NCT00358826,Inclusion Criteria,"[patient has documented coronary artery disease, female patients are to be of non-childbearing potential, patient has suffered an st elevation myocardial infarction (mi), non-st elevation mi, or unstable angina 21 days (±3 days) prior to study randomization]"
NCT00358826,Exclusion Criteria,"[cirrhosis, recent hepatitis, alt >1.5 x uln or alt > 1 x uln and at least one other liver function test, renal insufficiency defined as creatinine >1.5 x upper limit of normal (uln), planned additional cardiac intervention, recurrence of st elevation mi, non-st elevation mi, or unstable angina less than 18 days prior to randomization, uncontrolled diabetes mellitus within 1 month prior to study screening, current atrial fibrillation, atrial flutter, or frequent premature ventricular contractions, congestive heart failure (chf) defined by the new york heart association as functional class iii or iv, previous coronary artery bypass graft (cabg) surgery, acetaminophen use in any form in the 7 days before enrollment]"
NCT00303212,Exclusion Criteria,"[scheduled for cabg or pci within 90 days, has or scheduled for cardiac transplant or lvad, currently a prisoner, severe valvular disease, folstein mmse score less than 20, not expected to survive 6 months due to irreversible, life-threatening condition, resident of a nursing home, does not speak english or spanish]"
NCT00303212,Inclusion Criteria,"[age 18 years or older, hospitalized for heart failure within the past 30 days, access to telephone line]"
NCT00083473,Exclusion Criteria,"[more than three systemic treatment regimens for cll/sll (excluding immunotherapies and biologic therapies);, concurrent malignancy that the patient has not been free of for at least 5 years, excluding curatively treated carcinoma-in-situ or non-melanoma skin cancer;, receiving investigational agents within 4 weeks of the study treatment; and, known hiv-positive patients;, known allergy to reagents in the study., any underlying medical conditions or circumstances that would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints;, any pregnant or lactating females. females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control;]"
NCT00083473,Inclusion Criteria,"[eastern cooperative oncology group (ecog) performance status of 0, 1, or 2., a predicted life expectancy of at least 6 months; and, adequate renal function with creatinine <= 1.5 mg/dl;, age > 18 years;, adequate bone marrow function as determined by having platelets > 50,000/mm3 without transfusion in the preceding 2 weeks and an absolute neutrophil count (anc) => 1,500 cells/mm3 without growth factor support; unless cytopenias due to marrow infiltration;, patients must have a confirmed diagnosis of cll  or small lymphocytic lymphoma (sll) based upon the revised nci-sponsored working group guidelines for cll;, relapsed or refractory disease after previous chemotherapy treatment;, a minimum of 4 weeks must have elapsed from the completion of any previous treatment regimen, including radiation and biologic therapies (6 weeks if a prior nitrosourea or mitomycin c, 12 weeks if radioimmunotherapy) to treatment on day 1 cycle 1. patients must have recovery from treatment-associated toxicity(ies);, adequate liver function with alkaline phosphatase <= 2.5 x upper limit of normal, serum glutamic oxaloacetic transaminase (sgot), and serum glutamic pyruvic transaminase (sgpt) <= 2.5 x upper limit of normal; and total bilirubin <= 2.0 x upper limit of normal;, able to give informed consent;]"
NCT00023062,Inclusion Criteria,"[patients with established, dopa-responsive pd, hoehn and yahr stage i-iii, age 21 and older will be included., patients:, patients will be recruited from the ninds hmcs and etb clinical programs and from the community., healthy controls 21 and older will be recruited through the nih clinical research volunteer program and from the community., healthy controls:]"
NCT00023062,Exclusion Criteria,"[patients with persistent \""resting\"" tremor that precludes testing at rest may be excluded as well as any patient to whom the screening physician makes a judgment that withdrawal of medications poses a significant risk due to immobility or risk of falling., exclusionary criteria will be: any significant medical or psychiatric illness (other than pd), pregnancy, history of epilepsy, concurrent use of tricyclic antidepressants, neuroleptic agents, or any other licit or illicit drugs that could lower the seizure threshold or significantly affect cortical excitability., patients in hoehn and yahr stage iv will also be excluded, since they are least likely to tolerate medication withdrawal and are also unlikely to be able to maintain muscle relaxation for tms testing., persons with surgically or traumatically implanted foreign bodies in the head (other than dental appliances of fillings) that may pose a physical hazard during magnetic stimulation will also be excluded., patients on long-acting dopamine agonists will also be excluded., ages 21 and older will be recruited through the nih clinical research volunteer program (crvp) and from the community., no significant medical or psychiatric illness (other than pd), pregnancy, history of epilepsy, concurrent use of tricyclic antidepressants, neuroleptic agents, or any other licit or illicit drugs that could lower the seizure threshold or significantly affect cortical excitability., must not have surgically or traumatically implanted foreign bodies in the head (other than dental appliances or fillings) that may pose a physical hazard during magnetic stimulation., no significant medical or psychiatric illness (other than pd), pregnancy, history of epilepsy, concurrent use of tricyclic antidepressants, neuroleptic agents, or any other licit or illicit drugs that could lower the seizure threshold or significantly affect cortical excitability., patients:, must not have surgically or traumatically implanted foreign bodies in the head (other than dental appliances or fillings) that may pose a physical hazard during magnetic stimulation., all individuals will be processed through the crvp before participating.  recruitment will be focused on optimizing age, sex, educational, and racial matching with patient group. patients' spouses will be invited to participate., healthy controls:]"
NCT00405938,Exclusion Criteria,"[no history of myocardial infarction (mi), stroke or transient ischemic attacks in the last 6 months, no serious non-healing wound, ulcer or bone fracture, no significant vascular disease, no uncontrolled high blood pressure or history of hypertensive crisis, there are additional inclusion/exclusion criteria. the study center will determine if you meet all of the criteria. if you do not qualify for the trial, study personnel will explain the reasons. if you do qualify, study personnel will explain the trial in detail and answer any questions you may have. you can then decide if you wish to participate., no new york hear association class ii congestive heart failure, no symptoms of peripheral vascular disease, no history of significant psychiatric disorders, no history of abdominal fistula, gastrointestinal perforation or intrabdominal abscess in the past 6 months, no known hypersensitivity to phosphate, trehalose or polysorbate, no extensive cancer involvement of the liver or lungs, no metastatic disease to the central nervous system]"
NCT00405938,Inclusion Criteria,"[postmenopausal breast cancer (adenocarcinoma) estrogen (er)and/or progesterone (pr) receptor positive that is locally advanced or locally recurrent and not able to be surgically removed or with measurable and/or disease that is able to be assessed including isolated bone metastasis, radiation therapy to painful bone lesions or impending fractures is allowed as long as there is measurable or evaluable disease outside the radiated area., female patients 18 years or older, no prior chemotherapy or hormone therapy for metastatic breast cancer or inoperable breast cancer that is locally recurrent or locally advanced, documentation of er+ and/or pr+, measurable or evaluable disease, must have adequate bone marrow, renal and liver function, patients receiving prior treatment with an anthracycline based chemotherapy must have a normal left ventricle ejection fraction]"
NCT00251940,Exclusion Criteria,"[treatment with chronic insulin, creatine kinase above 3 times the upper limit of normal, creatinine levels above twice the normal range, received any investigational product in other clinical studies within 12 weeks, new york heart association heart failure class iii or iv, type 1 diabetes, any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study, history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells), history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin)]"
NCT00251940,Inclusion Criteria,"[treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents, provision of a written informed consent, diagnosed with type 2 diabetes, female patients:  postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control]"
NCT00586781,Exclusion Criteria,"[history of prior mental illness or patient demonstrates that their mental  capacity may interfere with their ability to follow the study protocol, severe osteoporotic or osteopenic condition or other conditions that may lead to inadequate implant fixation in the bone, insufficient ligament support, prior surgery and/or injury that has adversely affected the ankle bone stock, obesity (weight greater than 250 lbs), prior arthrodesis at the involved site, active or prior deep infection in the ankle joint or adjacent bones, patients who have not reached skeletal maturity, any physical condition precluding major surgery, history of current or prior drug abuse or alcoholism]"
NCT00586781,Inclusion Criteria,"[moderate or severe pain, loss of mobility and function of the ankle, at least six months of conservative treatment for severe ankle conditions, primary arthrosis, post traumatic arthrosis or rheumatoid arthrosis, bilateral ankle disease that have not been enrolled in the pivotal study or single ankle disease and enrolled in the pivotal study but have subsequently developed ankle disease in the contralateral ankle and require surgical intervention, willing and able to give informed consent]"
NCT00275340,Criteria,"[have access to and are able to communicate over a telephone, are able to read, write and understand english, are able to read, write and understand english, are not associated with the current in-hospital peer volunteer program, have undergone cabg surgery within the last 5 years, have access to and are able to communicate clearly over a telephone, are being discharged to home [either their own or to family/friends], are judged ready for discharge, are having first-time non-emergency cabg surgery, have attended a formal cardiac rehabilitation program, inclusion criteria (peers):  men and women who]"
NCT00281021,Exclusion Criteria,"[abnormal levels of k, mg, and/or ca, or conditions which cause such abnormalities (e.g. malnutrition, severe diarrhea, prolonged vomiting, dialysis, gi suction, untreated hypothyroidism, and use of diuretics, amphotericin b, steroids, or antacids), women who are pregnant or nursing, hypersensitivity to erlotinib and/or digoxin, no other prior malignancy is allowed except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage i or ii cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years, history of ventricular fibrillation, sinus node or av nodal disease, wolff parkinson white syndrome, evidence of congestive heart failure, chest pain with exertion, hemodynamically significant or life threatening cardiac arrhythmia, or evidence of prior myocardial infarction on ekg. ekg must have been done within 28 days prior to registration. a normal cardiac stress test within 182 days prior to registration is required for all patients over 50 years old or those with abnormal ekg or any history of cardiac disease.]"
NCT00281021,Inclusion Criteria,"[disease recurrences occurring greater than five years after original diagnosis must be biopsy proven, measurable or evaluable disease, diagnosis of non-small cell lung cancer, primary tumor must be documented by histopathic analysis, treatment with only one prior chemotherapy regimen for advanced disease (one additional prior regimen was allowed for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant therapy), must have a ct scan (chest & abdomen) within 4 weeks prior to registration, zubrod performance status of 0-3, serum creatinine < 2mg/dl, or a calculated creatinine clearance > 40cc/min using the following formula: (140-age) x wt(kg) x 0.85 (if female 0.72) x creatinine (mg/dl). tests must be done within 28 days prior to registration]"
NCT00565500,Inclusion Criteria,"[4. the patient requires or is eligible for chronic treatment with an antiinflammatory and/or analgesic drugs given to control osteoarthritis symptoms;, 5. female subjects of childbearing potential must have a negative pregnancy test, use adequate contraception during the study and not be lactating;, 1. male or female, age 18-75;, 6. written informed consent before undergoing any study procedure., 3. the patient is on long-term aspirin prophylaxis for the ischemic condition;, 2. subjects with osteoarthritis and documented stable ischemic heart disease;]"
NCT00565500,Exclusion Criteria,"[3. known hypersensitivity to cox-2 inhibitors, analgesics, antipyretics, sulfonamides or nsaids;, 10. pregnancy or lactation; female or childbearing potential without a clinical accepted contraceptive method;, 12. intake of antiaggregant, anticoagulant, diuretic, beta-blocker, ace- inhibitor, lithium, methotrexate, cimetidine, digoxin;, 13. contraindications to nsaids., 8. recent history or suspicion of alcohol abuse or drug addiction;, 6. evidence of neoplasm or any other severe disease of any organ, including any psychiatric illness;, 11. any severe pathology that can interfere with the treatment or the clinical or instrumental tests of the trial;, 4. treatment with any investigational drug within the previous 30 days;, 7. clinically relevant deviations from the normal range in laboratory tests;, 2. history of active peptic ulceration, gastrointestinal bleeding, esophageal, gastric or duodenal ulcer;, 1. active gastrointestinal disease (e.g. crohn's disease or ulcerative colitis) or any evidence of concomitant disease which may lead to early termination of the study;, 5. previous participation in this study;, 9. subjects unlikely to be collaborative or to give reliable answers;]"
NCT00058747,Inclusion Criteria,"[must be at least 18 years old, no other cancer within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin, not pregnant or breastfeeding and agree to use contraception during the course of the study, must have a complete hematologic response, ecog performance score of 0 or 1, must be philadelphia chromosome positive chronic myelogenous leukemia in first chronic phase, no prior allogeneic bone marrow transplant or be candidates for curative bmt, must have one of the following cytogenetic statuses:, no immunodeficiency or other serious illness, no current use of immunosuppressive medications, must have received gleevec™, ifn-α, cytarabine, busulfan, hydroxyurea, homoharringtonine (hht) or any combination thereof as long as the combination has been discontinued and the dosing of gleevec™ has been stable for 6 months or greater, (a) less than a ccr after receiving gleevec™ for at least one year at a minimum dose of 400 mg/day.  a stable dose of gleevec™ must have been maintained for the last six months prior to eligibility testing or (b) stable cytogenetic status without ccr (no cytogenic response or progression) in three consecutive determinations over six months while on a stable dose of gleevec™ (at a minimum of 400mg/day) for at least 6 months or (c) cytogenetic progression while on a stable dose of gleevec™ (at a minimum dose of 400mg/day)for at least 2 consecutive evaluations at least one month apart]"
NCT00343369,Criteria,"[more than 7 days since prior therapy with steroids, vincristine, or daunorubicin hydrochloride, patient characteristics:, high-risk disease, defined by any of the following:, prior concurrent therapy:, not specified, meets 1 of the following risk criteria:, b-precursor all, excluding pro-b all, wbc < 25/nl, chromosomal translocation 4/11, wbc ≥ 25/nl, diagnosed with acute b-precursor or t-cell acute lymphoblastic leukemia (all), t-cell all or pro-b all, more than 7 days since prior cytotoxic therapy, low-risk disease, defined by any of the following:]"
NCT00302913,Exclusion Criteria,"[severe impairment of liver or kidney function, platelet count < 100.000/µl, cancer, myocardial infarction or fibrinolytic therapy within the previous 14 days, cardiogenic shock, oral anticoagulation, contraindication for aspirin or clopidogrel, severe disorders of the coagulation system, troponin t on admission > 0.03 ng/ml, use of a gp iib/iiia-receptor antagonist during pci, pretreatment with heparin or a thienopyridine within the previous 14 days]"
NCT00302913,Inclusion Criteria,"[age > 18 years, patients undergoing elective coronary stenting, written consent, pretreatment with a bolus dose of 600mg of clopidogrel at least 2 hours prior to coronary stent implantation, pretreatment with aspirin ≥ 100 mg per day for at least 7 days]"
NCT00263211,Inclusion Criteria,"[no platelet inhibitor therapy within 1 month of study entry, normal kidney and liver function as defined by:, able to provide signed, informed consent., platelets >= 100,000, on stable hormone therapy for at least 2 months are also eligible for the study, women with metastatic breast cancer who are completing planned course of chemotherapy with planned treatment break, creatinine <= 2 x institutional normal, ast/alt <= 2 x institutional normal, estimated survival of at least 3 months, coagulation screening tests within normal range (inr between 0.81 and 1.20)]"
NCT00263211,Exclusion Criteria,"[patients on standing doses of nsaids or platelet function inhibitors, patients with history of significant bleeding related to peptic ulcer disease, patients on standing doses of anti-coagulants, patients going on to surgery, patients with a serious bleeding disorder that make them inappropriate candidates for nsaid therapy]"
NCT00170950,Exclusion Criteria,"[significant obstructive valvular cardiovascular disease or any valvular disease expected to lead to surgery during the course of the study., allergy to any of the drugs administered in this trial., evidence of hepatic disease (ast or alt values >= 2 x upper limit of normal)., secondary hypertension., impaired renal function (serum creatinine >= 2.5  mg/dl (221 µmol/l))., baseline serum potassium of  > 5.2  meq/l not on potassium supplements., history of symptomatic heart failure (nyha classes ii-iv) or ejection fraction < 40%., stroke or transient ischemic event (tia) within 3 months of visit 1., refractory hypertension defined as sbp >= 180 mmhg and/or dbp >= 110 mmhg unresponsive to triple-drug regimens of sympatholytics, diuretics and vasodilators., significant cardiovascular disease such as an aortic aneurysm ≥ 6 cm, likely requiring surgical intervention during the course of the study., other protocol-defined exclusion criteria applied to the study., history of clinically significant auto immune disorders such as systemic lupus erythematosus., significant non-cardiovascular illness or condition likely to result in death prior to trial completion, e.g., major organ transplant (life expectancy <5 years)., history of malignancy including leukemia and lymphoma (but not basal cell skin cancer) within the last 5 years., myocardial infarction, coronary revascularization (cabg or pci), unstable angina within one month of visit 1., current angina pectoris (ie, no anginal event requiring ntg within 1 month prior to visit 1).]"
NCT00170950,Inclusion Criteria,"[for patients >= 60 years, evidence of at least one cv disease or target organ damage, or for patients 55-59 years evidence of at least two cv diseases or target organ damage from two different organ systems as defined in the protocol., previously untreated or treated hypertension., at least 55 years of age.]"
NCT00123643,Exclusion Criteria,"[angina/new york health academy class iii/iv cardiac insufficiency, history of ketoacidosis, hemoglobinopathy, known contraindications to use of thiazolidinedione or sulfonylurea, body mass index (bmi) <22 or >42 kg/m2, subcutaneous insulin use, serum creatinine >160 mmol/l, uncontrolled hyperlipidemia according to american heart association (aha) guidelines, elevated liver enzymes (2.5 times the upper limit of the reference range), thiazolidinedione or sulfonylurea use in previous 30 days (may undergo washout period of 30 days), anemia (hb <11 g/dl for men or <10 g/dl for women), female patients must be postmenopausal, surgically sterile, or using adequate contraception, electrocardiographic evidence of marked left ventricular hypertrophy, uncontrolled hypertension according to aha guidelines]"
NCT00123643,Inclusion Criteria,"[type 2 diabetes mellitus for less than or    equal to 10 years, screening 110 mg/dl < fasting plasma glucose < 240 mg/dl after 2 weeks of metformin 500 mg twice daily (b.i.d.), pre-screening hba1c > 6.5 %, age 25-75 years]"
NCT00323895,Inclusion Criteria,"[study target lesion must be located in a restenotic native coronary artery >=2.25mm and <=3.5mm in lumen diameter and <=30mm in length by visual estimate and within a region up to 5mm to the proximal/distal stent edge;, diagnosis of angina pectoris as defined by canadian cardiovascular society classification (ccs i, ii, iii, iv) or unstable angina pectoris (braunwald classification b&c, i-ii-iii) or patients with documented silent ischemia;, study target lesion can not be located in a vessel containing another lesion requiring treatment. lesions located in other vessels may be treated with percutaneous revascularization at the time of the procedure, but they must be successfully treated prior to the treatment of the study target lesion;, patient is candidate for a current percutaneous revascularisation technique;, patient has an intra-des (taxus™ or cypher™) or intra-bms restenosis of  >= 50% and <100% (by qca online of the mld compared to the distal reference diameter) in a native coronary artery;, patient is willing to comply with the specified follow-up evaluations (including angiographic follow-up);, patient must provide written informed consent prior to the procedure using a form that is approved by the local ethics committee;, study target lesion must have undergone coronary interventional treatment >= 4 weeks previously. patients with one ore more prior ptca procedures at the target lesion are acceptable candidates.]"
NCT00323895,Exclusion Criteria,"[patient has experienced a q-wave or non-q-wave myocardial infarction with documented total ck >2 times normal within the preceding 72 hours and the ck enzymes remain above normal at the time of treatment;, documented left ventricular ejection fraction <=25%;, stent at the target restenosed lesion is neither taxus™ , cypher™  des nor a bms;, significant (>50%) stenoses of additional lesions proximal or distal to the target lesion(s) that might require revascularization or impede runoff;, stent implantation(s) is a non-elective, emergency procedure;, target lesion is in an internal mammary artery, saphenous vein bypass graft or is located in the left main or is ostial;, has unstable angina classified as braunwald a i-ii-iii;, unprotected left main coronary disease with ³50% stenosis;, totally occluded vessel (timi 0 level).]"
NCT00375752,Inclusion Criteria,"[adequate bone marrow, renal and hepatic function, good health status (ecog performance status of 0, 1 or 2), clinical stage t1c (size ≥ 1.5 cm), t2, t3, t4a, b, c, n0 or n1, m0 (tnm classification). according to the modified recist criteria, tumors of size ≥ 1.5 cm are considered measurable by mammography and can be determined as target lesions)., postmenopausal women with primary invasive breast cancer, histologically confirmed by core needle biopsy, whose tumors are estrogen (er) and / or progesterone (pgr) positive, tumor measurable by mammography, sonography and clinical examination.]"
NCT00375752,Exclusion Criteria,"[patients with unstable angina, or uncontrolled cardiac disease (e.g. class iii and iv new york heart association's functional classification, see appendix 9) or uncontrolled endocrine disorders., history of diseases with influence on bone metabolism, such as paget's disease, osteogenesis imperfecta, and primary or secondary hyperthyroidism within the 12 months prior to study entry, current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (onj), of exposed bone in the mouth, or of slow healing after dental procedures. recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)., prior treatment with letrozole or bisphosphonates. prior and concomitant anti-breast-cancer treatments such as chemotherapy, immunotherapy / biological response modifiers (brm's), endocrine therapy other than letrozole (including steroids), and radiotherapy. patients who have received hormone replacement therapy (hrt) will not be excluded, provided that hrt is discontinued at least 2 weeks prior to entry into the study., other protocol-defined inclusion/exclusion criteria may apply, evidence of inflammatory breast cancer or distant metastasis.]"
NCT00293865,Inclusion Criteria,"[no clinically involved axillary node (n0), surgeon must have performed its learning curve, no previous neoadjuvant treatment, performance status european cancer conference (ecco) grade ≤ 1, age > 18 years, patient's written informed consent to participate in the study according to french law, previous conservative surgical biopsy, secondary pathological diagnosis of infiltrative cancer]"
NCT00293865,Exclusion Criteria,"[lack of infiltrative breast carcinoma (in situ) pt4d > n0, pregnancy, indication for radical or partial mastectomy, known patent blue allergy, breast cancer relapse, patient unable to understand the trial]"
NCT00839150,Inclusion Criteria,"[sex and age matching with the diabetic patients, type 1 or type 2 diabetes mellitus, no diabetic retinopathy on fundus examination or fundus photographs, no diabetes, no familial or personal history of elevated blood sugar, for control subjects :, age between 20 and 55, diabetes duration of more than 5 years, for diabetic patients :]"
NCT00839150,Exclusion Criteria,"[presence of cataract or history of cataract surgery, systemic hypertension (defined as systolic blood pressure > 140 mmhg, diastolic blood pressure > 90 mmhg), other ocular disease, treatment with vasoactive drugs, tobacco consumption of more than 20 cigarettes a day, ametropia more than 3 diopters, anisometropia more than 1 diopter, astigmatism more than 1 diopter, abnormal score on the ishihara test, *for both diabetic patients and control subjects :, intraocular pressure of more than 21 mmhg]"
NCT00254020,Exclusion Criteria,"[significant acute neurologic illness including: impaired consciousness, parkinson's disease, huntington's chorea, progressive supranuclear paralysis, brain tumor, subdural hematoma, multiple sclerosis, hydrocephalus, binswanger's disease, or severe aphasia, intracranial hemorrhage, depressed group only: contraindications to receiving treatment with citalopram (including previous nonresponse) or serious risk of suicide, subarachnoid hemorrhage, presence of a premorbid axis i psychiatric diagnosis (eg. schizophrenia, bipolar disorder), significant acute medical illness including: drug overdose, severely disturbed liver, kidney or lung function, anemia, hypothyroidism, or uncontrolled diabetes]"
NCT00254020,Inclusion Criteria,"[age > 18 years, gender: male or female, clinical diagnosis of stroke according to world health organization monica project and recent (< 3 months) cerebral infarctions, depressed group only: diagnosis of a major depressive episode according to the depression module of the structured clinical interview for the dsm-iv (scid-iv), written, informed consent, language: speaks and understands english]"
NCT00317343,Criteria,"[medical condition or disease to be studied:  age > 18 years., non st elevation acute coronary syndrome with a pci planned later than 72 hours after the diagnosis without clinical instability (= \""cooled\"" non st elevation acute coronary syndrome). this type of patient is considered to be essentially stable and his/her level of risk can be comparable to the risk of patients who are candidates for elective pci with additional risk factors as listed above., pci on a degenerated venous bypass: in this particular case a distal protection device should always be used., planned stent > 6 cm long., patients are candidates for a pci with a planned anticoagulation regime other than unfractionated heparin in monotherapy. taking into consideration the national and international guidelines for this area and the registered indications of the drugs currently used for this purpose it is predicted that the patients will probably receive one of the following:, the allocation of any individual patient to the category of \""high risk\"" elective pci will be made independently and autonomously by the caring physician. however, it is recommended to consider the suitability of patients on the basis of these indicative elements:, having provided an informed consent (to anonymous data treatment)., known renal insufficiency, i.e. serum creatinine > 1.8 mg or glomerular filtration rate (gfr) > 60 ml/min (calculated with the cockroft formula)., multivessel or complex procedure., age > 75 years., unfractionated heparin as an intravenous (iv) bolus followed by iv bolus +, bivalirudin as an iv bolus followed by iv infusion, as per the pertinent summary of product characteristics (spcs)., infusion of a gpi (abciximab, tirofiban or eptifibatide); or, a planned anticoagulation regime means that any candidate patient should be identified on the basis of pre-procedural factors and requested to give his/her consent before the pci is initiated. patients receiving bail-out gpi for intraprocedural complications should not be considered for the inclusion. however, a pre-included patient could receive a bail-out gpi if deemed necessary., known diabetes mellitus (type i or type ii)., planned stent on a bifurcation.]"
NCT00317343,Exclusion Criteria,[there will be no specific exclusion criteria other than those listed in the summary of product characteristics of every individual agent.]
NCT00258752,Inclusion Criteria,"[score of at least 61 on the children's global assessment scale (cgas), indicating mild to moderate impairment, score of at least 16 on the center for epidemiologic studies short depression scale (ces-d), english-speaking, between grades 7 and 10 in school, currently experiencing at least 2 symptoms on the k-sads depression section, one of which is either depressed mood, irritability, or an inability to feel pleasure during normal activities]"
NCT00258752,Exclusion Criteria,"[attempted suicide or self-mutilation in the year prior to study entry, current dsm-iv diagnosis of psychosis, substance abuse or dependence, bipolar disorder, obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, or conduct disorder as determined by k-sads, current major depressive disorder or dysthymia as determined by k-sads, currently experiencing fewer than 2 depression symptoms on the k-sads or 2 or more symptoms on the k-sads with no report of depressed mood, irritability, or anhedonia, score of 15 or less on the ces-d scale, current active suicidal ideation and/or history of a clinically significant suicidal behavior (i.e., with intent to die and high medical lethality) or repeated patterns of self-injurious behavior, score of 60 or less on the cgas, indicating substantial functional impairment]"
NCT00347542,Inclusion Criteria,"[≥35 years of age, male, waist circumference ≥78 cm]"
NCT00347542,Exclusion Criteria,"[febrile illness or infective morbidity in the past 10 days, receiving vitamin d or calcium supplementation, on any medication within the last one month which could potentially influence insulin secretion, insulin sensitivity, vitamin d or calcium metabolism, past history of nephrolithiasis, chronic disease-renal/hepatic/malignancy/gastrointestinal, diabetic- fasting blood sugar >126 mg/dl or on anti-diabetic medication, bp>140/90 or on anti-hypertensive medication]"
NCT01690481,Inclusion Criteria,"[be between the ages of 3 to 10 years., to take part in the study, you or your child must meet the following inclusion criteria:, have been diagnosed with type 1 diabetes for at least 6 months., do not have plans to move out of the area within the next 36 months.]"
NCT01690481,Exclusion Criteria,"[head trauma with any loss of consciousness,, cystic fibrosis,, significant developmental delay (lack of single word speech or ability to walk independently by 18 months of age),, neurologic disease independent of diabetes (eg seizure disorder or medical contraindication to mri procedure (eg metal appliances such as braces), prematurity (born less than 30 weeks of gestation),, if the interested participant has a history of:]"
NCT00722059,Exclusion Criteria,"[pregnant or lactating women., prior breast augmentation with implants or silicon injection. male patients., breast density of almost entirely fatty/scattered fibroglandular densities., no two view mammogram as part of breast imaging evaluation., prior personal history of breast cancer.]"
NCT00722059,Inclusion Criteria,"[suspicious or palpable mass and scheduled for biopsy., has undergone clinical two view mammogram and diagnostic breast imaging evaluation., females 30 years of age or older., dense breasts.]"
NCT00287703,Inclusion Criteria,"[major depression, unaltered pharmacological treatment in last 4 weeks, age above 18 years, hamilton 17 item score above 13, treatment resistance]"
NCT00287703,Exclusion Criteria,"[women lactating or pregnant, antisocial, borderline or schizotypic personality disorder, unreliable contraception, suicidality, patient not able to come to appointed visits, psychotic disorder, abuse of alcohol or other substances, earlier treatment with pemf, mental retardation]"
NCT00537823,Inclusion Criteria,"[synchronous or metachronous colorectal metastases, medically suitable candidate for major liver resection, four or fewer metastases, no tumors in porta hepatis, technically resectable liver metastases, fdg-pet scan without metastatic disease outside the liver, resection of no more than 70% of liver needed]"
NCT00537823,Exclusion Criteria,"[pregnant patient (as cetuximab is a class c drug), renal insufficiency (cr > 2.5mg/dl), body mass index >/= 35 kg/m² (as the risk for steatohepatitis is increased), near-obstructing or obstructing colon lesions in patients in whom combined resection is planned (as delay for preoperative chemotherapy would be medially impossible), treatment with folfox or cetuximab within 12 months, patients unable to give informed consent, ecog performance score >/= 3, interstitial lung disease (because cetuximab has been rarely associated with development of interstitial lung disease), treatment with irinotecan within 12 months, peripheral neuropathy >/= grade ii (as oxaliplatin causes neuropathy to worsen), abnormal liver function (alt or ast > 5x uln, bilirubin > 3x uln)]"
NCT00790946,Inclusion Criteria,"[waist surrounding diameter   male≧85cm  female≧90cm, patient who is treating either high triglyceride,low hdl,or diabetes mellitus, systolic blood pressure (sbp)≧140mmhg and/or diastolic blood pressure (dbp)≧90 mmhg, untreated patients with hypertension,or patients is treated with antihypertensive agents except for ace-i and arb, out patients with hypertension  male and female, patient who is untreatment high triglyceride blood syndrome and low hdl blood syndrome,diabetes mellitus is triglceride≧150mg/dl and/or hdl cholesterol < 40 mg/dl or fasting blood glucose ≧110 mg/dl]"
NCT00790946,Exclusion Criteria,"[pregnant women, judgment by the physician that participation was unwise on the basis of     patient characteristics and drug safety, liver impairment, serum creatinine ≧ 3 mg/dl, history of allergy to valsartan, patient who is using ace-i and arb]"
NCT00536939,Exclusion Criteria,"[have a history of seizure, have had a minor surgical procedure, placement of an access device, or fine needle aspiration within 7 days prior to assignment to study treatment, have symptomatic peripheral vascular disease, have any clinical evidence of central nervous system (cns) metastases, have had a major surgical procedure within 4 weeks prior to assignment to study treatment]"
NCT00536939,Inclusion Criteria,"[have not had adjuvant or neoadjuvant taxane therapy within 12 months prior to assignment to study treatment, age 18 years or older at time of informed consent, have histologic or cytologic diagnosis of breast cancer with evidence of unresectable locally recurrent or metastatic disease, have not received any prior chemotherapy for locally recurrent or metastatic disease, must have signed an inform consent document]"
NCT00705731,Inclusion Criteria,"[average-risk subjects (no family history of crc, no personal history of polyps or crc)., primary care provider has agreed to refer patients for consideration of enrollment in the study., 50 years of age or greater, but less than 80 years old., upcoming appointment scheduled with primary care provider., due for crc screening.]"
NCT00705731,Exclusion Criteria,"[personal history of colonic adenomatous polyps, crc or inflammatory bowel disease., crc screening current (fobt within preceding 12 months, flexible sigmoidoscopy or double contrast barium enema within 5 years, or colonoscopy within 10 years)., comorbid illness precluding endoscopic evaluation (coronary artery disease with myocardial infarction within 6 months, unstable angina or congestive heart failure, chronic obstructive pulmonary disease requiring home oxygen, other diseases that limit life expectancy to less than 10 years)., symptoms for which colonoscopy or sigmoidoscopy would otherwise be performed (hematochezia, new onset diarrhea or constipation, abdominal pain)., family history of crc in a first-degree relative.]"
NCT00414297,Exclusion Criteria,"[congestive heart failure, abdominal aortic aneurysm, severe valve disease, occlusive peripheral artery disease, acute myocardial infarction within the last 3 months, pulmonary artery hypertension, cad treated best by cabg, atrial fibrillation, unstable cad, patients admitted as emergencies, coronary stenotic lesion to be treated ad-hoc or within < 4 weeks, thrombophlebitis and/or deep vein thrombosis]"
NCT00414297,Inclusion Criteria,"[at least 1 stenotic lesion suitable for pci within the next 4 weeks, no q-wave myocardial infarction in the area undergoing cfi measurement, stable angina pectoris, age > 18 years old, written informed consent to participate in the study, 1- to 3-vessel coronary artery disease (cad)]"
NCT00533039,Inclusion Criteria,"[men or women ≥ 18 years of age undergoing elective pci, with or without stenting]"
NCT00533039,Exclusion Criteria,"[moderate or severe renal impairment (creatinine > 1.5 × uln), recent active hepatitis, uncontrolled diabetes (hba1c > 11% 1 month prior to screening), biliary obstruction with hyperbilirubinemia (total bilirubin > 2 × uln), nyha class iii-iv heart failure, elevation of ck-mb or troponin i at baseline, recent (4 weeks) coronary bypass surgery, active chronic hepatitis, chronic inflammatory disease (e.g., lupus, rheumatoid arthritis, inflammatory bowel disease), or patients receiving steroid drugs, st elevation mi or any troponin elevation (non-stemi) within preceding 10days, left ventricular ejection fraction < 0.30, inability to provide consent., initiation of statin therapy within 30 days, presence of severe liver disease with cirrhosis, alt or ast > 3 × upper limit of normal (uln), nephrotic syndrome or subjects undergoing dialysis, severe valvular heart disease]"
NCT00641589,Exclusion Criteria,"[patients with a history of thrombotic vascular events (including by not limited to acute myocardial infarction (ami) within the previous 6 months, stroke, transient ischemic attack (tia), deep vein thrombosis,(dt) and pulmonary embolism (pe), patients with anemia due to blood loss., including but not limited to myelodysplastic syndrome, hematological malignancy, hemolytic syndromes, hemoglobinopathy), exclusion criteria include but are not limited to the following: patients with significant hematological disease (disorders of the blood and blood forming tissues, patients with new onset seizures (within the last 3 months) or seizures not controlled by medication prior to admission in to the study, patients with poorly controlled or uncontrolled hypertension, patients with liver function test results > 2 or more times the normal value]"
NCT00641589,Inclusion Criteria,"[patients with a hemoglobin (hg) < 11 g/dl at screening, patients with a transferrin saturation >= 20% or a ferritin >= 50 ng/ml., patients who have not received any erythropoietic agents within 6 weeks prior to the first study dose, patients with a glomerular filtration rate (gfr) within 15-60 ml/min/1.73m2 and stable creatinine over the past 6 months and no expected need for dialysis during the study, patients with reproductive potential must have a negative b-hcg pregnancy test within 14 days of the first dose of study drug and a negative urine pregnancy test on the day of the first dose of study drug, patients and their partners must be practicing an effective method of birth control before entry and throughout the study]"
NCT00438854,Inclusion Criteria,"[adequate organ function to tolerate chemotherapy, adequate method of contraception, cll/sll with cells positive by flow cytometry (or immunostaining) for cd19, cd23 and cd.  patients may be cd23 negative as long as they are also cyclin d1 negative., must have failed at least 1 prior fludarabine containing regimen or have failed at least 2 non-fludarabine containing regimens or have a contraindication to fludarabine use, 18 years of age or older, ecog performance status of 2 or better]"
NCT00438854,Exclusion Criteria,"[pregnant or breast-feeding women, patient known to be hiv positive, prolonged qtc interval on pre-entry electrocardiogram, drugs that are generally accepted to have a risk of causing torsades de pointes, known significant bleeding disorder unrelated to cll, drugs that interfere with platelet function or coagulation must be stopped at least 7 days prior to entry, diagnosed or suspected congenital long qt syndrome, history of clinically significant ventricular arrhythmias, uncontrolled angina within 3 months, uncontrolled hypertension]"
NCT00350701,Exclusion Criteria,"[use of investigational agent or therapeutic regimen within 30 days of study., h/o prostate cancer, hepatic or renal disease, any other life- threatening , non cardiac disease., uncontrolled bp, participation in any other concurrent clinical trial, high psa, high hemoglobin, coronary event or procedure in previous past 4 wks., congestive heart failure]"
NCT00350701,Inclusion Criteria,"[evidence of hypogonadism: low free testosterone., type 2 diabetes, bp under control even if on medication., people on stable doses of cholesterol lowering medications, blood pressure medications and multi-vitamins are allowed., if currently on testosterone replacement,testosterone treatment will be held for 8 weeks., males with age 35-75 years inclusive.]"
NCT00316368,Inclusion Criteria,[all elective/emergent patients requiring isolated coronary artery bypass graft (cabg) at st. michael's hospital.]
NCT00316368,Exclusion Criteria,"[sinus tachycardia > 100 beats per minute (bpm)., post-operative ci < 2., high inotrope dosage post-operation:, norepinephrine (levophed) if > 0.1 µg/kg/min., unable or unwilling to give informed consent., already participating in another clinical trial., known atrial fibrillation., need for intraaortic balloon pump (iabp)., dobutamine (dobutrex) if > 10 µg/kg/min., patient's age < 18 years., dopamine (intropin) if > 10 µg/kg/min., epinephrine if > 0.1 µg/kg/min.]"
NCT00947050,Inclusion Criteria,"[at least 1 stenotic lesion suitable for pci, 1- to 3-vessel coronary artery disease (cad), written informed consent to participate in the study, negative allen-test, stable angina pectoris, age more than or 18 years old]"
NCT00947050,Exclusion Criteria,"[severe valve disease, q-wave myocardial infarction in the area undergoing cfi measurement, pregnancy, patients admitted as emergencies, unstable cad, acute myocardial infarction, cad treated best by cabg]"
NCT00551083,Inclusion Criteria,"[had a baseline hrsd-17 score of at least 14, outpatients aged 18 and over, met criteria for non-psychotic major depressive disorder]"
NCT00551083,Exclusion Criteria,"[patient whose clinical status requires inpatient or day hospital treatment, women with a positive pregnancy test or who are lactating, patients with a current axis i diagnosis of somatization disorder, anorexia nervosa, bulimia, or obsessive-compulsive disorder, women of child-bearing potential who are not practicing a clinically accepted method of contraception, patients with current alcohol or substance dependence, patients with general medical conditions that contraindicate antidepressant medications]"
NCT00875355,Criteria,"[fertile patients must use effective contraception, must have brain metastases, no psychological, familial, social, or geographic situations that preclude clinical follow up, platelet count ≥ 100,000/mm³, no carcinomatous meningitis, no history of cancer except for basal cell carcinoma of the skin or carcinoma in situ of the cervix, not pregnant or nursing, creatinine < 1.5 times uln, liver transaminases ≤ 1.5 times upper limit of normal (uln), at least 10 days since prior chemotherapy, no prior brain radiotherapy, who performance status 0-2, prior concurrent therapy:, no other serious concurrent disease that is, in the opinion of the investigator, likely to interfere with study evaluation and treatment, patient characteristics:, anc ≥ 1,500/mm³, no patient deprived of liberty or under guardianship, unresectable disease or patient refused surgery, no contraindications to treatment with temozolomide, diagnosis of breast cancer]"
NCT00147342,Inclusion Criteria,"[stable insulin regimen for at least 1 month and not anticipating a change prior to the subject's completion of the study (stable is defined as no change in the overall insulin program, i.e., no change from sc injections to pump.), normal thyroid function (measured within the previous year), insulin regimen involves use of an insulin pump, bmi >5th and <95th percentiles for age and gender, hba1c <10.0% (the dca2000 will be used to assess eligibility.), age 8.0 to <18.0 years, clinical diagnosis of type 1 diabetes for at least 18 months (the diagnosis of type 1 diabetes is based on the investigator's judgment; c peptide level and antibody determinations are not needed.), weight >39.5 kg at reinfusion centers and >46.0 kg at discard centers]"
NCT00147342,Exclusion Criteria,"[anticipating a significant change in exercise regimen between visits (i.e. starting or stopping an organized sport), use of pseudoephedrine 48 hours prior to visit (if used in the 48 hours prior to the scheduled visit, the visit will be deferred), a recent injury to body or limb, addison's disease, muscular disorder, use of any medication or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the exercise protocol, severe hypoglycemia resulting in seizure or loss of consciousness in the 2 weeks prior to a visit (if a severe episode occurs within 2 weeks prior to the scheduled visit, the visit will be deferred), active infection (if at the time of the scheduled visit an infection is present, the visit will be deferred), current use of a beta blocker medication, asthma which has been medically treated within the last year, current use of glucocorticoid medication (by any route of administration)]"
NCT02242877,Inclusion Criteria,"[systolic blood pressure ≥ 130 and diastolic blood pressure ≥ 80 mmhg, if the patient has diabetes or chronic renal insufficiency, patient who has been treated and followed up for more than 12 months by the same general practitioner (gp), hypertension measured at least once during the past 12 months and not under control at the time of inclusion in the study:, isolated systolic hypertension, namely systolic blood pressure ≥ 140 mmhg and diastolic blood pressure < 90 mmhg or, systolic/diastolic hypertension, namely systolic blood pressure ≥ 140 mmhg and diastolic blood pressure ≥ 90 mmhg; or, decision by the gp to add telmisartan (either in combination with hydrochlorothiazide (hctz) or not) to the antihypertensive treatment; this decision is made by the treating doctor regardless of participation in the study. the prescription is issued in the normal way, in accordance with the conditions set down in the marketing authorisation, written informed consent of the patient to collect his/her data, treatment with one or more antihypertensives which remains unchanged during the month prior to collecting the data, age ≥ 55, with no upper limit]"
NCT02242877,Exclusion Criteria,"[change in the antihypertensive treatment during the month prior to collection of the data, the patient refuses to allow his/her data to be collected, blood pressure under control, the recommended target values corresponding to control of diastolic and systolic blood pressure are important because of the diseases associated with hypertension consequently, and in order to prevent the collection process becoming too complicated, data from patients with severe renal insufficiency or with proteinuria of ≥ 1 g/l or more are not collected in the context of this study]"
NCT00380380,Inclusion Criteria,"[blood glucose criteria must be met, bmi <40, cannot take any medications which may alter gastric motility except for cardiac medication at a stable dose, must be able to complete a 1-week wash-out of current anti-diabetic    medications]"
NCT00380380,Exclusion Criteria,"[abnormal liver function tests as defined by the protocol, patients with any history of gastrointestinal surgery or positive gastrointestinal symptons, history of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes, other protocol-defined inclusion/exclusion criteria may apply, need for insulin within 3 months or patients on thiazolidinediones, significant concommitant disease or complications of diabetes]"
NCT00402272,Exclusion Criteria,[patient is already participating in another device or drug study or has completed the follow-up phase of another study within the last 30 days.]
NCT00402272,Inclusion Criteria,"[evidence of myocardial ischemia, acceptable candidate for coronary artery bypass graft (cabg) surgery, target lesions must be de novo lesions, able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the xience v® eecss and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure, as approved by the appropriate medical ethics committee of the respective clinical site, target lesion ≤ 28 mm in length by visual estimate, artery morphology and disease is suitable to be optimally treated with a maximum of 4 planned xience v® eescc, target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate, undergo all cip-required follow-up examinations, at least 18 years]"
NCT00300131,Inclusion Criteria,"[target lesion must measure less/equal 8 mm in length by visual estimation for 3.0 x 12 mm, expanded to less/equal 14 mm in length by visual estimation when 3.0 x 18 mm stent is available, the target lesion(s) must be in a major artery or branch with a visually estimated stenosis of > 50% and < 100% with a timi flow of greater/equal 1, target lesion must be located in a native epicardial vessel with visually estimated nominal vessel diameter of 3.0 mm, non-clinical investigation, percutaneous intervention for lesions in a non-target vessel is allowed if done more/equal 90 days prior to or if planned to be done 6 months after the index procedure, non-clinical investigation, percutaneous intervention for lesions in the target vessel is allowed if done > 6 months prior to or if planned to be done 6 months after the index procedure]"
NCT00300131,Exclusion Criteria,"[patient has received brachytherapy in any epicardial vessel (including side branches), lesion involving a bifurcation greater/equal 2 mm in diameter and ostial lesion > 40% stenosed by visual estimation or side branch requiring predilatation, the target vessel contains visible thrombus, located within an arterial or saphenous vein graft or distal to a diseased (defined as vessel irregularity per angiogram and > 20% stenosed lesion by visual estimation) arterial or saphenous vein graft, another clinically significant lesion is located in the same epicardial vessel (including side branch) as the target lesion, total occlusion (timi flow 0), prior to wire passing]"
NCT01271517,Inclusion Criteria,"[diagnosis of diabetes and novel to insulin therapy, age 7 - 17 years, informed consent]"
NCT01271517,Exclusion Criteria,"[celiac disease or other chronic disease, moderate to severe ketoacidosis (ph<7.2 and/or standard bicarbonate <10 mmol/l), malignancy, suspected non-type 1, previous anorexia nervosa, hypothyroidism, if not well controlled, syndromes, ia2 and gad65: all-antibody negative, neuro-psychiatric disease]"
NCT00944970,Inclusion Criteria,[able to understand and sign an informed consent form.]
NCT00944970,Exclusion Criteria,"[previous heart transplant or listed to receive a heart transplant., women who are of childbearing potential., previous participation in a study of binodenoson., left ventricular ejection fraction greater than 35%, known prior to the first imaging procedure., any physical or psychosocial condition that, based on the investigator's judgment, would prevent the patient from completing the study., history of hemodynamically significant supraventricular tachycardia or sustained ventricular tachycardia., reactive airway disease or other contraindication that preclude a patient from receiving adenosine., history of vasospastic/prinzmetal angina., documented history of acute myocardial infarction within 30 days., presence of second- or third-degree av block (in the absence of permanent pacemaker)., inability to discontinue antianginal medications, aggrenox®, dipyridamole, and xanthine-containing drugs and foods (including caffeine) as required prior to each imaging procedure., very low likelihood of coronary artery disease (by american heart association and american college of cardiology standards)., presence of advanced heart failure, new york heart association class iv., percutaneous coronary intervention or coronary bypass graft surgery within 3 years, unless typical or atypical anginal symptoms are present., active (under treatment) cancer (except skin cancers)., cardiomyopathy (idiopathic dilated, restrictive, hypertrophic).]"
NCT00345098,Exclusion Criteria,"[patients with a lifetime history or presence of bipolar disorder, psychotic disorder, panic disorder and antisocial personality disorder., patients with a significant risk of suicide., patients with clinically significant abnormal laboratory value at screening, patients with a current depressive episode secondary to a general medical disorder., patients whose current depressive episode is diagnosed with psychotic features, catatonic  features, seasonal pattern or post-partum onset., the investigator will evaluate whether there are other reasons why a patient may not participate, patients with severe or unstable concomitant medical conditions]"
NCT00345098,Inclusion Criteria,"[patients diagnosed with major depressive disorder, recurrent according to dsm-iv-tr criteria diagnostic and statistical manual of mental disorders (fourth edition) and assessed with the mini international neuropsychiatric interview (mini), at w12 (v7), patients will be randomized into the double-blind treatment phase if they have madrs total score < 12, total score on the montgomery and asberg depression rating scale (madrs) > 28]"
NCT00465478,Inclusion Criteria,"[requiring daily exogenous insulin injection for the glycaemic control, type 1 or type 2 diabetes, with poor β-cell function, body mass index (bmi) < 28, between 16 to 65 years of age]"
NCT00465478,Exclusion Criteria,"[acute or chronic infections, history of thoracic or abdominal aorta diseases, acute or chronic pancreatitis, allergy to iodine, pregnancy, chronic uncompensated organic insufficiency including heart, liver, renal  and lung, any malignancies, congenital or acquired immunodeficiency, hematological diseases or coagulopathy]"
NCT00403299,Exclusion Criteria,"[heart transplantation less than a year ago., severe pulmonary disease making the patient unable to hold his/her breath in more than 10 seconds., hypotension (systolic blood pressure (bp) < 100 mmhg and/or diastolic bp<50 mmhg) or hemodynamic unstable patients., pregnancy, atrial fibrillation, known allergic reaction to ct contrast., renal insufficiency with estimated creatinine clearance < 50 ml/min., severe heart failure nyha class iv., history of contrast induced nephropathy.]"
NCT00403299,Inclusion Criteria,"[age 18 or above., heart transplanted patient]"
NCT00598377,Exclusion Criteria,"[congenital adrenal hyperplasia, topical corticosteroid use, history of recent major surgery, history of hypersensitivity to tetracosactin, history of thromboembolism, late onset congenital adrenal hyperplasia, a glomerular filtration rate below 60 ml/min, uncontrolled diabetes or hypertension, significant hirsutism (ferriman gallwey score≥8), pregnancy, lactation, systemic corticosteroid use (including previous use), menstrual irregularity, systemic infections with fever, history of psychosis]"
NCT00598377,Inclusion Criteria,"[diagnosis of autosomal dominant polycystic kidney disease, healthy subjects]"
NCT00763568,Inclusion Criteria,[chronic hepatitis c]
NCT00763568,Exclusion Criteria,"[males whose female partners are pregnant or plan to become pregnant., unable to take oral medication., previously failed to respond to at least 12 weeks of peginterferon plus ribavirin combination therapy., patients with hiv, hav, hbv or hdv., other causes of liver disease (for example, autoimmune hepatitis, decompensated liver disease)., patients with a history of alcoholism or with an alcohol consumption of more than 40 grams per day., patients with hemoglobinopathies (for example, thalassemia major, sickle-cell anemia)., history of hypersensitivity or intolerance to nitazoxanide or peginterferon., females who are either  pregnant, breast-feeding or not using birth control.]"
NCT00396071,Exclusion Criteria,"[a history of type 1 diabetes, insulin treatment for longer than 10 days within the past 6 months, other protocol-defined inclusion/exclusion criteria may apply, evidence of significant diabetic complications, treatment with any oral anti-diabetic other than metformin within 3 months prior to visit 1, a history of acute metabolic diabetic complications]"
NCT00396071,Inclusion Criteria,"[agreement to maintain the same dose of metformin throughout the study, agreement to maintain prior diet and exercise habits during the full course of the study, hba1c in the range of 7.0 to 9.0%, body mass index (bmi) in the range of 22-35 kg/m2, ability to comply with all study requirements and signed informed consent to participate in the study, fpg <200 mg/dl (11.1 mmol/l), patients with type 2 diabetes on metformin for at least 3 months and have been on a stable dose of at least 1500 mg daily for a minimum of 4 weeks]"
NCT00570024,Exclusion Criteria,"[atrial fibrillation, predominant pacemaker rhythm, significant conduction system disease, or automatic internal defibrillator*, participating in ta, or formal psychosocial stress management program, comorbid disease precluding survival during study, renal or liver failure, as clinically assessed, participation in another trial., cognitive, psychological or substance abuse-related impairment, as clinically assessed, significant valvular heart disease*, mi, unstable angina, cabg, ptca or stroke within 3 months*, hiv infection, chronic or active hepatitis or other blood-borne illness, class iii or iv heart failure*]"
NCT00570024,Inclusion Criteria,"[age > 21 years, consent and referring md approval, local residence, male or female, medically able to participate, cad by mi, cabg, ptca, or stroke (>3 months prior), or angiographic evidence >50% epicardial coronary artery stenosis in at least one coronary artery]"
NCT00321321,Inclusion Criteria,"[sufficient birth control in case of child bearing capacity, 25 > bmi > 40 kg/m2, hba1c > 7,5% for diet treated patients, age: 18 years or older, type 2 diabetes mellitus diagnosed according to who criteria, signed informed consent, hba1c > 7,0% for metformin treated patients, diet and/or metformin treatment]"
NCT00321321,Exclusion Criteria,"[pregnancy and/or breastfeeding, liver disease (alat > 2 x normal value), positive screening for islet-cell and/or gad-65 autoantibodies, type 1 diabetes i first degree relatives, anemia, diabetic nephropathy with s-creatinine > 130 microm and/or macroalbuminuria, gastrointestinal surgery with intestinal resection, proliferative retinopathy, cad (nyha group iii or iv)]"
NCT00312117,Inclusion Criteria,"[gfr < 60 ml/min/1.73m2. gfr will be adjusted by a correction factor as reported by our laboratory for patients self identifying as black., > 18 years and have at least one of the following risk factors for contrast nephropathy: diabetes (type 2), congestive heart failure, hypertension (> 140/90), or age > 75., both inpatients and outpatients will be offered enrollment.]"
NCT00312117,Exclusion Criteria,"[undergoing emergency cardiac catheterization, recent exposure to contrast within 2 days, pulmonary edema, patients unable to give consent, active congestive heart failure, kidney transplant status, on hemodialysis, recent significant change in kidney function (> 15% over 2d), receiving a contrast agent other than oxilan, severe valvular abnormality, already receiving sodium bicarbonate solution, one kidney]"
NCT00611247,Exclusion Criteria,"[6. prior allogeneic stem cell transplantation., 5. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements., 2. patients may not be receiving any other investigational agents., 8. prior radiation up to more than 25% of bone marrow., 1. patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin c) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier., 7. inability to swallow tablets, 4. history of gastrointestinal disease or significant bowel resection that could interfere with drug absorption., 3. history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or dtic]"
NCT00611247,Inclusion Criteria,"[7. patients must have normal organ and marrow function as defined below:, 5. life expectancy of greater than 3 months., 9. adequate renal function: serum creatinine within normal institutional limits or calculated creatinine clearance > 60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal., 8. adequate hepatic function: total bilirubin 1.5mg/dl, ast(sgot)/alt(sgpt) 2.5 x institutional upper limit of normal., 6. ecog performance status greater than 2., 3. for patients who have received no prior conventional chemotherapy, one of the following must be present:, 10. ability to understand and the willingness to sign a written informed consent document., secondary leukemia (prior hematologic disorder or therapy-related leukemia)., 2. patients must be considered unfit for conventional induction chemotherapy, unwilling to receive such treatment or have evidence of disease relapse or refractory disease., 1. patients must have histologically or cytologically confirmed acute myeloid leukemia, as defined by the who classification., 4. age > 60 years of age., poor risk cytogenetics (complex abnormalities, deletions of chromosome 7  or 5, 11q23 abnormalities, inv[3])]"
NCT00418860,Inclusion Criteria,"[stenting only with endeavor® stents, the sum of stent length is less than 60 mm for one lesion. the sum of stent length in multiple lesions does not matter., patients with clinically significant de novo coronary artery disease]"
NCT00418860,Exclusion Criteria,"[st-elevation myocardial infarction within 48 hours of symptom onset, hypersensitivity to clopidogrel or aspirin, patients who have to receive clopidogrel due to other conditions, patients who have to receive warfarin, cilostazol or other antiplatelet therapy, women who plan to become pregnant, patient with chronic renal failure (s-cr > 2.0 mg/dl), prior implantation of drug-eluting stents, cardiogenic shock, left main trunk lesion, stenting both branch of bifurcation lesion, left ventricular dysfunction (echocardiographic left ventricular ejection fraction < 25%), graft vessels, expectant survival less than 1 year, patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, gastrointestinal or genitourinary bleeding within the prior 3 months), patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.]"
NCT00477737,Inclusion Criteria,"[angiographically verified coronary artery disease, left ventricular ejection fraction higher than 40%, the degree i or ii of cardiac anesthesia risk evaluation score]"
NCT00477737,Exclusion Criteria,"[previously ventricular arrhythmias requiring antiarrhythmic treatment, myocardial infarction or stroke within 6 months, end-stage of obstructive or restrictive pulmonary disease, atrioventricular conduction disturbances, diabetes mellitus, atrial fibrillation with rapid ventricular response]"
NCT00322543,Exclusion Criteria,"[3. mi within 72 hours prior to the index procedure, 15. currently participating in another investigational drug or device study, 6. acute or chronic renal dysfunction, general exclusion criteria, 1. known sensitivity to pimecrolimus, the polymer (plga) or cobalt chromium., 10. any prior true anaphylactiod reaction to contrast agents, 2. planned treatment with any other pci device in the target vessel(s)., 7. contraindication to asa or to clopidogrel., 11. patient is currently taking chronic systemic steroid therapy or systemic immunosuppressant therapy or topical pimecrolimus., 12. female of childbearing potential., 5. cerebrovascular accident (cva) within the past 6 months., 14. co-morbid condition(s), 8. thrombocytopenia, 13. life expectancy of less than 24 months due to other medical conditions., 9. active gastrointestinal (gi) bleeding within the past 3 months., 4. the patient is in cardiogenic shock.]"
NCT00322543,Inclusion Criteria,"[general inclusion criteria, 3. left ventricular ejection fraction (lvef) ≥25%, 4. acceptable candidate for coronary artery bypass graft surgery (cabg)., 2. documented stable or unstable angina pectoris, 1. eligible for percutaneous coronary intervention (pci)., 5. target lesion < 25 mm in length with rvd of 2.5 to 3.5 mm with visually estimated stenosis of >= 50 and < 100 %.]"
NCT00714545,Exclusion Criteria,"[1. confirmed pregnancy at the time of index pci., 6. unsuccessful coronary revascularization procedure (residual stenosis > 30%)., 8. no previous intracoronary radiation to the target artery., 3. has known allergies or contraindication to heparin and bivalirudin (angiomax ®)., 5. any serious disease condition with life expectancy of less than 1 year., 2. has known allergies to aspirin, and to both clopidogrel (plavix ®) and ticlopidine (ticlid ®)., 4. has a significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study., 7. angiographic evidence of thrombus.]"
NCT00714545,Inclusion Criteria,"[1. age 18 years or older., 3. target lesion with recurrent restenosis (>50% by visual estimate) previously treated with any 2 or more combination of des stents., 5. target lesion is located within a native coronary artery or bypass graft., 4. signs or symptoms of ischemia attributable to the target lesion, or stenosis > 50% by visual estimation of the lesion during angiography., 2. eligible for percutaneous coronary intervention., 6. be reliable, cooperative and willing to comply with all protocol-specified procedures and follow-up., 7. able to understand and sign informed consent.]"
NCT02031952,Inclusion Criteria,"[the diameter of tumor is equal to or more than 3 cm;, without severe cirrhosis;, eastern cooperative oncology group (ecog) performance status is grade 0 or 1;, the liver resection could be assessed r0 (the define of r0 resection will be explained in the section of surgical procedures);, indocyanine green retention at 15 minutes (icg-r15) <15%;, age 18 to 65 years;, absence of extrahepatic metastasis., good liver function with pugh-child class a or b;]"
NCT02031952,Exclusion Criteria,"[with severe hepatic cirrhosis;, the diameter of tumor is less than 3 cm;, with the history of hepatic encephalopathy, ascites, and variceal bleeding;, with the history of upper abdominal surgery, it is tough to remove the regional lymph nodes; or it is unable to be resected when multiple lymph nodes mixed and fixed., tumor rupture;, palliative resection of tumor;]"
NCT00538460,Exclusion Criteria,"[12. inability to tolerate beta blockers, including those with copd or asthma requiring maintenance inhaled bronchodilators or steroids, complete heart block, second-degree atrioventricular block., 2. positive cardiac biomarkers (troponin, myoglobin, and/or creatinine phosphokinase mb fraction)., 6. inability or refusal to provide informed consent., 9. age less than 18 years., 7. psychological unsuitability or extreme claustrophobia., 15. patients with known allergy to gadolinium, x-ray dye, persantine, 14. use of viagra or cialis in the past 24 hours., 10. clinical instability as deemed by the attending physician; including cardiogenic shock, hypotension (systolic blood pressure < 90 mmhg), refractory hypertension (systolic blood pressure > 180 mmhg), sustained ventricular or atrial arrhythmia requiring intravenous medications., 18. patients with a body weight > 400 lbs, 3. presence of pre-existing cad (prior myocardial infarction, prior angiographic evidence of significant cad, prior coronary bypass surgery) or cardiomyopathy (ejection fraction < 45%), 11. patients with known allergy to iodine or shellfish., 1. electrocardiographic evidence of ischemia, including acute stemi (st elevation equal to or greater than 1mm in two or more leads), st segment depression and/or t wave inversion (not known to be old), or attending physician clinical decision for immediate invasive evaluation., 13. computed tomography imaging, or contrast administration, within the past 48 hours., 8. pregnancy or unknown pregnancy status., 4. renal insufficiency (creatinine ≥1.6) or renal failure requiring dialysis., 17. patients with metal implants that prevent mri scanning, 5. atrial fibrillation or other markedly irregular rhythm., 16. extreme claustrophobia.]"
NCT00538460,Inclusion Criteria,"[4. age equal to or greater than 18 years., 2. low risk timi risk score (ie. ≤3), 3. able to provide informed consent, 1. patients with chest pain or other symptoms suggestive of acute cardiac ischemia.]"
NCT02202564,Inclusion Criteria,"[no prior chemotherapy, radiation therapy, targeted therapy or other kind of biological treatment within 4 weeks., provide written informed consent, 18～70 years of age (male and female)., clinical diagnosis of advanced hepatocellular carcinoma who could accept liver transplantation, patients who had unresectable hcc >5 cm and no metastasis in lungs and bones were eligible to participate in this study. tumor involvement in the intrahepatic and extrahepatic portal branches was not considered to be an exclusion criterion.]"
NCT02202564,Exclusion Criteria,"[active pregnancy, unable or unwilling to sign informed consents, invasion in main vescular., accept clinical trials of other drugs, metastasis in lungs and bones, hypersensitivity to adenovirus, gcv or similar drugs, immunological deficit, contraindications of operation of other organ system, contraindications of liver transplantation]"
NCT00848094,Inclusion Criteria,"[solitary intrahepatic lesion with diameter bigger than 5 cm, without extrahepatic and/or distant metastases, pathologically confirmed or clinically diagnosed hcc, tolerate active breathing control (abc), karnofsky performance status (kps) of ≥ 70, normal renal function and adequate bone marrow reservation, surgically unsectable or medically inoperable diseases, or surgery declined by the patient, associated with cirrhosis of child-pugh a]"
NCT00848094,Exclusion Criteria,"[previous radiotherapy to the liver, indistinct tumor boundary in ct/mri image, child-pugh b or c liver cirrhosis score]"
NCT00497328,Exclusion Criteria,"[patient unable to give consent, allergic to radio-contrast, use of nsaid, aminoglycocide, cyclosporin, cysplatin within 48 hours prior to pci and throughout the study duration, gfr less than 15ml/min or patients diagnosed with end stage renal failure, preexisting dialysis, uncontrolled hypertension (untreated systolic blood pressure > 160 mmhg, or diastolic blood pressure > 100mmhg.), clinically vulnerable condition requiring continuous fluid therapy e.g. severe sepsis, administration of sodium bicarbonate solution or nac within 48 hours before the pci., emergency cardiac catheterization (i.e. patient presenting with st segment elevation myocardial infarction undergoing primary angioplasty), pulmonary edema or moderate to severe congestive heart failure (new york heart association [nyha] iii-iv), patient unable to withstand the fluid load and hemodynamics compromise, recent exposure to radiographic contrast (within two days of the study)., increase in serum creatinine levels of > 0.5mg/dl or 44umol/l in the previous 24 hours]"
NCT00497328,Inclusion Criteria,"[age > 21 year, written informed consent, scheduled to undergo elective pci, glomerular filtration rate (gfr) 15-60ml/min calculated by mdrd formula, able to receive 12 hours of pre-hydration]"
NCT00415142,Inclusion Criteria,"[diagnosis of major depressive disorder, recurrent, as defined by diagnostic and statistical manual of mental disorders, 4th edition, text revision (dsm-iv-tr) criteria (296.3) and confirmed by the semi-structured mini international neuropsychiatric interview (mini).]"
NCT00415142,Exclusion Criteria,"[patients with an mini mental state examination score of less than 23., duration of the current depressive episode less than 1 month or greater than 2 years., patients with alcohol/substance dependence or abuse in the past 12 months except nicotine or caffeine dependence., ham-d total score less than 17., total score of less than 23 on the madrs., patients with a history or presence of bipolar disorders or psychotic disorders., the investigator will evaluate whether there are other reasons why a patient may not participate, patients who have used the following prior to entry into acute phase: antipsychotics within 3 months, fluoxetine within 1 month, monoamine oxidase inhibitors within 4 weeks, other antidepressants, or mood-stabilizer (lithium, anticonvulsants) within 1 week.]"
NCT01163175,Exclusion Criteria,"[food allergies, subjects taking medications for hyperlipidemia or hypertension, elite athletes, body mass index > 30 kg/m2, men with extreme nutritional habits such as vegetarism or alcohol consumption > 2 drinks/day, previous history of cardiovascular disease, type 2 diabetes and monogenic dyslipidemia, endocrine disorders]"
NCT01163175,Inclusion Criteria,"[ldl-cholesterol concentration <3.4 mmol/l, smoking or not, stable body weight (+/- 2 kg) for 6 months before the beginning of the study, healthy men]"
NCT02323919,Inclusion Criteria,"[percutaneous transluminal coronary angiography (ptca), completing a phase ii cardiac rehabilitation program, myocardial infarction, cabg, age 55 years and older, all patients will be approved for the ability to safely perform exercise by the cardiac rehabilitation program prior to entrance into the study.]"
NCT02323919,Exclusion Criteria,"[2. decrease in systolic blood pressure >15 mmhg with exercise, renal (acute renal failure) or pulmonary complications (pneumonia, severe congestive heart failure), non-english speaking, presences of neurological deficits, 3. serious arrhythmias at rest or exercise induced, and (4) exercise-induced ischemia indicated by angina> 2 mm of st depression on the ecg, if they met criteria for being at high risk for safe exercise participation following a cardiac event., patients displaying any of the following cardiac characteristics at the time of discharge from the hospital also will be excluded:, obvious musculoskeletal functional disabilities, children, current valve surgery, 1. severe left ventricular dysfunction (ejection fraction <20%)]"
NCT00532857,Exclusion Criteria,"[patients who underwent surgery for breast cancer, patients who have history of cancer other than in situ uterine cervix cancer or nonmelanotic skin cancer, patients with a history of uncompensated congestive heart failure, patients who received hormonal, chemotherapy or radiotherapy for breast cancer, patients with node-negative stage iia (t2n0) breast cancer]"
NCT00532857,Inclusion Criteria,"[no breast operation other than biopsy to make diagnosis is allowed., 1. normal or nonspecific ekg taken within 1 mo of enrollment, adequate hepatic function: total bilirubin: £ 1.5 mg/dl, ast/alt: £ 2 times normal, alkaline phosphatase: £ 2 times normal-adequate cardiac function:, all patients must have histologically confirmed and newly diagnosed operable breast cancer, adequate renal function: serum creatinine £ 1.5 mg/dl, platelet ³100,000/mm3,  hemoglobin ³ 10 g/mm3, her2 positive (all fish +), absolute granulocyte count ³1500/mm3,, adequate hematopoietic function:, 2. lvef ³ 50% by muga or echocardiogram taken within 1 mo of enrollment, normal mental function to understand and sign the consent, axillary node positive (by pet or cytologically determine node by sonography) and/or tumor size > 5 cm -no prior hormonal, chemotherapy or radiotherapy is allowed., age: 18-years and older, not pregnant pre-, and postmenopausal women with good performance status (ecog 0-1)]"
NCT00292500,Exclusion Criteria,"[aspirin allergy, unable to meet study travel and general health requirements, previous cardiac surgery, acute or suspected systemic infection, recent history (<2 weeks) of cva, acute or chronic dialysis (creatinine > 200mmolor 2.3 mg/dl) within 30 days of surgery, preoperative need for iabp, need for ongoing immunosuppressive therapy, pregnancy, nyha class iv, refusal to give informed consent]"
NCT00292500,Inclusion Criteria,"[age between 50 and 85 years (inclusive), tolerate contrast media, life expectancy > 1 year, ejection fraction > 30%, diagnostically confirmed coronary disease, acceptable lima (conduit) and lad (target)for grafting]"
NCT00899197,Exclusion Criteria,"[psychiatric history that would preclude obtaining informed consent, severe anemia, defined as hemoglobin < 11 g/dl]"
NCT00899197,Inclusion Criteria,"[hormone receptor status:, initial pathologic stage i-iiib disease, no stage iv disease, pre- or post-menopausal, female, estrogen-receptor positive tumor, meets the following criteria for breast cancer therapy:, received prior primary local therapy for breast cancer, histologically confirmed invasive breast cancer, scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within 3 weeks, must be able to donate 20 ml of blood]"
NCT00528307,Exclusion Criteria,"[life expectancy < 1year from non-cardiac causes, previous coronary bypass surgery, previous myocardial infarction, poor ultra sound imaging quality., unwilling or unable to sign the informed consent, symptomatic obstructive coronary artery disease, poor left ventricle function (ef< 40%) from any cause]"
NCT00528307,Inclusion Criteria,"[referred for his ablation, drug-refractory, persistent or permanent atrial fibrillation, normal to nearly normal lvf (ef > 40%)]"
NCT00623441,Inclusion Criteria,"[lesion length and vessel diameter of the target lesion(s) are according to the \""indications for use\"" as mentioned in the \""instructions for use\"" that comes with every endeavor(tm) abt-578 eluting coronary stent system., the patient has consented to participate by signing the \""patient informed consent form\"" and/or has authorized the collection and release of his medical information by signing the \""patient data release consent form\""., patient is >18 years of age (or minimum age as required by local regulation), the patient is suitable for implantation of one or more endeavor(tm) abt-578 eluting coronary stent system in one or more native artery target lesions., the patient is willing and able to cooperate with registry procedures and required follow up visits.]"
NCT00623441,Exclusion Criteria,"[women with known pregnancy or who are lactating., patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon., patients with hypersensitivity or allergies to aspirin, heparin, clopidogrel, ticlopidine, drugs such as abt-578, rapamycin, tacrolimus, sirolimus or similar drugs, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media., patients in whom anti-platelet and/pr anticoagulation therapy is contraindicated., current medical condition with a life expectancy of less than 12 months., patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this registry., the subject is participating in another device or drug study. subject must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this trial. the subject may only be enrolled in this e-five registry once.]"
NCT00381316,Exclusion Criteria,"[3. the subject has known allergies to any product used in this study or its constituents, including subjects who are not able to exercise and have contraindications to adenosine (e.g., asthmatics)., 1. the subject was previously included in this study., 4. the subject presents any clinically active, serious, life-threatening disease, with a life expectancy of less than 1 month., 2. the subject received an imp within 30 days before or is scheduled to receive one during or in the next 30 days after imp administration., 5. the subject has no contraindications to any of the study procedures (e.g. physical exercise) or the involved drugs (myoview, thallium-201, adenosine or dipyridamole) such as e.g. 2nd or 3rd degree av-block, ss syndrome, bradycardia, bronchoconstrictive or bronchospastic lung disease.]"
NCT00381316,Inclusion Criteria,"[4. the subject is suspected of or known of having cad based on the subject's clinical signs, symptoms, or examinations ., 3. the subject is able and willing to comply with study procedures (i.e., 1 spect imaging at stress, 2 spect imagings at rest) and signed and dated informed consent is obtained., 1. the subject is 18 years old or older., 2. male subjects or non-lactating female subjects, who are either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or for women of childbearing potential, the results of a serum or urine human chorionic gonadotropin pregnancy test, performed at screening within 24 hours before dosing (with the result known before investigational medicinal product administration) must be negative., 5. the subject is referred for rest/stress (exercise or pharmacological) mps-spect for known or suspected cad (as clinically required).]"
NCT01221701,Inclusion Criteria,"[score of 12 or higher on edinburgh perinatal depression screen at 3 months postpartum, diagnosis of major depressive disorder using the structured clinical interview for the diagnostic and statistical manual for mental disorders, first-time mother participating in home visitation program, english speaking, 16 years of age or older, enrolled in home visitation program for at least 2 months]"
NCT01221701,Exclusion Criteria,"[current substance dependence, current antidepressant use or other mood altering medications and/or current involvement in psychotherapy, lifetime history of bipolar disorder, schizophrenia, mental retardation, organic brain syndrome, antisocial personality disorder, history of psychosis]"
NCT00325910,Inclusion Criteria,"[all subjects with physician-diagnosed symptomatic heart failure (nyha class i, ii, iii, iv) and type 2 diabetes., receiving oral antihyperglycemic agents or;, a diagnosis of type 2 diabetes defined as:, ≥11.1 mmol/l accompanied by acute metabolic decompensation or 2 hour plasma glucose in a 75 gram oral glucose tolerance test ≥11.1 mmol/l., a new diagnosis of type 2 diabetes during the visit within the heart failure clinic or hospital based on a fasting blood glucose ≥7.0 mmol/l or random blood glucose, a previous physician diagnosis of type 2 diabetes as documented in the subject's clinical record or;]"
NCT00325910,Exclusion Criteria,"[dementia/mental illness;, subjects currently receiving greater than 1500 mg of metformin therapy per day, those participating in another heart failure or diabetes clinical trial involving medication;, severe comorbidities or foreshortened life expectancy;, subjects who are unwilling to change their antidiabetic regimens;, serum creatinine ≥ 180 μmol/l;, subjects who do not provide written informed consent to participate., inability to communicate (language barrier);, subjects receiving insulin therapy;, a1c < 7.0 percent;, subjects unwilling to complete self-monitoring of serum blood sugars during the trial period., age < 18 years;]"
NCT00358631,Exclusion Criteria,"[duration of the current depressive episode less than 1 month or greater than 2 years., total score of less than 24 on the madrs., patients who have used the following prior to entry into acute phase: antipsychotics within 3 months, fluoxetine within 1 month, maois within 2 weeks, other antidepressants, anxiolytics, or mood-stabilizer (lithium, anticonvulsants) within 1 week except as allowed in the protocol., patients with a history or presence of bipolar disorders or psychotic disorders., ham-d total score less than 18., the investigator will evaluate whether there are other reasons why a patient may not participate, patients with alcohol dependence or abuse or substance dependence or abuse in the past 12 months except nicotine or caffeine dependence.]"
NCT00358631,Inclusion Criteria,"[diagnosis of major depressive disorder, as defined by dsm-iv criteria and confirmed by the semi-structured mini, recurrent episode.]"
NCT00319709,Inclusion Criteria,"[major depressive disorder (mdd) with a recurrent major  depressive episode (mde) according to dsm iv-tr criteria., madrs score equal of above 22., outpatients or inpatients]"
NCT00319709,Exclusion Criteria,"[patients with a lifetime history according to mini at screening of:bipolar disorder, psychotic disorder, antisocial personality disorder., history of seizures other than a single childhood febrile seizure., patients with mini-mental state examination (mmse) score < 25 at screening., the duration of the current depressive episode is greater than 2    years., patients with clinically significant ecg findings at screening., patients with a current history according to mini at screening of  anxiety disorders, alcohol dependence or abuse or substance dependence or abuse, patients whose current depressive episode is secondary to a general medical condition, patients who have taken an investigational drug in the last 3 months prior to screening., patients with abnormal thyroid functioning., any subject who has previously participated in a sr58611a protocol., patients with severe or unstable concomitant medical conditions., patients with a current significant risk of suicide in the  investigator's clinical judgment.]"
NCT00403533,Inclusion Criteria,"[total cholesterol >240 or, patients with chronic hcv., ldl >100 with diabetes or known coronary artery disease, patients who need treatment for their elevated cholesterol:, ldl >130 with two cardiac risk factors (hypertension, smoker, family history of heart attach, or hdl <40 for men or <50 for women) or, ldl >160 without cardiac risk factors or]"
NCT00403533,Exclusion Criteria,"[patients who are on hcv treatment, who plan to initiate hcv treatment within 3 months, or who discontinued hcv treatment within the last 3 months., a history of an adverse reaction to any hmg coa reductase inhibitor., patients whose aminotransferases are > 5 times the upper limit of normal., hcc, impaired mental ability preventing a subject from understanding the protocol or from completing the entire study.]"
NCT01600196,Exclusion Criteria,"[extrahepatic metastasis, an american society of anesthesiologists (asa) score ≥ 3, patients had access to sorafenib., child-pugh class b or c liver cirrhosis]"
NCT01600196,Inclusion Criteria,"[main tumor ≥ 7 cm, imaging confirmed the presence of pvtt in the first branches but not, resectable disease, the diagnosis of hcc was made according to aasld guidelines, eastern co-operative group performance, extend into the main trunk of portal vein]"
NCT00286962,Exclusion Criteria,"[participation in other trials, involving investigational products within 30 days prior to trial entry., plans to engage in activities which require them to go below 25 feet below sea level., known or suspected allergy against insulin or any component of the composition, cardiac problems: decompensated heart failure (nyha iii and iv); diagnosis of unstable angina pectoris; myocardial infarction within the last 12 months, renal function impairment: creatinin ≥ 150 micromol/l or a creatinin clearance < 50 ml/min, a history of cancer, excluding well differentiated thyroid carcinoma, breast carcinoma without lymph node metastases and skin carcinoma, insufficient knowledge of the dutch language to understand the requirements of the study., current use of systemic corticosteroids or suffering from a condition which caused systemic corticosteroid use more than once in the last year., severe untreated proliferative retinopathy., any condition that the investigator and/or coordinating investigator feels would interfere with trial participation or evaluation of results., mental retardation or psychiatric treatment for schizophrenia, organic mental disorder or bipolar disorder currently or in the past., substance abuse, other than nicotine]"
NCT00286962,Inclusion Criteria,"[type 1 diabetes mellitus, intermediate or poor glycemic control, defined as hba1c ≥ 7,5% and/or ≥ 5 incidents of hypoglycemia a week.]"
NCT00431145,Exclusion Criteria,"[suffer from myopathy, active peptic disease or arterial bleeding, diabetes mellitus type i, have significant or unexplained liver dysfunction or chronic increased levels of transaminases (alt, ast), are actually treated with any of itraconazole, ketoconazole, hiv-protease-inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone., current participation in another clinical trial, have a known hypersensitivity against niacin or statins, have a history of alcohol or drug abuse within 3 months of admission or factors making follow-up difficult or unlikely., women of childbearing potential, pregnancy or being lactating, have other severe concurrent illness (e.g., active infection, malignancy), actual therapy with ezetimibe]"
NCT00431145,Inclusion Criteria,"[be at least 18 years old, male or female, statin-therapy for more than 4 weeks, ldl > 100 mg/dl, give a written informed consent, have the ability to understand the requirements of the study, and agree   and be able to return for the required assessments., triglycerides < 400 mg/dl, no nicotine abuse for at least 3 months, hdl < 50 mg/dl, have stable coronary artery disease (i.e. no acute event like myocardial infarction or ptca less then 3 months ago)]"
NCT00336349,Exclusion Criteria,"[12. known allergy or sensitivity to the study medications or its components., 18. evidence of liver or renal function impairment, 7. use of aminoglycoside antibiotics, curare-like agents, or other agents that might interfere with neuromuscular function., 1. injection not possible due to physiologic barriers., 14. concurrent participation in another clinical trial within 30 days of the beginning of this study., 9. alcohol or drug abuse., 5. any condition that may put the subject at increased risk with exposure to botox®, including, 19. evidence old stroke, 2. subject is pregnant or lactating., 8. acute medication overuse in the investigator's best judgment., 15. previous use of botulinum toxin. (types a or b), 4. significant medical or psychiatric disease., 17. evidence of peripheral artery occlusion, 16. profound atrophy or excessive weakness of the muscles in the target area(s) or injection., 10. heavy smokers, 6. diagnosed myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function., 13. injections of anesthetics or steroids into the study targeted muscles within one month prior to the day of injection, 3. females of childbearing age who are not using a reliable method of avoiding pregnancy., 11. infection or skin problems at any of the injection sites.]"
NCT00336349,Inclusion Criteria,"[2. symptomatic polyneuropathy (stocking distribution and tingling pain), 5. willing and able to give written informed consent., 3. stable but not satisfactory effects of drugs for diabetic neuropathic foot pain (stable effects of medication for over 6 months), 1. type 2 diabetes with medication for diabetes＞ 3 years (established diagnosis, hba1c<10% ), 4. fitness of polyneuropathy on nerve conduction velocity (ncv) criteria, 6. willing and able to complete the entire study course and comply with study directions.]"
NCT00531765,Exclusion Criteria,"[cardiogenic shock, recent exposure to contrast agent within the last 3 days, emergency cardiac catheterization, patients who fall under any of the following categories will be excluded:, preexisting peritoneal or hemodialysis, pregnancy, patents on nsaids who can not stop using them for 48 hrs before and 48 hrs after procedure (except aspirin)., pulmonary edema / congestive heart failure, patients who received dopamine, mannitol, theophyllin or other medications known to affect renal function within one week from cardiac cath, use of n-acetylcystein, allergy to contrast or any of the above treatment, acute renal failure, renal transplant,]"
NCT00531765,Inclusion Criteria,"[all adult patients (18 years and above) who are scheduled for cardiac catechization and have abnormal but stable renal function will be eligible for enrollment. abnormal renal function is defined as a creatinine level exceeding the normal range (more than 115 or 96 um/l in males and females, respectively, in kfsh&rc laboratories) or egfr less than 60 ml/min]"
NCT00542282,Exclusion Criteria,"[potentially contagious skin lesion on the back, chest wall deformation, hirsutism, pregnant or lactating females., spine deformation (including severe scoliosis), skin lesion that would interfere with sensor placement]"
NCT00542282,Inclusion Criteria,"[male or female in the age range of 18-85 years, stable clinical condition at study baseline evaluation., able and willing to read, understand, and provide written informed consent, bmi > 21, subject is referred for pulmonary function testing with pre-and post- bronchodilator, patients referred for evaluation of known or suspected obstructive airways disease., patients who are treated with bronchodilators should go through a washout period prior the vri procedure according to the pulmonary function laboratory protocol.]"
NCT00294307,Inclusion Criteria,"[admitted from home to one of three hospital sites, resides within 30 miles of admitting hospital site, a primary caregiver (knowledgeable informant), defined as the spouse, family member, partner or friend, who will provide support following discharge to home and is reachable by telephone., speaks english, age >= 65 and older, a documented history of pre-existing dementia in their medical records or pre-screen positive for cognitive impairment using our pre-screen process.]"
NCT00294307,Exclusion Criteria,"[active untreated substance abuse or psychiatric conditions, end stage disease, primary cancer diagnosis (active treatment)]"
NCT00145951,Exclusion Criteria,"[those who meet dsm-iv criteria for minor depression (3-4 symptoms) or who report significant functional impairment (very difficult or above on the prime md functional impairment scale) will be notified and offered a referral for an evaluation by a mental health specialist (and will be strongly encouraged to attend)., those with 1-2 symptoms of depression will also be offered evaluation and treatment from a mental health specialist.   in each case, the primary care physician will be notified and the parents (if under the age of 19)., conduct disorder,, substance abuse or having suicidal ideation., criteria include meeting criteria or undergoing active treatment for major depression (5 or more symptoms nearly every day with functional impairment, minor depression),, bipolar disorder,, active treatment for depression is defined as receiving anti-depressant medication or counseling within one year of remission of symptoms from the most recent episode., panic disorder,]"
NCT00145951,Criteria,"[a family history of depression in a parent or sibling, or past personal history of depression or personal perception of risk depression and desire to participate, (2) one risk factor for developing depression in the next two years: sub-clinical depressed mood (not meeting criteria of major depression),, (1) age 14-18 years and]"
NCT00724503,Exclusion Criteria,"[peripheral neuropathy > grade 1 (nci-ctc)., pregnant or breast-feeding., previous radiotherapy delivered to the upper abdomen., dose limiting toxicity with previous adjuvant 5-fu or oxaliplatin chemotherapy., other active malignancy., non-malignant disease that would render the patient unsuitable for treatment according to the protocol., evidence of ascites, cirrhosis, portal hypertension, main portal or venous tumor involvement or thrombosis as determined by clinical or radiologic assessment., prior non-adjuvant chemotherapy for any malignancy.  adjuvant chemotherapy for colorectal cancer is not an exclusion criteria provided that it was completed more than 6 months before entry into the study.]"
NCT00724503,Inclusion Criteria,"[life expectancy of at least 3 months without any active treatment., unequivocal and measurable ct evidence of liver metastases which are not treatable by surgical resection or local ablation., suitable for either treatment regimen., who performance status 0-1., limited extra-hepatic metastases in the lung and/or lymph nodes are permitted (lung: 5 lesions total, < 1 cm, or 1 single lesion of up to 1.7 cm; lymph nodules in one single anatomic area (pelvis, abdomen or chest):  any number, < 2 cm)., prior chemotherapy for metastatic colorectal cancer is not allowed., adequate hematological, renal and hepatic function., willing and able to provide written informed consent., age 18 years or older.]"
NCT00606398,Inclusion Criteria,"[age 18 or older, all metastatic deposits must be resectable with clear margins, number of extra-hepatic metastases must be 3 or less on pre-operative imaging, patients with both intra-hepatic and extra-hepatic metastases from colorectal cancer, ecog performance of 0, 1 or 2, no contra-indications to major surgery, pregnant women or women of childbearing potential are eligible if they agree to use 2 methods of effective contraception during treatment protocol, written informed consent can be obtained]"
NCT00606398,Exclusion Criteria,"[significant medical or psychiatric conditions that preclude major surgery or may interfere with patient compliance, four or more extra-hepatic lesions on pre-operative imaging, patients receiving investigational drugs with unknown surgical risks, failure to meet inclusion criteria, colorectal primary in situ]"
NCT00393705,Exclusion Criteria,"[have congestive heart failure., are taking any other oral anti-diabetic medication (oam) not mentioned in inclusion criterion., have an irregular sleep/wake cycle (for example, patients who sleep during the day and work during the night)., have a body mass index greater than 40 kilograms per meter squared (kg/m2)., have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.]"
NCT00393705,Inclusion Criteria,"[have given written informed consent to participate in this study in accordance with local regulations., have been receiving hypoglycemic treatment with premixed insulin analogue (either with insulin lispro lm or biphasic insulin aspart 30/70) administered twice daily in combination with at least 1500 milligrams (mg) of metformin per day for at least 60 days immediately prior to the study., have at least 6 of 9 of the postprandial blood glucose values recorded in the period between visit 1 and visit 2 exceeding 180 milligrams per 100 milliliters (mg/dl) (10.0 millimole per liter [mmol/l])., are at least 30 years of age and less than 75 years of age., have type 2 diabetes (world health organization [who] classification)., have a hemoglobin a1c 1.2 to 1.8 times the upper limit of the normal reference range at the local laboratory at visit 1 or]"
NCT00270439,Inclusion Criteria,"[bmi 30-50, dyslipidemia, age 18-55, non-insulin dependent type 2 diabetes mellitus on oral hypoglycemics only]"
NCT00270439,Exclusion Criteria,"[history of ketoacidosis or current metabolic acidosis, significant hepatic enzyme elevations (more than 50% of upper limits of normal), intercurrent infections, positive pregnancy test (β-human chorionic gonadotrophin) for females, medicare patients, current use of oral anticoagulants, taking drugs that are known to affect carbohydrate or lipid metabolism (e.g. steroids, high dose niacin, β-adrenergic receptor agonists, but does not include anti-diabetic drugs), serum creatinine >1.5 mg/dl]"
NCT00355537,Inclusion Criteria,"[male patients greater than 18 years of age, ability to comply with all study requirements, agreement to maintain antihypertensive and anti-lipid treatments at prior doses during 3 months of study, serum testosterone less than 11 nmol/l on two consecutive samples taken on  different days, peripheral vascular disease as defined by abpi less than 0.92 and ischaemic leg pain (claudication or rest pain) or distal complications (non-healing arterial foot ulcer or gangrene, type 2 diabetes mellitus, ability to give written informed consent after verbal and written explanation in the english language]"
NCT00355537,Exclusion Criteria,"[investigational drug treatment in the 3 months prior to the trial, treatment with testosterone in the 3 months prior to the trial, current or previous prostate cancer, current or previous breast cancer, severe symptoms of benign prostatic hypertrophy ('prostatism'), raised prostate specific antigen or abnormal per rectal examination unless prostate cancer excluded after specialist urology opinion]"
NCT00256438,Inclusion Criteria,"[montgomery-asberg depression rating scale score of 25 or more, aged 18-65, dsm-iv major depressive episode of less than or equal to 3 years, may or may not be taking antidepressant medication]"
NCT00256438,Exclusion Criteria,"[metal in the cranium, pacemaker, cochlear implant, medication or other electronic device in the body, woman of child-bearing age in whom pregnancy cannot be ruled out by b hcg, not able to give written informed consent, history of neurological illness e.g epilepsy; neurosurgical procedure, significant other axis i psychiatric disorder e.g schizophrenia, bipolar, in imminent physical or psychological danger and needs a rapid clinical response due to inanition, psychosis or high suicidality, drug or alcohol dependence or abuse currently or in the last 12 months, on antipsychotic, anticonvulsant or benzodiazepine medication which cannot be withdrawn., failure to respond to ect in current or past episodes of depression]"
NCT00187421,Exclusion Criteria,"[women of childbearing potential, geographically inaccessible for follow-up angiography, known allergy to radiographic contrast media, co-morbid illness which precludes the use of follow-up angiography, severe peripheral vascular disease precluding femoral access, known allergy to indocyanine green contrast dye, renal insufficiency (creatinine >180 umol/l)]"
NCT00187421,Inclusion Criteria,"[left ventricular ejection fraction >20%, isolated aortocoronary bypass surgery, expect at least 2 bypass grafts]"
NCT00437138,Exclusion Criteria,"[diabetes mellitus, unstable coronary disease (acute coronary syndrome or unstable symptoms within 3 months), asthma, inter-current illness, angina pectoris (canadian cardiovascular society grade ≥2), renal or hepatic failure, occupational exposure to air pollution, current smokers, uncontrolled hypertension, history of arrhythmia]"
NCT00437138,Inclusion Criteria,"[on standard secondary preventative therapy, previous myocardial infarction (>6 months previously) treated by primary angioplasty and stenting]"
NCT00292500,Inclusion Criteria,"[diagnostically confirmed coronary disease, life expectancy > 1 year, ejection fraction > 30%, age between 50 and 85 years (inclusive), tolerate contrast media, acceptable lima (conduit) and lad (target)for grafting]"
NCT00292500,Exclusion Criteria,"[unable to meet study travel and general health requirements, previous cardiac surgery, recent history (<2 weeks) of cva, aspirin allergy, pregnancy, acute or suspected systemic infection, need for ongoing immunosuppressive therapy, nyha class iv, acute or chronic dialysis (creatinine > 200mmolor 2.3 mg/dl) within 30 days of surgery, preoperative need for iabp, refusal to give informed consent]"
NCT00897702,Inclusion Criteria,"[all patients:, cohort 1, cohort 2, patients not eligible for cohorts 1 or 2, but previously received treatment of any other kind for breast cancer., diagnosed with progressive, recurrent or metastatic her2+ or er+ breast cancer., evidence of disease progression or recurrence after prior therapy (e.g. radiologic progression by recist criteria or new metastasis)., patients who previously received treatment with hormonal therapy (including tamoxifen, toremifene, raloxifene, anastrozole, letrozole, exemestane, fulvestrant, arn-810) as a part of adjuvant therapy and now have progressive or recurrent breast cancer or patients who previously (or currently) receive hormonal therapy as part of a regimen for metastatic breast cancer and subsequently experienced evidence of disease progression., cohort 3, patients who previously received treatment with anti-her2 therapy (including trastuzumab, pertuzumab, tdm1, or lapatinib) as part of adjuvant chemotherapy and now have progressive or recurrent breast cancer or, patients who previously (or currently) received anti-her2 therapy as part of a regimen for metastatic breast cancer and subsequently experienced., prior tumor biopsy (may be original) defined as her2+ by amplification by fish (>1.9 gene copy number) or ihc 3+.]"
NCT00897702,Exclusion Criteria,"[patients for whom a repeat biopsy would be medically unsafe, patients who are unable to consent to a biopsy.]"
NCT00533338,Exclusion Criteria,"[2. have any of the following conditions as defined by the american college of sports medicine as relative contraindications to exercise testing (left main coronary stenosis; moderate stenotic valvular heart disease; electrolyte abnormalities; severe arterial hypertension at rest; hypertrophic cardiomyopathy and other forms of outflow tract obstruction; neuromuscular, musculoskeletal, or rheumatoid disorders that are exacerbated by exercise; high-degree atrioventricular block; ventricular aneurysm; uncontrolled metabolic disease; chronic infectious disease)., 4. baseline st segment or t wave changes that would make monitoring of the ecg stress test indeterminate., 3. right or left bundle branch block., 5. uncontrolled asthma., 7. have inflammatory breast cancer., 1. have any of the following conditions defined by the american college of sports medicine as absolute contraindications to exercise testing (a recent significant change in the resting ecg suggesting significant ischemia, recent myocardial infarction (within 2 days) or acute cardiac event; unstable angina; uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise; severe symptomatic aortic stenosis; uncontrolled symptomatic heart failure; acute pulmonary embolus or pulmonary infarction; acute myocarditis or pericarditis; suspected or known dissecting aneurysm; acute infection)., 6. have other medical contraindications as defined by the patient's physician.]"
NCT00533338,Inclusion Criteria,"[7. has physician clearance to engage in moderate physical activity., 1. woman with newly diagnosed stage ii or iii breast cancer., 4. speaks and reads english., 6. able to come to m. d. anderson once a week for intervention., 8. lives in harris county, texas or a county contiguous to harris county, texas., 5. oriented to person, place, and time., 3. beginning neo-adjuvant chemotherapy at m. d. anderson (no more than 3 weeks from the administration of the first cycle)., 2. over 18 years of age.]"
NCT00418067,Exclusion Criteria,"[patients with left main stem stenosis (>50% by visual estimate), female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study., the patient has a known hypersensitivity or contraindication to any of the following medications:, patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period., • heparin, aspirin, both clopidogrel and ticlopidine, sirolimus, paclitaxel, abt 578, stainless steel and/or contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. patients with true anaphylaxis to prior contrast media, however, should not be enrolled)., patients with ef<30%., patients with cardiogenic shock, creatinine level > 3.0mg/dl or dependence on dialysis., severe hepatic dysfunction (ast and alt > 3 times upper normal reference values)., current known current platelet count <100,000 cells/mm3 or hgb <10 g/dl., acute stemi patients within symptom onset < 12 hours needing primary angioplasty, non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)., an elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 12 months post enrollment., patients who have target lesion of in-stent restenosis at the stented segment of drug-eluting stent (in-stent restenosis of bare metal stent can be included).]"
NCT00418067,Inclusion Criteria,"[the patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site., significant coronary artery stenosis (>50% by visual estimate), the patient must be at least 18 years of age., patients with stable (ccs class 1 to 4) or acute coronary syndromes (unstable angina pectoris class ib, ic, iib, iic, iiib, iiic or nstemi) or patients with atypical chest pain or without symptoms but having documented myocardial ischemia, amenable to stent-assisted percutaneous coronary intervention]"
NCT01069328,Inclusion Criteria,"[adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose:, total bilirubin </= 1.5 times the upper limit of normal (uln), age >/= 18 years old, white blood cell (wbc) count >/= 2,500/mm3, serum creatinine </= uln or creatinine clearance (crcl) >/= 45 ml/min (crcl = wt (kg) x (140-age)/72 x cr level, female x 0.85) for patients with creatinine levels above institutional normal, alt and ast </= 2.5 x uln (</= 5 x uln for patients with liver involvement), absolute neutrophil count (anc) >/= 1,500/mm3, patients must have at least 1 evaluable lesion. lesions must be evaluated by ct scan or mri, hemoglobin >/= 9.0 g/dl, patients must have stage iiib (with malignant pleural effusions) or stage iv histological or cytological confirmation of non-small cell carcinoma (excluding squamous), inr </= 1.5 and aptt within normal limits, platelet count >/= 100,000/mm3, urinalysis (ua) must show less than 1+ protein in urine, or the patient will require a repeat ua. if repeat ua shows 1+ protein or more, a 24 hour urine collection will be required and must show total protein </= 1000 mg/24 hour to be eligible, ecog performance status of 0 to 1]"
NCT01069328,Exclusion Criteria,"[hiv infection or chronic hepatitis b or c, evidence or history of cns disease, including primary brain tumors, seizures disorders, or any brain metastasis, cardiac disease: congestive heart failure > class ii nyha; active coronary artery disease (mi more than 6 months prior to study entry is allowed); or serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted), uncontrolled hypertension defined as systolic blood pressure > 150 mmhg or diastolic pressure > 90 mmhg despite optimal medical management, active clinically serious infections (> grade 2 nci-ctc version 3.0), patients with squamous histology]"
NCT00415961,Exclusion Criteria,"[planned treatment with any other pci device in the target vessel(s)., known sensitivity to paclitaxel or polymeric matrices., general exclusion criteria:  -, active gi bleeding within past three months, mi within 72 hours prior to the index procedure, known allergy to cobalt chromium, any prior true anaphylactic reaction to contrast agents, cerebrovascular accident (cva) within the past 6 months, patient is in cardiogenic shock, acute or chronic renal dysfunction (creatinine >2.0 mg/dl or >150 µmol/l), contraindication to asa or to ticlopidine, thrombocytopenia]"
NCT00415961,Inclusion Criteria,"[eligible for percutaneous coronary intervention (pci), general inclusion criteria, eligible for coronary artery bypass graft surgery (cabg), documented stable or unstable angina pectoris (class i, ii, iii or iv), documented ischemia, or documented silent ischemia, documented lvef ≥25% within the last 6 weeks.]"
NCT00168779,Inclusion Criteria,"[2. age 18 years or older, 4. seated cuff dbp of ? 95 mmhg at visit 2 (baseline), 3. ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion), 1. ability to provide written informed consent.]"
NCT00168779,Exclusion Criteria,"[2. are nursing or pregnant, 3. are of child-bearing potential and are not practicing acceptable means of birth control, do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in studies of > 3-months duration. acceptable methods of birth control include oral, implantable, transdermal, or injectable contraceptives, and intra-uterine device (iud)., 1. sgpt (alt) or sgot (ast) > 2 times the upper limit of normal range, or, 14. chronic administration of any medications known to affect blood pressure, exc, 10. hereditary fructose intolerance., 1. are not surgically sterile and/or, 11. biliary obstructive disorders, cholestatis or moderate to severe hepatic in sufficiency., 4. hepatic and/or renal dysfunction as defined by the following laboratory parameters:, 13. history of drug or alcohol dependency within six months prior to start of run-in period., 6. clinically relevant hypokalemia or hyperkalemia., 2. serum creatinine > 3.0 mg/dl or creatinine clearance < 0.6 ml/sec., 3. mean seated sbp >= 180 mmhg or mean seated dbp >= 120 mmhg during any clinic visit prior to randomization., 5. bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one kidney., 12. patients who have previously experienced symptoms characteristic of angioedema during treatment with ace inhibitors or angiotensin ii receptor antagonists., 7. uncorrected volume depletion., 1. pre-menopausal women (last menstruation ? 1 year prior to start of run-in period) who:, 9. primary aldosteronism., 8. uncorrected sodium depletion., 2. known or suspected secondary hypertension.]"
NCT00776828,Exclusion Criteria,"[subject who has severe congestive heart failure (left ventricular ejection fraction <30%), subject who has liver cirrhosis (child class b or c), subject who is on the anticoagulation therapy, subject who has contraindication or allergy to anti-platelet agents (aspirin, clopidogrel or cilostazol), subject who has thrombocytopenia (<120,000/ul), subject who undergoes primary percutaneous coronary intervention due to acute st elevation myocardial infarction]"
NCT00776828,Inclusion Criteria,"[subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, silent ischemia, positive functional study or reversible changes in the electrocardiogram (ecg) consistent with ischemia. in subjects with coronary artery stenosis>75%, evidence of myocardial ischemia does not have to be documented., subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of cilostazol and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure., subject must have significant coronary artery stenosis (>50% by visual estimate), coronary lesions must be amenable for percutaneous coronary revascularization with drug eluting stents., subject must be at leat 18 years of age]"
NCT00615823,Inclusion Criteria,"[baseline six-minute walking distance between 100 and 460 m, patients in who functional class ii to iii, <=65 and >=18years old, vasodilator testing nonresponders, able to understand and willing to sign the informed consent form, diagnosis of pulmonary arterial hypertension (mean pulmonary artery pressure greater than 25 mm hg at rest with a pulmonary capillary wedge pressure less than 15 mm hg )that is a) idiopathic, b) familial, or c) associated with connective-tissue disease, d)congenital systemic-to-pulmonary shunt occurring after surgical/interventional repair that had been performed at least five years previously or in the absence of indications for surgery/intervention treatment e) chronic thromboembolism pah in the absence of indications for surgery]"
NCT00615823,Exclusion Criteria,"[bleeding disorder, history of transient ischemia attack or stroke within three months, current treatment with calcium-channel blockers or specific therapy (endothelin receptor antagonist, phosphodiesterase-5 inhibitor, or prostacyclin), previously diagnosed heart disease such as serious cardiac arrhythmias, unstable angina pectoris, myocardial infarction, history or suspicion of inability to cooperate, positive pregnancy test or breastfeeding practice, creatine kinase level five times above the upper limit of normal, inability to perform 6-minute walk test, pah related to other etiologies (groups 2, 3 and 5 pulmonary hypertension), a forced expiratory volume in one second/ forced vital capacity below 50% or a total lung capacity of less than 60 percent predicted value, a 6-minute walk distance of less than 100 or more than 460 m, a positive acute vasodilator response, serum transaminase level three times above the upper limit of normal]"
NCT00291356,Inclusion Criteria,"[if taking ace inhibitors, beta-blockers, calcium channel blockers, or statin type drugs, you may be eligible if your dose has been stable for at least 30 days prior to the start of the clinical trial., women may be eligible if they are post-menopausal or surgically sterile., must be medically able and willing to discontinue diabetic medications from at least 2 weeks prior to first study dose until the last study assessment., taking 850mg or more per day metformin, but not taking any other diabetes medications., hba1c (a measure of the average amount of sugar in blood over the last 2 or 3 months) levels are between 7.0 and 9.0., diabetic subjects who have not yet started taking diabetes medications or whose diabetes is controlled by diet alone may also be eligible to enroll if their hba1c is within 7.5 to 9.0., type 2 diabetes.]"
NCT00291356,Exclusion Criteria,"[require insulin therapy or oral antidiabetic medication other than metformin., have any major health problems other than type 2 diabetes., men who are unwilling to abstain from intercourse, or use a condom with a pregnant or nursing female, or who are unwilling to use a condom with another form of contraception with a female who could become pregnant., subjects who have had a urinary tract infection within 4 weeks of the start of the study or who have kidney disease., using illicit drugs, or have antibodies to hepatitis b, hepatitis c, or hiv., subjects with either low or high blood pressure.]"
NCT00619450,Inclusion Criteria,"[patient must sign an informed consent, implantable foreign objects acceptable, nsr or af, male or female, able to hold breath for a maximum of 15 seconds, creatinine < 1.7 and cleared by physician prior to case, sufficient kidney function to support a maximum of 200 cc of contrast in addition to whatever contrast will be given during the ep procedure, patients undergoing ep diagnostic or therapeutic procedure, age > 18 years, not pregnant - women without childbearing potential or women consenting to a pregnancy test, weight < 250 lbs]"
NCT00619450,Exclusion Criteria,"[creatinine (gfr value) greater than 60, patients should not have undergone a ct or cta scan in the 24 hours prior to this study.]"
NCT00898014,Criteria,"[life expectancy > 3 months, histologic block available for confirming pathologic diagnosis and measuring her-2 status via fish, diagnosis of stage iv breast cancer, patient characteristics:, measurable or evaluable disease, no prior chemotherapy for metastatic disease, scheduled to receive first-line chemotherapy with or without trastuzumab (herceptin®), depending on her-2 status, no other cancer in the past 5 years except for basal cell skin cancer or epithelial in situ cancer of the cervix, no geographic, social, or psychiatric reasons that would make treatment impossible, prior concurrent therapy:]"
NCT00350454,Exclusion Criteria,"[cardiogenic shock., in-stent restenosis., pregnancy (present, suspected or planned) or positive pregnancy test., previous enrollment in this trial., malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance., patient's inability to fully cooperate with the study protocol., known allergy to the study medications: aspirin, clopidogrel, rapamycin, stainless steel., target lesion located in the left main trunk or bypass graft.]"
NCT00350454,Inclusion Criteria,"[patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥50% de novo stenosis located in native coronary vessels., written, informed consent by the patient or her/his legally-authorized representative for participation in the study.]"
NCT01198275,Exclusion Criteria,"[nyha heart failure class iv or hemodynamic instability, any disease or other medical treatment that, in the opinion of the investigators, could interfere with the study., severe valvulopathy, significant pulmonary thyroid and hepatic disease, qt > 480 msec in the absence of bundle-branch block, cardiac surgery during the previous 3 months, hyperkalemia, contraindications to treatment with amiodarone or rass inhibitors, chronic renal dysfunction, myocardial infarction during the previous 6 months, left atrium size > 6 cm, diagnosis of paroxysmal af, unstable angina, pregnancy, bradycardia < 50 b/min]"
NCT01198275,Inclusion Criteria,"[history of at least one af relapse after previous electrical or pharmacological cardioversion, persistent atrial fibrillation (af) lasting > one month]"
NCT00225641,Exclusion Criteria,"[inability to comply with the control or intense follow-up program, local resection for colorectal cancer (e.g., tem-procedure), participation in other clinical trials interfering with the control-programs, previous malignancies (except for non-melanoma skin cancer), life-expectancy less than 2 years due to concurrent disease (e.g., cardiac disease, terminal multiple sclerosis, liver cirrhosis), a clinical diagnosis of hnpcc (non hereditary polyposis colorectal   cancer) or fap (familial polyposis coli), inability to provide informed consent or refusal to do so]"
NCT00225641,Inclusion Criteria,"[tumour stage: ii-iii (tany n1-2 m0, t3-4nanym0, dukes´ b - c), age < 75 years, radical surgery (r0-resection) for colorectal adenocarcinoma - with or without adjuvant treatment, \""clean colon\"" verified by perioperative barium enema or colonoscopy last 3 months post-surgery, provision of written informed consent for participation]"
NCT00535873,Inclusion Criteria,"[9. men must agree to use a condom during sexual contact with a female of child bearing potential even if they have had a successful vasectomy., 11. all patients must be able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to  acetylsalicylic acid (asa) may use warfarin or low molecular weight heparin., 8. females of childbearing potential (fcbp). a female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). must have a negative serum or urine pregnancy test with a sensitivity of at least 50 miu/ml within 10-14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 4 weeks before she starts taking lenalidomide. fcbp must also agree to ongoing pregnancy testing., 10. all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure., 4. adequate renal function indicated by serum creatinine less or equal to 2 and adequate hepatic function indicated as total bilirubin less or equal to upper level of normal and as alanine aminotransferase (alt) less or equal 2 upper limit of normal (uln)., 5. able to understand and sign informed consent after the investigational nature, study design, risks and benefits have been explained., 7. disease free of prior malignancies for 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma \""in situ\"" of the cervix or breast. patients with malignancies with indolent behavior such as prostate cancer treated with radiation can be enrolled in the study as long as they have a reasonable expectation to have been cured with treatment modality received., 1. patients with untreated cll or small lymphocytic lymphoma (sll) with indication to treatment according to nci working group guidelines.patients that have received single agent rituximab will be allowed to participate in this study., 3. eastern cooperative oncology group (ecog)/world health organization (who) performance status of 0-2., 6. able to adhere to the study visit schedule and other protocol requirements., 2. age 65 or older]"
NCT00535873,Exclusion Criteria,"[6. history of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs., 4. a serious medical condition, laboratory abnormality or psychiatric illness that would interfere with the ability of the patient to participate in this program according to the judgement of the principal investigator., 9. no known history of tuberculosis or recent exposure to tuberculosis., 8. pregnant or breast feeding females. lactating females must agree not to breast feed while taking lenalidomide., 1. known sensitivity to thalidomide or its derivatives., 2. documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood)., 5. active cardiovascular disease as defined by the new york heart association class 3 or 4., 7. concurrent use of other chemotherapy agents., 3. known positivity for hiv or active hepatitis (b or c).]"
NCT00611260,Exclusion Criteria,"[patients with life expectancy less than 6 months from non-cardiac causes, history of major psychosis., pregnant women, significant chronic liver, renal and pulmonary disease, smokers, active alcohol and drug abuse]"
NCT00611260,Inclusion Criteria,"[men and women aged 18 to 85, all patients with nyha class iii and iv symptoms, qrs complex of the ecg more than 120 ms, who received device for cardiac resynchronization at least 3 months prior to enrollment. these devices are placed when the two ventricles beat at slightly different times.  these devices also have the capacity to record arrhythmias as the defibrillators., all patients with nyha class ii to iii congestive heart failure symptoms from ischemic and non-ischemic etiology who received a defibrillator at least 3 months prior to enrollment.]"
NCT00296933,Exclusion Criteria,"[ects (unilateral) within the past 12 months or bilateral ect (ever), have received treatment within the last 30 days with an investigational drug, more than 2 failed adequate antidepressant treatments in the current episode, presence of significant axis ii disorder based on investigator judgment, presence or past history of adhd or significant learning disability, prior non-response to either bupropion-xl or escitalopram, presence of significant unstable medical condition, history of head injury or loss of consciousness for longer than 30 minutes, presence of anorexia nervosa or bulimia nervosa, antidepressant treatment within the last week (within the last 3 weeks fluoxetine), presence or history of epilepsy or other seizure disorders, pregnant or breast-feeding females, current treatment with zyban (bupropion hydrochloride), presence of primary anxiety disorder, bipolar i or ii disorder, or psychotic disorders]"
NCT00296933,Inclusion Criteria,"[able to give written informed consent, males and females, agree to use a reliable means of birth control during the study, as determined by the investigator (females of child-bearing potential only), ham-d >16, age: 18-50, recurrent major depressive disorder; current major depressive episode with at least one prior episode]"
NCT00528528,Exclusion Criteria,"[women who are pregnant (carrying an unborn baby), planning to be pregnant or breastfeeding or the partner of a woman who is pregnant or breastfeeding, contra-indications for starting anti-hcv therapy, infected with human immunodeficiency virus (a life-threatening infection which you can get from an infected person's blood or from having sex with an infected person) or hepatitis b, any evidence of significant liver disease in addition to hepatitis c, history or evidence of liver cirrhosis (serious liver disorder in which connective tissue replaces normal liver tissue, and liver failure often occurs) or decompensated liver disease]"
NCT00528528,Inclusion Criteria,"[chronic genotype 1 hepatitis (inflammation of the liver) c infection, never been treated for hepatitis c viral (hcv) infection, liver biopsy or \""fibroscan\"" test performed during screening or in the past 3 years, amount of hcv ribonucleic acid (rna) in the blood  more than 10,000 international units/milliliter (iu/ml) at entry, no clinically significant lab abnormalities]"
NCT00217516,Criteria,"[must have undergone ≥ a sextant biopsy, not specified, prior concurrent therapy:, endocrine therapy, performance status, chemotherapy, life expectancy, hematopoietic, other, not specified, not specified, prostate-specific antigen < 20 ng/ml, renal, radiotherapy, not specified, no prior radiotherapy, other, gleason score < 8, clinical stage t1a-t2a disease, more than 5 years, surgery, hepatic, patient characteristics:, no selenium at doses > 50 mcg/day as a dietary supplement, including multivitamin supplements, not specified, no prior hormonal therapy, histologically confirmed adenocarcinoma of the prostate, not specified, not specified, no other prior malignancy except nonmelanoma skin cancer, biologic therapy, more than 30 days since prior and no concurrent participation in another clinical trial involving a medical, surgical, nutritional, or lifestyle intervention (e.g., dietary modification or exercise), not specified]"
NCT00388531,Exclusion Criteria,"[failure (as defined by no clearance of the csf) to > 1 dose of prior intrathecal mtx or cytarabine or triple (mtx, arac, dexamethasone) therapy, history of previous severe neurotoxicity (grade iii-iv) attributed to intrathecal therapy or systemic high-dose therapy with methotrexate or cytarabine (vincristine induced peripheral neuropathy is accepted), prior cns relapse < 1 month before, uncontrolled infection, the patient must not be pregnant or breast feeding. if the patient is a female of child-bearing potential she must have a negative (urine or serum) pregnancy test and be using effective methods to prevent pregnancy]"
NCT00388531,Inclusion Criteria,"[age >18 years old, cns involvement must be demonstrated by:, the patient or guardian must be competent to provide informed consent and must provide written informed consent prior to the initiation of study procedures, recovery from grade iii/iv toxicities attributable to prior treatment with the exception of hematotoxicity., patients with acute lymphoblastic leukemia or very aggressive non-hodgkin-lymphoma (burkitt/burkitt-like) and cns relapse., characteristic signs and symptoms of neoplastic meningitis plus an mri or ct scan indicating the presence of meningeal involvement. patients with combined relapse in cns and other locations may be included in case that systemic therapy with cns active drugs (hdmtx;hdac, thiotepa) can be postponed for at least 2 weeks., no severe heart, lung, liver or kidney dysfunction., a positive ventricular or lumbar csf cytology defined as csf cell counts > 5/µl (19/3 cells), obtained within 10 days prior to inclusion or, karnofsky >60%]"
NCT00314977,Inclusion Criteria,"[adequate bone marrow function (within 14 days prior to registration): wbc ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l, her2/neu receptor analysis performed on the primary tumour in the biopsy material, age ≥18 years and age ≤70 years, no prior surgery other than biopsy and no prior chemotherapy or radiation therapy, karnofsky performance score ≥70%, adequate liver function (within 4 weeks prior to start treatment): bilirubin ≤1.5 x upper limit of normal (unl) range, alat and/or asat ≤2.5  x unl, alkaline phosphatase ≤5 x unl, estrogen and/or progesterone receptor analysis performed on the primary tumour in the biopsy material, measurable disease (breast and/or lymph nodes), patients must be accessible for treatment and follow-up, adequate renal function (within 4 weeks prior to start treatment): the calculated creatinine clearance should be ≥50 ml/min, written informed consent according to the local ethics committee requirements, women presenting with large resectable or locally advanced breast cancer (t2 ≥3 cm, t3, or t4, and/or ln positive), in case the tumor is er/pgr ³ 50% positive, (neo)adjuvant hormonal therapy in stead of chemotherapy should be considered (e.g. in team ii study)]"
NCT00314977,Exclusion Criteria,"[serious other diseases as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrythmias, patients with a history of another malignancy (except basal cell skin carcinoma and carcinoma-in-situ of the uterine cervix) within 5 years of study entry- pregnant or lactating women, or potentially fertile women not using adequate contraception, patients with a history of breast cancer, evidence of distant metastases (m1), patients with advanced pulmonary disease of any cause (oxygen dependent)- peripheral neuropathy > grade 2 whatever the cause]"
NCT00273364,Inclusion Criteria,"[8. resting lvef < 50 %, 3. positive pregnancy test, 10. serum creatinine > 2.0 mg/dl, exclusion criteria**, 12. presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have mri exams, 19. use of fingolimod (gilenya) within the previous 3 months, 1. any illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy., 3. an edss score of 2.0 to 6.0 (appendix ii)., 16. psychiatric illness, mental deficiency or cognitive dysfunction making compliance with treatment or informed consent impossible, 23. any hereditary neurological disease such as charcot-marie-tooth disease (cmt) or spinocerebellar ataxia (sca) are contraindications, for patients who clearly have inflamatory disease, an exception can be made if agreed upon by study pi and at least two study neurologists., 22. prior treatment with mitoxantrone, 24. use of tecfidera within the previous 3 months, 4. inability or unwillingness to pursue effective means of birth control from the time of evaluation for eligibility until 6 months posttransplant (if on transplant) or until appropriate for non-transplant treatment (if on control arm). effective birth control is defined as 1) abstinence defined as refraining from all acts of vaginal intercourse; 2) consistent use of birth control pills; 3) injectable birth control methods (depo-provera, norplant); 4) tubal sterilization or male partner who has undergone vasectomy; 5) placement of an intrauterine device (iud); or 6) use, with every act of intercourse, of diaphragm with contraceptive jelly and/or condoms with contraceptive foam., 13. diagnosis of primary progressive ms, 9. bilirubin > 2.0 mg/dl, 17. active infection except asymptomatic bacteriuria, 20. use of teriflunomide (aubagio) within the previous 2 years unless cleared from the body (plasma concentration < 0.02mcg/ml) following elimination from the body with cholestyramine 8g three times a day for 11 days, 18. use of natalizumab (tysabri) within the previous 6 months, 1. 1. age between18-55, inclusive., 6. fev1/fvc < 60% of predicted after bronchodilator therapy (if necessary), 2. prior history of malignancy except localized basal cell, squamous skin cancer or carcinoma in situ of the cervix.  other malignancies for which the patient is judged to be cured, such as head and neck cancer, or breast cancer will be considered on an individual basis., 4. inflammatory disease despite treatment with standard disease modifying therapy including at least 6 months of interferon or copaxone.  inflammatory disease is defined based on both mri (gadolinium enhancing lesions) and clinical activity (acute relapses *treated with iv or oral high dose corticosteroids and prescribed by a neurologist). minimum disease activity required for failure is defined as: a) two or more *steroid treated clinical relapses with documented new objective signs on neurological examination documented by a neurologist within the year prior to the study, or b) one *steroid treated clinical relapse within the year prior to study and evidence on mri of active inflammation (i.e., gadolinium enhancement) within the last 12 months on an occasion separate from the clinical relapse (3 months before or after the clinical relapse)., 11. known hypersensitivity to mouse, rabbit, or e. coli derived proteins, or to iron compounds/medications, 21. prior treatment with campath (alemtuzumab), 2. diagnosis of ms using revised mcdonald criteria of clinically definite ms (appendix i)., 7. dlco < 50% of predicted (for the transplant arm), 14. diagnosis of secondary progressive ms, a steroid treated relapse will include a relapse that was severe enough to justify treatment but due to patient intolerance of steroids, or a history of non-response to steroids, they were offered but not used., 5. failure to willingly accept or comprehend irreversible sterility as a side effect of therapy, 15. platelet count < 100,000/ul, wbc < 1,500 cells/mm3]"
NCT00532259,Inclusion Criteria,"[5. ecog performance status 0-1., 2. confirmed diffuse large b-cell lymphoma, transformed follicular lymphoma, diffuse mixed cell lymphoma or primary mediastinal large cell lymphoma with b-cell lineage., 3. the lymphoma is chemosensitive., 4. the lymphoma did not progress since pre-transplant chemotherapy., 1. patient's age is 18 years or older, both genders.]"
NCT00532259,Exclusion Criteria,"[7. positive hiv, hepatitis b surface antigen plus viremia, or hepatitis c antibody plus viremia., 5. clinical evidence of primary or secondary brain or spinal cord involvement by lymphoma., 8. pregnant or nursing (positive pregnancy test)., 9. other concurrent clinical study or investigational therapy., 2. active autoimmune disease., 3. type 1 diabetes., 1. serious other illness., 4. known immune deficiency., 6. active bacterial, fungal, or viral infection.]"
NCT00369837,Exclusion Criteria,"[severe hypertension known to be precipitated by use of, or withdrawal from, alcohol or illicit drugs, or intentional overdose of illicit or prescription drugs, participation in clinical research studies of other investigational drugs or devices within 30 days of enrollment, allergy to soybean oil or egg lecithin, expectation that the patient will not tolerate intravenous antihypertensive therapy for at least 18 hours, administration of an agent for treating hypertension within 2 hours of clevidipine administration, known liver failure or cirrhosis, known or suspected aortic dissection, intolerance to calcium channel blockers, sbp ≤180 mmhg and/or dbp ≤115 mmhg, positive pregnancy test]"
NCT00369837,Inclusion Criteria,"[age 18 years or older, written informed consent, systolic blood pressure >180 mmhg and/or diastolic blood pressure >115 mmhg assessed on two successive occasions, 15 minutes apart at baseline]"
NCT00275379,Exclusion Criteria,"[Use of herbal supplements (except for a daily multivitamin/mineral supplement not containing herbal components), Vaginitis or vaginal infection within 1 month before randomization, History of cancer (other than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer) with less than 5 years documentation of a disease-free state]"
NCT00275379,Inclusion Criteria,"[Subjects seeking medical treatment for symptoms consistent with IC that have been ongoing for > 9 months or seeking medical treatment for a previous documented diagnosis of IC, Alter 18 Jahre und älter, Subjects who are not surgically sterile or postmenopausal (amenorrheic > 12 months) must agree and commit to the use of a medically acceptable, highly-effective (i.e. double-barrier or IUD), non-hormonal form of birth control during the study and for 30 days after the last dose of test]"
NCT00304850,Exclusion Criteria,"[previous history of total mastectomy or partial contralateral mastectomy, inflammatory tumor requiring pre-operative radiotherapy, morphinic treatment during the 7 days before surgery, excessive alcohol consumption or addiction, chronic inflammatory disease treated by corticoids or nsai, anti-arrhythmic or anti-epileptic treatments, ketamine or neomycin contra-indication, chronic analgesic treatment, severe cardiovascular disease]"
NCT00304850,Inclusion Criteria,"[informed consent signed, asa 1-3, age : 18 - 75, complete lymphadenectomy within one  week following simple tumorectomy, left or right complete mastectomy with complete lymphadenectomy, left or right tumorectomy with complete lymphadenectomy, breast cancer (t1, t2, t3, n0, n1, m0)]"
NCT01902862,Exclusion Criteria,"[participants with malignant neoplasm (cancerous - new growth that is not normal; tumor) (except basalioma) within previous 5 years, participants with life-expectancy of less than 3 months, participants with peripheral (not central) neuropathy (a disturbance in the function of the brain or spinal cord that may affect the nerves and muscles of the body) common terminology criteria for adverse events (ctcae) grade greater than or equal to 2, participants with previous treatment with bortezomib within 6 months before enrollment or previous treatment with a combination of rituximab and bortezomib, participants with previous known allergic reaction to bortezomib, boron or mannitol]"
NCT01902862,Inclusion Criteria,"[women must be either postmenopausal or sterilized; negative pregnancy test at screening, participants with total bilirubin below 1.5-fold upper limit of normal (uln) and creatinine below 2-fold uln, participants with karnofsky status greater than or equal to 60 percent, participants with histologically confirmed relapsed or refractory follicular stage iii or iv, grade 1 and 2, cluster of differentiation 20 plus (cd20+) lymphoma (who-world health organization) that requires therapy, participants in whom treatment with rituximab is planned after greater than or equal to 2 cytostatic (inhibition of cell growth) previous therapies]"
NCT00368277,Inclusion Criteria,"[male or female outpatients ≥ 65 years old., patients who were eligible and able to participate in the study, and who consented to do so after the purpose and nature of the investigation had been explained to them (written informed consent)., patients with essential hypertension with an mssbp ≥ 140 mmhg and < 180 mmhg, and msdbp < 110 mmhg at visits 2 and 3. (visit 201 was deleted by the administrative changes document.), patients must have had a difference in mssbp of ≤ 20 mmhg between visit 3 and the visit immediately prior to visit 3.]"
NCT00368277,Exclusion Criteria,"[concurrent potentially life threatening arrhythmia or symptomatic arrhythmia., current unstable angina pectoris. patients on a stable dose of oral or topical nitrates or beta blockers for angina were acceptable., current diagnosis of heart failure (new york heart association class iii-iv)., history of hypertensive encephalopathy., history of transient ischemic cerebral attack or cerebrovascular accident within 6 months., history of renal artery stenosis., concurrent use of any antihypersensitive medications except a stable dose 3 months prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy (e.g., flomax for bph), beta blockers for angina, or beta blockers ophthalmic preparations., clinically significant valvular heart disease., known keith-wagener grade iii or iv hypertensive retinopathy., history of myocardial infarction, bypass surgery, or any percutaneous coronary intervention within 6 months.]"
NCT00334802,Inclusion Criteria,"[histologically and/or cytologically confirmed breast cancer, to have adequate organ function (bone marrow, liver and renal function), to have at least one measurable region, eastern cooperative oncology group (ecog) performance status: 0-1, received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen]"
NCT00334802,Exclusion Criteria,"[to have interstitial pneumonia or pulmonary fibrosis, to have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes), to have brain metastases with symptoms, within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery, to have inflammatory breast cancer]"
NCT00753935,Exclusion Criteria,"[anemia (hematocrit < 30%), uncontrolled hypertension (systolic bp > 180 mmhg), concurrent use of other anti-platelet agents, history of significant gi bleeding, decompensated congestive heart failure, use of nsaids or coxibs within the previous 2 weeks, pre-menopausal female, thrombocytopenia (platelet count < 135,000/ul), renal disease (creatinine >= 2 mg/dl), recent coronary syndrome (< 6 months)]"
NCT00753935,Inclusion Criteria,"[documented stable coronary artery disease or > 6 months after cabg or interventional cardiac procedure, written informed consent, on aspirin 81-325mg daily at time of enrollment]"
NCT00277381,Inclusion Criteria,"[fluency in english., age 45-65 inclusive., morisky score of less than or equal to 2 (explanation in 'equitable selection of subjects')., primary care physician consent to the patient taking part., prescription of a once-a-day dose of atenolol.]"
NCT00277381,Exclusion Criteria,"[patients with congenital or acquired cognitive impairment., patients with visual impairment or color-blindness., patients prescribed more than four medications in total., patients prescribed more than two anti-hypertensive agents., patients on secondary prevention following cardiac event or stroke., patients with a cardiac pacemaker, morisky score of more than 2.]"
NCT00455897,Inclusion Criteria,"[patient agrees to use birth control, tumor tissue confirmed to express the cd20 antigen by flow cytometry or immunohistochemistry, age > 18 years, measurable disease as defined by a tumor mass of 1cm or greater in one dimension, laboratory parameters as outlined in protocol, ecog performance status of 0-2, histologically confirmed diagnosis of diffuse large b cell non-hodgkin's lymphoma with characteristic immunophenotypic profile, patient has not received any prior anti-cancer therapy for lymphoma, stage ii (abdominal-not xrt appropriate), iii, or iv disease]"
NCT00455897,Exclusion Criteria,"[active rheumatologic disease which may be exacerbated by gm-csf, known hiv disease, any evidence of prior natural exposure to hepatitis b, patient is pregnant or nursing, cardiac ejection fraction less than 45%, patient is receiving other investigational drugs, known central nervous system involvement by lymphoma, serious uncontrolled concurrent illness such as active coronary artery disease, severe copd, chf, active alcohol abuse, active concurrent malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix]"
NCT00195897,Exclusion Criteria,"[history of chronic renal insufficiency, previous chemotherapy using anthracyclines, atrial fibrillation and significant arrhythmia, history of radiation therapy, contra indication to mr examination, pregnancy, history of congestive heart failure]"
NCT00195897,Inclusion Criteria,"[who score < or = 2, left ventricular ejection fraction > 50%, histologically proven lymphoma (hodgkin's or non-hodgkin's), informed consent, age > 18 y/o and < 70 y/o, life expectancy > 6 mo]"
NCT00505232,Inclusion Criteria,"[all histologic mcl subtypes (who classification), cardiac ejection fraction >50%, informed consent should be obtained, adequate organ (hepatic, cardiac and renal) and marrow function: hb> 10g/dl, neutrophil counts> 1500/ µl, platelet> 100000/ µl. creatinine < 2,5xuln, bilirubin, ast or alt<2,5xuln., age between 18 and 70 years old, for y90-ibritumomab tiuxetan administration:  bone marrow infiltration by lymphoma cells < than 25% ; platelet count >100,000/µl and neutrophil counts >1500/µl, performance status 0 to 2 (ecog)]"
NCT00505232,Exclusion Criteria,"[men and women with reproductive potential who are not using effective contraceptive methods during and at least 12 months after the end of the study, previous chemotherapy or radiotherapy treatment., known hypersensitivity to some of the drugs or other related compounds, hiv, hbv or hcv positive serology., limitation of the patient´s ability to comply with the treatment or follow-up protocol., symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia., acute or chronic active infection., no informed consent obtained, uncontrolled current illness: hepatic, renal, cardiovascular, neurological or metabolic illness., ann arbor stages i or ii without b symptoms or bulky disease (>10 cm).]"
NCT00330369,Exclusion Criteria,"[subjects who perform alternating shift or night work, symptomatic congestive heart failure requiring treatment, serum alt or ast >2 x the upper limit of the normal range (uln), average sitting systolic blood pressure ≥180 mmhg or diastolic blood pressure ≥110 mmhg, subjects who have participated  in a clinical study involving  another investigational drug or device within 4 weeks prior to screening, hemodynamically significant valvular heart disease, implanted pacemakers or implanted cardioverter defibrillator (icd), diagnosis or recurrence of malignancy within the past 3 years, subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident (cva) within 6 month; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia, type i diabetes mellitus, hemodialysis or peritoneal dialysis; or history of renal transplant, sleep apnea, unless a recent sleep study demonstrates arterial oxygen saturation greater than or equal to 90%]"
NCT00330369,Inclusion Criteria,"[subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmhg, female subjects of non-childbearing potential (i.e., post-menopausal for at lest 2 years; surgically sterile), aged 35 to 80 years, all other subjects must have a mean systolic blood pressure ≥140 mmhg, receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic, subjects who are competent to provide written consent]"
NCT00612807,Inclusion Criteria,"[willing to take antidepressant medication and participate in weekly marital therapy and assessments, either partner must report marital distress or tension, the depressed partner cannot be involved in any other psychosocial treatment, one partner must receive a clinical diagnosis of major depressive disorder based upon our assessment, couples must be living together, score above 24 on the mini mental status exam]"
NCT00612807,Exclusion Criteria,"[coexisting bipolar or psychotic disorder, evidence of active and severe domestic violence, both partners meet diagnostic criteria for major depressive disorder based on our evaluation, current ect treatment, evidence of a primary substance abuse or dependence disorder]"
NCT00917449,Inclusion Criteria,"[hypertension (>130 / >85 mmhg), diagnosis of igt after a standard glucose tolerance test  (ogtt, 75 g), moreover, in order to be considered affected by metabolic syndrome, they must have two or more of the following criteria:, hypertriglyceridemia (>150 mg/dl), male or female aged more than 35 years., written informed consent must be obtained before any procedure of the study is done., abdominal obesity (waist>120 cm for man, >88 cm for women), low hdl cholesterol  (<40mg/dl in man, <50 mg/dl in woman)]"
NCT00917449,Exclusion Criteria,"[presence of type 1 or type 2 diabetes mellitus, known renal insufficiency or creatinine levels more than 1.8 mg/dl,, fasting glucose levels >126 mg/dl, abuse of alcohol or abuse substances, sitting systolic arterial pressure >140mmhg, and sitting diastolic arterial pressure >90mmhg, presence of chronic hepatopathy or levels of alt and ast more than two standard deviations from normality levels, psychiatric disorders, pregnancy, presence of malignancy]"
NCT00389519,Inclusion Criteria,"[4. female subjects greater than or equal to 12 years of age, or who have had greater than or equal to 1 menstruation must: (a) have a negative serum pregnancy test at screening (i.e., subject is not pregnant), (b) not be lactating, and (c) use an acceptable method of contraception., 2. the subject can be safely withdrawn from antihypertensive medications during the screening period, and if given placebo during the treatment period in the judgment of the investigator., 1. previous, documented diagnosis of hypertension, or newly diagnosed hypertension according to the fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents (united states).  sisbp greater than or equal to the 95th percentile for age, gender, and height., 5. parents/guardians are able to demonstrate their ability to (a) use a home blood pressure monitor supplied for the study to monitor their child's blood pressure, and (2) mix and administer a liquid dose of study drug if needed., 3. the subject is male or female age 6 to 16 years (inclusive), and weighs greater than or equal to 20 kg.]"
NCT00389519,Exclusion Criteria,"[1. bilateral renal artery stenosis., 5. subjects with nephrotic syndrome not on stable maintenance therapy of prednisone or cyclosporine., 2. uncorrected coarctation of the aorta or corrected coarctation with a right arm/right leg blood pressure gradient greater than 10 mmhg., 7. clinically significant hematologic, hepatobiliary, or renal disease including a schwartz formula gfr less than 40 ml/min/1.73 m2, and/or serum potassium (k+) greater than 5.5 meq/l., 9. known sensitivity to angiotensin converting enzyme inhibitors or a history of angioneurotic edema., 3. severe hypertension., 4. renal transplantation or other previous solid organ transplantation less than 6 months prior to entering the study., 6. a history of cardiomyopathy, clinically significant structural heart disease, or atrioventricular conduction disturbance, sick sinus syndrome, atrial flutter, atrial fibrillation, clinically significant bradycardia or an accessory bypass tract, or clinical symptoms of congestive heart failure., 8. history of pancreatitis (active or inactive).]"
NCT00414492,Exclusion Criteria,"[patients who are not surgical candidates., patients who have received neoadjuvant therapy but who have had no response or who have had tumor progression., patients who do not have colon cancer metastases to the liver., patients who have not received neoadjuvant therapy., patients who are < 18 years old., patients who do not schedule or who cancel a liver resection.]"
NCT00414492,Inclusion Criteria,"[patients must be candidates and be scheduled for liver resection., patients must be ≥ 18 years old., patients must have signed institutional review board (irb) approved written consent form prior to registering in the study., patients must have received and have had a response to neoadjuvant therapy prior to liver resection., patients must have colon cancer metastases to the liver.]"
NCT00354991,Inclusion Criteria,"[patients with essential hypertension previously treated with antihypertensive medications for at least 4 weeks but did not reach the blood pressure goal, patient is male or female and = 18 years of age]"
NCT00354991,Exclusion Criteria,"[other antihypertensive medications or medications that may affect blood pressure, any known bleeding disorder, history of stroke or myocardial infarction (heart attack), known sensitivity or intolerance to the study medication (losartan or hydrochlorothiazide), previous history of severe essential hypertension, pregnant or breastfeeding, or expecting to conceive within the projected duration of the study, uncontrolled diabetes mellitus, history of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient/subject to participate, evidence of renal or liver disease]"
NCT00609401,Inclusion Criteria,"[life expectancy of greater than 3 months, cytohistological diagnosis of rcc, karnofsky ps >= 60%, measurable disease according to recist criteria, age >= 18 years, written informed consent]"
NCT00609401,Exclusion Criteria,"[chronic treatment with corticosteroids, brain metastasis or spinal cord compression, uncontrolled hypertension, prior medical treatment for metastatic rcc]"
NCT00247390,Inclusion Criteria,"[Based on sleep history, reports a subjective sleep latency greater than or equal to 45 min, Mean latency to persistent sleep of greater than 20 minutes on two consecutive screening nights with neither night less than 15 minutes, Based on sleep history, has had chronic insomnia for at least 3 months, A mean of 60 minutes of wake time during the 480 minutes in bed across two nights with no night less than 45 minutes, Based on sleep history, normally uses pharmacological assistance to sleep 0 to 4 times per week in the last 3 months, Based on sleep history, habitual bedtime is between 10:00 PM and 1:00 AM, Based on sleep history, reports a subjective total sleep time less than or equal to 6.5 hours, Females of childbearing potential who are sexually active must agree to use adequate contraception, Body mass index between 18 and 34, inclusive, Females of childbearing potential can neither be pregnant nor lactating from Screening throughout the duration of the study, Alter 18 Jahre und älter]"
NCT00247390,Exclusion Criteria,"[Ginkgo-biloba, Systemic steroids, Sedatives, Antipsychotics, Narcotic analgesics, Positive urine drug screen at Screening Visit 1 or any of the polysomnogram assessment visits, Hypnotics, Muscle Relaxants, Melatonin and all other drugs or supplements known to affect sleep/wake function, Decongestants, Sleep schedule changes required by employment (eg, shift worker) within three months prior to the administration of single-blind study medication, Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:, Antidepressants, History of alcohol abuse within the past 12 months, as defined in Diagnostic & Statistical Manual of Mental Disorders, 4th Edition Revised, or regularly consumes more than 14 alcoholic drinks per week, or consumed any alcoholic drinks within 24 hours of any polysomnogram visits, Respiratory stimulants, St. John's Wort, Over-the-counter and prescription diet aids, Uses tobacco products (including nicotine gum and patch) or any other products that may interfere with the sleep wake cycle during nightly awakenings, CNS active drugs (including herbal), Anxiolytics, Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer, Flown across greater than three time zones within 7 days prior to or during screening, Used any central nervous system medication or other drugs or supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug, whichever is longer) prior to the administration of single-blind study medication. These medications must not have been used to treat psychiatric disorders., Known hypersensitivity to ramelteon or related compounds, including melatonin, and melatonin related compounds, Intends to continue taking any disallowed medication or any prescription medication or over the counter medication that is known to affect the sleep/wake function or otherwise interfere with evaluation of the study medication. The subject must report all prescription and over the counter medications taken in the three weeks prior to screening, Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, neurological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of single-blind study medication, Has ever had a history of seizures, sleep apnea, restless leg syndrome, periodic leg movement syndrome, chronic obstructive pulmonary disease or fibromyalgia, Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of single-blind study medication, Periodic Leg Movement Syndrome with arousal index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night, History of psychiatric disorder within the past 6 months, History of drug abuse within the past 12 months, as defined in Diagnostic & Statistical Manual of Mental Disorders, 4th Edition Revised, Over-the-counter and prescription stimulants, Kava-kava, Any additional condition(s) that in the Investigator's opinion would affect sleep/wake function, prohibit the subject from completing  the study, indicate that continuation in the study would not be in the best interests of the subject, Apnea hypopnea index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night, Sedating H1 antihistamines, History of hepatitis B or hepatitis C, Positive breathalyzer test on any of the polysomnogram assessment visits, Anticonvulsants, Beta blockers]"
NCT00289484,Inclusion Criteria,"[participants must present with a first or new episode of dsm iv non-psychotic major depression warranting treatment with antidepressant mediation., must be able to give informed consent.]"
NCT00289484,Exclusion Criteria,"[history of allergy to omega-3 supplements, finfish or shellfish., patients who, in the investigator's judgment pose a current serious suicidal or other safety risk, or patients who will not likely be able to comply with the study protocol., hepatic or renal impairment or other medical conditions that may interfere with the absorption and metabolism of omega-3 polyunsaturated fatty acids, non-english speaking or otherwise unable to provide historical information., having taken omega-3 dietary supplements in the last 3 months., current drug or alcohol abuse or dependence or history of abuse or dependence over the last 12 months., coagulopathy or anticoagulant treatment due to theoretical bleeding risk., unstable thyroid function, history of psychosis or mania/hypomania or personality disorder., post-natal depression, pregnancy, breast feeding or plans to become pregnant during course of study.]"
NCT00349778,Criteria,"[dlco >=60% predicted., age 18-75 years., alt and ast must be < 2x normal.  total bilirubin less than 2 mg/dl., patients must be hiv negative., serum creatinine < 2.0 or 24-hour creatinine clearance e 60 ml/min., pregnant or lactating women will not be eligible to participate., patients must provide signed, informed consent., patients who have undergone prior autologous hematopoietic cell transplantation will not be eligible for this study., patients must have their pathology reviewed and the diagnosis confirmed at stanford university medical center.  patients with smoldering multiple myeloma, monoclonal gammopathy of unknown significance, or primary amyloidosis will be excluded from this study.  patients with multiple myeloma and amyloidosis may be eligible for this trial, with approval by the principle investigator., exclusion criteria:- severe psychological or medical illness, patients must have a karnofsky performance status > 70%.]"
NCT00363636,Criteria,"[prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months prior to study day 1., recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs., cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to study day 1 (6 weeks if nitrosourea or mitomycin c)., prior allogeneic transplant., key exclusion criteria:, new york heart association class iii or iv cardiac disease or myocardial infarction within 6 months prior to study day 1., relapsed or progressive disease after at least 1 prior chemotherapy requiring treatment., transfusion-dependent subjects., rituximab refractory or refractory to anti-cd20 radioimmunotherapy (no response to prior rituximab or prior rituximab-containing regimen, or a response with a ttp of less than 6 months)., bidimensionally measurable disease with at least 1 lesion >= 2.0 cm in a single dimension., another primary malignancy requiring active treatment (except hormonal therapy)., key inclusion criteria:, acceptable hematologic, hepatic, and renal function parameters., autologous bone marrow or stem cell transplant within 6 months prior to study day 1., histologically confirmed follicular grade 1-3a nhl., prior lymphoma vaccine therapy within 12 months prior to study day 1., serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions, which would compromise protocol objectives in the opinion of the investigator and/or the sponsor., aged >= 18 years old at the time of informed consent., follicular lymphoma grade 3b.]"
NCT00818103,Inclusion Criteria,"[brain mri not meeting diagnostic criteria for multiple sclerosis, criteria for neuromyelitis optical, 3. positive csf, 2. positive spinal cord mri (two focal t2 lesions), two or more attacks; objective clinical evidence of one lesion, dissemination in space, demonstrated by: mri or two or more mri-detected lesions consistent with ms plus positive csf or wait further clinical attack implicating a different site, or, optic neuritis, one attack; objective clinical evidence of one lesion (monosymptomatic presentation; clinically isolated syndrome), dissemination in space, demonstrated by: mri or two or more mri-detected lesions consistent with ms plus positive csf and dissemination in time, demonstrated by: mri or second clinical attack, or, criteria for multiple sclerosis:, two or more attacks; objective clinical evidence of two or more lesions, or, 1. positive brain mri (nine t2 lesions or four or more t2 lesions with positive vep), acute myelitis, at least two of three supportive criteria:, contiguous spinal cord mri lesion extending over >= 3 vertebral segments, insidious neurological progression suggestive of ms, one year of disease progression (retrospectively or prospectively determined) and two of the following:, nmo-igg seropositive status, one attack; objective clinical evidence of two or more lesions, dissemination in time, demonstrated by: mri or second clinical attack, or]"
NCT00818103,Exclusion Criteria,"[allergic to drug: atorvastatin, β-interferon, epo, immunoglobulin, serious mental disorders and depression, late neuromyelitis optical or edss > 6.0, > 65 yrs old, heavy damage of heart, lung, liver, renal function, serious hypertension and diabetes]"
NCT00833560,Inclusion Criteria,"[participants without preceding cytostatic (tending to retard cellular activity and multiplication) treatment (pretreatment with radiation or dexamethasone is allowed), adequate laboratory test values, agree to use one of the contraception methods as defined in the protocol, cytologically or histologically diagnosed with multiple myeloma stage ii/iii, karnofsky performance status 60 percent or more]"
NCT00833560,Exclusion Criteria,"[history of cancer (except basal cell carcinoma) in the last 5 years, positive human immunodeficiency virus test and active hepatitis b and/or hepatitis c, pregnant or breast-feeding female participants, peripheral neuropathy (disorder of the peripheral nerves) grade 2 or more, estimated life expectancy less than 3 months, non-secretory multiple myeloma]"
NCT00933439,Inclusion Criteria,"[screening and baseline hamilton rating scale for depression (hrsd) 17-item score greater than or equal to 16 or clinical global impression (cgi) score of at least 4, ability and willingness to provide written informed consent, primary diagnosis of major depressive disorder (mdd), subjective report of difficulties with cognition and/or concentration and score of 2 or greater on the inventory for depressive symptomatology (ids-c(30)) item addressing this symptom (#16: concentration and decision making), age 18-45]"
NCT00933439,Exclusion Criteria,"[presence of other psychological disorders, including depression due to other comorbid conditions, currently suicidal or high suicide risk, current or past psychotic disorders of any type, bipolar disorder (i, ii, or nos), schizophrenia, or schizoaffective disorder, anorexia, bulimia, obsessive compulsive disorder, alcohol or substance abuse within the last 6 months, or patients with comorbid psychiatric conditions that are relative or absolute contraindications to the use of duloxetine, patient report or evidence (based on physical examination or laboratory tests) of existing liver disease, presence of significant comorbid condition based on laboratory tests, physician information, or evidence at examination, for women, currently pregnant, planning to become pregnant in the next year, or breastfeeding, hospitalization for mental illness within the past year, concomitant pharmacological or psychotherapeutic treatment including but not limited to antidepressants, anxiolytics, neuroleptics, mood stabilizers, and/or other agents without proven antidepressant efficacy, cognitive behavioral therapy; current use of other medications that would be contraindicated with duloxetine, as determined by the study doctor, not fluent in spoken and written english]"
NCT00356525,Inclusion Criteria,"[you have non-small cell lung cancer that has come back (relapsed) after initial treatment with surgery and chemotherapy., you have good kidney, liver, and bone marrow organ function., you are fully active or able to carry out light work such as housework or office work.]"
NCT00356525,Exclusion Criteria,"[you are unable or unwilling to take the folic acid pills or vitamin b12 injections that are required for the study, you are currently receiving another treatment for your relapsed lung cancer, or have had chemotherapy or certain other therapies for relapsed lung cancer in the past, you have had a heart attack in the last 6 months, or have other heart problems that are not controlled with medication, you have received pemetrexed or gemcitabine in the past for lung cancer, you are unable to stop taking aspirin or other drugs that control inflammation for certain periods of time during the study, you are unable to take corticosteroid drugs like dexamethasone]"
NCT00593489,Exclusion Criteria,"[fps working in an academic environment, fps who anticipate retiring within the post-intervention period, moving their practice to another city, or having locum coverage of their practice for more than 4 weeks during the post-intervention period, fps currently participating in a diabetes behaviour-change intervention trial, fps unlikely to comply with protocol, (uncooperative attitude, unlikelihood of completing the study)., fp does not attend workshop or complete educational training using workshop dvd with dne guidance]"
NCT00593489,Inclusion Criteria,"[attendance at the scheduled workshop (if unable to attend the workshop must be available to be educated and trained by dne using a workshop dvd), support the generation of a diabetes practice profile prior to the deadline established, a minimum of 50 patients with type 2 diabetes in their practice., a minimum of 6 insulin-eligible patients, generation of a practice list of patients with t2dm, full time physicians >25 hours per week in office, ability to generate a listing of patients with type 2 diabetes (t2dm) from their practice or billing records.]"
NCT00419822,Exclusion Criteria,"[suspected or diagnosed fibromyalgia, previous shoulder injuries for the specific arm that will undergo axillary dissection, double mastectomy at the time of current axillary surgery, previous acupuncture (lifetime), unable to provide written informed consent, known or suspected drug or alcohol abuse as determined by the investigator, previous mastectomy, any diagnoses of autoimmune disease, pregnant or lactating women, decreased range of motion (rom) as evidenced on standard preoperative exam]"
NCT00419822,Inclusion Criteria,"[expected survival at least 6 months or greater, female subjects, greater than 21 years of age, greater than 6 nodes removed during surgery, has had surgery with axillary dissection]"
NCT00308178,Exclusion Criteria,"[patients with stage iv breast cancer, patients with sickle cell disease, known history of hyperviscosity syndrome, receiving any other investigational agents, pregnant or nursing, patients on lithium, immune deficiency when treated with marrow-suppressive therapy or hiv-positive patients receiving anti-retroviral therapy, uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements, current grade ii or greater peripheral neuropathy or prior history of grade ii or greater neuropathy, previous cytotoxic chemotherapy or therapeutic radiation therapy for any reason]"
NCT00308178,Inclusion Criteria,"[histologically or cytologically confirmed breast cancer, with clinical stage i, ii, or iii disease, ecog performance status of 0 or 1, must register at the beginning of adjuvant or neoadjuvant chemotherapy, 18 years of age or older, normal organ and marrow function]"
NCT00403065,Criteria,"[must be able to respond to weekly telephone assessment questions, more than 1 month since prior chemotherapy, the benefit or lack of benefit of whole-brain radiotherapy (wbrt) cannot be clearly defined, histologically or cytologically confirmed primary non-small cell lung cancer, more than 1 month since prior surgery for brain metastases, patient characteristics:, unresectable disease or surgery is deemed inappropriate, must have brain metastases confirmed by ct scan or mri, prior concurrent therapy:, more than 1 week since prior epidermal growth factor receptor inhibitors, no prior radiotherapy to the brain, no prior or concurrent uncontrolled illness that could preclude study treatment or comparisons, any known certainty of the benefit or lack of benefit of wbrt is not allowed]"
NCT00305188,Inclusion Criteria,"[measurable disease., prior radiotherapy is permitted if it was not administered to target lesions identified for this study - unless progression within the radiation portal is documented - and provided it has been completed at least 3 weeks before randomization., who performance status (ps) : 0 or 1., metastatic disease not amenable to potentially curative treatment (eg: inoperable metastatic disease)., male or female aged >18 years., signed written informed consent prior to study entry., disease-free interval from end of adjuvant therapy of at least 6 months (1 year if oxaliplatin was part of the adjuvant therapy)., histologically or cytologically-proven metastatic cancer of the colon or rectum., main inclusion criteria :, no prior chemotherapeutic regimen for metastatic disease.]"
NCT00305188,Exclusion Criteria,"[any condition or past medical history that contra-indicates treatment with oxaliplatin and 5-fu, as reported in approved labeling information., concurrent active cancer originating from a primary site other than colon or rectum., concomitant treatments with drugs/ingredients reported to have a potential activity in preventing peripheral sensory neuropathy., presence of any symptom suggesting brain metastasis., peripheral neuropathy >grade 1., main exclusion criteria :, received chemotherapeutic agents other than 5-fu, lv, levamisole, irinotecan, capecitabine, oxaliplatin as part of adjuvant therapy.]"
NCT00401778,Exclusion Criteria,"[history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.  symptoms may include any reaction such as bronchospasm, generalized urticaria, systolic bp ≤ 80mm hg, and angioedema., patient is unable to swallow rad001 tablet., known hypersensitivity to everolimus, sirolimus, or any of its excipients., final eligibility for a clinical trial is determined by the health professionals conducting the trial., patient has incurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements., patient has received previous treatment for nsclc., patient is pregnant or breast-feeding., history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of the malignancy being present within the past five years.]"
NCT00401778,Inclusion Criteria,"[life-expectancy greater than 6 months., must meet pre-entry requirements for timing of study parameters as specified in section 7.0., final eligibility for a clinical trial is determined by the health professionals conducting the trial., adequate bone marrow, renal, hepatic, pulmonary and cardiac function as defined in the protocol., eastern cooperative oncology group (ecog) performance status of 0, 1, or 2., female patients of child-bearing potential must have a negative serum pregnancy test within 48 hours of study initiation and be non-lactating., patients of child-bearing potential must agree to use an effective form of contraception while on study and for 3 months following completion of study treatment., patient must be at least 18 years of age., patient must have histologically confirmed stage i-iiia non-small cell lung cancer (nsclc) which is accessible to biopsy., the use of granulocyte-colony stimulating factor (g-csf) will be permitted in study participants.]"
NCT00615667,Exclusion Criteria,"[7. scr > 4mg/dl (353umol/l);, 5. continuous dialysis starting more than 2 weeks before randomization into the induction phase and/or continuous dialysis with an anticipated duration of more than 8 weeks;, 1. inability or unwillingness  to provide written informed consent ;, 3. usage of immunosuppression  therapy (mmf, ctx, cysa, mtx ect) for more than 1 week within 1 month prior to first randomization;, 8. active hepatitis, with liver dysfunction;, 6. previous kidney transplant or planted transplant;, 10. participation in another clinic trial and/or receipt of investigational drugs within 4  weeks prior to screening ., 2. known hypersensitivity or contraindication to tacrolimus, cyclophosphamide, azathioprine, corticosteroids;, 9. diagnosed dm;, 4. pregnancy, nursing or use of a non-reliable method of contraception;]"
NCT00615667,Inclusion Criteria,"[2. diagnosis of nephrotic syndrome with hypoalbuminemia (<3.0g/dl) and heavy proteinuria (> 3.5g/24hr);, 3. provision of written informed consent by subject or guardian;, steroid resistant: persistence of proteinuria despite prednisone therapy 1mg/kg/d for 16 weeks; steroid dependent: ns recurs when steroid dosage decease.twice within 6 months, and 3 times within 1 year., 1. subjects of either sex, 14-65 years of age;, 4. refractory nephrotic syndrome:]"
NCT00822367,Exclusion Criteria,"[inability to read and/or speak english, patients on hemodialysis or peritoneal dialysis, gastrointestinal disorders affecting digestion and absorption of nutrients such as lactose intolerance, chronic diarrhea, pancreatic insufficiency., patients with type 2 diabetes mellitus treated with insulin secretagogues (sulfonylurea and non-sulfonylurea), pramlintide (symlin), glp-1 analogs (byetta), insulin, or alpha-glycosidase inhibitors, fasting blood glucose < 70 or > 250 mg/d, a1c under 7.0% or over 10.0%, clinical history of documented gastroperesis., pregnancy]"
NCT00822367,Inclusion Criteria,"[ages 18-75 years, expected to be in the dc metropolitan for the duration of the study, controlled with diet /exercise and/or on oral anti-diabetic agents which are non-insulin secretatgogues, i.e. metformin and/or pioglitazone, fasting blood glucose between 70 and 250 mg/dl, type-2 diabetes mellitus for  over  3 months, a1c of 7.0 - 10.0% within the past 3 months, able to give informed consent]"
NCT00273767,Inclusion Criteria,"[coronary bypass surgery., left ventricular ejection fraction (lvef) > 40., informed consent form signed., surgery not urgent.]"
NCT00273767,Exclusion Criteria,"[allergy to erythropoietin., myocardial infarction less than 30 days., malignant tumour., uncontrolled hypertension., carotid bypass surgery., risk of deep venous thrombosis., previous programmed blood donation., unstable angina., previous history of cardiac surgery., kidney failure (creatinine > 200 µmol/l)., vascular cerebral attack less than 30 days., surgery with beating heart, with or without cardiopulmonary bypass., phenylketonuria., pregnancy and feeding., valvular surgery.]"
NCT00411528,Exclusion Criteria,"[known brain metastasis, recent radiation therapy (within 4 weeks), allergic reactions to patupilone or docetaxel or prednisone or similar compounds, significant illnesses such as heart disease, diabetes, or chronic or uncontrolled infections, active diarrhea, other protocol-defined inclusion/exclusion criteria may apply, peripheral neuropathy]"
NCT00411528,Inclusion Criteria,"[must be ≥ 18 years of age, chemotherapy-naïve, confirmed and documented diagnosis of prostate cancer, low testosterone levels, confirmed and documented evidence of progression of disease (hormone refractory)]"
NCT00527449,Exclusion Criteria,"[distant metastases, pregnant or nursing women, t2-tumour < 3cm and g1, known hypersensitivity against epirubicin or other anthracycline or against carboplatin or other platin derivatives or against docetaxel or against substances in the preparing solutions, existing motoric or sensoric neurotoxicity > grade 2]"
NCT00527449,Inclusion Criteria,"[ecog 0-2, histologically assured breast cancer, written informed consent, age >= 18 years, sufficient renal and liver function, bone marrow function: neutrophils >= 1.5x109/l, platelets >= 100x109/l, hemoglobin >=6.2 mmol/l]"
NCT00740415,Criteria,"[lvef > 50%, no neuromeningeal disease, stage ii-iv disease, prior concurrent therapy: not specified, diagnosis of mantle cell lymphoma, hepatitis b- and c-negative, no prior cancer except for carcinoma in situ of the cervix or basal cell skin cancer, hiv-negative, no hepatocellular, renal, or bone marrow insufficiency unrelated to lymphoma, who performance status 0-2]"
NCT00313573,Criteria,"[see disease characteristics, fertile patients must use effective contraception, no moderately severe cognitive impairment, life expectancy ≥ 6 months, no disability claim currently being adjudicated for pain, pain must be at least moderate in severity (brief pain inventory score ≥6), no depression directly precipitated by cancer therapy for which depression is a well known side effect (e.g., interferon, corticosteroids), not in hospice care, not pregnant, cancer-related pain, diagnosis of cancer and 1 or both of the following:, prior concurrent therapy:, persisted despite using ≥ 2 analgesics, and cancer-related, must speak english, depressed mood and/or anhedonia endorsed, no schizophrenia or other psychosis, patient characteristics:, depression must be of at least moderate severity (phq-9 score ≥ 10), clinical depression, if the only pain is due to a pre-existing condition (e.g., migraine, headache, arthritis, etc), the patient may not be eligible]"
NCT00396487,Exclusion Criteria,"[adjuvant chemotherapy < 6 months before inclusion, previous chemotherapy for metastatic disease, other malignant disease within the last 5 years except for non-melanoma skin cancer and carcinoma in situ of cervix uteri, patients with cns metastases, patients with previous major toxic or allergic reaction to the protocol drugs]"
NCT00396487,Inclusion Criteria,"[histopathological verification of the primary tumor, metastatic colorectal cancer, life expectancy > 3 months, age >= 60 years, anc >=1.5 x 109/l and platelets >= 100 x 109/l, performance status >=2, adequate liver and kidney function as evaluated by bilirubin <= 3 times of normal upper limit, alat <= 3 times upper normal limit (<= 5 times upper normal limit in case of liver metastases), serum creatinine <= 1.5 times normal upper limit., single agent chemotherapy indicated, informed consent, measurable disease according to resist criteria]"
NCT00387517,Exclusion Criteria,"[history of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack, myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention., previous or current diagnosis of heart failure., other protocol-defined inclusion/exclusion criteria may apply, severe hypertension (msdbp >= 110 mmhg and/or mssbp >=180 mmhg).]"
NCT00387517,Inclusion Criteria,"[male or female outpatients 18 years old or older., patients with a diagnosis of hypertension defined as follows:, newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to visit 1 must have a msdbp >= mmhg and < 110 mmhg at visit 1., patients who are eligible and consent to participate in the study, all patients who have been treated for hypertension within the 4 weeks prior to visit 1 must have a msdbp >= 85 mmhg and < 110 mmhg at visit 2., all patients must have a msdbp >= 90 mmhg and < 110 mmhg at visit 5.]"
NCT00572169,Inclusion Criteria,"[patients must have received no more than one cycle or one month of prior chemotherapy for this disease.  patients may have received prior radiotherapy provided approval has been obtained by the principal investigator., patients must have a performance status of 0-2 based on swog criteria.  patients with a poor performance status (3-4), based solely on bone pain, will be eligible., patients must have newly diagnosed active mm requiring treatment.  patients with a previous history of smoldering myeloma will be eligible if there is evidence of progressive disease requiring chemotherapy., ejection fraction by echo or muga ≥ 40% performed within 60 days prior to registration., patients must have adequate pulmonary function studies > 50% of predicted on mechanical aspects (fev1, fvc, etc) and diffusion capacity (dlco) > 50% of predicted, within 60 days of registration.  if the patient is unable to complete pulmonary function tests due to mm related pain or condition, exception may be granted if the principal investigator documents that the patient is a candidate for high dose therapy., all patients must be informed of the investigational nature of this study and must have signed an irb-approved informed consent in accordance with institutional and federal guidelines., protein criteria must be present (quantifiable serum m-component of igg, iga, igd, or ige; urinary kappa or lambda light chain; or serum free light chain (sflc) levels in order to evaluate response. non-secretory patients are eligible provided the patient has > 20% plasmacytosis or multiple (>3) focal plasmacytomas or focal lesions on mri or diffuse hyperintense signal on stir images in the absence of hematopoietic growth factors., patients must be <75 years of age at the time of initial registration.]"
NCT00572169,Exclusion Criteria,"[5.1.2.2 grade > 2 peripheral neuropathy., patients must not have light chain deposition disease or creatinine > 3 mg/dl, hypersensitivity to bortezomib, boron, or mannitol., evidence of chronic obstructive or chronic restrictive pulmonary disease., uncontrolled diabetes., platelet count < 30 x 109/l, unless myeloma-related., pregnant or nursing women.  women of child-bearing potential must have a negative pregnancy test documented within one week of registration.  women and men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method., patients must not have significant co-morbid medical conditions or uncontrolled life threatening infection., patients must not have prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has not received treatment for one year prior to enrollment.  other cancers will only be acceptable if the patient's life expectancy exceeds five years., recent (< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias.]"
NCT00517218,Inclusion Criteria,"[eastern cooperative oncology group performance status < 2, measurable disease as primarily established by the national cancer institute-sponsored working group(nci-wg) guidelines for the diagnosis of cll, requiring therapy for active disease, as primarily defined by the nci-wg guidelines, previously untreated subjects with intermediate-or high-risk cll(modified rai stages i-iv), adequate organ function determined , 14 days prior to the first dose of study medication]"
NCT00517218,Exclusion Criteria,"[active serious infection requiring systemic anti-infective therapy, failure to recover from any serious adverse effect of surgery, prior chemotherapy or other therapy for cll, including allogeneic transplant, less than 3 weeks from any prior major surgery at the time of informed consent, absolute lymphocyte count > 100,000/ul, history of autoimmune hemolytic anemia or autoimmune thrombocytopenia]"
NCT00720668,Inclusion Criteria,"[no previous treatment of hbv except lamivudine, no history of encephalopathy, ascites refractory to diuretics or variceal bleeding, after percutaneous radiofrequency ablation;, age 18 - 75 years, no hcv or hiv co-infection, no previous treatment of hcc, hbv carrier with hcc]"
NCT00720668,Exclusion Criteria,"[prior use of systemic investigational agents for hcc, history of organ allograft, excluded therapies and medications, previous and concomitant, active clinically serious infections ( > grade 2 national cancer institute [nci]-common terminology criteria for adverse events [ctcae] version 3.0), substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results, autologous bone marrow transplant or stem cell rescue within four months of start of study drug, known history of human immunodeficiency virus (hiv) infection, patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry, known central nervous system tumors including metastatic brain disease, prior use of any systemic anti-cancer treatment for hcc, eg. chemotherapy, immunotherapy or hormonal therapy (except that hormonal therapy for supportive care is permitted). antiviral treatment is allowed, however interferon therapy must be stopped at least 4 weeks prior randomization, distantly extrahepatic metastasis, patient compliance is poor]"
NCT01679860,Exclusion Criteria,"[serum bilirubin levels > 2 the upper normal limit, psychiatric disease, central nervous system localization, clearance of creatinine < 50 ml/min, ejection fraction < 45% (or myocardial infarction in the last 12 months), dlco < 50%, type i hypersensitivity or anaphylactic reactions to proteins drugs, pregnancy or lactation, patient not agreeing to take adequate contraceptive measures during the study, active secondary malignancy, histological ptcl subset other than ptcl-u, aild-t alcl-alkneg, intestinal t - nhl, positive serologic markers for human immunodeficiency virus (hiv), hepatitis b virus (hbv), and hepatitis c virus (hcv) infection, any active, uncontrolled infection]"
NCT01679860,Inclusion Criteria,"[age ≥18  <60 years (patients older than 60 years are excluded because of the intensive chemotherapy and transplant procedures), written informed consent, advanced stage disease (stage ii-iv) or stage i and aaipi score ≥ 2, histologically proven diagnosis of ptcl, including the following categories: ptcl-u (peripheral t-cell lymphoma, unspecified), aild-t (angioimmunoblastic-like t-cell lymphoma), alkneg alcl (alk-negative anaplastic large cell lymphoma),intestinal t -]"
NCT00293826,Inclusion Criteria,"[must be taking mtx consecutively for >/= 12 weeks and at a stable dose of methotrexate at 15-25 mg weekly for at least 4 weeks prior to screening, subjects with active rheumatoid arthritis as diagnosed by meeting acr classification criteria for at least 6 months.]"
NCT00293826,Exclusion Criteria,"[pregnant or nursing, any other dmards other than methotrexate within 6 weeks of screening, presence of serious infection, receipt of live vaccines within 3 months, receipt of commercial or experimental biologic therapies for the treatment of inflammatory disease, class iv rheumatoid arthritis, felty's syndrome, prior or current history of tuberculosis infection or exposure]"
NCT00322114,Criteria,"[no existing gastrointestinal disease or cancer, able to supply blood and urine samples, prior concurrent therapy:, at least 2 weeks since prior lycopene (in supplement form), healthy participants, not abusing alcohol or non-prescribed drugs, not allergic to tomatoes or tomato products, no concurrent participation in another clinical trial, patient characteristics:, able to answer demographic and dietary recall questionnaires, no hospital inpatients, no existing prostate disease]"
NCT00942487,Inclusion Criteria,"[with a daytime ambulatory blood pressure >140 and/or >90 mm hg, aged 18 years or older, men and women, hospitalized and outpatients, with a history of primary arterial hypertension, with left ventricular hypertrophy: lvmi > 125 g/m2 for men, and > 110 g/m2 for women, by devereux formula, as recommended by the esh-esc guidelines (14), consented, by signing the informed consent, in sinus rhythm]"
NCT00942487,Exclusion Criteria,"[any history of cerebrovascular disease, concomitant treatment with other beta-blockers, more than mild valvar (mitral or aortic) regurgitation, contraindication to beta-blocker therapy, severe arterial hypertension (systolic blood pressure > 180 mm hg and/or diastolic blood pressure > 110 mm hg), cor pulmonale, pregnancy or lactating women, hypertrophic cardiomyopathy, pericarditis, left ventricular global systolic dysfunction (ef < 45%), renal impairment (creatinine > 1.5 mg% for men, > 1.4 mg% for women), any history of coronary heart disease (stable angina, acute coronary syndromes, myocardial infarction), any significant co-morbidities, participation to another investigational study in the last 3 months]"
NCT00402103,Inclusion Criteria,"[outpatients 18 years of age or older, male or female patients are eligible, for previously treated patients with essential hypertension defined as msdbp ≥ 90 and < 110 mmhg after 2 to 4 weeks of washout (visit 4), for newly diagnosed/untreated patients with essential hypertension defined as msdbp ≥, 90 and < 110 mmhg at visit 1 and visit 4]"
NCT00402103,Exclusion Criteria,"[history of hypertensive encephalopathy or cerebrovascular accident., other protocol-defined inclusion/exclusion criteria may apply, severe hypertension, history or evidence of a secondary form of hypertension]"
NCT00438568,Exclusion Criteria,"[major psychiatric disorders (e.g., untreated major depression and schizophrenia), clinically significant elevations in liver function tests, cholesterol, or triglycerides, chronic use of the following types of medications: anti-psychotic, anxiolytic, and opiates, chronic sinus problems/allergies with chronic use of nasal decongestants or antihistamines, significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease, significant neurologic disease that might affect cognition (other than ad), such as stroke, parkinson's disease, multiple sclerosis, severe head injury with loss of consciousness for more than 30 minutes or with permanent neurologic symptoms, preexisting diabetes or current or previous use of hypoglycemic agents or insulin; participants will be excluded if they have a fasting blood sugar greater than 165 on baseline ogtt]"
NCT00438568,Inclusion Criteria,"[participants on stable doses of memantine (namenda) or cholinesterase inhibitors will be eligible, age 55 or greater, good physical health, memory impairment with a diagnosis of mild cognitive impairment (mci) or alzheimer's disease (ad)]"
NCT00216697,Inclusion Criteria,"[response (cr, pr, mr or nc) was obtained in 6 cycles treatment during the preceding phase i/ii study and investigator considers that the patient is expected to have benefit such as antitumor effect, pain relief or improvement of performance state, investigator considers that the patient is expected to have benefit of this drug such as antitumor effect, pain relief or improvement of performance state., complete 6 cycles treatment in preceding phase i/ii study, patients who did not have grade >=3 non-hematologic toxicity or grade 4 hematologic toxicity during the preceding phase i/ii study or extension treatment of this study]"
NCT00216697,Exclusion Criteria,"[patients who receive g-csf product or blood transfusion within 7 days before the start of treatment, patients who suffer grade >=2 peripheral neuropathy or grade >=2 neuropathic pain, patient has new york heart association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, acute ischemia or active conduction system abnormalities., patient is known to be hbs antigen positive, hcv antibody positive or hiv antibody positive (check is required for patients who received blood product during phase i/ii study), disease progress was observed during the phase i/ii or this study when patients receive recommended dose]"
NCT00362388,Inclusion Criteria,"[i. high risk lesion ii. extensive lesion iii. diffuse, small vessel disease, i. cardiac scintigraphy ii. magnetic resonance imaging iii. dobutamine-atropine stress-echocardiogram, to provide a signed, written informed consent, according to the national guidelines for clinical trials., diagnosis of chronic, severe, diffuse, multivessel atherosclerotic coronary artery disease (cad) referred for cabg., non-candidates for a percutaneous coronary intervention (pci) due to any of the following:, angina (or equivalent) functional class ii to iv (canadian cardiovascular society) despite maximally tolerated medical therapy., echocardiogram-assessed lvef between 25 and 55% (simpson's rule)., abnormal myocardial perfusion tests:, non-candidates for a complete cabg, or candidates for a complete cabg in whom, according to an expert panel, there is a high probability of failure of the grafts due to the extension and severity of the disease, with diffuse, small vessel involvement.]"
NCT00362388,Exclusion Criteria,"[history of neoplasia., any acute coronary syndrome in the past 3 months., malignant ventricular arrhythmias (like vt), unless an icd have been placed., enrollment in any cell therapy trial in the past 2 years., serologic diagnostic of chagas' disease., end-stage renal disease requiring maintenance dialysis., symptoms of heart failure, even from an ischemic etiology, in the absence of objectively documented myocardial ischemia., drug or alcohol abuse., life expectancy below 2 years., severe valve heart disease requiring surgical repair.]"
NCT00324467,Inclusion Criteria,"[the patient must sign the consent form prior to registration, advanced stage disease  defined as - patients with stage iii or stage iv disease; or patients with stage i or stage ii disease with one of the following additional criteria: b-symptoms, or disease that is not radio- encompassable within a single involved field, or not a candidate for brief chemotherapy and irradiation, or the presence of bulky disease (any single mass => 10 cm), 18 years of age or older, previously untreated or treated with up to 3 cycles of standard dose 3- weekly r-chop chemotherapy prior to enrollment (i.e. patients may be enrolled prior to initiation of the fourth cycle of r-chop chemotherapy), ecog performance status 0,1 or 2 at time of enrollment, newly diagnosed histologically proven cd-20 positive diffuse large b- cell lymphoma by tissue biopsy, listed under peripheral b-cell neoplasm according to the who/real classification (diffuse large b-cell lymphoma, mediastinal large b-cell lymphoma, t-cell rich b-cell lymphoma, intravascular large b-cell lymphoma), no evidence of progressive disease while on r-chop chemotherapy]"
NCT00324467,Exclusion Criteria,"[cardiac contraindication to doxorubicin therapy (e.g. abnormal contractility on echocardiography). if history of cardiac disease, ejection fraction must be within normal limits for age., pregnancy or lactation.  men and women of childbearing age must be using adequate contraception., neurologic contraindication to vincristine (e.g. peripheral neuropathy), known hepatitis b virus infection, absolute neutrophil count <1.5 x 109/l (unless due to bone marrow involvement with lymphoma or due to initiation of r-chop chemotherapy), platelet count < 100 x 109/l (unless due to splenomegaly, bone marrow involvement with lymphoma or due to initiation of r-chop chemotherapy), patients with a history of prior or concurrent malignancies within 5 years of the current diagnosis, except adequately treated non- melanoma skin cancer, and curatively treated in-situ cancer of the cervix, significant renal insufficiency (serum creatinine > 200 mmol/l), unless due to lymphoma, known hiv infection, patients with a history of any other lymphoproliferative disorder, including prior history of indolent nhl, evidence of active systemic infection, any medical condition that in the opinion of the investigator would compromise treatment delivery, add toxicity or impair assessment, significant hepatic insufficiency (serum total bilirubin > 30 mmol/l), unless due to lymphoma]"
NCT01279070,Exclusion Criteria,"[currently participating in social skills training or cognitive remediation, current acute illness exacerbation, diagnosis of alcohol or drug dependence within 6 months of trial commencement., change of antipsychotic medication one month before the trial or during the 40 study weeks, mental retardation, neurological disorder which impairs cognition]"
NCT01279070,Inclusion Criteria,"[more than 2 years illness duration, diagnosis of schizophrenia or schizoaffective disorder, mini mental status examination score over 24, literate, global assessment of functioning scores between 40 and 70]"
NCT00644904,Exclusion Criteria,"[history of cardiac arrhythmia, baseline (25(oh)d) level <20 mmol/l (frank deficiency) and >150 mmol/l, history of renal disease and nephrolithiasis, pregnancy or inability/unwillingness to use contraception, edss => 7.0, history of granulomatous disease or lymphoma, relapse activity or steroid use in the past 60 days, current vitamin d3 use >4000 iu/d]"
NCT00644904,Inclusion Criteria,"[clinically definite ms, edss 0-6.5, age 18-55]"
NCT00450281,Criteria,"[prior concurrent therapy:, adequately treated basal cell or squamous cell skin cancer, never smoker, defined as < 100 cigarettes in lifetime, former smoker, defined as no smoking for ≥ 1 year, concurrent participation in therapeutic trials allowed, patient characteristics:, other cancer for which the patient has been disease free for five years, pleural fluid is deemed too small to safely tap, no diagnosis by cytology alone, histologically confirmed non-small cell lung cancer, prior smoking history meeting 1 of the following criteria:, current smoker, defined as all others (closed to accrual as of 7/15/07), no prior chemotherapy or radiotherapy, no pericardial effusions, stage i, ii, iiia, or iiib (t4 or n3) disease, benign pleural fluid, no malignant pleural effusion; if pleural fluid is present, 1 of the following criteria must be met:, in situ cervical cancer, newly diagnosed disease, must have tumor blocks/slides available and must be willing to provide tissue samples, pleural fluid is due to prior thoracotomy, no other prior malignancy except for 1 of the following:]"
NCT00603408,Inclusion Criteria,"[serum creatinine <= 1.5 x upper limit of institutional normal., bilirubin <= 1.5 x upper limit of institutional normal., normal left ventricular function (lvef > 50%) by muga or echo., tumor does not express the following biomarkers: estrogen receptor, progesterone receptor, her2/neu, patients must be >= 18 years of age, patients must be newly diagnosed with primary invasive ductal breast adenocarcinoma., tumor classified as clinically stage t2, t3 or t4 with any n (nx, n1, n2, or n3)., adequate organ function defined as:, alt, ast, alk phos <= 1.5 x upper limit of institutional normal.]"
NCT00603408,Exclusion Criteria,"[no evidence of distant metastasis present by ct, bone scan, or physical exam. if the bone scan or ct scans demonstrate indeterminate lesions, the nature of these lesions should be further clarified by additional testing such as pet or mri., patients with known history neural deficiencies (e.g. peripheral neuropathy)., male patients, karnofsky performance status of <= 70., no prior malignancies with the exception of curatively treated basal or squamous carcinoma of the skin or history of previous malignancies, treated with at least greater than 5 years disease free survival., patients with a known hearing impairment (hearing loss or severe tinnitus)., women of child bearing potential may not be currently pregnant or breastfeeding at time of registration and must agree to use adequate contraception.]"
NCT00586950,Criteria,"[history of ischemic stroke, diagnosis of hypertrophic cardiomyopathy(hcm) or dilated cardiomyopathy(dcm) before start of dialysis, within 3 months after initiation of hemodialysis therapy, hypersensitivity to bmipp or its analogue, dialysis hypotension, smoker, hypertension, history of revascularization(pci, cabg) or prior diagnosis of myocardial infarction, peritoneal dialysis, judged unsuitable for the study for any other reasons by physicians., family history of juvenile coronary artery disease, obliterative arteriosclerosis in the lower extremities, exclusion criteria:hemodialysis patients who meet any one of the following conditions will be excluded., history of heart failure requiring hospitalization, severe valvular disorder requiring treatment, hyperlipidemia, diabetes mellitus]"
NCT00313079,Inclusion Criteria,"[3.1.2 diagnosis, 3.1.8.3 adequate liver function defined as:, 3.1.9.1 all patients must sign a written informed consent. 3.1.9.2 all institutional (irb) and fda requirements for human studies must be met., sgpt (alt) <= 5 x upper limit of normal (uln) for age, 3.1.2.3 for patients with prior allogeneic bmt:, 1. second or subsequent bone marrow relapse, 1. myelosuppressive chemotherapy:  must not have received within one week of entry onto this study., 3.1.2.1 histologic verification patients must have had histologic verification of b-lineage all with bone marrow relapse or refractory disease that is unresponsive to traditional chemotherapy., shortening fraction of >= 27% by echocardiogram, or, 3.1.6 life expectancy must be at least 8 weeks., 3.1.3 confirmation of antibody reactivity 3.1.3.1   patient's leukemic blasts (peripheral blood or marrow) must be documented to bind mab 216 in vitro (teng lab) 3.1.3.2 patient's rbc documented to not express fetal \""i\"" antigen and rbc shown to not bind mab 216 in vitro (teng lab), 3.1.2.2 for patients without prior allogeneic bmt:, ejection fraction of >= 50% by gated radionuclide study., 3.1.8 organ function requirements, 3.1.8.4 adequate cardiac function defined as:, total bilirubin <= 2 x upper limit of normal (uln) for age, and, 2. m3 marrow or m2 (>5 % and <25% blasts) if cytogenetic or vntr confirmation, 3. m3 marrow (>25% blasts) or >25% leukemic blasts in peripheral blood, 3.1.8.2 adequate renal function defined as:, 1. first or subsequent bone marrow relapse post-bmt, a serum creatinine that is less than or equal to 2 x normal for age, 3.1.7 prior therapy patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study., 3. hydroxyurea can be used up to 72 hours before study entry, 3.1.8.1 bone marrow function: 3.1.8.1.1 no hematologic criteria for wbc, hgb or platelets 3.1.8.1.2 patients with thrombocytopenia should be responsive to platelet transfusions and must not have uncontrolled bleeding., 3.1.4     patient must not be eligible for therapies of higher priority, 3.1.1 age patients must be >= 18 years old at the time of study entry., 2. primary refractory marrow disease, 3.1.5 performance level (see appendix i) karnofsky >= 50%, 3.1.9  regulatory, 2. biologic, including monoclonal antibodies: at least 2 weeks since the completion of therapy with a biologic agent including monoclonal antibodies.]"
NCT00313079,Exclusion Criteria,"[3.2.1 cns 3 or refractory cns leukemia, 3.2.2 isolated extramedullary relapse, 3.2.4 lack of mab 216 binding to patient's leukemic blasts in vitro, 3.2.3 uncontrolled infection, 3.2.5 binding of mab 216 to the \""i\"" antigen on patient's erythrocytes]"
NCT00770952,Exclusion Criteria,"[pretreatment with thiazolidinediones within the last 12 months., a history of significant cardiovascular (new york heart association stage i - iv), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.8 mg/dl; glomerular filtration rate less than 40 ml/min as estimated by the cockroft-gault formula), neurological, psychiatric and/or hematological disease, history of macular edema., history of hypersensitivity to the study drugs or to drugs with similar chemical structures., cyp2c9 inhibitors, rifampicin, progressive fatal disease., cyp2c9 inductors, is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:, more than one unexplained episode of severe hypoglycemia within 6 months prior to entering the study., fluconazole, blood donation within the last 30 days., type 1 diabetes mellitus., drugs used for treating type 2 diabetes (insulin, insulin analogous compounds and oral antidiabetic drugs), history of drug or alcohol abuse during the last 5 years.]"
NCT00770952,Inclusion Criteria,"[females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study., type 2 diabetes according to the american diabetes association criteria., treatment with glimepiride monotherapy (1-3 mg per day) 3 months before entering the study., glycosylated hemoglobin greater than 6.5%, but less than 8.5% and/ or fasting plasma glucose greater than 7 mmol/l within the last 4 weeks.]"
NCT00943787,Exclusion Criteria,"[pregnancy, symptomatic  heart disease (e.g., history of myocardial infarction,   history of coronary bypass or stenting procedure, angina, episode of chest pain of cardiac etiology with documented ekg changes, positive stress test or catheterization with coronary blockages > 50%), active substance abuse, hematocrit < 36% (females); < 38% (males), age < 18, use of oral steroids, history of an ischemic cerebrovascular event, mental retardation, psychosis, severe depression]"
NCT00943787,Inclusion Criteria,"[since our major goal is the investigation of hypoglycemia, we will preferentially recruit patients with a history of severe hypoglycemia/moderate hypoglycemia anticipating that approximately (~) half of the recruited subjects will have had two or more severe or moderate hypoglycemia episodes in the past 12 months, have type 1 diabetes mellitus defined by american diabetes association criteria or judgment of physician, 18 years of age or older, participated in and satisfied all of the inclusion criteria of nct00315939]"
NCT00403481,Inclusion Criteria,"[patients with a mean seated systolic blood pressure (mssbp) greater than or equal to 140 mmhg but <200 mmhg and a msdbp less than or equal to 114 mmhg following a 3 to 4-week single-blind placebo run-in period, if female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study, patients diagnosed with type ii diabetes that are on stable treatment with hypoglycemic agents, patients with a mean daytime (8am - 4pm) sbp > 130 mmhg and less than or equal to 199 mmhg and a mean daytime dbp less than or equal to 114 as measured by an ambulatory blood pressure monitoring device (abpm) following placebo run-in period, the difference in mssbp between visits 3 and 4 or between visits 4 and 4x must be less than or equal to 10 mmhg]"
NCT00403481,Exclusion Criteria,"[type i or type ii diabetes requiring insulin, patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or cushing's syndrome, presence of overt proteinuria at screening, severe hypertension (dbp greater than or equal to 115 mmhg or sbp greater than or equal to 200 mmhg), presence of heart block greater than first degree sinoatrial block, wolff-parkinson-white syndrome, sick sinus syndrome, atrial fibrillation, or atrial flutter, history of stroke or transient ischemic attack (tia) within the last one year, evidence of symptomatic resting bradycardia, congestive heart failure, or hemodynamically significant cardiac valvular disease, history of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months]"
NCT00199537,Exclusion Criteria,"[gastrointestinal (gi) pathology (eg. malabsorption syndrome), metastatic disease to bone, renal failure (serum creatinine > 200 umol/l), parathyroid disease, medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant), co-morbidity factors affecting bone density (ie: paget's, rheumatoid arthritis), cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial, factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)]"
NCT00199537,Inclusion Criteria,"[willing and able to consent, diagnosis of advanced prostate cancer  (ie: prostate-specific antigen [psa] less than 25 ug/l and undergoing continued treatment with leuteinizing hormone-releasing hormone [lhrh] therapy), men, age of 40 years or greater]"
NCT00390806,Inclusion Criteria,"[must sign written informed consent, must have adequate bone marrow, renal, and live capacities, must be easter cooperative oncology group (ecog) performance status 0, 1, 2, women must be of non-childbearing potential or practice adequate birth control, at least one measurable cancerous lesion in the brain from primary non-small cell lung cancer (nsclc), males must practice adequate methods of birth control, at least 4 weeks must have elapsed since any radiation to a non-cns site, must be 18 years of age of greater, at least 2 weeks must have elapsed since any surgery, must have received previous chemotherapy]"
NCT00390806,Exclusion Criteria,"[uncontrolled emesis, brain metastasis at time of initial diagnosis of nsclc, gastrointestinal conditions that affect gi absorption or motility, investigational agent within 30 days or 5 half-live, concomitant therapy with inhibitors of breast cancer resistance protein (bcrp) or p-glycoprotein such as erlotinib or gefitinib, prior treatment with topotecan, history of other malignancy except in situ carcinoma of cervix; nonmelanomatous skin cancer, low grade prostate cancer, pregnant or intending to become pregnant or intending to father a baby, previous whole brain radiation therapy, primary or secondary immunodeficiencies, any severe concurrent medical condition that could affect compliance.]"
NCT00413036,Criteria,"[at least one prior combination chemotherapy regime, eastern cooperative oncology group (ecog) performance score of 0, 1 or 2, history of other malignancies within the past year, measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter, serum total bilirubin > 2.0 mg/dl (34 µmol/l)/conjugated bilirubin >0.8mg/dl., subjects who are candidates for and willing to undergo an autologous stem cell transplant., relapsed or refractory to previous therapy for lymphoma, platelet count < 60,000/mm^3 (60*10^9/l)., diffuse large b-cell lymphoma., calculated creatinine clearance of <50ml/min, key exclusion criteria, follicular center lymphoma grade 3., positive human immunodeficiency virus (hiv) or active hepatitis b or c, history of active central nervous system (cns) lymphoma within the previous 6 months, biopsy proven aggressive non-hodgkin's lymphoma, mantle cell lymphoma., transformed lymphoma., willing to follow the pregnancy precautions, serum glutamic oxaloacetic transaminase/aspartate aminotransferase (sgot/ast) or serum glutamic pyruvic transaminase/alanine transaminase (sgpt/alt) 5.0 times upper limit of normal (uln)., any of the following laboratory abnormalities., absolute neutrophil count (anc) < 1,500 cells/mm^3 (1.5*10^9/l).]"
NCT00350051,Exclusion Criteria,"[additional criteria determined at screening visit, active infection, symptomatic brain tumors requiring radiation to the brain, any previous cytotoxic chemotherapy for prostate cancer, use of any investigational drug in the last 4 weeks]"
NCT00350051,Inclusion Criteria,"[must have evidence of confirmed metastatic prostate cancer, additional criteria determined at screening visit, psa level must be elevated, serum testosterone must be less than 50 ng/ml, disease must be progressing despite anti-androgen therapy]"
NCT00411242,Inclusion Criteria,"[only patients who complete the core protocol are eligible to participate in the open-label extension phase, diagnosis of major depressive disorder, single or recurrent episode, according to dsm-iv criteria, cgi-severity score > or = 4 at screening and baseline, ham-d17 total score > or = 22 at screening and baseline]"
NCT00411242,Exclusion Criteria,"[psychotherapy of any type, concomitant psychotropic medication, including herbal preparations and melatonin, female patients of childbearing potential who are not using effective contraception, other protocol-defined inclusion/exclusion criteria may apply, substance or alcohol abuse in the last 30 days, dependence in the last 6 months, history of bipolar disorder (i or ii), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder, any current axis i disorder other than major depressive disorder which is the focus of treatment]"
NCT00386607,Criteria,"[for previously treated patients with essential hypertension defined as msdbp ≥ 90 and < 110 mmhg after 2 to 4 weeks of washout (visit 4), patients who were eligible and able to participate in the study and who consented to do so after the purpose and nature of the investigation had been clearly explained to them (written informed consent)., male and female outpatients 18 years of age and older., for newly diagnosed/untreated patients with essential hypertension defined as msdbp ≥, 90 and < 110 mmhg at visit 1 and visit 4]"
NCT00386607,Exclusion Criteria,"[severe hypertension (msdbp ≥ 110 mmhg and/or mssbp ≥ 180 mmhg), women of child-bearing potential, unless they met definition of post-menopausal or were using acceptable methods of contraception., other protocol-defined inclusion/exclusion criteria may apply., history or evidence of a secondary form of hypertension., history of hypertensive encephalopathy or cerebrovascular accident.]"
NCT00303615,Inclusion Criteria,"[evaluable symptoms (pain, shortness of breath, fatigue, anorexia), over 18 years of age, ct scan with or without contrast (lesions must be greater than 2 mm), bilateral mammogram performed within one year before registration, performance status of 0, 1, or 2, er negative and pr negative, chest wall or skin recurrence (digital photo to capture evaluable disease), evaluable disease by either:, progression of disease in the metastatic setting despite taxane or other chemotherapeutic therapies including herceptin (patients on herceptin may continue this therapy while on study), maximized chemotherapy in the metastatic setting or patient experienced side effects contributing to decreased quality of life and elects to defer chemotherapy, pet scan, or bone scan, or plain skeletal films]"
NCT00303615,Exclusion Criteria,"[central nervous system metastasis, bilirubin greater than 5.5, uncontrolled congestive heart failure greater than 2 nyha class, performance status of greater than 2, uncontrolled hypercalcemia greater than 11, concomitant steroid use]"
NCT00415779,Inclusion Criteria,"[performance status < or = 2 (ecog), left ventricular ejection fraction > or = 50% (measured by cardiac ultrasound or muga scan), written informed consent, hormone refractory prostate cancer, neutrophils > 1500/mm3; platelets >100000/mm3; hemoglobin >10 g/100 ml· life expectancy of at least 3 months, serum creatinine < 1.5 mg/100ml, serum  bilirubin < or = 1.25 x unl (upper normal limit) (or < or =  1.5 x unl in the presence of hepatic metastases); sgot e sgpt < or =  1.5 x unl (or < or = 2.5 x unl in presence of hepatic metastases), no immunotherapy, hormonal therapy or radiotherapy within the previous month, stage iv disease with bone metastasis]"
NCT00415779,Exclusion Criteria,"[comorbidities that would, in the investigator's opinion, contraindicate the use of the drugs in the study, previous malignancies with the exception of radically treated epithelioma, severe cardiac arrhythmias, severe uncontrolled congestive heart failure, severe ischemic cardiac disease or myocardial infarction within the previous 6 months, uncontrolled diabetes, previous chemotherapy, cerebral metastasis, severe infection, pre-existing motor or sensory neurotoxicity > or = grade 2 according to ctc (common toxicity criteria).]"
NCT00347971,Inclusion Criteria,"[adequate bone marrow function, disease measurable by computed tomography (ct) scan, eastern cooperative oncology group (ecog) performance status of 0 or 1, has failed at least one prior systemic therapy for nhl, adequate hepatic and renal function, diagnosis of cd20+ b-cell nhl]"
NCT00347971,Exclusion Criteria,"[presence of acute infection or other significant systemic illness, received systemic corticosteroids, chemotherapy, immunotherapy, biologic therapy, antibody therapy (e.g., rituximab), radiation therapy, and/or investigational agent(s) within 1 month of enrollment, previous allogenic transplant or autotransplant within 6 months of enrollment, white blood cell (wbc) count > 50,000/mm3 in peripheral blood, other current malignancy or known history of cancer within 5 years, central nervous system involvement by malignancy]"
NCT00542061,Exclusion Criteria,"[illiteracy, patients treated primary by a pulmonologist, when the gp considers it detrimental to the patient to participate in the study, serious other pulmonary diseases that effect bronchial symptoms and/or lung function, e.g. sarcoidosis, lung cancer, lung fibrosis, patients currently participating in another respiratory intervention study, serious other non-pulmonary diseases (or disease-stages) that are presumed to lead to \""lost to follow-up\"" because of the severity of the disease course (like diseases with low survival rate or mental deterioration)]"
NCT00542061,Inclusion Criteria,"[the gp of the patient is willing to participate in the trial., the patient is categorised as asthmatic disease with persistent airway obstruction or copd in the monitoring system shl confirmed by the most recent lung function assessment (fev1/fvc < 70% after bd and fev1 ≥ 50% pred after bd) or (fev1 < 80% predicted after bd and ≥ 9% reversibility), written informed consent of participant, the patient is monitored by the ac service of the shl.]"
NCT00441103,Exclusion Criteria,"[have received within 30 days prior to baseline oral or systemic corticosteroids or acth, have received within 3 months prior to baseline any approved disease-modifying therapy for ms, cytokine or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, any investigational drug, or experimental procedure, other protocol defined exclusion criteria could apply, have received or have used anytime monoclonal antibodies, mitoxantrone, cytotoxic or immunosuppressive therapy (excluding systemic steroids and adrenocorticotrophic hormone [acth]), or total lymphoid irradiation, have complete transverse myelitis or bilateral optic neuritis, have any disease other than ms that could better explain his/her signs and symptoms]"
NCT00441103,Inclusion Criteria,"[have disease duration for more than 12 months, have relapsing remitting multiple sclerosis (rrms) according to the revised mcdonald criteria 2005, female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study, be willing and able to comply with the protocol for the duration of the study, have brain and/or spinal mri with findings typical of multiple sclerosis (ms), have disease activity characterized by at least one clinical event and one or more gadolinium-enhancing mri lesions within the 6 months prior to randomization, males and females between 18 and 60 years of age, have given written informed consent prior to any study-related procedure not part of the normal medical practice, have score of <=5.5 on the expanded disability status scale (edss)]"
NCT00574847,Inclusion Criteria,"[age 21 or greater, less than 90, stable ischemic heart disease]"
NCT00574847,Exclusion Criteria,"[current substance abuse or history of substance abuse in the previous 6 months, unable to perform exercise testing, recent myocardial infarction, coronary artery bypass graft surgery, or other revascularization procedures (less than 3 months ago), pregnancy, unable to withdraw from anti-anginal medications during ischemic assessment phase, current or previous history of bipolar disorder, cyclothymia, schizophrenia, schizoaffective or schizophreniform disorder, or other psychotic disorders, left ventricular ejection fraction(lvef) < 15% measured by echocardiography, radionuclide ventriculography (rnv), or cardiac catheterization, active suicidal ideation, significant cardiac, pulmonary, metabolic, renal, hepatic disease, or malignancy, interfering with patient's participation in this study, seizure (history and/or present) with/without treatment, life threatening arrhythmia or arrhythmia interrupting the interpretation of ischemia, currently taking antidepressants that cannot be discontinued]"
NCT00383968,Exclusion Criteria,"[known diabetics will be excluded., unable to give informed consent]"
NCT00383968,Inclusion Criteria,"[male:          >1.4mg/dl, male:       2.0-20.0mg/mmol or 20, elevated serum creatinine:, female:   3.0-30.0mg/mmol or 30-300mg/g, female:      >1.2mg/dl, albumin concentration of 20-200mg/l, with albumin-to-creatinine ratio of 3-30mg/mmol or 30-300mg/g, microalbuminuria:, hypertension: systolic blood pressure ≥140, and /or diastolic blood pressure ≥ 90 with or without antihypertensive drugs., known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation.]"
NCT00335348,Exclusion Criteria,"[prior therapy with bortezomib, neuropathy > grade 2 with pain by nci-ctcae criteria, primary dexamethasone resistance, prior severe allergic reactions to bortezomib (velcade), boron or mannitol]"
NCT00335348,Inclusion Criteria,"[female patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study., patient is of a legally consenting age, as defined by local regulations., patient is, in the investigator's opinion, willing and able to comply with the protocol requirements., patient has a life-expectancy >3 months., male patient agrees to use an acceptable method for contraception for the duration of the study., patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care., patient was previously diagnosed with multiple myeloma based on standard criteria and currently requires second or *third line therapy because of pd, defined as a 25% increase in m-protein, or development of new or worsening of existing lytic bone lesions or soft tissue plasmacytomas, or hypercalcemia (serum calcium >11.5 mg/dl), or relapse from cr.*patients will only be eligible for bortezomib as 3rd line therapy if they have received dexamethasone alone, thalidomide alone (or with corticosteroids) or revlimid alone (or with corticosteroids) as one of the 2 prior therapies., patient has a karnofsky performance status ≥60%., patient has measurable disease]"
NCT00418535,Exclusion Criteria,"[previous history of chemotherapy or radiotherapy, acute or active infection requiring intravenous (iv) antibiotics, pregnant, lactating women, grade 2 or greater peripheral neuropathy, serious medical illnesses (congestive heart failure, angina, respiratory failure, and renal failure), other malignancies except for treated non-melanoma skin cancers and cervical cancer in situ, concomitant medication that may influence the study drugs, allergic reaction to study drugs]"
NCT00418535,Inclusion Criteria,"[written informed consent, ecog performance status 0 - 2, normal liver function (total bilirubin < 2x upper limit of normal [uln], transaminase < 3x uln), normal renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50 ml/min), normal marrow function (hemoglobin ≥ 9.0 g/dl; absolute neutrophil count ≥ 1,500/mm3; platelet count ≥ 100,000/mm3), expected life span of at least 12 weeks, pathologically confirmed nk/t-cell lymphoma, localized (ann arbor stage i/ii) disease, age > 18, at least one measurable lesion]"
NCT00411099,Exclusion Criteria,"[other protocol-defined inclusion/exclusion criteria may apply, any current axis i disorder other than major depressive disorder which is the focus of treatment, concomitant psychotropic medication, including herbal preparations and melatonin, psychotherapy of any type, substance or alcohol abuse in the last 30 days, dependence in the last 6 months, history of bipolar disorder (i or ii), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder, female patients of childbearing potential who are not using effective contraception]"
NCT00411099,Inclusion Criteria,"[ham-d17 total score > or = 22 at screening and baseline, diagnosis of major depressive disorder, single or recurrent episode, according to dsm-iv criteria, cgi-severity score > or = 4 at screening and baseline, only patients who complete the core protocol are eligible to participate in the open-label extension phase]"
NCT00374049,Inclusion Criteria,"[no chemotherapy or radiation therapy within 6 weeks of enrolling on this protocol., ecog performance status 0 or 1, patients must have adequate organ and marrow function, 18 years of age or older and must have histologically confirmed adenocarcinoma of the prostate with systemic disease are potentially eligible. patients with an early relapse must have undergone and failed definitive surgery and/or radiation.  patients can either be hormone naive, may be on concurrent hormone therapy with lhrh analogues, or may be hormone refractory (see  section 3.1.4 of the full protocol), men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation., no other investigational therapy within 4 weeks of enrolling on this protocol, patients may be hormone-refractory (rising psa, despite castrate testosterone levels, i.e., < 50 ng/ml); may have metastatic disease; and maybe on bisphosphonates.  if patients are on anti-androgens (flutamide/casodex), they must have been off of these agents for  at least 28 days prior to enrollment for flutamide, and at least 42 days prior to enrollment for bicalutamide (casodex)), without a drop in psa.  if hormone refractory, patients will continue lhrh analogues., must have evidence of systemic immunosuppression as evidenced by the presence of one or more of the following: 1) low or absent t cell zeta chain expression in peripheral blood (pb), 2) low level cytokine production ( i.e., ifn-gamma , il-4 ) by t cells in pb, 3) upregulation of granulocyte activation markers (cd 15) in pb, availability of at least 2 psa measurements over 2 to 6 weeks, clearly documenting a rising psa.  the minimum rise in psa must be at least 50% from baseline psa. the last of these psa values must be > 2 ., no concomitant therapy with steroids, signed written informed consent given by the patient before or at enrollment in the study and following receipt of verbal and written information about the study.]"
NCT00374049,Exclusion Criteria,"[presence of an active acute or chronic infection, including urinary tract infection, hiv (as determined by elisa and confirmed by western blot) or viral hepatitis (as determined by hbsag and hepatitis c serology). hiv patients are excluded based on immunosuppression which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections., patients with a history of auto-immune disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis., uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements., no concurrent use of other investigational agents., patients with either previously irradiated or new cns (central nervous system) metastases at entry are excluded. pre-enrollment head ct is not required if not indicated by clinical signs or symptoms., subjects with active prior malignancy within the past 5 years (with exception of non-melanoma skin cancers and carcinoma in situ of the bladder)., patients who have had chemotherapy or radiation therapy within 6 weeks of study entry.]"
NCT01606384,Exclusion Criteria,"[patients who have used the following prior to entry into segment b: any antipsychotic within 3 months; fluoxetine within 1 month; any monoamine oxidase inhibitor (maoi) within 2 weeks; any other antidepressant, anxiolytic, sedative-hypnotic, or mood-stabilizer (lithium, anticonvulsants) within 7 days except permitted concomitant medications, outpatients unwilling to be hospitalized a total of 6 nights and 8 days., patients whose current depressive episode is diagnosed with psychotic features, catatonic features, seasonal pattern or post-partum onset or is secondary to a general medical disorder., total score of less than 21 (<21) on the 17-item hamilton depression rating scale (ham-d) at visit 1 (day -7) or visit 5 (day -1)., patients with alcohol dependence or abuse or substance dependence or abuse in the past 12 months according to the mini, except nicotine or caffeine dependence., the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.]"
NCT01606384,Criteria,"[diagnosis of major depressive disorder as defined by the diagnostic and statistical manual of mental disorders, 4th edition-text revision (dsm-iv-tr) and the mini international neuropsychiatric interview (mini) criteria.]"
NCT00281593,Inclusion Criteria,"[a mean seated cuff diastolic blood pressure >=95 and <=119 mmhg main, male and female patients >=18 years of age with stage i or ii hypertension defined as:]"
NCT00281593,Exclusion Criteria,"[severe renal dysfunction, breast-feeding, secondary hypertension, stroke within the last 6 months, sbp>=180 mmhg, dbp>=120 mmhg, hepatic insufficiency, pregnant, unwilling to use birth control during the study, myocardial infarction, cardiac surgery, percutaneous transluminal coronary angioplasty, unstable angina or coronary artery bypass graft within the past three months, unstable or uncontrolled diabetes, history of angioedema of either of the study drugs, and hypersensitivity to the study drugs.]"
NCT00578045,Exclusion Criteria,"[liver function: total bilirubin > 2x uln or ast/alt > 3x uln., creatinine  > 3.0 mg/dl.]"
NCT00578045,Inclusion Criteria,"[release of cord blood., age > 18 years., an expected survival of > 3 months., subjects must have signed an irb-approved consent and been  informed about the investigational nature of the study., patients with advanced hematological malignancies who have failed at  least two lines of therapy., cord blood must have negative serology for hiv., the nucleated cell count of the cbu shall equal or exceed    1 x 107 per kg of recipient body weight., karnofsky performance score > 60, unless due to disease and then > 50.]"
NCT00333229,Exclusion Criteria,"[current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (onj), of exposed bone in the mouth, or of slow healing after dental procedures and recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants), prior treatment with bisphosphonates and estrogens or treatments for osteoporosis in addition to calcium and vitamin d, known hypersensitivity to bisphosphonates, abnormal renal function, severe physical or psychological concomitant diseases and other known concurrent, severe medical disorder jeopardizing the life of the patient in the immediate future (e.g., myocardial infarction in previous six months, angina pectoris despite treatment, uncontrolled severe arterial hypertension, progressive cardiac or respiratory failure)]"
NCT00333229,Inclusion Criteria,"[female patients with histologically confirmed incident invasive breast cancer (t1-4) with no evidence of regional lymph node metastasis (n0) or distant metastasis (m0) and after complete primary tumor resection and axillary lymph node dissection less than 90 days before start of study drug treatment., patient receives adjuvant standard chemotherapy with approved cytotoxic chemotherapeutic drugs (e.g. ac 4-6 cycles) (prior neoadjuvant ct is allowed), hormone receptor status is negative, patient is premenopausal (spontaneous and regular menses with premenopausal estradiol levels (>10ng/dl), bone density at study entry > -2.5 t-score]"
NCT00224549,Exclusion Criteria,"[contraindication to beta blockers because of bronchopathy or auriculoventricular block, history of cough with acei or gynecomastia with antialdosterones, arm circumference > 42 cm, unstable angina, history of stroke or coronary heart disease (coronary by-pass or angioplasty) in the previous 3 months, heart failure (new york heart association [nyha] iii-iv), renal failure with creatinine clearance < 40ml/min (cockroft evaluation), secondary hypertension, diabetes mellitus (type 1 or 2) with hba1c > 8%]"
NCT00224549,Inclusion Criteria,"[primary hypertension, resistant hypertension defined by mean day-time sbp > 135 mmhg and dbp > 85 mmhg (determined with abpm device) after a standardized 4-week regimen including irbesartan, amlodipine and hctz.]"
NCT00464711,Criteria,"[men or women aged 18-65, agrees to use an effective form of contraception throughout the study, agrees to use an effective form of contraception throughout the study, meet diagnostic criteria for current major depressive disorder, medication-free for one week prior to the start of the study, medication-free for one week prior to the start of the study, men or women aged 18-65, inclusion criteria (healthy volunteers):]"
NCT00464711,Exclusion Criteria,"[patients who are currently taking medications active on gaba, including benzodiazepines., anyone with a history of seizure disorder or hypothyroidism, anyone with a history of intolerance or multiple adverse drug reactions or allergy to (es)citalopram., anyone with a serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, anyone who is suicidal, pregnant or breastfeeding women, anyone with a history of psychiatric disorders including bipolar disorder, schizophrenia, psychoses, or substance abuse (including alcohol abuse active within the last 12 months)]"
NCT00290940,Exclusion Criteria,"[serum creatinine (scr) > 1.4 mg/dl (females) or 1.5 mg/dl (males), serum bicarbonate < or = to 19 meq/l, poorly controlled diabetes, contraindication to metformin, history of diabetic ketoacidosis or hyperosmolar, nonketonic coma within one year of screening, current insulin therapy]"
NCT00290940,Inclusion Criteria,"[drug naive or newly diagnosed type 2 diabetic subjects:, no oral antihyperglycemic or insulin therapy for more than 6 months since original diagnosis and, hba1c>6.7% and < or = to 10% at screening, no insulin therapy within one year of screening, with the exception of use during hospitalization or for use in gestational diabetes and, no antihyperglycemic therapy for more than three consecutive days, or a total of of seven non-consecutive days, during the 8 weeks prior to screening., never received oral antihyperglycemic or insulin therapy or]"
NCT00301080,Exclusion Criteria,"[patients cannot be currently receiving antibiotic therapy for tuberculosis (e.g. isoniazid)., patients will not have secondary cause of neuropathic pain including: hiv/aids,traumatic injury, or a personal history of non chemotherapy-induced neuropathy., patients will not have a history of seizures., patients will not have a history of major depression or severe anxiety., women of childbearing age will agree to take measures to prevent pregnancy and will not breast-feed while on the study medication. women who are currently pregnant will not be invited to participate in this study.]"
NCT00301080,Inclusion Criteria,"[patient's will have bilateral peripheral neuropathic pain symptoms primarily involving the feet, patients will be experiencing moderate to severe peripheral neuropathic pain, patients must not concurrently use gabapentin or pregabalin or must be willing to wean off their anti-convulsant medications prior to starting the trial., patients may be on chronic adjuvant pain medications such as antidepressants but must be on stable doses for at least one week prior to admission., patients may have diabetes mellitus (type 1 or 2) as long as there is no preexisting neuropathy., patients must have chronic peripheral neuropathic pain will be defined as pain of 3 or more months duration which began in association with chemotherapy., patients must have breast cancer (any stage), patients must have an ecog performance status < 3 and be able to attend the physician study visits, patients must be able to read and speak english and provide informed consent., patients will be at least 18 years of age., patients may be receiving chemotherapy as long as the agents are not known to cause a peripheral neuropathy., patients may be taking concurrent opioids but they must be willing to allow us to monitor their opioid use while on the trial.]"
NCT00834665,Criteria,"[10. evidence or history of other significant cardiac, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease which might increase the risks of participating in the study, 2. patients must have a diagnosis of myeloma, 9. active immune-mediated diseases including:  connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis., 3. known history of myelodysplasia, key exclusion criteria, 5. patients must be between ages 18-80 (inclusive)., 1. written informed consent must be obtained from all patients before entry into the study, 4. known history of chronic active hepatitis or liver cirrhosis (if suspected by laboratory studies, should be confirmed by liver biopsy)., 2. hiv, htlv-1/2 seropositivity, 8. women of child-bearing potential (wocbp) and their spouses or partners must be willing to use adequate contraception for the duration of the active treatment phase of the study and for at least 4 months after the last dose of chemotherapy.  in addition, contraceptive measures must be continued as long as the patient remains on maintenance thalidomide in accordance with the steps program., 8. history of severe autoimmune disease requiring steroids or other immunosuppressive treatments., myeloma has responded partially to initial therapy but neither a complete nor a near-complete response has developed after at least 3 cycles or months of initial therapy., 7. ecog performance status 0-2, 7. more than 4 distinct, prior courses of therapy for myeloma, myeloma has high-risk features, subjects who meet any of the following criteria cannot be enrolled in the study:, myeloma has relapsed, progressed, or failed to respond after at least one prior course of therapy., 1. pregnant or nursing females, 4. patients must have measurable disease on study entry., 11. active bacterial, viral or fungal infections., 3. patients must meet one of the following criteria:, 6. prior autotransplant or allogeneic transplant, 5. active hepatitis b, 6. patients should have adequate vital organ function.]"
NCT00299169,Inclusion Criteria,"[established diagnosis of type 1 or 2 diabetes, willingness to re-try a statin despite previous apparent intolerance, age 18-80 years, indication for a statin by the 2003 canadian diabetes association (cda) clinical practice guidelines, provision of signed informed consent]"
NCT00299169,Exclusion Criteria,"[any other condition deemed to render the study harmful to the participant, presence of a condition such as malignancy for which the one-year prognosis is poor, impaired renal function: severe renal insufficiency (creatinine clearance <30 ml/min), inability of the patient to comply with the rigorous conditions of the trial, contraindication to a statin: previous rhabdomyolysis, active liver disease or unexplained persistent elevations of serum transaminases (ck, ast, alt >three times upper limit of normal), pregnancy or lactation]"
NCT00413959,Exclusion Criteria,"[prior therapy for lymphoma excluding antibiotic treatment for malt-type nhl., known hiv positive status, known cns involvement]"
NCT00413959,Inclusion Criteria,"[small lymphocytic lymphoma, able to read, understand, and sign an irb approved informed consent, marginal zone lymphoma, malt lymphoma that has only failed antibiotic therapy or involved field radiation., lymphoplasmacytic lymphoma including waldenstrom's macroglobulinemia, ecog performance status of 0, 1, or 2, follicular cell lymphoma (grades i and ii), mantle cell lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant, adequate bone marrow function, renal function, and hepatic function as outlined in details below.]"
NCT00376597,Eligibility Criteria,"[no diagnosed lymphedema, no documented cardiac conduction disturbances, unstable angina, dementia, or any other chronic disease which, in the opinion of the treating physician, significantly increases mortality over the next 2 years, patients scheduled to receive any type of radiation therapy to the breast or axilla are eligible; however, they must be registered to this study with pre-surgery measures taken prior to receiving neoadjuvant therapy, willing to return to the study site for the duration of the study (18 months), patients scheduled to receive neoadjuvant chemotherapy are also eligible; however, they must be registered to this study with pre-surgery measurements taken prior to receiving neoadjuvant therapy, may be enrolled on other treatment trials; however, patients enrolled on surgery trials where only one treatment arm is full axillary node dissection are not eligible; note: patients enrolled on american college of surgeons oncology group (acosog)-z1071 are eligible to participate in this study; patients concurrently enrolled on this study and acosog-z1071, may not also be enrolled on the acosog-z1071 lymphedema sub-study, sentinel (snd) or full axillary node dissection (and) (no minimum number of nodes required), no prior history of carcinoma in situ, lobular carcinoma in situ (lcis), ductal carcinoma in situ (dcis), or invasive breast cancer, * patients with a history of other invasive malignancies are eligible as long as they have completed treatment and are 5 years post-diagnosis; patients with basal cell and squamous cell cancer of the skin are eligible, in order to be properly fitted for the elastic sleeve, eligible patients must have arm measurements for axilla, elbow, and wrist that fall within the ranges for one of the six sleeve sizes, neoadjuvant therapy, newly diagnosed with stage i-iii cancer of the female breast, patients with double mastectomy, axillary node dissection and/or radiation on both arms are ineligible; patients who undergo these treatments (i.e., surgery and/or radiation) on the contralateral arm after registration to step 2 are still eligible to remain in the study; however, it should be documented appropriately on form c-1628 at the conclusion of study participation, able to participate in a mild exercise program, not currently homebound or dependent upon a walker or wheelchair for mobility, patients receiving no neoadjuvant therapy are eligible]"
NCT01018381,Exclusion Criteria,"[portal vein body thrombosis, used immunotherapy or corticotherapy for 6 months, tumor size is too big (over 12 cm), multiple tumors (over 3 tumors or diffuse tumor type), prothrombin under 60%, hcc patient criteria of exclusion, pregnant woman, severe liver or/ and renal insufficiency, chronic hepatitis b patient criteria of exclusion]"
NCT01018381,Inclusion Criteria,"[alt was over or equal 2 times uln, general condition: average/ good, hcc patient criteria of inclusion, patient have been carrying hbsag over 6 months, liver biopsy: hcc positive, chronic hepatitis b patient criteria of inclusion, stage of disease: okuda i,ii and child pugh a,b, hbv-dna level: 104 (log10 copies/ml) with hbeag(-) patient  and 105 (log10 copies/ml) with hbeag(+) patient, patient had ≤3 tumors (1 tumor under 12cm/ or 2 tumor under 5cm /or 3 tumor under 3cm)]"
NCT00698412,Exclusion Criteria,"[start regular physical activity in the last month, previously cane use, symptomatic heart or pulmonary disease, joint injection in the previous 3 months, pt in the previous 3 months, other symptomatic disease in the lower limb or in the upper limb that will carry the cane, severe systemic disease]"
NCT00698412,Inclusion Criteria,"[vas for knee pain between 3 and 7, no changes the nsaid intake or physical activity in the previous 3 months, primary knee osteoarthritis (acr criteria)]"
NCT00304759,Exclusion Criteria,"[1. histologic diagnosis of carcinoma of the prostate more than six months prior to study entry;, 6. previous pelvic radiotherapy;, 4. any other active malignancy (untreated, progressive or recurrent), except for non-melanoma skin cancer. any inactive malignancy diagnosed within 5 years of entry, except for non-melanoma skin cancer;, 2. previous therapy for carcinoma of the prostate other than biopsy or transurethral resection;, 7. inflammatory bowel disease., 3. patients previously on more than 12 weeks of hormone therapy for treatment of their prostate cancer;, 5. treatment plan cannot meet dose constraints for the hypofractionation arm of the trial;]"
NCT00304759,Inclusion Criteria,"[2. intermediate risk prostate cancer (that is, t1-2a, gleason score <6, psa 10.1-20.0 ng/ml; t2b-c gleason <6, psa ≤ 20.0 ng/ml; t1-2, gleason 7, psa ≤ 20.0 ng/ml)., 1. histologic diagnosis of carcinoma of the prostate within 6 months of entry without evidence of metastatic disease to the lymph nodes, bone or lung;]"
NCT00474669,Inclusion Criteria,"[medically fit for surgery, ability to understand and the willingness to sign a written informed consent document., second surgery to be performed no more than 3 months from last course of initial chemotherapy, patients must have had a complete clinical response (negative clinical examination, ca125 and ct scan of chest, abdomen and pelvis) to front-line therapy for stage ii/iii ovarian, primary peritoneal or fallopian tube carcinoma. this will have included initial surgery followed by combined iv/ip chemotherapy with cisplatin and paclitaxel. patients must have had a minimum of three courses of ip therapy with both paclitaxel and cisplatin, gog performance status less than 2, age greater than 18 years and negative pregnancy if has child-bearing potential, patients must have normal organ and marrow function as defined in the protocol hepatic function total bilirubin  uln ast and alt and alkaline phosphatase must be within the range allowing for eligibility.  in determining eligibility the more abnormal of the two values ast or alt) should be used., the effects of docetaxel on the developing human fetus are unknown.  for this reason and because taxanes are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.  should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.]"
NCT00474669,Exclusion Criteria,"[uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements., uncontrolled intercurrent illness or other conditions that would limit compliance with study requirements should be excluded., no prior chemotherapy other than for front-line ovarian cancer  or radiation for any reason., patients with stage iv disease including previous parenchymal liver disease, brain metastasis or  cytologically-confirmed chest metastasis, patients who have completed front-line therapy for ovarian cancer more than 3 months prior to hipec., stomatitis of any grade, patients receiving any other investigational agents., pregnant, breast-feeding or  known to be hiv positive, prior malignancy other than non-melanomatous skin cancer more than 5 years ago, more than grade 2 peripheral neuropathy from prior chemotherapy, patients with a history of severe hypersensitivity reaction to taxotere® or other drugs formulated with polysorbate 80.  history of allergic reactions attributed to compounds of similar chemical or biologic composition used in this study in addition to taxotere.]"
NCT00392743,Exclusion Criteria,"[history of bleeding disorder or are taking medication that affects blood clotting, claustrophobia, gross head deformity., history of substance dependence (except nicotine), if you have taken part in investigations you should not receive a radiation dose of more than 10 msv over any 3 year period., have received other antipsychotic during the last month or neuroleptics during the last year., the presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies., unable to lie still in the pet or spect camera for 1 hour and a half.]"
NCT00392743,Inclusion Criteria,"[healthy volunteers with no neurological or psychiatric illness., no abnormality in clinical examination, clinical laboratory test or ecg., patients with at least 1 month antipsychotic monotherapy with either risperidone, olanzapine or clozapine., not pregnant or becoming pregnant during the study., patients with schizophrenia, schizophreniform disorder or schizoaffective disorders., not taking drugs]"
NCT00839774,Inclusion Criteria,"[hypercholesterolemic, bmi between 25 and 40 kg/m2]"
NCT00839774,Exclusion Criteria,"[angina, myocardial infarction, eating disorders, smoking, diabetes, cancer, congestive heart failure,, chronic alcohol usage (> 2 drinks/day)., inflammatory bowel disease, use of prescription and natural lipid lowering therapies, coronary artery bypass, renal disease, pancreatitis, expending > 4000 kcal/week through exercise]"
NCT00478595,Exclusion Criteria,"[the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial., primary hyperlipidemia, within 12 weeks prior to screening visit: use of oral antidiabetic drugs (other than a sulfonylurea or alpha-glucosidase inhibitor) and/or insulin, of anti-obesity drugs or other drugs for weight reduction, secondary obesity, positive serum pregnancy test in females of childbearing potential, type 1 diabetes, within 4 weeks prior to screening visit: administration of systemic long-acting corticosteroids or prolonged use (more than one week) of other systemic corticosteroids, change in lipid lowering treatment]"
NCT00478595,Inclusion Criteria,"[hba1c ≥ 7.0 % and ≤ 10.0 %, body mass index ≥ 25 kg/m², type 2 diabetes mellitus patients on monotherapy with oral anti-diabetic drug (sulfonylurea or α-glucosidase inhibitor)]"
NCT00559871,Criteria,"[other clinically significant conditions apart from those typically associated with parkinson's disease., intake of an investigational drug within 30 days prior to initial screening., intake of medication associated with exacerbation of dyskinesia or with extrapyramidal side effects and tardive dyskinesia or induction of liver enzymes; neuroleptics; or specified drugs known to be substantially metabolized through the following cytochrome p450 isoenzymes: 1a2, 2b6, 2c19, 2c9, 2d6, and 2e1., stable parkinson's medication for at least 1 month prior to randomization., idiopathic parkinson's disease., levodopa/ddi associated peak-dose dyskinesia which is at least moderately disabling and present for ≥25% of the waking day (updrs part iv, items 32 and 33, each ≥ 2)., hoehn and yahr stages 1 to 4 during 'off' period., use of st. john's wort or ginkgo biloba within 48 hrs prior to randomization and until the last treatment day with the study medication., demonstrated ability to comprehend and give informed consent., main exclusion criteria:, ability to complete patient diary.]"
NCT00912080,Exclusion Criteria,"[tumoral residue not removed, all metastatic affect, all chemotherapy, hormonotherapy or radiotherapy before surgery, history of invasive neoplasm, mammary or other (except in situ carcinoma of cervix uteri and epithelioma), tumor classed >= t4a: cutaneous invasion, deep adherence, inflammatory breast, any suspect clinic or radiologic lesion, in the contralateral breast, which is not controlled]"
NCT00912080,Inclusion Criteria,"[clinical presentation which allowed a complete surgery with healthy limits, the beginning of the chemotherapy within 6 weeks following the primary surgery, histological evidence for homolateral axillary ganglionic invasion, whatever is the number of node invaded (n > 1), women aged between 18 and 70, absence of metastasis detectable at clinical examination or radiology, patient with life condition < 2 (who scale), one-sided breast adenocarcinoma with a histological evidence (all type)]"
NCT00968409,Inclusion Criteria,"[not currently pregnant or nursing:  subject must be surgically sterile (has had a documented bilateral oophorectomy and / or documented hysterectomy), post menopausal (cessation of menses for more than 1 year), non lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of ffnp) is negative., tumor estrogen-receptor and progesterone-receptor status already determined or scheduled to be determined at time of surgery without intervening therapy., female patients 18 years of age or older, primary lesion size ≥ 1.5 cm as determined by imaging studies (ultrasonography, mammography, ct or mri) or physical examination, able to give informed consent, biopsy-proven breast cancer]"
NCT00968409,Exclusion Criteria,"[no previous history of hormone therapy; note - subjects who were treated with hormone therapy for reasons other than breast cancer or breast cancer prevention may be allowed to participate after review of history by the primary investigator, unable to tolerate 60-90 minutes of pet imaging per imaging session, patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years]"
NCT00504127,Exclusion Criteria,"[hepatic or renal impairment, uncontrolled hypertension or diabetes, current or expected use of anti-coagulant, candidates for imminent joint replacement, a history of alcohol or drug abuse, participation within 30 days prior to screening in another investigational study, clinical relevant abnormal ecg]"
NCT00504127,Inclusion Criteria,"[men and woman (40 or older) with a diagnosis of primary oa of the knee., must discontinue all analgesic therapy at screening, must be a current chronic user of nsaids or acetaminophen]"
NCT00471055,Inclusion Criteria,"[6. has documented radiographic evidence of oa of the knee from the screening visit radiograph of grade 2 or 3 according to kellgren and lawrence radiographic grading., 9. subject is able to understand and complete pain/function, global arthritis evaluation, and health outcome assessment., 7. subjects with baseline minimum joint space width in the medial compartment of the index knee of > 1.5 mm at baseline, measured from radiographs using the mtp view., 8. subjects with baseline minimum joint space width in the lateral compartment of the index knee of > 2.5 mm at baseline, measured from radiographs using the mtp view., 1. subjects who are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form., 3. subjects who withdraw pain medication or nutritional supplements for symptom relief for knee oa for a total of at least 15 days before screening visit 0., 4. pain at or below 80 mm on a 100 mm vas in the index knee., 2. ambulatory nom pregnant females  and males 40-<80 years of age., 5. a documented diagnosis of oa of the knee, or meeting american college of rheumatology (acr) clinical criteria for classification of idiopathic (primary) oa for at least 6 months prior to screening. if oa is presented in both knees the investigator will identify which knee will be x-rayed for study entry, with preference for the knee with more severe pain (<80mm vas)., subjects eligible for enrollment in the study must meet all of the following criteria:]"
NCT00471055,Exclusion Criteria,"[chronic systematic corticosteroids, 6. treatment with other drugs potentially affecting bone or cartilage metabolism as described below:, subjects with any of the following criteria must not be enrolled in the study:, 4. significant prior injury to the index knee within 12 months prior to screening v0., 5. disease of the spine or other lower extremity joints of sufficient degree to affect the index knee., 3. a history of lower extremity surgery within 6 months prior to screening v0., 1. subjects with history of hypersensitivity to capsaicin., 2. subjects with skin lesion at the index knee., hyaluronan injection into the index knee with in the previous 6 months., diacerin treatment within the last 12 months.]"
NCT00484861,Criteria,"[caucasian women: individuals will be considered to be caucasian if they self-identify as caucasian., bmi between 20 and 45 kg/m2: women in both ethnic groups will be recruited across bmi nonobese and obese categories. therefore we will enroll approximately equal  numbers of women from each ethnic group in both bmi categories bmi between 20 and 30 kg/m(2) and bmi between 30 and 45 kg/m(2)., african american women: individuals will be considered to be african american if they self-identify as african american and were born in the united states. further they must describe both parents as being african american., weight less than 136 kg (300 lbs): this weight restriction is necessitated by the limitations of the dxa scanner. the dxa platform cannot accommodate subjects who weigh more than 136 kg., age between 18 and 65 years:  this age range is chosen because tg levels across the lifespan from early adulthood through to postmenopausal status. weare using 65 years of age as a conventional upper limit. in addition, 65 years of age has been used as an age category cut-off by national health and nutrition examination surveys. our goal is to detect ethnic differences in the pathways that allow vascular disease to develop. enrolling women between the ages of 18 and 65 years, maximizes our ability to detect differences in mechanism of action that are truly secondary to ethnicity., healthy volunteers: the potential enrollee must self identify as a normal volunteer and have this confirmed by having at the screening visit a normal complete blood count, glucose, bun creatinine, liver and thyroid panel.]"
NCT00484861,Exclusion Criteria,"[medications which affect parameters under investigation: examples include corticosteroids, oral contraceptives, hypoglycemic (oral or injection), hypolipidemic, antihypertensive and antipsychotic agents. oral contraceptives, in particular, are exclusion criteria because the estrogen component of oral contraceptives increase tg levels and would therefore obscure the effect of the test meal on tg levels., hispanics: the relationship between tg and insulin resistance in hispanic white women is midway between african american and caucasian women. therefore in this initial study to be able to determine the maximum ethnic difference in the relationship between tg and insulin resistance, we will enroll in this protocol study women who self-identify as african american and caucasian and not enroll women who self-identify as hispanic., medical conditions which affect parameters under investigation: examples include diabetes, thyroid disease, liver disease, pancreatitis, nephrotic syndrome., refusal to agree to use barrier contraception: the dxa scan and ct scan should not be performed if the participant is pregnant. in addition, tg levels are directly affected by pregnancy. even though we will perform pregnancy tests within 7 days of each visit, we also require that the subject agree to abstinence or barrier contraception throughout the study.]"
NCT00239187,Inclusion Criteria,"[clinical diagnosis type 2 diabetes requiring treatment with metformin and/or tzd and who are otherwise healthy, on a stable metformin and/or tzd regimen for at least 60 days prior to screening, patient cannot live alone during the treatment phase and up to 1 month in follow-up, informed consent obtained from participants, maximum stimulated c-peptide level > 0.6 nmol/l (1.8 ng/ml), currently self monitoring blood glucose levels (i.e. daily), no episodes of severe hypoglycemia for 60 days prior to screening, body mass index within the range 25-40 kg/m2]"
NCT00239187,Exclusion Criteria,"[history or presence of proliferative retinopathy, severe non-proliferative retinopathy, macular edema or presence of untreated diabetic eye disease, serum creatine superior or equal to 2.0 mg/dl, history of treated peripheral or autonomic neuropathy, known of suspected history of significant liver, or other gi disease, history of cancer, history of peptic ulcer disease and/or gi bleeding/perforation, non-healed diabetic ulcer, history of hypoglycemic unawareness, history of significant cardiovascular disease including stroke, peripheral vascular disease or any related symptoms]"
NCT00971919,Criteria,"[speaks english, planning to undergo primary surgical excision of the tumor (e.g., breast conservation surgery or mastectomy with or without axillary surgery [sentinel node biopsy, axillary sample, or axillary clearance]), resectable disease, planning to undergo standard adjuvant therapy after surgery, including radiotherapy, chemotherapy, and/or hormonal therapy, as per existing standard protocols, see disease characteristics, no history of mental illness, histologically confirmed invasive breast cancer or carcinoma in situ of the breast by core biopsy or fine needle aspiration, stage i-iii disease, not pregnant, prior concurrent therapy:, being treated in the aberdeen, dundee, perth, or inverness breast unit, newly diagnosed disease, no detectable metastatic disease, patient characteristics:]"
NCT00693511,Exclusion Criteria,"[previously diagnosed with any major illness since birth (e.g. chronic birth asphyxia, cancer, etc.)., presently taking medication(s) or diagnosed with any syndrome or disease that could influence physical activity, body composition and fat distribution, or insulin action., children who have any physical, cognitive, or psychological disabilities that would prevent them from participating in an exercise program., children with type 1 and/or type 2 diabetes will be excluded and referred to a physician. children with impaired glucose tolerance (fasting glucose >100 mg/dl during a fasting blood draw) and/or conditions associated with insulin resistance (e.g. acanthosis nigricans, hypertension, dyslipidemia) will be eligible, as long as they are not receiving treatment and meet other eligibility criteria., children who live farther than 20 miles away from the gcrc., currently, or in the past 6 months, involved with any dietary, physical activity or weight loss program.]"
NCT00693511,Inclusion Criteria,"[at risk of overweight and overweight (age- & sex-specific body mass index ≥ 85th percentile based on cdc bmi growth charts [us department of health and human services, 2000]. there will not be an upper bmi limit. in our experience, we have had numerous children above the 99th percentile for bmi complete the outcome measures, and this group could benefit greatly from participation., latino origin all four grandparents must be of hispanic heritage (reported on screening forms). this approach is consistent with all of our previous and ongoing work., gender & age: females from grades 9th to 12th (approximately 14-18 years of age). we chose to study adolescents because pubertal youth will likely possess the requisite hormonal milieu needed to elicit physiologically and metabolic changes in response to resistance and aerobic training. in addition physical activity declines are more pronounced in minority females. by limiting the study to just females, we will retain a more homogenous group. this will eliminate sensitive gender issues related to exercise such as body image concerns, goal setting, and motivations for behavioral changes. to reduce effects of the menstrual cycle, all females will be tested during the follicular phase, while those with irregular/unpredictable menses will be studied at random times.]"
NCT00521781,Inclusion Criteria,"[patients meeting these criteria are eligible even without any radiographically demonstrable abnormality. all patients must have an elevated psa prior to initial hormone exposure defined as: 1) for patients with prior prostatectomy, the psa must be rising with an associated doubling time of ≤ 3 months. 2) for patients with prior radiation therapy, the psa must be ≥ 1.0 ng/ml with an associated doubling time of ≤ 3 months., patients may have had previous exposure to androgen deprivation therapy if it was given for ≤ 6 months to, \""downstage\"" the primary, and provided such therapy completed at least 12 months prior to entry into this study., patients must belong to one of four groups: 1) local/regional with prior definitive therapy: patients with local/regional recurrence following prostatectomy or radiation therapy who still have a normal bone scan. 2) local/regional without prior definitive therapy: patients felt to be unresectable, or are felt not to be candidates for, radiation therapy. 3) low volume bone disease: patients with 1 or 2 bone metastases. 4) high volume bone/visceral disease: patients with ≥ 3 metastatic bone sites or visceral metastases., patients must have adequate physiologic reserves as evidenced by zubrod performance status (zps) of ≤ 2, adequate bone marrow function, renal function and liver function and no evidence of active ischemia on ecg (if clinically indicated, documentation of ef ≥ 40%.), 3) for patients with the prostate in place, the psa must be elevated with biopsy proven disease and are not candidates for local therapy., patients must be free of serious co-morbidity and have a life expectancy of ≥ 3 years., histologic proof of adenocarcinoma of the prostate., patients may be on an lhrh agonist (with or without an anti-androgen), or already medically castrated, at the time of study entry, provided such therapy was started within 3 months of study entry., no previous cytotoxic systemic therapy of any kind is allowed, including systemic irradiation with strontium-89 and samarium. previous definitive radiotherapy to one metastatic site is acceptable. at least 8 weeks must have elapsed since radiation therapy to the pelvis. patients having limited irradiation of a single metastatic site are eligible 4 weeks following the completion of radiation.]"
NCT00521781,Exclusion Criteria,"[patients must not have a serious intercurrent medical or psychiatric illness, including serious active infection., patients must not have a second malignancy unless there is confidence of previous curative therapy., patients must not have sensory neuropathy of grade 1 or greater., patients with a recent history of tia (within 6 months), or are requiring regular antianginal therapy or are having claudication sufficient to limit activity are not eligible. patients with a previous history of deep venous thrombosis or pulmonary embolism (within 12 months) are not eligible.]"
NCT00482014,Inclusion Criteria,"[no weight loss greater than 10% in 3 months prior to enrolling in trial, inoperable non small cell lung cancer, adequate lung function, adequate liver function, adequate kidney function]"
NCT00482014,Exclusion Criteria,"[active infection, heart attack within past 6 months, previous chemotherapy or radiation therapy or lung cancer, previous surgery to remove lung tumor, inability to take vitamin supplementation]"
NCT00477945,Inclusion Criteria,"[primary refractory (achievement less than complete response), diffuse large cell non-hodgkin's lymphoma, mediastinal b-cell lymphoma, or peripheral t-cell lymphoma that is:, serum creatinine ≤ 2.0 mg/dl or estimated creatinine clearance of ≥60 ml/min, 4. performance status ecog 0-1, 1. documentation of disease. patients must have one of the following disease types:, ast and alt < 1 x upper limit of normal value., 3. patient age 18-70 years, lvef > 45% corrected, 2. patients who received prior autologous stem cell transplantation are not eligible., relapsed or primary refractory follicular lymphoma (fl) with a high fl international prognostic index., relapsed and refractory (achievement less than a partial response) to at least a single salvage therapy, large cell transformation of lymphoma from a more indolent lymphoma (e.g., follicular, marginal zone, etc.), primary refractory (achievement less than complete response), 5. required baseline laboratory values:, 6. signed written informed consent. patient must be capable of understanding the investigational nature of the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent, mantle cell lymphoma that is:, dlco > 50% of predicted value (corrected for hemoglobin), relapsed (regardless of chemosensitivity of relapsed disease), bilirubin < 1 x upper limit of normal value.]"
NCT00477945,Exclusion Criteria,"[1. no active infection. patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection., 2. no hiv disease. patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies., 3. non-pregnant and non-nursing. treatment under this protocol would expose a fetus to significant risks. women of childbearing potential should have a negative pregnancy test prior to study entry. women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (norplant®), or double barrier method (diaphragm plus condom).]"
NCT00573495,Inclusion Criteria,"[stage iv breast cancer that has failed at least one conventional therapy for metastatic disease, measurable or evaluable disease, ecog performance status 0-1, negative pregnancy test within 14 days of treatment for women of childbearing potential, hla-a2 positive, negative contrast ct or mri scan of the brain within 30 days of treatment]"
NCT00573495,Exclusion Criteria,"[initiation of hormonal agent in the 30 days before treatment, history of brain metastases within the last 4 years, the use of chemotherapy, radiation therapy, immunosuppressive drugs, systemic glucocorticoids, growth factors, or experimental therapy, and anti-coagulants within 14 days prior to treatment, pregnant or lactating, history of bone marrow or stem cell transplantation, initiation of herceptin in the 30 days prior to treatment.]"
NCT00668642,Exclusion Criteria,"[bilateral orchiectomy, known intolerance or allergy to dutasteride, concomitant chemotherapy, biologic therapy, or xrt to prostate, prior malignancy within 5 years of registration]"
NCT00668642,Inclusion Criteria,"[must have an intact prostate (no previous surgery or xrt), signed informed consent, ecog performance status 0-2, recovery from any major infection or surgical procedure, histologically proven prostate cancer, patients either to begin androgen ablation therapy with lhrh agonist or already receiving therapy with lhrh agonist, advanced prostate cancer with either positive pelvic nodes or bone/visceral metastasis, patients are hormone-naive]"
NCT00478972,Exclusion Criteria,"[positive serum pregnancy test in females of childbearing potential, the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial., type 1 diabetes, within 4 weeks prior to screening visit: administration of systemic long-acting corticosteroids or prolonged use (more than one week) of other systemic corticosteroids, change in lipid lowering treatment, primary hyperlipidemia, within 12 weeks prior to screening visit: use of oral antidiabetic drugs and/or insulin, of anti-obesity drugs or other drugs for weight reduction, secondary obesity]"
NCT00478972,Inclusion Criteria,"[body mass index ≥ 25 kg/m², type 2 diabetes mellitus patients inadequately treated with diet and exercise alone (not drug treated), hba1c ≥ 7.0 % and ≤ 10.0 %]"
NCT01041326,Inclusion Criteria,"[a negative bone scan,, no prior invasive malignancy, except non- melanomatous skin cancer unless disease free for a minimum of 5 years. carcinoma in-situ of the bladder or head and neck region is permissible., subjects must have, subjects must freely sign informed consent to enroll in the study., no prior pelvic radiation therapy, chemotherapy, or androgen deprivation,, kps must be >/= 80,, be medically fit to undergo surgery as determined by treating urologist,, biopsy-confirmed \""high-risk\"" prostate cancer, defined as a. psa > 20, b. gleason score (gs) >/= 8, and/or c. clinical stage t3 disease per ajcc staging manual, 6th edition; or d. at least two out of three of the following: psa 10-19.9, gs = 7, or clinical stage = t2b / t2c., age > 18,]"
NCT01041326,Exclusion Criteria,"[prior invasive malignancy, except non- melanomatous skin cancer, carcinoma in-situ of the bladder or head and neck region, unless disease free for a minimum of 5 years., declared high-risk for anesthesia by attending anesthesiologist, cardiologist, or other physician., metastatic disease as demonstrated by bone scan, ct scan or mri of the pelvis, or chest x-ray., history of prior pelvic radiation therapy., history of androgen deprivation therapy or chemotherapy., prior pelvic radiation therapy, chemotherapy, or androgen deprivation,, pathologically documented positive pelvic lymph nodes.  if pre-operative ct scan or mri (ordered at the discretion of the treating physicians) demonstrates lymph nodes which are suspicious for involvement, then biopsy must be undertaken and nodes proven negative before patient can enroll on this trial.]"
NCT00597818,Inclusion Criteria,"[patient has confirmed osteoarthritis (oa) and/or rheumatoid arthritis (ra) and could benefit from nsaid therapy., no current gastrointestinal h. pylori infection., patient is more than 40 and less than 70 years of age.]"
NCT00597818,Exclusion Criteria,"[known allergy or hypersensitivity to nsaids, or has any other contraindicated condition(s) to nsaid therapy., medical history includes prior or active gi complications and/or disorders, including but not limited to barrett's esophagus, erosive esophagitis, esophageal stricture or ring, gastric obstruction, irritable bowel syndrome (ibs), or inflammatory bowel disease (ibd)., active symptomatic peptic ulcer disease or gi bleeding., patient has undergone a gastrointestinal or abdominal surgical procedure within 90 days prior to the screening visit, or has had a bowel resection at any time., patient has received cobiprostone (spi-8811; ru-8811) or amitiza (lubiprostone, spi-0211, or ru-0211) at any time prior to participation in this study.]"
NCT00499239,Exclusion Criteria,"[receiving chronic, systemically administered steroids, uncontrolled concurrent illness, subjects with nhl who present exclusively with non-measurable lesions, evidence of pulmonary fibrosis, subjects with mm who have non-secretory and/or non-measurable disease, aids-related lymphoma, recent anticancer therapy (chemotherapy, radiotherapy, and/or biotherapy)within four weeks prior to starting treatment, known hypersensitivity to nucleoside analogues, other concurrent malignancy]"
NCT00499239,Inclusion Criteria,"[ecg without evidence of clinically significant ventricular arrhythmias, relapsed or refractory cll, nhl or mm, adequate organ function (protocol defined), ecog performance status of 0, 1, or 2]"
NCT01003925,Inclusion Criteria,"[age 65 or older, able to travel to family medicine offices, if in the treatment group, able to answer questions on a computer screen, knee pain over the past month on most days, able to read and understand english]"
NCT01003925,Exclusion Criteria,"[unable to get to a doctor for knee pain if needed, currently taking coumadin or blood-thinning medication, prior total knee replacement or scheduled to get knee replacement in painful knee(s), diagnosis of lupus (ever), psoriatic arthritis (ever), gout (current or within past year), rheumatoid arthritis (ever), or coronary artery disease (ever), history of gi bleeding (ever), satisfied with current knee pain treatment, history of ruptured ulcer (ever), bleeding or non-bleeding ulcer within the last year]"
NCT00601120,Exclusion Criteria,"[patients currently on anticoagulation, medical contraindication to mr imaging (pacemaker, metal debris in eye, etc.), pregnant or lactating, prior rf to the index tumor, history of bleeding diathesis or unexpected surgical bleeding]"
NCT00601120,Inclusion Criteria,"[patients who are on antiangiogenic therapy for a minimum of 4 weeks and have isolated metastatic lesions showing either persistence or resistance to therapy that might benefit from local therapy such as rf ablation., at least one lesion that has not completely resolved while on antiangiogenic therapy, safe access to the tumor for a needle placed under ultrasound guidance, clinical, radiographic, or pathologic diagnosis of clear cell rcc, candidate lesions of 1cm or greater in diameter, ongoing treatment with sorafenib or sunitinib, off clinical trials, ecog performance status of 0 or 1, male or female patients 18 years of age or older, acceptable risk for general anesthesia in the judgement of the study investigator and by the department of anesthesiology upon preoperative testing., adequate bone marrow, and renal as assessed by the laboratory requirements outlined in the protocol]"
NCT00505843,Exclusion Criteria,"[patient has a systolic bp or less than 80 mm hg or greater than 150 mm hg, patient has known intolerance or hypersensitivity to levodopa or carbidopa, patients have a history of the following:  seizure disorder, stroke or head trauma, pronounced cognitive impairment, psychiatric disorder, cardiovascular disease, cancer, diabetes as defined by hba1c of greater than 8%, patient has atypical parkinson's syndrome due to drugs, identified metabolic and/or neurologic disorders, encephalitis, or other degenerative syndrome, patient has been on anticholinergics or memantine within 30 days prior to dosing]"
NCT00505843,Inclusion Criteria,"[patient is in general good health based on screening assessments, patient is willing to discontinue anti-parkinson's medications at least 8 hours prior to dosing, parkinson's disease patients between the ages of 40 and 80 inclusive, patient is not a heavy smoker or drinker, patient taking selective serotonin inhibitors (ssris), sleep medications and neuroleptics, have been on a stable dose for at least 30 days and has not experienced any cns-related side effects, patient is levodopa responsive with levodopa-induced peak-dose dyskinesias]"
NCT00500448,Exclusion Criteria,"[history of tibial osteotomy surgery, previous adverse reaction to electrical stimulation, patients who have torn any knee ligament (acl, pcl, mcl, lcl), patients who have undergone a total knee arthroplasty, significant peripheral or central nervous system disease, enrollees who have a demand-type cardiac pacemaker or are pregnant, subjects  will be allowed to take buffered aspirin and naproxen sodium while enrolled in the study, inability to ambulate without the use of an assistive device (i.e cane, walker), concurrent bilateral radiographic evidence of tibiofemoral osteoarthritis, enrollees who are concurrently undergoing physical therapy for pain or oa, enrollees who have a body mass index of greater than 40 (morbidly obese), concurrent clinically active arthritis of the hip, ankle, hindfoot or midfoot in either limb, enrollees who have previously undergone quadriceps nmes therapy, enrollees who are taking cox-2 inhibitors or are receiving corticosteroid injections, enrollees who have a car > .95 (e.g. patients whose quadriceps are uninhibited)]"
NCT00500448,Inclusion Criteria,"[all participants must be female, subjects must have radiographic osteoarthritis of grade 2 severity according    to the kellgren and lawrence scale on the posterior-anterior semi-flexed view with definite osteophytes present in the medial and not lateral compartment., all participants must be at least 18 years of age]"
NCT00515112,Exclusion Criteria,"[uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, patients receiving renal dialysis, patients may not be receiving any other investigational agents, patients who have known hypersensitivity to any of the androgel ingredients, including testosterone that is chemically synthesized from soy, patients with significant pulmonary disease who have received chronic or pulse steroid therapy within the last 3 months prior to randomization will be excluded, patients with a history of any previous cytotoxic therapy or radionuclide therapy (such as rhenium, strontium, or samarium)]"
NCT00515112,Inclusion Criteria,"[prostate cancer, no evidence of distant metastatic disease, patients must have normal hepatic function, patient must have had a previous trial of anti-androgen therapy, ecog performance status < 2, patient was surgically or pharmacologically castrated at least 6 months prior to starting the study, patient must have received primary definitive local therapy to the prostate (surgery and/or radiotherapy), patient must have a rising psa, age >18 years]"
NCT00493298,Criteria,"[the decision to treat with tysabri must precede enrollment, history of progressive multifocal leukoencephalopathy or other opportunistic infections, or an increased risk of opportunistic infections, note:  other protocol defined inclusion/exclusion criteria may apply., key exclusion criteria:, patient immunocompromised at the time of enrollment, history of positive anti-natalizumab antibodies, patient must be a new tysabri user, and must not have had more than 3 tysabri infusions prior to enrollment, women must not be breast feeding or pregnant, or planning to become pregnant (must use birth control unless surgically sterile), must have had at least one relapse in the previous year, and must satisfy locally approved therapeutic indications for tysabri, documented diagnosis of relapsing remitting multiple sclerosis, concomitant immunomodulatory or immunosuppressive therapy during therapy with tysabri, known active malignancy]"
NCT00576914,Exclusion Criteria,"[right side pneumonectomy or any kind of incompletely resected surgery., women with pregnant or lactation., with allergic constitution or possible allergic reflection to any known research drugs., any concurrent acute or chronic systemic diseases or psychiatric diseases, which might both increase the risks of the research itself or the medical therapy and influence the research results analysis. the researchers can make a judge for the following conditions to tell whether they are fit for this research:uncontrolled high blood pressure, unstable angina , myocardial infarction , uncontrolled arrhythmia,or congestive heart failure with clinical symptoms within 12 weeks before randomization.evidence of anemia from electrocardiographic manifestation or heart valve disease with confirmed clinical diagnosis.clinically significant active infection state due to bacteria, virus and fungi invasion. patients with grade ii arrhythmia, grade ii myocardial anemia, grade ii abnormal cardiac troponin t, grade ii high blood pressure or left ventricle ejection fraction (lvef) less than 50 percent according to ctc 3.0 are not permitted to enrol the study., before enter the group,the patients had other malignant tumors except for non-melanoma skin cancer, carcinoma in situ and cured early-stage prostate cancer., the recruitment time are beyond 8 weeks from surgery., not proper for the research according to the researchers' judgment., the histological or cytological documents do not match the inclusion criteria., poor compliance.]"
NCT00576914,Inclusion Criteria,"[no evidence of tumor relapse prior to adjuvant therapy., age 18-70, ecog performance status 0-1., no history of chemotherapy or radiotherapy;, normal hematologic function.renal function , hepatic and cardiac function will be within the acceptable ranges as following:serum bilirubin, ast and alt levels below 1.5 times of normal value., the time from surgery to first dose of adjuvant chemotherapy are mandatory between 4-8 weeks., histologically confirmed non-small cell lung cancer, the pathology type includes squamous cell carcinoma, adenocarcinoma, large-cell carcinoma, and any mixed type of the 3 types mentioned above., the patient should have well compliance for chemotherapy and follow up.informed consent should be obtained before treatment., stage ib-iiia non-small cell lung cancer, tumor was completely resected (the type of surgery including lobectomy, left side pneumonectomy,bi-lobectomy).]"
NCT00905983,Exclusion Criteria,"[patients with symptomatic brain metastases., history of hypersensitivity reaction to study drugs., participation in clinical trials within 30 days of study entry., no measurable bone metastases or malignant pleural effusion as only measurable lesion., concurrent treatment with other experimental drugs., history of prior malignancies, except curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years., current peripheral neuropathy nci grade 2., major surgery, open biopsy or traumatic lesion 28 days before to study start., prior systemic chemotherapy for advanced disease.]"
NCT00905983,Inclusion Criteria,"[liver function: bilirubin <= 1.5 x uln; alkaline phosphatase <= 5 x uln;ast and alt <= 1.5 x uln., renal function: serum creatinine <= 2mg/dl., bone marrow: anc >= 2.0x10(9)cells/l; platelet count >= 100x10(9)cells/l; leukocyte count >= 4000x10(6)/l; hemoglobin >= 10 g/dl., patients must have at least one measurable lesion, no previously irradiated., histologically or cytologically confirmed diagnosis of advanced nsclc., life expectancy of at least 12 weeks., patients are 70 years old., patients with 1 > ecog ps =1., stage iii with pleural effusion and stage iv., adequate organ function according to the following criteria:]"
NCT00506077,Inclusion Criteria,"[patient has total positive and negative syndrome scale (panss) score between 36 and 75 at screening and at the first baseline visit, patient is in general good health based on screening assessments, females are not pregnant, and those who can have children agree to remain abstinent or use acceptable birth control throughout the study, patient is clinically stable, on current antipsychotic medication for at least 3 months and current dose for 2 months, patient has had a stable living arrangement for at least 3 months prior to study start, patient has a clinical global impressions - severity (cgi-s) score less than or equal to 4 at screening and at the first baseline visit, patient has a 6th grade reading level or better]"
NCT00506077,Exclusion Criteria,"[patient has had warfarin treatment, mao inhibitors, clonazepam or clozapine within 1 month of screening, patient has a major disease/disorder that may interfere with cognitive testing (such as mental retardation) and/or pose a risk upon study participation, patient has had ect treatment within 6 months of screening, patient has a history of alcohol or drug dependence within the past year or alcohol or drug abuse within 3 months of screening, patient has a history of head trauma with loss of consciousness greater than 15 minutes, patient requires treatment with antihistamines or certain other medications listed in the protocol, patient has a history of liver disease that has been active within the last 2 years, or a history of cancer within the past 5 years]"
NCT00907465,Exclusion Criteria,"[a woman who is intending to become pregnant, or who is pregnant, unwilling or unable to perform activities in protocol, on medications]"
NCT00907465,Inclusion Criteria,"[self-classify yourself as african american, are willing to stay in metabolic chamber for 8.5 hours (8:00am until 4:30 pm), are free of serious medical conditions that would prevent participant from engaging in physical activity., are free of serious medical condition, such as cancer, cardiovascular disease, or emphysema., are willing to have a scan completed that measures your body composition, weigh less than 250 lbs., are willing to wear an accelerometer for 2, one-week periods following your chamber stay. there will be one week in-between the 2, one-week periods., are willing to complete questionnaire related to your level of activity, are aged 18 years or older]"
NCT00372151,Inclusion Criteria,"[at least 4 on the clinical global impression scale, dsm-iv criteria for schizophrenia or schizoaffective disorder, ability and willingness to sign an informed consent form for participation in the study., age 18-60 years, men or women, at least two weeks of ongoing treatment with current antipsychotic agents.]"
NCT00372151,Exclusion Criteria,"[patients receiving mood stabilizing medications., evidence of serious neurologic or endocrine disorder, for example severe   head trauma, seizure disorder, dementia, cushings disease, or thyroid disorder, mental retardation, alcohol or drug abuse., renal disease, hepatic dysfunction, pregnant women]"
NCT01726335,Exclusion Criteria,"[previous history of refractivity to the other second generation antipsychotics, contraindication or known hypersensitivity to risperidone, previous history of unsatisfactory response to risperidone, use of antipsychotic of intramuscular deposit in the last 12 months, other mental disturbances of dsm-iv axis]"
NCT01726335,Inclusion Criteria,"[previous history of bad adhesion to oral antipsychotic treatment in the last 12 months, have schizophrenia diagnosis by diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv), be not pregnant as showed on negative pregnancy serum test, be on treatment with oral antipsychotic of first or second generation, for a minimum time of 12 months, total positive and negative syndrome scale score less than or equal to 90, the conceptual disorganization, hallucinatory behavior, suspicion and not usual content of thought must be less than or equal to 4]"
NCT00374062,Exclusion Criteria,"[subjects who have diabetes mellitus or any other condition determined by the pi to affect healing., subjects who are unable to understand the protocol or to give informed consent, subjects who are taking medications that may affect healing such as prednisone, or any immunosuppressants., subjects who have had prior mohs surgery., subjects who are immunocompromised., subjects with known mental illness or other psychological conditions, such as psychotic disorders, mood disorders, anxiety disorders, cognitive disorders, depression with psychotic features, dissociative disorders., subjects who have wound healing problems., subjects who have a history of bleeding disorders., subjects who are currently using anticoagulation therapy, subjects who are smokers.]"
NCT00374062,Inclusion Criteria,"[subjects are undergoing micrographic mohs surgery for facial basal and squamous cell carcinoma., age 25 and older, the subjects have willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator., the subjects are in good health.]"
NCT00322023,Exclusion Criteria,"[serious or unstable medical illness, taking investigational medication within 2 weeks of study entry, history of a kidney impairment, contraindication to study medication, pregnant or breastfeeding, high extrapyramidal symptom (eps) levels, diagnosed with neurodegenerative disease or a seizure disorder, began, discontinued, or adjusted psychotropic medication within 2 weeks of study entry, currently taking more than two antipsychotic medications, currently taking stimulants or cholinesterase inhibitors, currently taking clozapine, alcohol or drug abuse within 6 months of study entry]"
NCT00322023,Inclusion Criteria,"[calgary depression inventory total score of 10 and suicide score less than 2, panss total score between 60 and 110, willing to use an effective form of birth control throughout the study if sexually active, structured clinical interview for dsm-iii-r diagnosis of schizophrenia or schizoaffective disorder, simpson-angus scale total score of 12 or less, panss 3 factor negative symptom inclusion score greater than 20 prior to study entry, chlorpromazine (cpz) equivalent of 1500 or less, no change in clinical global impressions (cgi) scale score prior to study entry]"
NCT00472797,Exclusion Criteria,"[15. visual or physical impairment that precludes completion of diaries and questionnaires., 10. subject has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (ast) or alanine aminotransferase (alt) or alkaline phosphatase > 2.5 times the upper limit of the normal values., 13. subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol, 1. use of any other injectable medications on a regular basis during the week prior to the screening period or during the screening or treatment periods. receiving a single injection for treatment or prophylaxis of a condition unrelated to the subject's multiple sclerosis or the subject's rebif® therapy (e.g., receiving a influenza or pneumococcus vaccination) is acceptable, 2. subject receiving ms therapy in addition (i.e., combination therapy) to rebif® within 3 months prior to study enrollment or at any time during study protocol., 9. subject received oral or systemic corticosteroids or acth within 30 days of visit 1 (prior to enrollment)., 8. subjects that use any investigational drug or experimental procedure within 12 weeks of visit 1., 5. subject with history of any chronic pain syndrome., 11. subject has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal., 4. subject with progressive forms of multiple sclerosis (ms)., 12. subject suffers from other current autoimmune disease., 14. subject is pregnant or attempting to conceive, 6. subject has any other disease apart from ms that could better explain the subjects signs and symptoms., 3. subjects who have previously been on rebif new formulation (rnf)., 7. subject has complete transverse myelitis or bilateral optic neuritis.]"
NCT00472797,Inclusion Criteria,"[4. subject is between 18 and 60 years old inclusive, 8. female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either: i) being post-menopausal or surgically sterile, or ii) using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study. (confirmation required within 30 days prior to start of the study), 7. subject has given written informed consent and signed hipaa, 3. subject currently using rebiject ii and 29 gauge needle, 2. subject currently taking rebif 44mcg tiw, and has been on this treatment for at least 6 months (24 weeks) prior to study enrollment, 5. subject is able to read and understand english, 1. subject with a relapsing form of ms; diagnosis of ms is in accordance with the mcdonald criteria, 6. subject is willing to follow study procedures]"
NCT00841958,Exclusion Criteria,"[failure to provide informed consent., history of moderate to severe aortic stenosis or prosthetic aortic valve, previous heart, kidney, liver, or lung transplantation., thrombosis in lv, based on echocardiography data, plan for pci or cabg., non-cardiac illness with a life expectancy of less than 3 year., permanent atrial  fibrillation, recent acute myocardial infarction (ami) within 90 days of study entry, current participation in another clinical trial in which a patient is taking an investigational drug or receiving an investigational medical device., successful coronary revascularization (сabg or pci) within 12 months of study enrollment, conditions/circumstances likely to lead to poor treatment adherence (e.g., history of poor compliance, alcohol or drug dependency, psychiatric illness, no fixed abode).]"
NCT00841958,Inclusion Criteria,"[lvef less than 35% measured by echocardiography or spect within three months of study entry, men and women who are not of childbearing potential, patients with cad, nyha and ccs angina iii-iv functional class, unsuitable for initial or repeated conventional revascularization (cabg or pci), age 21-75 years.]"
NCT00468923,Inclusion Criteria,"[at least one additional cv risk factor including:, dysglycemia, low hdl cholesterol, women aged > 60 years and men > 55 years, family history of premature chd in first degree relatives, history of current or recent smoking (regular tobacco use within 5 years), waist/hip ratio ≥ 0.90 in men and ≥ 0.85 in women;, renal dysfunction]"
NCT00468923,Exclusion Criteria,"[symptomatic hypotension, clear indication or contraindication for statin and/or arb or ace inhibitor and/or thiazide diuretic therapy, significant psychiatric illness, senility, dementia, alcohol or substance abuse, which could impair the ability to provide informed consent and to adhere to the trial procedures, documented clinically manifest atherothrombotic cvd, concurrent treatment with cyclosporine or a condition likely to result in organ transplantation and the need for cyclosporine, other serious medical illness likely to interfere with study participation or with the ability to complete the trial, chronic liver disease, renal impairment, inflammatory muscle disease, concurrent treatment with a statin, fibrate, angiotensin receptor blocker, ace inhibitor, or a thiazide diuretic, concurrent use of an experimental pharmacological agent]"
NCT00590798,Exclusion Criteria,"[known peripheral arterial disease, complications during catheterization procedure, unable to walk 20 feet with out rest, blood pressure greater than 180/110, blood thinning medication within 5 days before catheterization, pregnant or lactating, anemic or low blood count]"
NCT00590798,Inclusion Criteria,"[be a candidate for hospital discharge following catheterization, patients admitted to for an outpatient left heart catheterization, able to receive the star-close vascular closure system, able to ambulate at least 20 feet, catheterization through the femoral artery]"
NCT00482430,Exclusion Criteria,"[patient requires treatment with antihistamines or certain other medications listed in the protocol, patient has a history of liver disease that has been active within the last 2 years, or a history of cancer within past 5 years, patient has had warfarin treatment, mao inhibitors, clonazepam, clozapine or st. john's wort within 1 month of screening, patient has a history of head trauma with loss of consciousness greater than 15 minutes, patient has a history of alcohol or drug dependence within past year or alcohol or drug abuse within 3 months of screening, patient has a major disease/disorder that may interfere with cognitive testing (such as mental retardation) and/or pose a risk upon study participation, patient has had ect treatment within 6 months of screening]"
NCT00482430,Inclusion Criteria,"[patient has a 6th grade reading level or better and has completed at least 6 years of formal education, females are not pregnant, and those who can have children agree to remain abstinent or use acceptable birth control throughout study, patient is clinically stable, on current antipsychotic medication for at least 3 months and current dose for 2 months, patient has had a stable living arrangement for at least 3 months prior to study start, patient is in general good health based on screening assessments]"
NCT00583739,Exclusion Criteria,"[patients with known metastasis., patients who are actively participating in a yoga class., patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier., known uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would compromise subject health during yoga.]"
NCT00583739,Inclusion Criteria,"[karnofsky ≥ 60%; see appendix a., potential subjects must have had histologically or cytologically confirmed breast cancer. this includes, but is not limited to: breast cancer-in situ; ductal carcinoma in situ; lobular carcinoma in situ; cystosarcoma phyllodes; inflammatory breast carcinoma; invasive breast carcinoma; and breast cancer not otherwise specified; cancer must be stage 0 through stage iii., ability to understand and the willingness to sign a written informed consent document., women of childbearing potential are eligible for this study., pregnant women are eligible for this study pending a doctor's note., the ability to understand and complete the study questionnaires., age ≥ 18 years. while breast cancer can occur in the pediatric population, the pediatric population is best served by trials specifically designed for their age group., treatment completion within the past calendar year., life expectancy of greater than 1 year.]"
NCT00520546,Exclusion Criteria,"[bradycardia (pulse rate < 55/min), allergic reaction against neurotropan, surgical treatment within 3 month before pet, cardiac infarction, severe liver damage, clinical or chemical detection of an acute infection, medical drugs with choline, bronchial asthma, small metal implants (e.g., clips, cochlea-implants, etc.), claustrophobia, cardiac pacemaker, secondary cancer, missing patient agreement, total endo-prothesis of the hip region]"
NCT00520546,Inclusion Criteria,"[no food containing choline within 24 hous before pet, radical prostatectomy as primary treatment, no nutrition within 12 hours before positron-emission-tomography (pet), age > 50 years, histologically diagnosed prostate cancer (needle biopsy)]"
NCT00884767,Criteria,"[no other severe illness that may worsen during treatment, including unstable cardiac disease, myocardial infarction within the past 6 months, or active uncontrolled infection, histologically confirmed colorectal cancer, no psychiatric illness that would preclude comprehension of the study or of the informed consent, no psychological, social, familial, or geographical reason that would preclude study follow-up, no dihydropyrimidine dehydrogenase deficiency, life expectancy > 3 months, fertile patients must use effective contraception, anc ≥ 1 x 10^9/l, no brain metastases or symptomatic meningitis, who performance status 0-2, prior chemotherapy allowed (except for platinum derivatives or taxanes), transaminases ≤ 3 times uln, no prior or concurrent clinical neuropathy (regardless of the etiology), total bilirubin ≤ 2 times upper limit of normal (uln), patient characteristics:, not pregnant or nursing, platelet count ≥ 100 x 10^9/l, other cancer within the past 5 years allowed provided treatment did not include platinum derivatives or taxanes, prior concurrent therapy:, requires treatment with oxaliplatin (as part of a folfox regimen), see disease characteristics, alkaline phosphatase ≤ 5 times uln]"
NCT00591344,Inclusion Criteria,"[hoehn and yahr score: ii - iii while in the \""off\"" pd medication state, able to stay on stable pd medications for at least 6 months, a diagnosis of pd, live within a 30 mile radius of chicago, able to walk for six minutes (may take rest breaks), on at least 1 da drug, may be on several pd medications, able to come off their pd medication for testing (12 hour overnight withdrawal of antiparkinsonian medications), up to the age of 67]"
NCT00591344,Exclusion Criteria,"[depression that may interfere with regular exercise, hallucinations or being treated for hallucinations, history of any other neurological disorder as determined by medical history and neurological exam, a score less than 23 on the mini-mental state examination, known cardiac problem or significant hypertension, currently involved in an active, ongoing formal exercise program deep brain stimulation surgery, history of a known injury, disease, or other disorder that might interfere with motor function in the proposed experiments]"
NCT00492115,Inclusion Criteria,"[apnea hypopnea index >10 (i.e., 10 apneas plus hypopneas per hour of sleep), stable health, over the age of 50 years, fluent english speaking, patients will be allowed to continue dopaminergic medications, acetylcholinesterase inhibitors, psychotropic medications, memory enhancers, health food supplements, etc. as long as they have been stable on the same dose for at least two months prior to participation and agree to continue on this dose for the duration of the 6-week study., clinical diagnosis of dementia due to parkinson's disease (according to the fourth edition of the diagnostic and statistical manual of mental disorders (code 294.1), mmse score between 18 and 26, inclusive; cognitive symptoms must occur at least one year after the diagnosis of pdd]"
NCT00492115,Exclusion Criteria,"[current diagnosis of active seizure disorder; presence of any neurodegenerative disorder other than pdd or other causes of dementia, symptomatic coronary or cerebral vascular disease (history of myocardial infarction, angina, stroke, or transient ischemic attacks), history of life-threatening arrhythmias, cardiomyopathy, or current alcohol or drug abuse, any behavioral or physical problem that would preclude completion of the primary evaluation or treatment with cpap., current treatment for sleep apnea (to avoid discontinuing already established treatment for sleep apnea and any carry over confounding effect of treatment on cognition)., central sleep apnea, use of medications known to influence sleep (i.e. sedative hypnotics, narcotics) if the dose cannot remain stable for the duration of the study., bronchospastic and symptomatic chronic obstructive pulmonary disease as indicated by regular use of bronchodilators, steroids, history of carbon dioxide retention, waking hypoxemia (pao2 <60 mmhg or spo2 <92 % by pulse oximetry), or use of supplemental oxygen.]"
NCT00089323,Inclusion Criteria,"[histologic diagnosis of invasive adenocarcinoma of the breast diagnosed by core, incisional, or excisional biopsy., all of the following staging criteria must be met: primary tumor must be operable and staged as ct1-3 by clinical evaluation. ipsilateral nodes must be cn0-1 by clinical evaluation. no evidence of metastatic disease (m0).]"
NCT00089323,Exclusion Criteria,"[bilateral malignancy (including dcis)., treatment including radiation therapy, chemotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to study entry.  the only exception is hormonal therapy, which may have been given for up to a total of 28 days after diagnosis and before study entry., other non-breast malignancies unless the patient is considered disease-free for 5 years before study entry and is deemed by their physician to be at low risk for recurrence.  patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, melanoma in situ, colon carcinoma in situ, and basal cell and squamous cell carcinoma of the skin., patients with any history of breast malignancy including dcis (patients with a history of lobular carcinoma in situ (lcis) are eligible)., patients who will be receiving preoperative chemotherapy.]"
NCT01669148,Inclusion Criteria,"[any ethnic origin, no contraindication for routine bilateral mammography, female]"
NCT01669148,Exclusion Criteria,"[any contraindications to mammographic screening, including, but not limited to:, under the age of 30 at the time of consent, pregnant, unable to understand and execute written informed consent, significant existing breast trauma, lactating, potential subjects with any of the following will not be enrolled in the study:, prior surgeries, breast implants]"
NCT00880009,Exclusion Criteria,"[disease refractory (ie, progressive disease (pd) within 6 months from initiation of therapy) to previous adjuvant antiestrogen therapy., adjuvant endocrine therapy <=12 months prior to day 1 of treatment., serious concurrent illness., major surgery or radiotherapy within 14 days of treatment day., any other cancer within 5 years of  screening with the exception of er+ contralateral breast carcinoma, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin., prior endocrine treatment for locally advanced or metastatic breast cancer (up to one prior adjuvant aromatase inhibitor (ai) agent/regimen is permitted)., extensive visceral disease or active central nervous system (cns) disease., prior letrozole (except in adjuvant setting), prior bosutinib, or any other prior src inhibitor., bone or skin as the only site of disease., inadequate hepatic/renal/bone marrow function., more than 1 prior chemotherapy regimen in locally advanced or metastatic breast cancer., history of clinically significant or uncontrolled cardiac disease.]"
NCT00880009,Inclusion Criteria,"[at least 1 radiologically measurable lesion as defined by response evaluation criteria in solid tumors (recist)., surgically sterile or post-menopausal women., locally advanced or metastatic, or loco-regional recurrent breast cancer not amenable to curative treatment with surgery or radiotherapy., documented er+ and/or pgr+ and erbb2- tumor based on most recently analyzed biopsy, as documented by a local laboratory., confirmed pathologic diagnosis of breast cancer., eastern cooperative oncology group (ecog) performance status 0-2.]"
NCT01305915,Inclusion Criteria,"[have undergone initial treatment for breast cancer;, are able to speak, read and write english., are receiving adjuvant radiation therapy as last hospital-based component of treatment;, have a diagnosis of breast cancer;, outpatients attending treatments at pmh]"
NCT01305915,Exclusion Criteria,"[local recurrence, metastatic disease, cognitive impairment, if they are an inpatient]"
NCT00892268,Criteria,"[hormone receptor-positive disease, no prior acupuncture for aromatase inhibitor-associated pain syndrome, patients with other underlying pain syndromes (e.g., osteoarthritis) are eligible, but the arthralgia must have worsened since starting anastrozole, history of bilateral salpingo-oophorectomy with or without hysterectomy, not needle phobic, age < 55 with hysterectomy without oophorectomy or with unknown status, and serum fsh in post-menopausal range within the past 4 weeks, concurrent therapy with anastrozole for the adjuvant treatment of breast cancer, concurrent antidepressant medications allowed, but doses must be stable for ≥ the past 3 months, age > 55 with hysterectomy with or without oophorectomy, at least 12 months without spontaneous menstrual bleeding, see disease characteristics, at least 6 months since prior acupuncture, diagnosis of breast cancer, concurrent chronic narcotics or nsaids allowed, but doses must be stable for ≥ the past month, post-menopausal status meeting the following criteria:, patient characteristics:, prior concurrent therapy:, must have moderate or worse arthralgia, as defined by a baseline womac pain scale score ≥ 48, patients with a contraindication to nsaids (i.e., prior gastrointestinal bleed secondary to nsaids or severe renal insufficiency) are eligible, but will be treated with alternative analgesics such as narcotics or acetaminophen]"
NCT00439231,Criteria,"[4. platelet count  greater than or equal to 20,000/mcl., 2. failed prior standard of care therapy for cll., 3. neutrophil count (anc) greater than or equal to 500/microliter (mcl)., 1. diagnosed with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll)., 5. age 21-99.]"
NCT00439231,Exclusion Criteria,"[6. creatinine greater than 1.5 times the upper limit of normal., 7. women who are pregnant or nursing, as well as women of childbearing potential who are unwilling to use a dual method of contraception., 2. eastern cooperative oncology group (ecog) performance greater than 2., 3. other concurrent anticancer therapies., 5. moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to tolerate protocol therapy., 4. less than 4 weeks from last systemic therapy for cll. steroids up to 2 weeks before the start of treatment are permissible., 9. inability to understand the investigational nature of the study; inability to provide informed consent., 8. men who are unwilling to use a barrier protection., 1. chronic or current clinically significant infection, including hiv positivity or uncontrolled infection.]"
NCT00421447,Inclusion Criteria,"[ambulatory, healthy, age-matched postmenopausal women, postmenopausal breast cancer patients (stage 1 and 2), group 2: control group, non-institutionalized, prescribed anastrozole within the preceding 1-2 weeks, ability to read and comprehend study protocol and informed consent, ability to read and comprehend study protocol and informed consent, non-institutionalized, group 1: treatment group, ambulatory]"
NCT00421447,Exclusion Criteria,"[known congenital metabolic bone disease (e.g., osteogenesis imperfecta), patients with disorders known to affect bone metabolism including diabetes mellitus, systemic lupus erythematosus, cushing's disease, hyperparathyroidism, chronic liver disease, chronic renal failure, paget's disease, geographically inaccessible for follow-up, conditions preventing pqct measurement (e.g., unable to lie flat or still for 15 minutes), prior tamoxifen or raloxifene therapy, concomitant treatment with corticosteroids, patients with a history of endocrine disorders or surgical parathyroidectomy]"
NCT00859651,Inclusion Criteria,"[at least one breast available for imaging. no bilateral breast implants., baseline mammographic density ≥25% as assessed qualitatively by the mammographer (25-50% = \""scattered fibroglandular densities\""; >50-75% = \""heterogeneously dense breasts\""; >75% = \""extremely dense breasts\"")., normal serum calcium., postmenopausal defined as > 6 months since the last menstrual period, prior bilateral oophrectomy, or serum fsh/lh values consistent with institutional normal values for the postmenopausal state., adequate renal and hepatic function: serum creatinine, bilirubin, ast, alt and alkaline phosphatase < 2.0 x the institutional upper limit of normal (iuln)., prior tamoxifen or raloxifene use is allowed provided treatment is discontinued at least 28 days prior to enrollment., willingness to not take vitamin d supplements during the one year intervention, but up to 1000mg of calcium supplementation is allowed., zubrod performance status of 0 or 1., baseline serum 25-hydroxyvitamin d <32 ng/ml., elevated risk of breast cancer defined as having at least one of the following: (1) predicted 5-year modified gail model risk of 1.67% or greater, (2) lobular carcinoma in situ, (3) known brca1 or brca2 deleterious mutation carrier, (4) prior history of ductal carcinoma in situ, if no current tamoxifen use or prior radiation to the contralateral breast., normal breast exam and mammogram (birads score of 1 or 2) or abnormal breast imaging with a benign breast biopsy without evidence of cancer. normal baseline breast mri (birads score of 1, 2, or 3)., age 21 years or older.]"
NCT00859651,Exclusion Criteria,"[on estrogen replacement therapy., history of kidney stones., hypersensitivity reactions to vitamin d., other prior malignancy. the following is allowed: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage i or ii cancer from which the participant is currently in complete remission, or any other cancer (including breast cancer) for which the participant has been disease-free for 5 years., significant medical or psychiatric condition that would preclude study completion.]"
NCT00812058,Inclusion Criteria,"[bipolar i disorder, most recent episode depressed, history of 2 or more manic or mixed episodes, at least one of which required pharmacologic treatment for manic symptoms]"
NCT00812058,Exclusion Criteria,"[current manic, hypomanic or mixed episode, rapid cycling bipolar disorder (4 or more mood episodes in the last year), current seizure disorder, alcohol or drug dependence within 6 months; alcohol or drug abuse within 3 months, women who are pregnant, breast feeding or refuse to use adequate birth control, serious suicidal or homicidal risk, axis ii diagnosis likely to interfere with study compliance, sensitivity to any of the drug ingredients, including lactose, dementia or any other axis i diagnosis (besides bipolar i) that requires treatment, positive urine drug test for amphetamines, cocaine metabolites, opiates and/or phencyclidine(pcp), current episode of depression is longer than 1 year]"
NCT01169870,Inclusion Criteria,"[4. previous adjuvant taxane chemotherapy in an adjuvant setting is allowed, if taxane-free interval is more than 12 months, 1. histologically or cytologically diagnosed stage iv or recurrent breast cancer patients according to american joint committee on cancer (ajcc 6th ed.), 15. adequate major organ function including the following:, 8. no other forms of cancer therapy, such as radiation, immunotherapy or chemotherapy for at least 4 weeks before the enrollment in therapy., ②hepatic function: bilirubin   1.5 x unl , ast/alt levels   2.5 x unl, 2. prior chemotherapy at least one anthracycline-containing regimen, in either adjuvant or metastatic setting is requested., 18. women of childbearing age should use non-hormonal contraceptive method., 10. at least 18 years old, 17. patients should sign an informed consent, ③renal function: serum creatinine   1.5mg/dl, 13. estimated life expectancy of at least 12 weeks., 11. performance status of 0, 1 and 2 on the ecog criteria., 9. major surgery other than biopsy within the past two weeks., 14. patient compliance that allow adequate follow-up., 16. grade of baseline neuropathy should not be more than grade 1 by nci ctc v.3.0, 5. previous chemotherapy for metastatic disease is not allowed except for the regimen including anthracycline., 1,500/mm3, platelet count ³ 100,000/mm3, lesions that can be accurately measured in at least one dimension > 10 mm with chest x-ray, spiral ct scan, mri, or physical examination, 3. previous hormonal therapy in adjuvant setting is allowed., 12. disease status must be that of measurable disease defined as recist:, 6. previous chemotherapy including taxane for metastatic disease is not allowed., 7. prior radiation therapy is allowed as long as the irradiated area is not the only source of measurable disease., ①hematologic function: wbc ³ 3,000/mm3 or absolute neutrophil count (anc) ³]"
NCT01169870,Exclusion Criteria,"[4. uncontrolled cns disease (eligible if the cns disease is controlled with radiotherapy or corticosteroid), 3. psychiatric disorder that would preclude compliance., 2. other malignancy with the past 5 years except adequately treated cutaneous basal cell carcinoma or uterine cervix in situ cancer, 1. serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complication of study therapy]"
NCT00662103,Criteria,"[menopausal status not specified, no concurrent medication that would contraindicate participation in moderate intensity exercise training, as determined by physician clearance and the principal investigator, no medical condition or movement or neurological disorder that would contraindicate participation in moderate intensity exercise training, as determined by physician clearance and the principal investigator, patient characteristics:, stage 0-iii disease, hormone receptor status not specified, diagnosis of breast cancer, no cognitive difficulties that would preclude answering the survey questions, participating in the performance tests, or giving informed consent, has obtained medical clearance to participate in study exercise programs, completed chemotherapy or radiotherapy > 2 years ago, no stage iv breast cancer, is not a regular participant in moderate aerobic exercise (i.e., jogging, swimming) or moderate resistance exercise (> 3 times/week for ≥ 30 minutes/session) or in vigorous aerobic or resistance exercise (> 3 times/week for ≥ 20 minutes/session), see disease characteristics, concurrent hormonal therapy (e.g., selective estrogen receptor modulator (serm) or aromatase inhibitor) for breast cancer allowed, prior concurrent therapy:]"
NCT00632359,Inclusion Criteria,"[4. adequate renal and hepatic function (creatinine equal to or less than 2mg/dl - total bilirubin equal to or less than 2)., 2. patients with cll/small lymphocytic lymphoma (sll) that achieve a complete or stable partial remission after combination of chemotherapy. patients in complete remission need to have documentation of residual disease by immunophenotyping and/or pcr molecular testing., 8. men must agree to use a latex condom during sexual contact with a fcbp even if they have had a successful vasectomy. all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure., 7. fcbp must also agree to ongoing pregnancy testing weekly for the first four weeks and then every 28 days while on therapy and at discontinuation of treatment., 6. fcbp must have a negative serum or urine pregnancy test with a sensitivity of at least 50 miu/ml within 10-14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control; one highly effective and one additional effective method at the same time at least 28 days before starting taking lenalidomide., 3. eastern cooperative oncology group (ecog)/world health organization (who) status of 0-2., 10. signed, written irb-approved informed consent., 9. age 18 and older., 1. patients should have completed their chemotherapy 3 months prior to start of treatment with lenalidomide and not more than 9 months prior to treatment initiation., 5. females of childbearing potential (fcbp). a female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; 2) or has not been naturally postmenopausal for at least 24 consecutive months (has not had menses at any time in the preceding 24 consecutive months).]"
NCT00632359,Exclusion Criteria,"[6. any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study., 7. use of any other experimental drug or therapy within 28 days of baseline., 4. history of tuberculosis within the last five years or recent exposure to tuberculosis equal to or less than 6 months., 8. concurrent use of other anti-cancer agents or treatments, 5. any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form., 1. known sensitivity to lenalidomide or thalidomide or it's derivatives, 2. known positivity for hiv or active hepatitis b or c., 3. pregnant or breast feeding females. lactating females must agree not to breast feed while taking lenalidomide.]"
NCT00810680,Inclusion Criteria,"[adequate liver function (bilirubin<2 mg/dl,astoralt <3xthe upper limit of normal) and renal function (serum creatinine<2 mg/dl or creatinine clearance>30 ml/min) unless abnormalities are as a result of disease involvement., age 18 years or older., active cll (as defined by the national cancer institute working group), absolute neutrophil count>1500/cmm and platelet count >30,000/cmm unless the low counts are due to the disease., full recovery from previous treatments., good general condition as defined by an eastern cooperative oncology group-, performance status (ecog-ps) </=2., patients must have received at least one prior therapy for cll and have been treated with a nucleoside analogue.]"
NCT00810680,Exclusion Criteria,"[pregnancy., any therapy for cll within 4 weeks before initiating treatment on this study.]"
NCT01630226,Inclusion Criteria,"[5. eastern cooperative oncology group [ecog] performance status of 0 and 1., 7. signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrolment., 8. willingness and ability to comply with scheduled visits, treatment plans laboratory tests, and other study procedures., 3. measurable disease of any size by mammography or ultrasound., 2. documentation of the presence of a germ-line brca1 mutation, 6. evidence of adequate organ function (liver, bone marrow, kidney), 1. histologically or cytologically proven diagnosis of invasive breast cancer (stage i-iii)., 4. female diagnosed with breast cancer between the ages of 20 to 70., patients must meet all of the following inclusion criteria to be eligible for enrolment into the trial:, 9. polish resident.]"
NCT01630226,Exclusion Criteria,"[3. receiving any medication that may markedly affect renal function., 2. previous or current diagnosis of any other malignancy except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix., 4. pregnant or breastfeeding women., patients presenting with any of the following will not be included in the trial:, 1. previous chemotherapy for current cancer., 5. uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements.]"
NCT00820690,Inclusion Criteria,"[women with locally advanced women breast cancer, ecog 0 or i, histology: ductal ou lobular invasive histology, agreement to take part in the study and signature of the informed consent, clinical condition to receive  doxorubicin/cyclophosphamide and paclitaxel]"
NCT00820690,Exclusion Criteria,"[previous treatment, inflammatory breast cancer, pregnancy, absence of clinical condition to receive chemotherapy, not clinical stage iii, previous diagnosis of cancer (except basal cell or squamous cell skin carcinoma and non-invasive cervical carcinoma)]"
NCT00727831,Criteria,"[no clinically significant effusions or edema, diffuse large b-cell lymphoma histology, previously untreated disease, histologically confirmed newly diagnosed primary cns lymphoma (pcnsl), must be clinically eligible to receive standard 3 g/m² methotrexate if outside trial, patient characteristics:]"
NCT00727831,Exclusion Criteria,"[other serious or uncontrolled medical conditions, no concurrent co-trimoxazole, no concurrent prophylactic antibiotics, prior malignancy, except adequately treated nonmelanoma skin cancer or carcinoma in situ, no prior cytotoxic chemotherapy, hiv positivity, prior concurrent therapy:, dementia or neurological dysfunction not considered to be due to the pcnsl]"
NCT00727831,Inclusion Criteria,"[platelet count ≥ 100 x 10^9/l, neutrophils ≥ 1 x 10^9/l, glomerular filtration rate (initially measured by edta/isotope method) ≥ 50 ml/min, bilirubin < 1.5 times upper limit of normal, fertile patients must use effective contraception during and for 6 months after completion of study therapy, not pregnant or nursing, negative pregnancy test, ecog performance status 0-3]"
NCT00389155,Inclusion Criteria,"[new york heart association classification stage iii-iv congestive heart failure, measurable disease documented by imaging with at least one uni-dimensional lesion, clinical diagnosis of transitional cell carcinoma of the urothelium that is locally advanced or metastatic, adequate performance status (ecog 0, 1, or 2), calculated creatinine clearance ≤60 ml/min: or, ineligible for cisplatin-based therapy because of at least one of the following two medical conditions:, men and women ≥18 years of age]"
NCT00389155,Exclusion Criteria,"[prior radiation to ≥ 30% of bone marrow, inadequate renal function:  serum creatinine clearance ≤ 20 ml/min, patients in whom radiation or surgery is indicated, prior allergy to any vinca alkaloid, current neuropathy ≥ ctcae grade 3]"
NCT00938340,Exclusion Criteria,"[intake of anti-inflammatory medications (containing aspirin or nsaids) on a regular basis or if an acute intake, within 48 hours of a test day, use of prescription cholesterol-lowering or blood pressure-lowering medications during the study, high alcohol consumption > 21 units/week (female subjects) or > 28 units/week (male subjects), dietary restrictions such as a medically prescribed diet, or a slimming diet prior to or during the trial, treatment with drugs acting on the gut, such as ezetimibe, bile acid-binding resins, orlistat, diabetes, liver, kidney, thyroid (unless controlled and stable on replacement medication) or other endocrine disorders from self-reported medical history, intake of vitamin and mineral supplements within the past 3 weeks or unwillingness to discontinue for 3 weeks prior to screening and for entire study., intake of other putative cholesterol-lowering supplements (excl. psyllium, fish oil capsules, soy lecithin, phytoestrogens), lactation 6 weeks before the start of and during study, pregnant or wishing to become pregnant 3 months before or during the study, weight loss or gain of 10% body weight or more during a period of 6 months before pre-study examination., blood/plasma donation for reason(s) other than the present study prior to the study (1 month for a male subject or 2 months for a female subject), or during the study]"
NCT00938340,Inclusion Criteria,"[body mass index 25-39 kg/m2, ldl cholesterol >110 mg/dl, tg < 350 mg/dl, <95 percentile for age and gender for both (based on nhanes data), age 21 - 60 years]"
NCT00778843,Inclusion Criteria,"[absence of significant alcohol ingestion (weekly ethanol consumption of less than 40 g), hcv infection confirmed on a positive test for anti-hcv antibody and hcv    rna detectable in serum by polymerase chain reaction., ability to provide informed consent., patients who were non-responders to previous treatment with pegylated interferon and ribavirin or who had contraindicated the antiviral treatment., age between 18 and 65 years., histological diagnosis of chronic hepatitis.]"
NCT00778843,Exclusion Criteria,"[severe psychiatric conditions., concomitant disease with reduced life expectancy., pregnancy or lactation., absence of clinical and ultrasonographic evidence of liver cancer, with α-fetoprotein levels ≤ 200 ng/ml., drug dependence., decompensated cirrhosis., co-infection with hepatitis a or b or hiv., refusal to participate in the study., presence of other form of liver diseases (viral or autoimmune hepatitis, drug-induced liver disease, nonalcoholic steatohepatitis, metabolic and hereditary liver disease and α-1 antitrypsin deficiency)., pregnancy.]"
NCT00818792,Exclusion Criteria,"[age >85 years, cabg indication by consensus (cardiovascular team), left main coronary artery disease, st-elevation mi (<3 days), severe valvular heart disease, saphenous vein graft disease, coronary vessel diameter <2.5 or > 4 mm, contraindication to long-term double antiplatelet therapy, informed consent not obtained]"
NCT00818792,Inclusion Criteria,"[chronic renal insufficiency (creatinine clearance <60 ml/min, in dialysis patients included) with at least two significant (>70%) coronary lesions in two major coronary vessels.]"
NCT00773695,Inclusion Criteria,"[adult patients, >=18 years of age;, ecog/whoperformance status <=2;, her2-negative breast cancer, >=2.5cm in size;, normal baseline cardiac function (lvef).]"
NCT00773695,Exclusion Criteria,"[previous treatment for localized breast cancer < 24 months from diagnosis of present breast cancer;, stage iv (metastatic) disease;, current or recent use of aspirin (>325mg/day);, other previous or current cancer except for basal cell cancer or in situ cervical cancer;, clinically significant cardiovascular disease.]"
NCT00149409,Exclusion Criteria,"[restrictive cardiomyopathy, acute myocarditis, current treatment with omacor or other fish oil products, life expectancy <1 year due to non-cardiac causes, uncorrected significant valvular heart disease, mechanical assist device, participation in another study with an intervention within the last 3 months., heart failure due to congenital heart disease, current participation in another intervention study, alcoholic heart disease, inability to perform bicycle testing, ischemic cardiomyopathy, continuous i.v. therapy for heart failure, known hypersensitivity to the study drug, women of childbearing potential not practicing a save contraception method]"
NCT00149409,Inclusion Criteria,"[optimized heart failure therapy, lvef < 35 %, nyha functional class iii-iv, Age, chronic heart failure of non-ischemic origin, plasma nt-bnp >2000pg/ml]"
NCT00656669,Inclusion Criteria,"[5. ecog performance status 0 or 1., 1. patients must have histologically-confirmed adenocarcinoma of the breast with operable or inoperable stage 1c (primary tumor > 1.0 cm), ii or iii disease., 3. pre-treatment core or incisional biopsy.  patients may not have had definitive primary surgery., 6. adequate organ function as defined in the protocol., 2. measurable disease by physical examinations or diagnostic breast imaging (mammography, ultrasonography or mr)., 4. male or female, 18 years of age or older.]"
NCT00656669,Exclusion Criteria,"[1. prior radiation therapy, cytotoxic therapy or systemic therapy for breast cancer. prior use of tamoxifen or raloxifene as chemoprevention is allowed but must be discontinued prior to study entry., 11. other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study., 7. hypertension that cannot be controlled by medications., 8. current treatment with therapeutic doses of any anti-coagulant. prophylactic use of anticoagulants is allowed., 9. known human immunodeficiency virus (hiv) infection., 2. metastatic (stage iv) breast cancer, 10. pregnancy or breastfeeding. all female patients with reproductive potential must have a negative pregnancy test prior to first day of study medication., 6. ongoing cardiac dysrhythmias of nci ctcae grade >=2, atrial fibrillation of any grade, or qtc interval >450 msec for males or >470 msec for females., 3. patients who have had only a pre-treatment fine needle aspiration (fna) are excluded., 4. current therapeutic treatment on another clinical trial with an investigational agent., 5. any of the following within the 6 months prior to starting study treatment:-myocardial infarction -severe/unstable angina -coronary/peripheral artery bypass graft -congestive heart failure -cerebrovascular accident including transient ischemic attack -pulmonary embolus]"
NCT00926315,Exclusion Criteria,"[parathyroid disease, history of hypercalcemia or nephrolithiasis, absence of clinical condition to receive supplementation, previous chemotherapy, hormonotherapy or radiotherapy, current use of corticosteroids, vitamin d supplementation,  hrt]"
NCT00926315,Inclusion Criteria,"[clinical conditions for breast surgery, agreement to take part in the study and sign the informed consent, no previous neoadjuvant treatment for breast cancer, postmenopausal women, invasive breast carcinoma]"
NCT01027065,Exclusion Criteria,"[history of clinical autoimmune disease or active auto-immune disease, previous treatment by lamivudine and/or nucleosides analogues, infection by hcv, severe asthma, presently on chronic medications, type i diabetes mellitus, apart from hbv infection, presence of active infection requiring a specific treatment or a hospitalization, infection by hiv-1 and /or hiv-2, other liver disease (notably from alcoholic, metabolic or immunological origin), inactive carrier, cirrhosis]"
NCT01027065,Inclusion Criteria,"[ongoing treatment by entecavir or tenofovir at screening note: previous treatment with pegylated ifn monotherapy, before the start of entecavir or tenofovir, is acceptable, hbeag-negative patients, age > 18 years, patient with a hbv dna undetectable (<70 copies/ml) stable for at least 3 months under entecavir or tenofovir treatment., patients with active chronic hepatitis at the start of the antiviral treatment, chronic hbv-infected patients]"
NCT00657137,Inclusion Criteria,"[must have measurable disease by recist, muga scan or echocardiogram results show left ventricular ejection fraction greater than or equal to 50%, females with pathologically determined locally advanced or metastatic human epidermal growth factor receptor 2 positive (her2/neu+) breast cancer, ecog ps of 0,1, or 2, have progressed after treatment with chemotherapy including a taxane and trastuzumab]"
NCT00657137,Exclusion Criteria,"[history of mi, stroke, ventricular arrhythmia, or symptomatic conduction abnormality, symptomatic central nervous system metastases, pregnant or nursing women, severe renal insufficiency, concurrent severe or uncontrolled medical disease, history of congenital qt prolongation, prior lapatinib therapy, history of upper gi bleeding, ulceration, or perforation- concurrent use of potent cyp3a4 inhibitors and cyp3a4 inducers, patients on anti-arrhythmic treatment, evidence of new york heart association class iii or greater cardiac disease, hypersensitivity or intolerance to apricoxib, lapatinib, capecitabine, 5-fu, sulfonamides, aspirin, or nsaids, radiation therapy within 2 weeks, chemotherapy within 3 weeks, or noncytoxic investigational agents within 4 weeks of initiating study treatment, prior treatment with capecitabine]"
NCT00524667,Exclusion Criteria,"[patients with a calculated creatinine clearance < 30 ml/min using the cockroft and gault formula, patients with platelets < 50 x 109/l or an absolute neutrophil count < 1.5x109/l, patients with active secondary malignancy or who have central nervous system involvement with cll, patients with a history of  autoimmune cytopenias, patients diagnosed with more an aggressive lymphoproliferative disorder such as richter's transformation, patients who are receiving drugs that affect vpa protein binding or metabolism, patients who are pregnant or breastfeeding, patients with a history of pancreatitis, patients with hepatic disease or an ast/alt 6x above the upper limit of normal, patients with active infection, hiv or active viral hepatitis]"
NCT00524667,Inclusion Criteria,"[active cll (as defined by the national cancer institute working group), patients must have received at least one prior therapy for cll and have been treated with a nucleoside analogue., recruitment will be limited to those with an ecog performance status of 2 or less.]"
NCT00451256,Exclusion Criteria,"[subject has history of a stroke or transient ischemic attack within the prior 6 months, subject has chronic renal insufficiency (i.e., serum creatinine >180 mmol/l) or co-morbid illness which precludes follow-up angiography, subject has a non-cardiac illness imposing substantial operative mortality, subject has a pci planned during the 30 days immediately following the cabg procedure, subject has a concurrent medical condition resulting in a life expectancy of less than 3 years, subject has a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, or sensitivity to contrast media which cannot be adequately pre-medicated, subject has a known left ventricular ejection fraction of <35%, subject will have valve replacement or repair during cabg procedure, subject has had a percutaneous coronary intervention (pci) for coronary artery disease treatment 30 days prior to cabg, subject has chronic atrial fibrillation, subject is currently participating in an investigational drug or another device study., subject has an active peptic ulcer or has had clinically significant upper or lower gi bleeding within the prior 6 months, subject has a poor quality donor vessel (poor or turbulent flow, varicose), subject has a history of a bleeding diathesis or coagulopathy or will refuse blood transfusions]"
NCT00451256,Inclusion Criteria,"[subject is ≥ 18 years of age, female subjects of childbearing potential must have a documented negative serum pregnancy test within 2 days before the cabg procedure, subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the institutional review board/ethics committee of the respective clinical site., subject is a suitable candidate for aortocoronary bypass (cabg) procedure. subjects undergoing cabg procedure without the use of coronary artery bypass (off pump) are preferred. however, subjects requiring coronary artery bypass will not be excluded from the study, subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits]"
NCT00927199,Exclusion Criteria,"[inflammatory disease, smoking, kidney disease, documented cardiovascular/atherosclerotic disease, cancer, chronic alcohol consumption (> 2 servings/day), excessive exercise expenditure (> 4000 kcal/week), other systemic diseases, diabetes, use of lipid lowering therapy, uncontrolled hypertension]"
NCT00927199,Inclusion Criteria,"[fasting serum ldl-cholesterol >3.0 mmol/l, body mass index (bmi) between 22-36 kg/m2]"
NCT00434629,Inclusion Criteria,"[performance status 0 or 1, cells/kg), no active cns disease, bone marrow cellularity ≥ 15% on histopathologic bone marrow examination, cd20 positive b-cell lymphoma, availability of adequate stored autologous stem cell product (≥ 2 x 106 cd34+, age ≤ 75 years, no detectable bone marrow involvement by lymphoma on histopathologic bone marrow examination, total bilirubin, ast, and alt ≤ 1.5 x upper limit of normal (unless bilirubin due to gilbert's), creatinine ≤ 1.5 or calculated creatinine clearance ≥ 60 ml/min, confirmed relapsed/refractory disease following autologous transplant]"
NCT00434629,Exclusion Criteria,"[prior total body radiation therapy, life expectancy of ≤ 2 months, active infection, subjects not using contraceptives are excluded from the study, anc ≤ 1,500/μl and/or platelet count ≤ 100,000/μl, positive human anti-mouse antibody (hama) testing, pregnant woman are excluded from the study, prior anti-b-cell radioimmunotherapy (e.g., zevalin or bexxar) [patients who have received prior anti-b-cell monoclonal antibody therapy (e.g., rituximab or epratuzumab) will not be excluded.]]"
NCT00249015,Criteria,"[are 18 years or older, received approval from their treating oncologist, are not pregnant, have not received previous chemotherapy (previous cancer is not an exclusion criteria), willing to complete all assessments (except blood) at all timepoints including 6, 12, and 24 month follow-ups, able to understand and provide written informed consent in english or french (ottawa), willing to accept randomization and complete their assigned exercise program, no uncontrolled hypertension, cardiac illness or psychiatric condition or any other medical condition that would be a contraindication to exercise, are scheduled to receive adjuvant chemotherapy (receiving neoadjuvant chemotherapy for locally advanced cancer is an exclusion criteria), complete maximal aerobic and strength tests.  no contraindication to exercise as determined by fitness tests, have not received transabdominal rectus abdominis muscle (tram) reconstructive surgery, willing to travel to fitness center 3 times/week to complete exercise program, must not have a planned/known absence of greater than 2 weeks during the intended intervention period and must be able/willing to perform exercise sessions on their own during any planned absences of less than 2 weeks, if participant is currently exercising (e.g., swimming at the y 3 times per week) must be willing to give this up in place of their randomly assigned program]"
NCT00847912,Inclusion Criteria,"[veteran who is at high risk for developing skin cancer defined as 2 keratinocyte carcinomas in the past 5 years, at least one of which was located on the face or ears]"
NCT00847912,Exclusion Criteria,"[patients with known dihydropyrimidine dehydrogenase (dpd) enzyme deficiency by self report or noted in the medical record (they have increased toxicity from systemic 5-fu, although screening for this is not part of dermatologic practice and will not be part of this study)., basal cell nevus syndrome, participants with kc at randomization, solid organ transplant recipients, such as renal, hepatic, or cardiac transplant patients, exclusions 6-l0: we will exclude the small proportion who get their kcs for special reasons other than ultraviolet radiation exposure (see list below), since that etiologic difference, which is associated with a prognostic difference, could be associated with a biologic difference in response to chemoprevention efforts. these will include:, for women of childbearing potential an initial pregnancy test and ongoing birth control will be required for participation., those who, in the opinion of the recruiting investigator, have very high mortality risk at randomization (less than 50% chance of surviving 4 years) due to co morbid illness such as metastatic cancer or copd., individuals with genetic disorders associated with very high cancer risk such as:, participants currently using or having used field therapy for aks on the face or ears in the past 3 years. the vast majority of these field treatments would have been with 5-fu cream. we will allow recent use of therapies that are applied to individual ak lesions (e.g. cryotherapy), but not those that were used on an entire area (field) in the study treatment area participants currently using or having used systemic 5-fluorouracil or oral capecitabine (xeloda) within the past 3 years participants with known allergy to sunscreen, triamcinolone and/or 5-fluorouracil., patients on methotrexate (these will constitute about 1% of potentially eligible individuals) because they may have more severe reactions to topical 5-fu., arsenic exposure, puva (psoralen plus uva) treatment, prior or current radiation therapy to the face and/or ears., erythrodysplasia verruciformis, cutaneous t-cell lymphoma, additional exclusions (12-15) are:, participants who are unable to speak english, xeroderma pigmentosum]"
NCT01068392,Inclusion Criteria,"[failure to achieve a clinical benefit (≥sd) with the initial treatment, or recurrent disease, at least one or more bi-dimensionally measurable lesion(s) defined as; ≥2 cm by conventional ct or ≥ 1 cm by spiral ct or skin lesion (photographs should be taken) or measurable lesion by physical examination, ann arbor stage iii or iv, histologically confirmed marginal zone b-cell lymphomas, ann arbor stage i or ii, which is not adequate for rt or surgical approach (e.g. multiple lung lesions, multiple colon involvement, remote abdominal ln with stomach involvement), performance status (ecog) ≤2, age ≥ 20, adequate liver functions defined as; transaminases < 3 x upper normal values; bilirubin < 2 mg%, adequate kidney functions defined as; cr < 2.0 mg% or ccr > 60 ml/min, adequate bone marrow functions defined as; anc > 1500/㎕, platelet > 75000/㎕, written informed consent approved by institutional review board or ethic committee]"
NCT01068392,Exclusion Criteria,"[serious co-morbid diseases, during this study duration, patients who take other clinical trial medication, chemotherapy, hormonal therapy, or immunotherapy, pregnancy or breast feeding, previous history of drug allergy to one of the drugs in the study regimen, any other malignancies within the past 5 years except skin basal cell ca or cis of cervix]"
NCT00437359,Inclusion Criteria,"[breast cancer diagnosed histologically with a breast removed or preserved., her2 evaluation., patient status (ps): 0 or 1., written consent obtained for study participation., expected to live for at least three months (or longer) after study commencement., fully functional heart, liver, kidneys, and bone marrow., positive er or pr testing by immunohistochemistry (ihc), enzyme immunoassay (eia) and who meet the criteria of each institution., more than one year since last menstruation or tested postmenopausal from estradiol (e2) and follicle-stimulating hormone (fsh) levels based on evaluation standard of each institution.]"
NCT00437359,Exclusion Criteria,"[multiple cancers., bilateral or inflammatory breast cancer., life-threatening metastases., history of serious hypersensitivity., judged ineligible for the study by the study doctor., pregnant or breast feeding.]"
NCT00648739,Inclusion Criteria,"[patients must have a standard indication for treatment of their malignancy, relapsing or refractory b cll or mm, anticipated survival of greater than 6 months., ecog performance status 0-2, is willing and able to give written informed consent., female patients of childbearing potential must agree to use two forms of contraception]"
NCT00648739,Exclusion Criteria,"[prior history of autoimmune hemolysis requiring therapy., clinically significant renal, hepatic or heart disease., neurosurgery or cranial radiation therapy within one year of enrollment., platelet count < 50,000 x 109/l, absolute neutrophil count (anc) < 1000 x 109/l, pregnant or lactating women., prior chemotherapy for the applicable malignancy within 30 days of enrollment., ongoing corticosteroid treatment equivalent to the mineralocortacoid potency of 10 milligram (mg) /day of prednisone, or greater, for any condition., positive coombs' test (neither direct or indirect), prior stem cell transplantation within 4 weeks prior to enrollment., prior history of immune thrombocytopenia., active autoimmune disease requiring immunosuppressive therapy.]"
NCT01926288,Exclusion Criteria,"[3. patients have participated in another therapeutic clinical trial in 3 months., 1. patients were infected with other viruses as hav, hcv, hdv, hev, cmv, ebv, hiv etc., 5. patients with severe heart, kidney, endocrine hematopoietic system and neuropsychiatric diseases., 2. patients with cirrhosis or liver cancer., 7. pregnant woman, lactating women or those who wre allergic for study drug., 6. patients with metabolic or autoimmune diseases such as systemic lupus erythematosus., 4. granulocyte count <1.5 × 109 / l, hemoglobin (hb)<100g / l, sera alpha-fetoprotein(afp)> 100μg / l, patients' b ultrasonography  pointed space-occupying lesions.]"
NCT01926288,Inclusion Criteria,"[9. if patients take intermittently with interferon, nucleoside (acid) analogues, α1 thymosin before enrollment with 24 weeks, the time is  no more than 12 weeks., 3. patients  with previously hbsag-positive, hbeag-positive for 24 weeks, hbv-dna> 105copies/ml. hbeag-negative for 24 weeks or more, hbv-dna> 105 copies/ml., 7. wbc ≥ 3.5 × 109 / l, plt ≥ 70 × 109 / l, serum albumin (alb)≥ 35 g / l., 1. subjects diagnosed of hbeag  positive or negative chronic hepatitis b, 5. total serum bilirubin (tbil) ≤ 2.5 × uln., 6. prothrombin activity (pta) ≥ 60% or prothrombin time prolonged than normal ≤    3 seconds)., 10. patients signed an informed consent form and compliance was good., uln., 8. creatinine (cr) ≤ 1.5 × uln., 4. 1.3 times the upper normal limit (1.3 × uln) ≤ alanine aminotransferase (alt) ≤ 10 ×, 2. aged 18 to 70 years old，male or female]"
NCT00543114,Exclusion Criteria,"[pregnant or breast-feeding females, diagnosis of mantle cell lymphoma, any condition, including the presence of abnormal laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, use of any other experimental drug or therapy within 28 days of baseline, development of erythema nodosum characterized by a desquamating rash while taking thalidomide or similar drugs, known hypersensitivity to thalidomide, concurrent use of other anti-cancer agents or treatments, prior use of lenalidomide, chronic active hep b patients not on prophylactic lamivudine, any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent document, known positive for hiv]"
NCT00543114,Inclusion Criteria,"[no prior systemic therapy for cll/sll, including chemotherapy or antibody therapy, able to take aspirin daily as prophylactic anticoagulation, ecog performance status of 0-2, measurable disease, 18 years of age or older, diagnosed with b-cll/sll based on the standard histologic and immunophenotypic criteria described in the who classification, laboratory test results within parameters outlined in protocol, currently needs therapy based on 1996 nci-wg criteria]"
NCT00661531,Inclusion Criteria,"[may have had radiation therapy but not to the only site of disease., may have had chemotherapy for adjuvant &/or metastatic disease., clinically determined evaluable disease, ecog performance status </= 2., life expectancy of > 6 months, previous clinical benefit from prior anti-estrogen therapies and subsequent failure of at least 2 prior endocrine therapies., histologically confirmed estrogen and/or progesterone receptor-positive breast cancer metastatic breast cancer, post-menopausal woman]"
NCT00661531,Exclusion Criteria,"[current vaginal bleeding, brain metastasis, hypercalcemia or hypocalcemia, prior history of or active thrombophlebitis, deep venous thrombosis or pulmonary embolus, history of or active hepatic adenoma, no other malignancies within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix, chemotherapy or radiotherapy within 1 week of beginning treatment in the clinical trial]"
NCT00443794,Inclusion Criteria,"[informed consent., current smoker or, at least any one of the following cvd risk factors:, stable type 2 diabetes mellitus or, hypertension or, a waist to hip ratio > 0.85 for women and >0.9 for men or, elevated lipids., age between 45 and 80 years]"
NCT00443794,Exclusion Criteria,"[any clear indication or a contraindication to the use of  any of the study medications,, symptomatic hypotension,, uncontrolled blood pressure,, history of coronary/cerebrovascular events,, pregnancy or lactating or women of child-bearing potential with inadequate contraception and / or an inability to attend follow up visits., on any of the study medications,]"
NCT00824408,Exclusion Criteria,"[12. platelet count less than 100,000/mm3, 16. serum creatinine level >133µmol/l and/or creatinine clearance (measured or calculated) <45 ml/min, 8. concomitant intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situation that would limit compliance with trial requirement or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, 19. pregnancy or breast feeding, 17. clinically relevant qtc prolongation, 22. any known hypersensitivity to the trial drugs or their excipients, 18. women and men who are sexually active and unwilling to use a medically acceptable method of contraception, 14. total bilirubin >26µmol/l, 15. alanine amino transferase (alt) and/or aspartate amino transferase (ast) less than 2.5 x uln, except in case of known liver metastasis where maximum 5 x uln is acceptable, 2. anti-cancer therapy for nsclc (except radiotherapy for palliative reasons) within the past 28 days prior to treatment day 1 of cycle 1 of this trial, 11. absolute neutrophil count (anc) less than 1,500/mm3, 20. known or suspected active alcohol or drug abuse, 3. any persisting toxicities which are deemed to be clinically significant from the previous therapy, 6. active brain metastases (stable for <28 days, symptomatic, or requiring concurrent steroids).  patients who have received prior whole brain irradiation and whose brain metastases are stable according to the criteria above will not be excluded., 9. patients unable or unwilling to interrupt concomitant administration of nsaids 5 days prior to, the day of and 2 days after the administration of pemetrexed, with the exception of lose dose aspirin 81mg daily, 1. treatment with an investigational drug in another clinical study within the past 28 days prior to the start of therapy or concomitantly with this study, 4. patients who have received more than one prior chemotherapy regimen for advanced disease (not including prior adjuvant therapy). patients may have received prior epidermal growth factor receptor tyrosine kinase inhibitors., 10. patients who have received prior therapy with pemetrexed, 5. patients who are unwilling or unable to take folic acid and vitamin b12 supplementation, 21. patients unable to comply with the protocol, 13. hemoglobin <90g/l, 7. other active malignancy diagnosed within the past 3 years (other than non melanomatous skin cancer and cervical intraepithelial neoplasia)]"
NCT00824408,Inclusion Criteria,"[5. patients aged 18 years or older, 2. recurrent, advanced or metastatic nsclc that has progressed following one prior platinum based chemotherapy regimen (not counting adjuvant or neoadjuvant chemotherapy if completed more than 12 months prior to platinum based therapy), 1. pathologic or cytologic confirmed diagnosis of nsclc, 3. patients who are eligible for pemetrexed as second line chemotherapy, 6. life expectancy of at least three (3) months, 4. measurable disease by one or more techniques (ct, mri) according to recist, 7. eastern cooperative oncology group (ecog) performance score 0-2, 8. written informed consent that is consistent with ich-gcp guidelines and local legislation]"
NCT01953770,Exclusion Criteria,"[1. all is a second malignant tumor;, 2. the disease is a relapse of previously misdiagnosed and, therefore, inadequately treated all;, 5. the patient was treated before for a long time with cytotoxic drugs;, 4. there is a lack of important basic data needed for the exact adherence to the cytostatic therapy according to a specific protocol of chemotherapy (differential diagnosis of acute lymphoblastic/myeloid leukemia is not possible, stratification according to risk group is not possible);, 3. there is severe concomitant disease, which significantly impedes chemotherapy protocol (such as multiple malformations, heart diseases, metabolic disorders, etc.);, 6. there were deviations in the treatment not covered by the protocol and/or not due to side effects of treatment and/or complications of the disease]"
NCT01953770,Inclusion Criteria,"[4. informed consent of the parents (guardians) of the patient to be treated in one of the clinics included in this multicenter study., 1. age at diagnosis at 1 to 18 years., 2. the start of induction therapy within a time interval of study recruitment phase., 3. the diagnosis of all is to be proved by the morphological, cytochemical, and immunological analysis of tumor cells in bone marrow.]"
NCT01611727,Exclusion Criteria,"[patients with known brain metastases are not eligible., patients previously treated with a platinum-based chemotherapy are not eligible.]"
NCT01611727,Inclusion Criteria,"[adequate hematologic, in addition, the following are required:, life expectancy of at least 12 weeks, adequate recovery from recent surgery and/or radiation therapy, patients could have received up to four prior chemotherapies for metastatic disease., recovery from all prior treatment-related toxicities (to grade < 2 according to national cancer institute common toxicity criteria, version3.0, except alopecia), female patients aged ≥ 18 years, with measurable (defined by response evaluation criteria in solid tumors (recist) criteria (14)) metastatic (stage iv) breast cancer, and who are known to carry a brca1 mutation, are eligible., eastern cooperative oncology group (ecog) performance status of 0 or 1.   -, renal, and hepatic function]"